0000012208-23-000072.txt : 20231027 0000012208-23-000072.hdr.sgml : 20231027 20231027163115 ACCESSION NUMBER: 0000012208-23-000072 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231027 DATE AS OF CHANGE: 20231027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-RAD LABORATORIES, INC. CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 231355971 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 FORMER COMPANY: FORMER CONFORMED NAME: BIO RAD LABORATORIES INC DATE OF NAME CHANGE: 19920703 10-Q 1 bio-20230930.htm 10-Q bio-20230930
000001220812/312023Q3falsehttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent00000122082023-01-012023-09-300000012208us-gaap:CommonClassAMember2023-01-012023-09-300000012208us-gaap:CommonClassBMember2023-01-012023-09-300000012208us-gaap:CommonClassAMember2023-10-20xbrli:shares0000012208us-gaap:CommonClassBMember2023-10-2000000122082023-09-30iso4217:USD00000122082022-12-310000012208us-gaap:CommonClassAMember2023-09-300000012208us-gaap:CommonClassAMember2022-12-310000012208us-gaap:CommonClassBMember2023-09-300000012208us-gaap:CommonClassBMember2022-12-310000012208us-gaap:TreasuryStockCommonMember2023-09-300000012208us-gaap:TreasuryStockCommonMember2022-12-310000012208bio:TreasuryClassAMember2023-09-300000012208bio:TreasuryClassAMember2022-12-3100000122082023-07-012023-09-3000000122082022-07-012022-09-3000000122082022-01-012022-09-30iso4217:USDxbrli:shares00000122082021-12-3100000122082022-09-300000012208us-gaap:CommonStockMember2022-12-310000012208us-gaap:AdditionalPaidInCapitalMember2022-12-310000012208us-gaap:TreasuryStockCommonMember2022-12-310000012208us-gaap:RetainedEarningsMember2022-12-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000012208us-gaap:CommonStockMember2023-01-012023-03-310000012208us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000012208us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000012208us-gaap:RetainedEarningsMember2023-01-012023-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-3100000122082023-01-012023-03-310000012208us-gaap:CommonStockMember2023-03-310000012208us-gaap:AdditionalPaidInCapitalMember2023-03-310000012208us-gaap:TreasuryStockCommonMember2023-03-310000012208us-gaap:RetainedEarningsMember2023-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100000122082023-03-310000012208us-gaap:CommonStockMember2023-04-012023-06-300000012208us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000012208us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000012208us-gaap:RetainedEarningsMember2023-04-012023-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-3000000122082023-04-012023-06-300000012208us-gaap:CommonStockMember2023-06-300000012208us-gaap:AdditionalPaidInCapitalMember2023-06-300000012208us-gaap:TreasuryStockCommonMember2023-06-300000012208us-gaap:RetainedEarningsMember2023-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000000122082023-06-300000012208us-gaap:CommonStockMember2023-07-012023-09-300000012208us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000012208us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000012208us-gaap:RetainedEarningsMember2023-07-012023-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000012208us-gaap:CommonStockMember2023-09-300000012208us-gaap:AdditionalPaidInCapitalMember2023-09-300000012208us-gaap:TreasuryStockCommonMember2023-09-300000012208us-gaap:RetainedEarningsMember2023-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000012208us-gaap:CommonStockMember2021-12-310000012208us-gaap:AdditionalPaidInCapitalMember2021-12-310000012208us-gaap:TreasuryStockCommonMember2021-12-310000012208us-gaap:RetainedEarningsMember2021-12-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000012208us-gaap:CommonStockMember2022-01-012022-03-310000012208us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000012208us-gaap:TreasuryStockCommonMember2022-01-012022-03-310000012208us-gaap:RetainedEarningsMember2022-01-012022-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-3100000122082022-01-012022-03-310000012208us-gaap:CommonStockMember2022-03-310000012208us-gaap:AdditionalPaidInCapitalMember2022-03-310000012208us-gaap:TreasuryStockCommonMember2022-03-310000012208us-gaap:RetainedEarningsMember2022-03-310000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100000122082022-03-310000012208us-gaap:CommonStockMember2022-04-012022-06-300000012208us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300000012208us-gaap:TreasuryStockCommonMember2022-04-012022-06-300000012208us-gaap:RetainedEarningsMember2022-04-012022-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-3000000122082022-04-012022-06-300000012208us-gaap:CommonStockMember2022-06-300000012208us-gaap:AdditionalPaidInCapitalMember2022-06-300000012208us-gaap:TreasuryStockCommonMember2022-06-300000012208us-gaap:RetainedEarningsMember2022-06-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000000122082022-06-300000012208us-gaap:CommonStockMember2022-07-012022-09-300000012208us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000012208us-gaap:TreasuryStockCommonMember2022-07-012022-09-300000012208us-gaap:RetainedEarningsMember2022-07-012022-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000012208us-gaap:CommonStockMember2022-09-300000012208us-gaap:AdditionalPaidInCapitalMember2022-09-300000012208us-gaap:TreasuryStockCommonMember2022-09-300000012208us-gaap:RetainedEarningsMember2022-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-30xbrli:pure0000012208country:US2023-07-012023-09-300000012208country:US2022-07-012022-09-300000012208country:US2023-01-012023-09-300000012208country:US2022-01-012022-09-300000012208srt:EuropeMember2023-07-012023-09-300000012208srt:EuropeMember2022-07-012022-09-300000012208srt:EuropeMember2023-01-012023-09-300000012208srt:EuropeMember2022-01-012022-09-300000012208srt:AsiaPacificMember2023-07-012023-09-300000012208srt:AsiaPacificMember2022-07-012022-09-300000012208srt:AsiaPacificMember2023-01-012023-09-300000012208srt:AsiaPacificMember2022-01-012022-09-300000012208srt:AmericasMember2023-07-012023-09-300000012208srt:AmericasMember2022-07-012022-09-300000012208srt:AmericasMember2023-01-012023-09-300000012208srt:AmericasMember2022-01-012022-09-300000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300000012208us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member2023-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2023-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMember2023-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2023-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2023-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2023-09-300000012208us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel1Member2023-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-09-300000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-09-300000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-09-300000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2022-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BankTimeDepositsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel1Member2022-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMember2022-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2022-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashEquivalentsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2022-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2022-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryAndGovernmentMember2022-12-310000012208us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2022-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310000012208us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310000012208us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-12-310000012208bio:RestrictedInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000012208bio:RestrictedInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherInvestmentsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300000012208bio:OrdinaryVotingSharesMember2023-09-300000012208bio:PreferenceSharesMember2023-09-300000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMemberus-gaap:ShortTermInvestmentsMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2023-09-300000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:USTreasuryAndGovernmentMember2023-09-300000012208us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2023-09-300000012208us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMemberus-gaap:ShortTermInvestmentsMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2022-12-310000012208us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:USTreasuryAndGovernmentMember2022-12-310000012208us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-12-310000012208bio:ForwardforeignexchangecontracttosellforeigncurrencyMember2023-09-300000012208bio:ForwardforeignexchangecontracttosellforeigncurrencyMember2023-07-012023-09-300000012208bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember2023-09-300000012208bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember2023-07-012023-09-30utr:Rate0000012208bio:LifeScienceMember2022-12-310000012208bio:ClinicalDiagnosticsMember2022-12-310000012208bio:LifeScienceMember2023-01-012023-09-300000012208bio:ClinicalDiagnosticsMember2023-01-012023-09-300000012208bio:LifeScienceMember2023-09-300000012208bio:ClinicalDiagnosticsMember2023-09-300000012208us-gaap:CustomerRelationshipsMember2023-09-300000012208bio:KnowHowMember2023-09-300000012208us-gaap:DevelopedTechnologyRightsMember2023-09-300000012208us-gaap:LicensingAgreementsMember2023-09-300000012208us-gaap:TradeNamesMember2023-09-300000012208us-gaap:NoncompeteAgreementsMember2023-09-300000012208us-gaap:InProcessResearchAndDevelopmentMember2023-09-300000012208us-gaap:CustomerRelationshipsMember2022-12-310000012208bio:KnowHowMember2022-12-310000012208us-gaap:DevelopedTechnologyRightsMember2022-12-310000012208us-gaap:LicensingAgreementsMember2022-12-310000012208us-gaap:TradeNamesMember2022-12-310000012208us-gaap:NoncompeteAgreementsMember2022-12-310000012208us-gaap:InProcessResearchAndDevelopmentMember2022-12-310000012208bio:A33SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2023-09-300000012208bio:A33SeniorNotesDue2027Memberus-gaap:SeniorNotesMember2022-12-310000012208us-gaap:SeniorNotesMemberbio:A37SeniorNotesDue2032Member2023-09-300000012208us-gaap:SeniorNotesMemberbio:A37SeniorNotesDue2032Member2022-12-310000012208us-gaap:SeniorNotesMemberus-gaap:SeniorNotesMember2023-09-300000012208us-gaap:SeniorNotesMemberus-gaap:SeniorNotesMember2022-12-310000012208bio:FinanceLeaseObligationsMemberbio:FinanceLeasesandOtherDebtMember2023-09-300000012208bio:FinanceLeaseObligationsMemberbio:FinanceLeasesandOtherDebtMember2022-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000012208us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-09-300000012208us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000012208us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000012208us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000012208us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000012208bio:LifeScienceMember2023-07-012023-09-300000012208bio:ClinicalDiagnosticsMember2023-07-012023-09-300000012208us-gaap:AllOtherSegmentsMember2023-07-012023-09-300000012208bio:LifeScienceMember2022-07-012022-09-300000012208bio:ClinicalDiagnosticsMember2022-07-012022-09-300000012208us-gaap:AllOtherSegmentsMember2022-07-012022-09-300000012208us-gaap:AllOtherSegmentsMember2023-01-012023-09-300000012208bio:LifeScienceMember2022-01-012022-09-300000012208bio:ClinicalDiagnosticsMember2022-01-012022-09-300000012208us-gaap:AllOtherSegmentsMember2022-01-012022-09-300000012208us-gaap:OperatingSegmentsMember2023-07-012023-09-300000012208us-gaap:OperatingSegmentsMember2022-07-012022-09-300000012208us-gaap:OperatingSegmentsMember2023-01-012023-09-300000012208us-gaap:OperatingSegmentsMember2022-01-012022-09-300000012208us-gaap:InterestExpenseMemberus-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300000012208us-gaap:InterestExpenseMemberus-gaap:MaterialReconcilingItemsMember2022-07-012022-09-300000012208us-gaap:InterestExpenseMemberus-gaap:MaterialReconcilingItemsMember2023-01-012023-09-300000012208us-gaap:InterestExpenseMemberus-gaap:MaterialReconcilingItemsMember2022-01-012022-09-300000012208us-gaap:ForeignCurrencyGainLossMemberus-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300000012208us-gaap:ForeignCurrencyGainLossMemberus-gaap:MaterialReconcilingItemsMember2022-07-012022-09-300000012208us-gaap:ForeignCurrencyGainLossMemberus-gaap:MaterialReconcilingItemsMember2023-01-012023-09-300000012208us-gaap:ForeignCurrencyGainLossMemberus-gaap:MaterialReconcilingItemsMember2022-01-012022-09-300000012208us-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300000012208us-gaap:MaterialReconcilingItemsMember2022-07-012022-09-300000012208us-gaap:MaterialReconcilingItemsMember2023-01-012023-09-300000012208us-gaap:MaterialReconcilingItemsMember2022-01-012022-09-300000012208us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300000012208us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:MaterialReconcilingItemsMember2022-07-012022-09-300000012208us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:MaterialReconcilingItemsMember2023-01-012023-09-300000012208us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:MaterialReconcilingItemsMember2022-01-012022-09-300000012208bio:EuropeanReorganizationMember2021-02-012023-09-300000012208bio:EuropeanReorganizationMemberbio:LifeScienceMember2022-12-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2022-12-310000012208bio:EuropeanReorganizationMember2022-12-310000012208bio:EuropeanReorganizationMemberbio:LifeScienceMember2023-01-012023-09-300000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2023-01-012023-09-300000012208bio:EuropeanReorganizationMember2023-01-012023-09-300000012208bio:EuropeanReorganizationMemberbio:LifeScienceMember2023-09-300000012208bio:ClinicalDiagnosticsMemberbio:EuropeanReorganizationMember2023-09-300000012208bio:EuropeanReorganizationMember2023-09-300000012208bio:EuropeanAndAmericanReorganizationMember2023-02-012023-09-300000012208bio:EuropeanAndAmericanReorganizationMemberbio:LifeScienceMember2022-12-310000012208bio:ClinicalDiagnosticsMemberbio:EuropeanAndAmericanReorganizationMember2022-12-310000012208bio:EuropeanAndAmericanReorganizationMember2022-12-310000012208bio:EuropeanAndAmericanReorganizationMemberbio:LifeScienceMember2023-01-012023-09-300000012208bio:ClinicalDiagnosticsMemberbio:EuropeanAndAmericanReorganizationMember2023-01-012023-09-300000012208bio:EuropeanAndAmericanReorganizationMember2023-01-012023-09-300000012208bio:EuropeanAndAmericanReorganizationMemberbio:LifeScienceMember2023-09-300000012208bio:ClinicalDiagnosticsMemberbio:EuropeanAndAmericanReorganizationMember2023-09-300000012208bio:EuropeanAndAmericanReorganizationMember2023-09-300000012208bio:EuropeanAndAmericanReorganizationMember2023-06-012023-09-300000012208bio:AdditionalEuropeanAndAmericanReorganizationMemberbio:LifeScienceMember2022-12-310000012208bio:ClinicalDiagnosticsMemberbio:AdditionalEuropeanAndAmericanReorganizationMember2022-12-310000012208bio:AdditionalEuropeanAndAmericanReorganizationMember2022-12-310000012208bio:AdditionalEuropeanAndAmericanReorganizationMemberbio:LifeScienceMember2023-01-012023-09-300000012208bio:ClinicalDiagnosticsMemberbio:AdditionalEuropeanAndAmericanReorganizationMember2023-01-012023-09-300000012208bio:AdditionalEuropeanAndAmericanReorganizationMember2023-01-012023-09-300000012208bio:AdditionalEuropeanAndAmericanReorganizationMemberbio:LifeScienceMember2023-09-300000012208bio:ClinicalDiagnosticsMemberbio:AdditionalEuropeanAndAmericanReorganizationMember2023-09-300000012208bio:AdditionalEuropeanAndAmericanReorganizationMember2023-09-300000012208us-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-09-300000012208us-gaap:OtherNoncurrentLiabilitiesMember2023-09-300000012208us-gaap:CostOfSalesMember2023-07-012023-09-300000012208us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300000012208us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000012208us-gaap:CostOfSalesMember2023-01-012023-09-300000012208us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300000012208us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000012208srt:MinimumMember2023-01-012023-09-300000012208srt:MaximumMember2023-01-012023-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period endedSeptember 30, 2023
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from______________to __________
Commission file number1-7928
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Delaware94-1381833
(State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.)
1000 Alfred Nobel Drive,Hercules,California94547
(Address of principal executive offices)(Zip Code)
(510)724-7000
(Registrant's telephone number, including area code)
No Change
(Former name, former address and former fiscal year, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per shareBIONew York Stock Exchange
Class B Common Stock, Par Value $0.0001 per shareBIObNew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes☒No☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files).
Yes☒No☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.  (Check one):
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes☐No☒
.
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Shares Outstanding at October 20, 2023:
Class A - 24,059,355Class B - 5,085,815



BIO-RAD LABORATORIES, INC.

FORM 10-Q SEPTEMBER 30, 2023

TABLE OF CONTENTS

2

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this report include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our future financial performance, operating results, plans and objectives. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including, but not limited to, the impact of the COVID-19 pandemic, supply chain issues, global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, reductions in government funding or capital spending of our customers, international legal and regulatory risks, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, natural disasters and other catastrophic events beyond our control, and other risks and uncertainties identified under “Part II, Item 1A, Risk Factors” of this Quarterly Report on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

3

PART I – FINANCIAL INFORMATION

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share data)

September 30, 2023December 31, 2022
ASSETS:(Unaudited)
Cash and cash equivalents$457,850 $434,215 
Short-term investments1,301,143 1,356,457 
Restricted investments5,560 5,560 
Accounts receivable, less allowance for credit losses of $15,108 as of September 30, 2023 and $15,029 as of December 31, 2022
457,402 494,645 
Inventory775,818 719,316 
Prepaid expenses123,910 124,179 
Other current assets25,087 23,604 
Total current assets3,146,770 3,157,976 
Property, plant and equipment1,538,545 1,508,020 
Less: accumulated depreciation and amortization(1,027,156)(1,009,408)
Property, plant and equipment, net511,389 498,612 
Operating lease right-of-use assets200,013 180,952 
Goodwill, net406,953 406,488 
Purchased intangibles, net314,187 332,147 
Other investments7,218,161 8,830,892 
Other assets98,470 94,599 
Total assets$11,895,943 $13,501,666 
















The accompanying notes are an integral part of these condensed consolidated financial statements.
4





BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(continued)
(In thousands, except share data)

September 30, 2023December 31, 2022
LIABILITIES AND STOCKHOLDERS’ EQUITY:(Unaudited) 
Accounts payable$111,859 $135,041 
Accrued payroll and employee benefits154,946 194,790 
Current maturities of long-term debt and notes payable476 465 
Income and other taxes payable103,978 32,428 
Current operating lease liabilities39,116 36,336 
Other current liabilities147,801 169,648 
Total current liabilities558,176 568,708 
Long-term debt, net of current maturities1,198,713 1,197,716 
Deferred income taxes1,369,556 1,770,481 
Operating lease liabilities167,179 153,597 
Other long-term liabilities186,121 195,912 
Total liabilities3,479,745 3,886,414 
Stockholders’ equity:  
Class A common stock, shares issued 25,163,999 and 25,162,075 as of September 30, 2023 and December 31, 2022, respectively; shares outstanding 24,059,355 and 24,521,583 as of September 30, 2023 and December 31, 2022, respectively
2 2 
Class B common stock, shares issued and outstanding, 5,085,815 as of September 30, 2023 and 5,074,130 as of December 31, 2022, respectively
1 1 
Additional paid-in capital439,455 447,454 
Class A treasury stock at cost, 1,104,644 and 640,492 shares as of September 30, 2023 and December 31, 2022, respectively
(436,620)(263,586)
Retained earnings8,910,921 9,898,203 
Accumulated other comprehensive loss
(497,561)(466,822)
Total stockholders’ equity8,416,198 9,615,252 
Total liabilities and stockholders’ equity$11,895,943 $13,501,666 













The accompanying notes are an integral part of these condensed consolidated financial statements. 
5



BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Income (Loss)
(In thousands, except per share data)
(Unaudited)
 Three Months EndedNine Months Ended
 September 30,September 30,
 2023202220232022
Net sales$632,124 $680,800 $1,990,078 $2,071,961 
Cost of goods sold296,441 308,233 929,495 901,728 
Gross profit335,683 372,567 1,060,583 1,170,233 
Selling, general and administrative expense201,199 211,113 634,576 615,598 
Research and development expense43,535 66,808 183,528 190,689 
Income from operations90,949 94,646 242,479 363,946 
Interest expense12,398 11,663 37,078 26,431 
Foreign currency exchange (gains) losses, net(1,680)4,364 (5,280)3,133 
(Gains) losses from change in fair market value of equity securities and loan receivable(36,425)288,999 1,576,542 6,172,306 
Other income, net(20,446)(3,062)(87,365)(42,369)
Income (loss) before income taxes137,102 (207,318)(1,278,496)(5,795,555)
(Provision for) benefit from income taxes(30,845)44,510 291,464 1,340,286 
Net income (loss)$106,257 $(162,808)$(987,032)$(4,455,269)
Basic earnings (loss) per share:  
Net income (loss) per share$3.65 $(5.48)$(33.63)$(149.41)
Weighted average common shares - basic29,102 29,733 29,349 29,819 
Diluted earnings (loss) per share:  
Net income (loss) per diluted share$3.64 $(5.48)$(33.63)$(149.41)
Weighted average common shares - diluted29,223 29,733 29,349 29,819 


The accompanying notes are an integral part of these condensed consolidated financial statements. 



6

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Comprehensive Income (Loss)
(In thousands)
(Unaudited)
Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Net income (loss)$106,257 $(162,808)$(987,032)$(4,455,269)
Other comprehensive income (loss):
Foreign currency translation adjustments, net of income taxes(126,165)(305,666)(34,342)(653,301)
Foreign other post-employment benefits adjustments, net of income taxes(342)481 (72)1,004 
Net unrealized holding gain (loss) on available-for-sale debt investments, net of income taxes1,808 (6,643)3,675 (17,364)
Other comprehensive loss, net of income taxes(124,699)(311,828)(30,739)(669,661)
Comprehensive loss$(18,442)$(474,636)$(1,017,771)$(5,124,930)



The accompanying notes are an integral part of these condensed consolidated financial statements.

7

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands, unaudited)
 Nine Months Ended
 September 30,
 20232022
Cash flows from operating activities:  
Cash received from customers$2,007,482 $1,981,952 
Cash paid to suppliers and employees(1,722,173)(1,800,487)
Interest paid, net(46,394)(23,974)
Income tax payments, net(40,966)(137,863)
Dividend proceeds and miscellaneous receipts, net
81,828 51,146 
Proceeds from forward foreign exchange contracts, net14,119 44,016 
Net cash provided by operating activities293,896 114,790 
Cash flows from investing activities:  
Payments for purchases of property, plant and equipment(114,435)(77,987)
Proceeds from dispositions of property, plant and equipment104 114 
Proceeds from divestiture of a division— 1,360 
Payments for acquisitions, net of cash received— (100,746)
Payments for purchases of marketable securities and investments(537,540)(1,807,148)
Proceeds from sales of marketable securities and investments339,033 542,639 
Proceeds from maturities of marketable securities and investments260,849 292,727 
Net cash used in investing activities(51,989)(1,149,041)
Cash flows from financing activities:  
Proceeds from issuance of Notes, net of debt financing costs— 1,186,220 
Payments on long-term borrowings(349)(367)
Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options14,168 13,218 
Tax payments from net share settlement(10,118)(13,876)
Payments for purchases of treasury stock(228,728)(125,000)
Net cash (used in) provided by financing activities(225,027)1,060,195 
Effect of foreign exchange rate changes on cash6,891 21,167 
Net increase in cash, cash equivalents and restricted cash23,771 47,111 
Cash, cash equivalents and restricted cash at beginning of period434,544 471,133 
Cash, cash equivalents and restricted cash at end of period$458,315 $518,244 

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that agrees to the same amounts shown in the condensed consolidated statements of cash flows (in thousands):
September 30, 2023September 30, 2022
Cash and cash equivalents$457,850 $517,943 
Restricted cash included in Other current assets79 12 
Restricted cash included in Other assets386 289 
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$458,315 $518,244 

These restricted cash items are primarily related to performance guarantees and other restricted deposits.

The accompanying notes are an integral part of these condensed consolidated financial statements.

8



BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Changes in Stockholders' Equity
(In thousands)
(Unaudited)
Common StockAdditional Paid-in CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
Balance at December 31, 2022$3 $447,454 $(263,586)$9,898,203 $(466,822)$9,615,252 
Net income— — — 68,962 — 68,962 
Other comprehensive income, net of tax— — — — 58,470 58,470 
Stock compensation expense— 16,608 — — — 16,608 
Issuance of treasury stock— (660)5,290 (206)— 4,424 
Balance at March 31, 2023$3 $463,402 $(258,296)$9,966,959 $(408,352)$9,763,716 
Net loss— — — (1,162,251)— (1,162,251)
Other comprehensive income, net of tax— — — — 35,490 35,490 
Stock compensation expense— 12,559 — — — 12,559 
Purchase of treasury stock— — (207,407)— — (207,407)
Issuance of treasury stock, net of shares withheld— (2,089)6,919 (44)— 4,786 
Balance at June 30, 2023$3 $473,872 $(458,784)$8,804,664 $(372,862)$8,446,893 
Net income— — — 106,257 — 106,257 
Other comprehensive loss, net of tax— — — — (124,699)(124,699)
Issuance of common stock, net of shares withheld— (5,111)— — — (5,111)
Stock compensation expense— 15,952 — — — 15,952 
Purchase of treasury stock— — (23,608)— — (23,608)
Issuance of treasury stock, net of shares withheld— (45,258)45,772 — — 514 
Balance at September 30, 2023$3 $439,455 $(436,620)$8,910,921 $(497,561)$8,416,198 







9

BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Changes in Stockholders' Equity
(continued)
(In thousands)
(Unaudited)
Common StockAdditional Paid-in CapitalTreasury StockRetained EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders' Equity
Balance at December 31, 2021$3 $441,733 $(106,290)$13,525,343 $(175,553)$13,685,236 
Net loss— — — (3,367,347)— (3,367,347)
Other comprehensive loss, net of tax— — — — (132,303)(132,303)
Issuance of common stock— 4,177 — — — 4,177 
Stock compensation expense— 13,521 — — — 13,521 
Balance at March 31, 2022$3 $459,431 $(106,290)$10,157,996 $(307,856)$10,203,284 
Net loss— — — (925,114)— (925,114)
Other comprehensive loss, net of tax— — — — (225,530)(225,530)
Issuance of common stock, net of shares withheld— (443)— — — (443)
Stock compensation expense— 13,571 — — — 13,571 
Purchase of treasury stock— — (125,000)— — (125,000)
Issuance of treasury stock, net of shares withheld— (696)4,950 13 — 4,267 
Balance at June 30, 2022$3 $471,863 $(226,340)$9,232,895 $(533,386)$8,945,035 
Net loss— — — (162,808)— (162,808)
Other comprehensive loss, net of tax— — — — (311,828)(311,828)
Issuance of common stock, net of shares withheld— (7,550)— — — (7,550)
Stock compensation expense— 15,735 — — — 15,735 
Issuance of treasury stock, net of shares withheld— (49,501)48,079 305 — (1,117)
Balance at September 30, 2022$3 $430,547 $(178,261)$9,070,392 $(845,214)$8,477,467 


The accompanying notes are an integral part of these condensed consolidated financial statements. 

10

BIO-RAD LABORATORIES, INC

Notes to Condensed Consolidated Financial Statements
(Unaudited)

1. BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.

Revenue Recognition

We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the standalone selling price for
11

each distinct product or service. The method used to determine the standalone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.

We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.

At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation.

We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.

The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements

Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification as operating or sales-type lease. The lease term used in performing the lease classification test, includes the noncancellable period of the lease together with those periods covered by lease extension options if the customer is reasonably certain to exercise that option, the periods covered by lease termination options if the customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term for reagent rental agreements, including the impact from any associated contractual termination penalties, is subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee to purchase the underlying asset.

We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and
12

consideration of any fixed/minimum payments as well as estimates of variable consideration. After we have allocated the transaction price to the lease and non-lease elements, the amount of variable payments allocated to such elements are recognized as income in accordance with ASC 842 or ASC 606, as applicable.

Maintenance services and reagents are allocated to the non-lease elements. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.

Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial, and we do not enter into direct finance leases.

Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and nine months ended September 30, 2023 and September 30, 2022. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).

Contract costs:

As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss).

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
United States$275.4 $284.1 $858.8 $848.2 
EMEA193.1 200.1 609.1 636.3 
APAC118.9 156.8 398.9 470.3 
Other (primarily Canada and Latin America)44.7 39.8 123.3 117.2 
Total net sales$632.1 $680.8 $1,990.1 $2,072.0 

The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).

Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2023 and December 31, 2022 was $66.5 million and $71.9 million, respectively. The short-term deferred revenue balance at September 30, 2023 and December 31, 2022 was $49.1 million and $52.2 million, respectively.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).

13

Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the nine months ended September 30, 2023 and 2022 were as follows (in millions):
Nine Months Ended
September 30,
20232022
Balance at beginning of period$10.6 $12.7 
Provision for warranty6.4 6.7 
Actual warranty costs(9.0)(8.8)
Balance at end of period$8.0 $10.6 

Accounts Receivable and Allowance for Credit Losses

We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.

Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.


Changes in our allowance for credit losses were as follows (in millions):
Nine Months Ended
September 30,
20232022
Balance at beginning of period$15.0 $15.1 
Provision for expected credit losses0.9 1.2 
Write-offs charged against the allowance(1.3)(2.3)
 Recoveries collected0.5 0.1 
Balance at end of period$15.1 $14.1 

Recent Accounting Pronouncements Issued and to be Adopted

There are no new accounting pronouncements recently issued or newly effective that had, or are expected to have, a material impact on the Company's condensed consolidated financial statements.


2. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•Level 1: Quoted prices in active markets for identical instruments
14

•Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2023 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $7.5 $— $7.5 
Time deposits— 44.7 — 44.7 
Money market funds120.1 — — 120.1 
Total cash equivalents (a)120.1 52.2 — 172.3 
Restricted investments (b)6.9 — — 6.9 
Equity securities (c)6,947.6 — — 6,947.6 
Loan under the fair value option (d)— — 290.5 290.5 
Available-for-sale investments:
Corporate debt securities— 590.6 — 590.6 
U.S. government sponsored agencies— 283.7 — 283.7 
Foreign government obligations— 10.0 — 10.0 
Municipal obligations— 13.9 — 13.9 
Asset-backed securities— 342.5 — 342.5 
Total available-for-sale investments (e)— 1,240.7 — 1,240.7 
Forward foreign exchange contracts (f)— 0.7 — 0.7 
Total financial assets carried at fair value$7,074.6 $1,293.6 $290.5 $8,658.7 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (g)$— $1.0 $— $1.0 
Contingent consideration (h)— — 17.1 17.1 
Total financial liabilities carried at fair value$— $1.0 $17.1 $18.1 


15

Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $21.1 $— $21.1 
Time deposits5.7 — — 5.7 
Asset-backed securities— 1.4 — 1.4 
U.S. government sponsored agencies— 6.0 — 6.0 
Money market funds31.5 — — 31.5 
Total cash equivalents (a)37.2 28.5 — 65.7 
Restricted investments (b)6.8 — — 6.8 
Equity securities (c)8,530.4 — — 8,530.4 
Loan under the fair value option (d)— — 322.6 322.6 
Available-for-sale investments:
Corporate debt securities— 699.3 — 699.3 
U.S. government sponsored agencies— 230.7 — 230.7 
Foreign government obligations— 13.5 — 13.5 
Municipal obligations— 23.1 — 23.1 
Asset-backed securities— 333.4 — 333.4 
Total available-for-sale investments (e)— 1,300.0 — 1,300.0 
Forward foreign exchange contracts (f)— 1.5 — 1.5 
Total financial assets carried at fair value$8,574.4 $1,330.0 $322.6 $10,227.0 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)$— $6.2 $— $6.2 
Contingent consideration (h)— — 35.6 35.6 
Total financial liabilities carried at fair value$— $6.2 $35.6 $41.8 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2023December 31, 2022
Restricted investments$5.6 $5.6 
Other investments1.3 1.2 
    Total$6.9 $6.8 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2023December 31, 2022
Short-term investments$60.3 $56.5 
Other investments6,887.3 8,473.9 
        Total$6,947.6 $8,530.4 

16

(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.

(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.

(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023.

Level 1 Fair Value Measurements

As of September 30, 2023, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the ordinary outstanding shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of September 30, 2023. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.

The changes in fair market value of our investment in Sartorius for the three and nine months ended September 30, 2023 was a gain of $42.5 million and a loss of $1,556.1 million respectively, which is recorded in our condensed consolidated statements of income (loss).

Level 2 Fair Value Measurements

To estimate the fair value of Level 2 debt securities as of September 30, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

17

Available-for-sale investments consist of the following (in millions):
 September 30, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$598.0 $0.3 $(7.7)$590.6 
Municipal obligations14.1 — (0.2)13.9 
Asset-backed securities347.3 — (4.8)342.5 
U.S. government sponsored agencies287.1 — (3.4)283.7 
Foreign government obligations10.2 — (0.2)10.0 
 $1,256.7 $0.3 $(16.3)$1,240.7 

The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2023 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$473.6 $469.5 
Mature in one to five years636.7 627.8 
Mature in more than five years146.4 143.4 
Total$1,256.7 $1,240.7 

Available-for-sale investments consist of the following (in millions):
 December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$709.9 $0.2 $(10.8)$699.3 
Municipal obligations23.4 — (0.3)23.1 
Asset-backed securities339.6 0.1 (6.3)333.4 
U.S. government sponsored agencies233.9 — (3.2)230.7 
Foreign government obligations13.8 — (0.3)13.5 
Total$1,320.6 $0.3 $(20.9)$1,300.0 


As of September 30, 2023, there were no significant continuous unrealized losses greater than 12 months.

Our evaluation of credit losses for available-for-sale investments included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.

At September 30, 2023, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of September 30, 2023.
18

Included in Other current assets are $11.2 million and $11.6 million of interest receivable as of September 30, 2023 and December 31, 2022, respectively, primarily associated with securities in our available-for-sale investments portfolio. The interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the nine months ended September 30, 2023, we have not written-off any uncollected interest receivable.

As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of September 30, 2023 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss).

The following is a summary of our forward foreign exchange contracts (in millions):
 September 30,
 2023
Contracts maturing in October through December 2023 to sell foreign currency: 
Notional value$701.5 
Unrealized loss$(0.4)
Contracts maturing in October through December 2023 to purchase foreign currency: 
Notional value$80.1 
Unrealized gain$0.1 

Level 3 Fair Value Investments

During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (the “Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in (Gains) losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss).
19

The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the three months ended September 30, 2023 was a loss of $4.9 million, which includes a $10.8 million loss from change in fair market value of the Loan and a $5.9 million gain from change in fair market value of the value appreciation right. The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the nine months ended September 30, 2023 was a loss of $28.9 million, which includes a $0.4 million loss from change in fair market value of the Loan and a $28.5 million loss from change in fair market value of the value appreciation right. The decrease in the fair market value of the value appreciation right was due to a decline in the value of the Sartorius ordinary shares. As of September 30, 2023, the €400 million principal amount of the loan is still due on January 31, 2029.

The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):

December 31, 2022$322.6 
Net decrease in estimated fair market value of the loan included in (Gains) losses in fair market value of equity securities and loan receivable
$(28.9)
Foreign currency exchange gains (losses), net$(3.2)
September 30, 2023$290.5 


3. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment are as follows (in millions):
Life
Science		Clinical
Diagnostics		Total
Balances as of December 31, 2022:
Goodwill$333.3 $408.4 $741.7 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net291.5 115.0 406.5 
Acquisitions— 0.40.4 
Foreign currency adjustments— 0.1 0.1 
Period increase, net— 0.5 0.5 
Balances as of September 30, 2023:
Goodwill333.3 408.9 742.2 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$291.5 $115.5 $407.0 

Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):
20

September 30, 2023
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.2$104.3 $(93.6)$10.7 
Know how2.0165.1 (156.2)8.9 
Developed product technology12.2215.5 (128.4)87.1 
Licenses5.158.8 (41.1)17.7 
Tradenames5.86.0 (4.5)1.5 
Covenants not to compete2.56.5 (4.7)1.8 
     Total finite-lived intangible assets556.2 (428.5)127.7 
In-process research and development186.5 — 186.5 
     Total purchased intangible assets $742.7 $(428.5)$314.2 

 December 31, 2022
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.0$104.7 $(89.9)$14.8 
Know how2.8166.2 (153.9)12.3 
Developed product technology12.8211.1 (121.6)89.5 
Licenses5.859.0 (38.5)20.5 
Tradenames6.66.1 (4.5)1.6 
Covenants not to compete3.16.4 (4.0)2.4 
     Total finite-lived intangible assets553.5 (412.4)141.1 
In-process research and development191.0 — 191.0 
     Total purchased intangible assets $744.5 $(412.4)$332.1 

Amortization expense related to purchased intangible assets is as follows (in millions):

Three Months EndedNine Months Ended
 September 30,September 30,
 2023202220232022
Amortization expense$6.2 $6.2 $18.1 $18.8 



4. INVENTORY

Following are the components of Inventory at September 30, 2023 and December 31, 2022 (in millions):

21

September 30, 2023December 31, 2022
Inventory:
  Raw materials$230.4 $228.8 
  Work in process244.5 220.9 
  Finished goods 300.9 269.6 
      Total Inventory$775.8 $719.3 


5. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):
Nine Months Ended
September 30, 2023September 30, 2022
Net loss$(987.0)$(4,455.3)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization108.7 101.8 
Reduction in the carrying amount of right-of-use assets30.7 29.8 
Share-based compensation45.1 42.8 
Losses from change in fair market value of equity securities and loan receivable1,576.5 6,172.3 
Gain on divestiture of a division— (1.4)
Changes in fair value of contingent consideration(18.5)— 
Payments for operating lease liabilities(30.4)(28.1)
(Increase) decrease in accounts receivable31.6 (44.5)
Increase in inventories(61.7)(150.6)
(Increase) decrease in other current assets15.0 (11.9)
Decrease in accounts payable and other current liabilities(72.4)(69.7)
Increase (decrease) in income taxes payable56.4 (39.2)
Decrease in deferred income taxes(397.4)(1,439.1)
Increase (decrease) in other long-term liabilities3.9 (2.0)
Other(6.6)9.9 
Net cash provided by operating activities$293.9 $114.8 
Non-cash investing activities:
Purchased property, plant and equipment$2.9 $3.3 
Purchased marketable securities and investments$— $11.8 


6. LONG-TERM DEBT

22

The principal components of long-term debt are as follows (in millions):
September 30,
2023		December 31,
2022
3.3%, Senior Notes due 2027
$400.0 $400.0 
3.7%, Senior Notes due 2032
800.0 800.0 
Less unamortized discounts and debt issuance costs(11.0)(12.4)
Long-term debt less unamortized discounts and debt issuance costs1,189.0 1,187.6 
Finance leases and other debt10.2 10.6 
Less current maturities(0.5)(0.5)
Long-term debt$1,198.7 $1,197.7 
23


7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions):
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of December 31, 2022:$(466.5)$10.0 $(10.3)$(466.8)
Other comprehensive income (loss), before reclassifications(34.4)0.3 3.7 (30.4)
Amounts reclassified from Accumulated other comprehensive income (loss)— (0.4)1.1 0.7 
Income tax effects0.1 — (1.1)(1.0)
Other comprehensive income (loss), net of income taxes(34.3)(0.1)3.7 (30.7)
Balances as of September 30, 2023:$(500.8)$9.9 $(6.6)$(497.5)
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of December 31, 2021:$(170.5)$(10.9)$5.8 $(175.6)
Other comprehensive income (loss), before reclassifications(654.4)1.4 (23.3)(676.3)
Amounts reclassified from Accumulated other comprehensive income (loss)— 0.2 0.6 0.8 
Income tax effects1.1 (0.5)5.3 5.9 
Other comprehensive income (loss), net of income taxes(653.3)1.1 (17.4)(669.6)
Balances as of September 30, 2022:$(823.8)$(9.8)$(11.6)$(845.2)

All amounts reclassified out of accumulated other comprehensive income (loss) were reclassified into other income, net in the condensed consolidated statements of income (loss). The reclassification adjustments are calculated using the specific identification method.

The impact to income (loss) before income taxes for amounts reclassified out of accumulated other comprehensive
income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in
millions):
24

Three Months EndedNine Months Ended
September 30,September 30,
Components of comprehensive income (loss)2023202220232022
Amortization of foreign other post-employment benefit items$0.2 $(0.1)$0.4 $(0.2)
Net holding gains (losses) on equity securities and available-for-sale investments$(0.1)$(0.2)$(1.1)$(0.6)


8. EARNINGS (LOSS) PER SHARE

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.

We compute net income (loss) per share of Class A Common Stock (Class A) and Class B Common Stock (Class B) using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Earnings (loss) is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the three and nine months ended September 30, 2023 and 2022.

Accordingly, basic earnings (loss) per share is computed by dividing net income (loss) attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands):
Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Basic weighted average shares outstanding29,102 29,733 29,349 29,819 
Effect of potentially dilutive stock options, restricted stock and performance stock awards121 — — — 
Diluted weighted average common shares outstanding29,223 29,733 29,349 29,819 
Anti-dilutive shares154 541 229 541 


25

9. OTHER INCOME, NET

Other income, net includes the following components (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Interest and investment income$(17.3)$(8.0)$(84.1)$(45.7)
Net realized losses on investments0.1 0.2 1.6 0.6 
Current expected credit losses on loans— 5.1 — 5.1 
Gain on divestiture of a division— — — (1.4)
Escrow receipts on prior acquisition(2.5)— (2.5)— 
Other income(0.7)(0.4)(2.4)(1.0)
Other income, net$(20.4)$(3.1)$(87.4)$(42.4)



10. INCOME TAXES

Our effective income tax rate was 22.5% and 21.5% for the three months ended September 30, 2023 and 2022, respectively. Our effective income tax rate was 22.8% and 23.1% for the nine months ended September 30, 2023 and 2022, respectively.

The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of September 30, 2023, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $15.2 million for the period ended September 30, 2023 compared to the year ended December 31, 2022.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

Our gross unrecognized tax benefits were $92.0 million and $85.5 million as of September 30, 2023 and December 31, 2022, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions.

As of September 30, 2023, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $18.8 million. Substantially all such amounts will impact our effective income tax rate if recognized.
26

11. SEGMENT INFORMATION

Information regarding operating profit (loss) for the three months ended September 30, 2023 and 2022 is as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2023$263.5 $368.1 $0.5 
 2022$317.9 $361.9 $1.0 
Operating profit (loss)2023$13.0 $78.0 $(0.1)
 2022$51.4 $43.9 $(0.7)



Information regarding operating profit (loss) for the nine months ended September 30, 2023 and 2022 is as follows (in millions):
Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2023$887.3 $1,100.3 $2.5 
2022$987.5 $1,081.4 $3.1 
Operating profit (loss)2023$76.7 $166.1 $(0.3)
 2022$197.6 $167.8 $(1.5)

Segment results are presented in the same manner as we manage our business internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments.

The following reconciles total segment profit to consolidated loss before income taxes (in millions):

Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Operating profit$90.9 $94.6 $242.5 $363.9 
Interest expense(12.3)(11.6)(37.2)(26.5)
Foreign currency exchange gains (losses), net1.7 (4.4)5.3 (3.1)
Change in fair market value of equity securities and loan receivable36.4 (289.0)(1,576.5)(6,172.3)
Other income, net20.4 3.1 87.4 42.4 
Consolidated income (loss) before income taxes$137.1 $(207.3)$(1,278.5)$(5,795.6)


27

12. LEGAL PROCEEDINGS

We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


13. RESTRUCTURING COSTS

In February 2021, we announced a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacted our operations in EMEA and included the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan was implemented in phases and is substantially complete as of September 30, 2023. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits. From February 2021 to September 30, 2023, total expenses were $70.0 million.

The following table summarizes the activity of our February 2021 plan restructuring reserves (in millions):
Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2022:$1.9 $29.7 $31.6 
Adjustment to expense— 1.4 1.4 
Cash payments(1.6)(16.5)(18.1)
Foreign currency adjustments— (0.1)(0.1)
Balances as of September 30, 2023:$0.3 $14.5 $14.8 

In February 2023, management approved a new restructuring plan to implement identified opportunities to further streamline and improve operating performance. The additional restructuring activities are being implemented in phases and are expected to be substantially complete by the end of 2023. From February 2023 to September 30, 2023, total expenses were $15.4 million, representing estimated termination benefits to employees.

The following table summarizes the activity of our February 2023 plan restructuring reserves (in millions):

Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2022:$— $— $— 
Charged to expense - employee termination benefits3.3 12.1 15.4 
Cash payments(1.4)(3.8)(5.2)
Foreign currency adjustments0.1 0.1 0.2 
Balances as of September 30, 2023:$2.0 $8.4 $10.4 

In June 2023, management approved an additional restructuring plan to implement identified opportunities to further streamline and improve operating performance. The additional restructuring activities are expected to be substantially complete by the end of 2023. From June 2023 to September 30, 2023, total expenses were $9.0 million, representing estimated termination benefits to employees.
28


The following table summarizes the activity of our June 2023 plan restructuring reserves (in millions):

Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2022:$— $— $— 
Charged to expense - employee termination benefits4.3 4.7 9.0 
Cash payments(2.9)(1.8)(4.7)
Foreign currency adjustments— — — 
Balances as of September 30, 2023:$1.4 $2.9 $4.3 

Combined, the liability of $29.5 million as of September 30, 2023 consisted of $29.0 million recorded in Accrued payroll and employee benefits and $0.5 million recorded in Other long-term liabilities in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the three months ended September 30, 2023 were $0.2 million, $1.3 million and $0.0 million, respectively, in the condensed consolidated statements of income (loss). The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the nine months ended September 30, 2023 were $3.9 million, $16.6 million and $5.3 million, respectively, in the condensed consolidated statements of income (loss).


14. LEASES

We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 16 years, which includes our determination to exercise renewal options.

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our condensed consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.

The components of lease expense were as follows (in millions):
29

Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
Operating lease cost$15.7 $14.2 $47.2 $43.2 
Finance lease cost:
  Amortization of right-of-use assets$0.1 $0.1 $0.3 $0.3 
  Interest on lease liabilities0.2 0.2 0.6 0.6 
        Total finance lease cost$0.3 $0.3 $0.9 $0.9 

Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.

Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three and nine months ended September 30, 2023 and 2022. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three and nine months ended September 30, 2023 and 2022.

Supplemental cash flow information related to leases was as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
Cash paid for amounts included in the measurement of lease liabilities:
  Operating cash flows from operating leases$10.6 $9.5 $30.4 $28.1 
  Operating cash flows from finance leases$0.2 $0.2 $0.6 $0.6 
  Financing cash flows from finance leases$0.1 $0.1 $0.3 $0.3 
Right-of-use assets obtained in exchange for new lease obligations:
  Operating leases$36.7 $2.3 $49.0 $9.4 

Supplemental balance sheet information related to leases was as follows (in millions):
September 30, 2023December 31, 2022
Operating Leases
  Operating lease right-of-use assets$200.0 $181.0 
  Current operating lease liabilities$39.1 $36.3 
  Operating lease liabilities167.2 153.6 
     Total operating lease liabilities$206.3 $189.9 

Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions):
30

September 30, 2023December 31, 2022
Finance Leases
  Property, plant and equipment, gross$11.8 $11.9 
  Less: accumulated depreciation and amortization(5.7)(5.5)
      Property, plant and equipment, net$6.1 $6.4 
  Current maturities of long-term debt and notes payable$0.5 $0.5 
  Long-term debt, net of current maturities9.7 10.1 
      Total finance lease liabilities$10.2 $10.6 

September 30, 2023December 31, 2022
Weighted Average Remaining Lease Term
  Operating leases - in years77
  Finance leases - in years1415
Weighted Average Discount Rate
  Operating leases3.8 %3.0 %
  Finance leases6.4 %6.3 %

Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,Operating LeasesFinance Leases
2023 (excluding the nine months ended September 30, 2023)
$10.4 $0.3 
202445.5 1.2 
202542.6 1.1 
202631.2 1.1 
202724.7 1.1 
Thereafter82.7 11.9 
   Total lease payments237.1 16.7 
Less imputed interest(30.8)(6.5)
    Total$206.3 $10.2 

The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over.

As of September 30, 2023, operating leases that have not commenced are not material.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This discussion should be read in conjunction with the information contained in both our consolidated financial statements for the year ended December 31, 2022 and the condensed consolidated financial statements for the three and nine months ended September 30, 2023.

Overview.  We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products. Our business is organized into two reportable segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and health care specialists with products needed for clinical diagnostics.
31


We sell more than 12,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components. As our customers require standardization for their experiments and test results, much of our revenues are recurring in nature.

We rely on the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control government social spending by many governments limits opportunities for growth. Approximately 43% of our year-to-date 2023 consolidated net sales are derived from the United States and approximately 57% are derived from international locations, with Europe being our largest international region. The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens. When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.

We are impacted by global economic conditions and our business was negatively impacted by the recent economic constraints in China and the ongoing challenges impacting the biopharma market and small biotech companies. We expect that these conditions will continue to negatively impact our business through at least the remainder of 2023.

Results of Operations

The following table shows cost of goods sold, gross profit, components of operating expense, losses from change in fair market value of equity securities and loan receivable, and net loss as a percentage of net sales:
Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Net sales100.0 %100.0 %100.0 %100.0 %
Cost of goods sold46.9 45.3 46.7 43.5 
Gross profit53.1 54.7 53.3 56.5 
Selling, general and administrative expense31.8 31.0 31.9 29.7 
Research and development expense6.9 9.8 9.2 9.2 
(Gains) losses from change in fair market value of equity securities and loan receivable(5.8)42.4 79.2 297.9 
Net loss16.8 (23.9)(49.6)(215.0)


Critical Accounting Policies and Estimates

An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably likely to occur could materially impact the financial statements.  Management believes that there have been no significant changes during the three and nine months ended September 30, 2023 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.  

32

There have been no substantial changes in our significant accounting policies during the three and nine months ended September 30, 2023, compared with the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2022.
33


Three Months Ended September 30, 2023 Compared to
Three Months Ended September 30, 2022

Results of Operations -- Sales, Margins and Expenses

Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period monthly average foreign exchange rates for that currency and comparing that to current period sales.

Net sales (sales) for the third quarter of 2023 were $632.1 million compared to $680.8 million in the third quarter of 2022, a decrease of 7.1%.  COVID-related sales were approximately $0.3 million in the third quarter of 2023 compared to approximately $17.2 million in the third quarter of 2022. Excluding the impact of foreign currency, third quarter 2023 sales decreased by approximately 7.9% compared to the same period in 2022. Currency neutral sales decreased in Asia Pacific and EMEA, partially offset by increased sales in the Americas. Excluding COVID-related sales, sales decreased 5.5% on a currency neutral basis from the third quarter of 2022. Sales in the third quarter of 2023 were negatively impacted by the continued demand constraints from biopharma and small biotech customers in the biopharma market impacting sales of our Life Science segment and the deteriorating economic environment in China, impacting both our Life Science and Clinical Diagnostic segments.

The Life Science segment sales for the third quarter of 2023 were $263.5 million, a decrease of 17.1% compared to the same period last year.  On a currency neutral basis, sales decreased 17.8% compared to the third quarter in 2022. Currency neutral sales decreased in all regions. COVID-related sales were $0.3 million in the third quarter of 2023 compared to approximately $15.9 million in the third quarter of 2022. Excluding COVID-related sales, sales decreased 13.7% on a currency neutral basis driven by decreased sales of qPCR, process chromatography and western blotting products, as a result of the demand constraints from biopharma and small biotech customers.

The Clinical Diagnostics segment sales for the third quarter of 2023 were $368.1 million, an increase of 1.7% compared to the same period last year.  On a currency neutral basis, sales increased 1.0% compared to the third quarter in 2022.  Currency neutral sales increased in the Americas and EMEA, partially offset by a decline in the Asia Pacific region. There were no COVID-related sales in the third quarter of 2023 compared to approximately $1.3 million in the third quarter of 2022. Excluding COVID-related sales, sales increased 1.4% on a currency neutral basis. The currency neutral sales increase was primarily driven by an increased demand for our diagnostic testing systems, primarily for blood typing, diabetes and quality controls products.

Consolidated gross margins were 53.1% for the third quarter of 2023 compared to 54.7% for the third quarter of 2022.  Gross margins for the Life Science segment for the third quarter of 2023 decreased by approximately 4.2 percentage points from the same period last year. The decrease in gross margin was primarily driven by product mix, higher material costs, as well as inventory reserves, partially offset by lower logistics costs. Gross margins for the Clinical Diagnostics segment for the third quarter of 2023 increased by approximately 0.7 percentage points from the same period last year. The increase in gross margin was primarily driven by lower logistics costs, partially offset by higher material costs and product mix.

Selling, general and administrative (SG&A) expenses for the third quarter of 2023 were $201.2 million or 31.8% of sales, compared to $211.1 million, or 31.0% of sales for the third quarter of 2022. SG&A expenses in the third quarter of 2023 compared to the prior year period reflected lower employee-related expenses.

Research and development (R&D) expenses for the third quarter of 2023 were $43.5 million or 6.9% of sales, compared to $66.8 million or 9.8% of sales in the third quarter of 2022. The decrease in R&D expenses in the third quarter of 2023 compared to the prior year period was primarily due to a change in the fair value of contingent consideration and lower employee-related expenses.

Results of Operations – Non-operating

34

Interest expense for the third quarter of 2023 and 2022 was $12.4 million and $11.7 million, respectively, an increase of $0.7 million compared to the prior year period. Interest expense results primarily from our $1.2 billion Senior Notes.

Foreign currency exchange (gains) and losses consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk.  Foreign currency exchange gains, net were $1.7 million for the third quarter of 2023 compared to foreign currency exchange losses, net of $4.4 million for the third quarter of 2022. Gains and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany debt payments, market volatility, and the change in the fair value of our foreign exchange contracts.

(Gains) losses from change in fair market value of equity securities and loan receivable was a gain of $36.4 million and a loss of $289.0 million for the third quarter of 2023 and 2022, respectively. The change in the fair market value primarily resulted from the recognition of holding gains of $42.5 million in the third quarter of 2023 compared to holding losses of $267.8 million in the third quarter of 2022 on our position in Sartorius AG. In addition, lower losses from the change in fair value of our loan receivable of $4.9 million in the third quarter of 2023 compared to losses of $19.4 million in the third quarter of 2022 contributed to the change.

Other income, net for the third quarter of 2023 was $20.4 million compared to $3.1 million for the third quarter of 2022. Other income, net increased by $17.4 million primarily due to an increase in interest and investment income on our investments as a result of cash invested from the $1.2 billion Senior Notes issued in March 2022. The increase to other income, net also resulted from no credit loss in 2023 compared to a $5 million credit loss on an investment in 2022.

Our effective income tax rate was 22.5% and 21.5% for the third quarter of 2023 and 2022, respectively. The effective tax rate reported in the third quarter of 2023 was primarily affected by an unrealized gain in equity securities and the effective tax rate reported in the third quarter of 2022 was primarily affected by an unrealized loss in equity securities. The difference in the rate is primarily driven by geographical mix of earnings.


Nine Months Ended September 30, 2023 Compared to
Nine Months Ended September 30, 2022

Results of Operations -- Sales, Margins and Expenses

Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period monthly average foreign exchange rates for that currency and comparing that to current period sales.

Net sales (sales) for the first nine months of 2023 were $1.99 billion compared to $2.07 billion in the first nine months of 2022, a decrease of 4.0%.  COVID-related sales were approximately $3.4 million in the first nine months of 2023 compared to approximately $95.7 million reported in the first nine months of 2022. On a currency neutral basis, the first nine months of 2023 sales decreased by approximately 2.8% compared to the same period in 2022. Currency neutral sales decreased in both APAC and EMEA, partially offset by increased sales in the Americas. Excluding COVID-related sales, sales increased 1.6% on a currency neutral basis from the first nine months of 2022.

The Life Science segment sales for the first nine months of 2023 were $887.3 million, a decrease of 10.1% compared to the same period last year.  On a currency neutral basis, sales decreased 9.0% compared to the first nine months of 2022. The currency neutral sales decrease was mainly in EMEA and Asia Pacific, while the Americas saw currency neutral sales growth. COVID-related sales were $2.9 million in the first nine months of 2023 compared to approximately $92.3 million in the first nine months of 2022. Excluding COVID-related sales, sales decreased 0.1% on a currency neutral basis driven by lower process chromatography sales, offset by increases in ddPCR sales.
35


The Clinical Diagnostics segment sales for the first nine months of 2023 were $1.10 billion, an increase of 1.7% compared to the same period last year.  On a currency neutral basis, sales increased 2.8% compared to the first nine months of 2022. COVID-related sales were $0.5 million in the first nine months of 2023 compared to approximately $3.4 million in the first nine months of 2022. Excluding COVID-related sales, sales increased 3.1% on a currency neutral basis. The currency neutral sales increase was primarily driven by growth in diabetes, blood typing, and quality controls products, especially in Asia Pacific and EMEA, despite supply chain constraints having an impact on instrument deliveries.
Consolidated gross margins were 53.3% for the first nine months of 2023 compared to 56.5% for the first nine months of 2022. Gross margins for the Life Science segment and the Clinical Diagnostics segment for the first nine months of 2023 decreased by approximately 4.9 percentage points and 1.4 percentage points respectively from the same period last year. The decrease in gross margins was primarily driven by product mix, increased manufacturing costs and inventory reserves. 

Selling, general and administrative (SG&A) expenses increased to $634.6 million or 31.9% of sales for the first nine months of 2023 compared to $615.6 million or 29.7% of sales for the first nine months of 2022.  The increase to SG&A expenses was primarily driven by restructuring costs as well as higher marketing and travel expenses.

Research and development (R&D) expenses decreased to $183.5 million or 9.2% of sales in the first nine months of 2023 compared to $190.7 million or 9.2% of sales in the first nine months of 2022. The decrease in R&D expenses in the first nine months of 2023 compared to the prior year period was primarily due to a change in the fair value of contingent consideration, partially offset by higher restructuring costs and continued investment in research and product development products.

Results of Operations – Non-operating

Interest expense for the first nine months of 2023 and 2022 was $37.1 million and $26.4 million, respectively, an increase of $10.6 million compared to the prior year period. The increase was primarily due to the sale in March 2022 of the $1.2 billion Senior Notes.

Foreign currency exchange (gains) and losses consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk.  Foreign currency exchange gains, net were $5.3 million for the first nine months of 2023 compared to foreign currency exchange losses, net of $3.1 million for the first nine months of 2022. Gains and losses are primarily due to the estimating process inherent in the timing of product shipments and intercompany debt payments, market volatility, and the change in the fair value of our foreign exchange contracts.

(Gains) losses from change in fair market value of equity securities and loan receivable was a loss of $1.58 billion and $6.17 billion for the first nine months of 2023 and 2022, respectively. The change in the fair market value primarily resulted from the recognition of lower holding losses of $1.56 billion in the first nine months of 2023 compared to holding losses of $6.0 billion in the first nine months of 2022 on our position in Sartorius AG. In addition, lower losses from the change in fair value of our loan receivable of $28.9 million in first nine months of 2023 compared to holding losses of $149.0 million in the first nine months of 2022 contributed to the change.

Other income, net for the first nine months of 2023 was $87.4 million compared to $42.4 million for the first nine months of 2022. Other income, net increased by $45.0 million primarily due to an increase in our interest and investment income attributable to an increase in our investments as a result of cash invested from the $1.2 billion Senior Notes issued in March 2022. The increase to other income, net also resulted from a $3 million higher dividend from Sartorius AG in 2023 compared to 2022 and no credit loss in 2023 compared to a $5 million credit loss on an investment in 2022.

36

Our effective income tax rate was 22.8% and 23.1% for the first nine months of 2023 and 2022, respectively. The effective tax rate reported in the first nine months of both 2023 and 2022 was primarily affected by an unrealized loss in equity securities. The difference in the rate is primarily driven by geographical mix of earnings.

Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade.  Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world.  Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price.  Gross margins are generally sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows for capital expenditures, interest and taxes.  In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our $200.0 million unsecured revolving credit facility (Credit Agreement, as amended) that we entered into in April 2019, and to a lesser extent international lines of credit.  Borrowings under the Credit Agreement, as amended, are available on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the 2019 Credit Agreement, as amended, as of September 30, 2023, however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability. As of September 30, 2023, our short-term investments include the net cash proceeds from the sale of Senior Notes of $1.186 billion. Interest is payable semiannually in arrears on May 15 and September 15 of each year. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and acquisitions of reasonable proportion to our existing total available capital.

At September 30, 2023, we had available $1.76 billion in cash, cash equivalents and short-term investments, of which approximately 13% was held in our foreign subsidiaries. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as acquisitions and borrowings. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows).

It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. 


Cash Flows from Operations

Net cash provided by operations was $293.9 million compared to cash provided by operations of $114.8 million for the nine months ended September 30, 2023 and 2022, respectively.  The increase in operating cash flows was primarily due to lower income tax paid, lower cash paid to suppliers and employees, higher dividends proceeds and miscellaneous receipts and higher cash received from customers, partially offset by lower proceeds from foreign exchange contracts and higher interest paid.

Cash Flows from Investing Activities

Net cash used in investing activities was $52.0 million and $1,149.0 million for the nine months ended September 30, 2023 and 2022, respectively. The decrease in cash used in investing activities was primarily due to the timing of our purchases, maturities and sales of marketable securities and investments as a result of the cash proceeds from the sale of Senior Notes issued in March 2022 and net cash flows for the acquisition of Curiosity Diagnostics in 2022, partially offset by higher capital expenditures.

Cash Flows from Financing Activities

37

Net cash used in financing activities was $225.0 million compared to cash provided by financing activities of $1,060.2 million for the nine months ended September 30, 2023, and 2022, respectively. This decrease in financing activities was primarily attributable to the sale in March 2022 of the Senior Notes which yielded net cash proceeds of $1,186.2 million and higher payments for purchases of treasury stock.

Treasury Shares

During the third quarter of 2023, 113,908 shares of Class A treasury stock with an aggregate total cost of $45.8 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $45.3 million from share reissuance activity during the quarter.

During the third quarter of 2023, we repurchased 58,478 shares of Class A common stock for $21.3 million under our Share Repurchase Program. We designated these repurchased shares as treasury stock. As of September 30, 2023, $478.7 million remained available for repurchases under the Share Repurchase Program.

In July 2023, the board of directors authorized a new share repurchase program granting the Company authority to repurchase, on a discretionary basis, up to $500 million of the outstanding shares of the Company’s common stock.

During the second quarter of 2023, 17,428 shares of Class A treasury stock with an aggregate total cost of $6.9 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $2.1 million from share reissuance activity during the quarter.

During the second quarter of 2023, we repurchased 549,863 shares of Class A common stock for $207.4 million under our Share Repurchase Program. We designated these repurchased shares as treasury stock. As of June 30, 2023, the Company had repurchased a total of $650.0 million under the Share Repurchase Program, which completed the level of authorized purchases under that Share Repurchase Program.

During the first quarter of 2023, 12,853 shares of Class A treasury stock with an aggregate total cost of $5.3 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $0.7 million from share reissuance activity during the quarter.

During the third quarter of 2022, 111,144 shares of Class A treasury stock with an aggregate total cost of $48.1 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $49.5 million from share reissuance activity during the quarter.

During the second quarter of 2022, 11,609 shares of Class A treasury stock with an aggregate total cost of $4.95 million were reissued to fulfill grants to employees under our restricted stock program and our Employee Stock Purchase Program. Upon reissuing the Class A treasury stock, Additional paid-in-capital was reduced by $0.7 million from share reissuance activity during the quarter.

During the second quarter of 2022, we repurchased 255,284 shares of Class A common stock for $125.0 million under our Share Repurchase Program. We designated these repurchased shares as treasury stock. In July 2022, the Board of Directors authorized increasing the amount available under the Share Repurchase Program to allow the Company to repurchase up to an additional $200.0 million of stock.

Recent Accounting Pronouncements Adopted

See Note 1 to the condensed consolidated financial statements for recent accounting pronouncements adopted.


Item 3. Quantitative and Qualitative Disclosures about Market Risk

38

During the nine months ended September 30, 2023, there have been no material changes from the disclosures about market risk provided in our Annual Report on Form 10-K for the year ended December 31, 2022.


Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the CEO and CFO have concluded that, as of such date, our disclosure controls and procedures were effective to meet the objective for which they were designed and operate at the reasonable assurance level.

Changes to Internal Control Over Financial Reporting

We identified no changes in internal control over financial reporting that occurred during our quarter ended September 30, 2023 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.
39



PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are a party to various claims, legal actions and complaints arising in the ordinary course of business. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


Item 1A. Risk Factors

In evaluating our business and whether to invest in any of our securities, you should carefully read the following risk factors in addition to the other information contained in this report. We believe that any of the following risks could have a material effect on our business, results of operations or financial condition, our industry or the trading price of our common stock. We operate in a continually changing business environment, and new risks and uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor can we assess the extent to which any such new risks and uncertainties or the extent to which the risks and uncertainties set forth below may adversely affect our business, results of operations, financial condition, our industry, the value of our equity holdings, or the trading price of our common stock. Please carefully consider the following discussion of significant factors, events and uncertainties that make an investment in our securities risky and provide important information for the understanding of the “forward-looking” statements discussed this report. In addition to the effects of the COVID-19 pandemic and resulting global disruptions on our business and operations discussed in this report, additional or unforeseen effects from the COVID-19 pandemic and the global economic climate may give rise to or amplify many of these risks discussed below.

Business, Economic, Legal and Industry Risks

Pandemics or disease outbreaks, such as the COVID-19 pandemic, have affected and could materially adversely affect our business, operations, financial condition and results of operations.

The COVID-19 pandemic has had, and if conditions deteriorate again could again have, an adverse effect on the United States and global economies, as well as on aspects of our business, operations and financial condition and those of third parties on whom we rely.

During the height of the COVID-19 pandemic, we experienced increased demand for certain of our products used in fighting the COVID-19 pandemic and some decreases in product demand in certain of our other businesses. If conditions related to the pandemic were to deteriorate, we expect that parts of our business could again suffer negative impacts from the pandemic.

On the supply side, we are experiencing continued but moderating challenges with the supply of raw materials and components used in the production of our products. Challenges in ramping up new production facilities are contributing to a backlog of sales orders, some of which we consider to be significant, and some delays in certain new product development activities. Some of the backlog of sales orders has continued into 2023 but has been moderating as the year has proceeded. We have experienced raw material cost increases as a result of the COVID-19 pandemic, which will likely continue. In addition, while logistics capacity constraints are improving, we continue to experience freight surcharges and expect these to continue at least for the near term. Some countries continue to impose measures that may restrict the movement of our goods.

Although the severity of the COVID-19 pandemic has been waning, it is difficult to predict the full extent of potential impacts the pandemic could have in the future on our business, operations and financial results, or on our customers, suppliers, logistics providers, or on the global economy.
40


A reduction or interruption in the supply of components and raw materials has adversely affected and could continue to adversely affect our manufacturing operations and related product sales.

The manufacture of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply, but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. The COVID-19 pandemic created delays and shortages in the supply of components and raw materials. These shortages, along with challenges in ramping up new production facilities, have caused a backlog of sales orders, some of which we consider to be significant, and some delays in certain new product development activities. Some of the backlog of sales orders has continued into 2023 but has been moderating as the year has proceeded. We have experienced raw material cost increases as a result of the COVID-19 pandemic, which will likely continue. In addition, due to the regulatory environment in which we operate, we may need to cease use of certain essential components and materials and be unable to quickly establish acceptable replacement sources for such components or materials. When our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner is adversely affected, which adversely affects our ability to sell our products. See also our risk factor regarding the COVID-19 pandemic above.

Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.

We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and during the nine months ended September 30, 2023 our foreign entities generated 57% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements, labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, tariffs, duties, quotas and other trade barriers, export requirements, U.S. laws such as the Foreign Corrupt Practices Act ("FCPA") and other U.S. federal laws and regulations established by the office of Foreign Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. In addition, changes in laws or regulations potentially could be disruptive to our operations and business relationships in the affected regions.

Given the high level of complexity of the foreign and U.S. laws and regulations that apply to our international operations, we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. In addition, we operate in some countries in which the business environment is subject to a higher risk of corruption. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with laws and regulations, and our global policies and procedures.

Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. See also our risk factors regarding the COVID-19 pandemic above and regarding government regulations and global economic conditions below.

The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively.

41

The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have greater financial resources than we do, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts, or to source high-demand materials and components. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition.

We may not be able to grow our business because of our failure to develop new or improved products.

Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new product lines and extensions that integrate technological advances. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new product lines and extensions successfully and in a timely manner, our business, results of operations and financial condition will be adversely affected. The COVID-19 pandemic and supply chain disruptions have caused some delays to our ability to develop and introduce new products. We have experienced product launch delays in the past and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition.

Breaches of our information systems could have a material adverse effect on our business and results of operations.

We have experienced and expect to continue to experience attempts by computer programmers and hackers to attack and penetrate our layered security controls, like the December 2019 Cyberattack that was previously discussed in Item 7 of our Annual Report for the period ended December 31, 2019. Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our web site. We also acquire and retain information about suppliers and employees in the normal course of business. Such information on our systems includes personally identifiable information and, in limited instances, protected health information. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. The Company is also subject to phishing and other fraud schemes including fraudulent vendor communications with requests for payments and fraudulent attempts to redirect payments to improper bank accounts, some of which have been successful. While the Company has adopted training and process changes to limit the success of such fraudulent activity, the Company will be unable to stop all such fraudulent activity which may lead to unrecoverable payments to criminal accounts. Increased use of remote work arrangements in response to the COVID-19 pandemic exposes us to additional risk of cyberattack and disruption. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and often are not recognized until launched against a target, we may not be able to anticipate all of these techniques or to implement adequate preventive measures. Computer hackers have attempted to penetrate and will likely continue to attempt to penetrate our and our vendors’ information systems and, if successful, could misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers and suppliers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted, as they were in the December 2019 Cyberattack. Any significant
42

breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our information technology systems and our enterprise resource planning system (ERP) implementation below.

If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed.

Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT systems (which increasingly include cloud-based systems provided by third party vendors) could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory and collect accounts receivable. Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service. We may experience disruption of our IT systems due to redundancy issues with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency.

Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes. We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business. We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems or migrate to cloud-based systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our data security above and ERP implementation and events beyond our control below.

We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition.

As stated above, a significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. In addition, we hold investments and a loan receivable that are subject to foreign exchange fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition.

Changes in the market value of our position in Sartorius AG materially impact our financial results.
Changes in the market value of our position in Sartorius AG will continue to materially impact our consolidated statements of income and other financial statements. A decline in the market value of our position in Sartorius AG will result in losses due to write-downs in the value of the equity securities. An increase in the market value of our position in Sartorius AG will result in a favorable impact to net income independent of the actual operating performance of our business. Depending on the extent of the decline or of the increase in the market value of our position in Sartorius AG, these negative or positive impacts on us could be significant and material.

Our share price may change significantly based upon changes in the market value of our position in Sartorius AG, and such change is independent of the actual performance of our business. Additionally, non-operating income for a period may be significantly impacted by any distribution of dividends by Sartorius AG, particularly when the dividends amount varies in comparison to prior year periods.

The value of our position in Sartorius AG might cause us to be deemed an investment company under the Investment Company Act of 1940.
43


As a result of the market value of our position in Sartorius AG, we might be deemed to be an “investment company” under Section 3(a)(1)(C) of the Investment Company Act of 1940, as amended (the “Investment Company Act”) The Company does not believe it is an investment company primarily in reliance on Section 3(b)(1) of the Investment Company Act because we are “primarily engaged” in a business other than that of investing, reinvesting, owning, holding or trading in securities. Rather, we are primarily engaged in the development, manufacturing and marketing of products for the life science research and clinical diagnostic markets, and we believe that our historical development, our public representations of policy, the activity of our officers and directors, the nature of our present assets, the sources of our present income, and the public perception of the nature of our business all support the conclusion that we are an operating company and not an investment company. Although we have discussed this issue with the staff of the SEC and we are comfortable with our position, if it is determined later that the Company may not rely on Section 3(b)(1) or any other exemption under the Investment Company Act and the Company were deemed to be an unregistered investment company, such determination would have a material adverse effect on our business as we would need to register as an investment company and be subject to the regulations of the Investment Company Act which are designed to restrict and regulate mutual funds rather than operating companies. It could also call into question the validity of all contracts to which the Company is a party. If it appeared likely that we would be deemed to be an investment company, we may modify our position in Sartorius AG in order to avoid such determination.

We may incur losses in future periods due to write-downs in the value of financial instruments.
We have positions in a variety of financial instruments including asset backed securities and other similar instruments. Financial markets are volatile and the markets for these securities can be illiquid. The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions, low trading volume of the securities, or other market considerations.

As discussed further in the Notes to Condensed Consolidated Financial Statements, in Note 2. Fair Value Measurements, under the heading “Level 3 Fair Value Investments”, we made a loan of 400 million Euros to Sartorius-Herbst Beteiligungen II GmbH in November 2021 that is secured by the pledge of certain trust interests which upon termination of the trust represent the right to receive Sartorius ordinary shares (the "Loan"). Prior to a termination of the trust, the trust interests, which are provided as collateral for the Loan, are not tradable on the capital markets and may, in case of an enforcement, have to be sold with a significant discount to the value of the underlying shares.

We also have positions in equity securities, including our position in Sartorius AG. Financial markets are volatile and the markets for these equity securities can be illiquid as well. A decline in the market value of our investments in equity securities could result in significant losses due to write-downs in the value of the equity securities. Also, if we need to convert these positions to cash, we may not be able to sell these equity securities without significant losses. In addition, a significant decline in the value of the Sartorius ordinary shares would reduce the value of the collateral for the Loan discussed in the previous paragraph, and in such circumstances the value of the collateral may be insufficient to cover the repayment of the Loan, and Sartorius-Herbst Beteiligungen II GmbH will likely have no other assets from which to repay the Loan. Furthermore, the change in the market value of Sartorius ordinary shares will have an impact on the value appreciation rights acquired in connection with the Loan discussed in the previous paragraph.

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties, as we already have with some of our earlier deployments. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. We expect to
44

implement the remaining smaller phases of the ERP platform over the next few years. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may continue to disrupt our operations and negatively impact our business, results of operations and financial condition.

Recent and planned changes to our organizational structure could negatively impact our business.

We made significant changes to our organizational structure over the past few years, including the reorganization of aspects of our European operations that was announced in February 2021. These changes may have unintended consequences, such as distraction of our management and employees, labor unrest, business disruption, disruption of supply, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.

Risks relating to intellectual property rights may negatively impact our business.

We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products. However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us. For instance, unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages or royalties to an infringed party. Any of the foregoing matters could adversely impact our business, results of operations and financial condition.

Global economic and geopolitical conditions could adversely affect our operations.

In recent years, we have been faced with very challenging global economic conditions. The COVID-19 pandemic, as discussed above, has caused disruptions to global economic conditions. Russia’s invasion of Ukraine and sanctions against Russia also are causing disruptions to global economic conditions and are negatively impacting our business in Russia. The escalation in October 2023 of the conflict between Israel and Hamas also could cause disruptions to global economic conditions and effect the stability of the Middle East region and our business in that region. It is unknown how long any of these disruptions will continue and whether such disruptions will become more severe. In addition, we expect moderating economic growth and changing government policies in China will continue to affect our commercial opportunities in the country. The bank failures in March 2023 and the resulting volatility in the banking sector could cause disruptions to global economic conditions and may impact access to cash and other financial resources by our customers and suppliers. A deterioration in the global economic environment may result in a decrease in demand for our products, increased competition, downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions is also adversely affecting our suppliers, which could continue to result in interruptions in the supply of the components and raw materials necessary for our products and raw material cost increases. Additionally, the United States and other countries, such as China and India, recently have imposed tariffs on certain goods. While tariffs imposed by other countries on U.S. goods have not yet had a significant impact on our business, further escalation of tariffs or other trade barriers could adversely impact our profitability and/or our competitiveness. See also our risk factors regarding the COVID-19 pandemic and our international operations above and regarding government regulations below.

Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition.

45

Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies. The capital spending programs of these institutions and companies have a significant effect on the demand for our products. Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods. If funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected.

Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.

There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include:

•The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices. Consolidation among healthcare providers and consolidation among other participants in the healthcare industry has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage. In particular, there has been a consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and competitive forces place constraints on the levels of overall pricing and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets.

•Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Laboratories and clinicians may decide not to order or perform certain clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates.

To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected. If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.

We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.

Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts. The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety
46

of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.

The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed. In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Any delay in, or failure to receive or maintain, clearance or approval for our products or changes in regulation could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.

Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. For example, the EU in-vitro Diagnostics Regulation (the “EU IVDR”) includes broad changes regarding in vitro diagnostic devices and medical devices. The implementation date for the EU IVDR was May 2022, though the EU Council and Parliament signed an amendment that delays certain previously mandated deadlines to allow more time for Notified Body to manage the entire portfolio of IVD products on the European market. The EU IVDR requires us to modify or re-register some products and will result in additional costs. Failure to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations to the EU requirements. In addition, Russia has enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. The United Kingdom's withdrawal from the European Union is resulting in additional regulatory requirements associated with goods manufactured and sold in the United Kingdom and additional complexities and delays with respect to goods, raw materials and personnel moving between the United Kingdom and the European Union. In addition, new government administrations may interpret existing regulations or practices differently. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, as well as the potential for reduced sales and/or fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Certain tenders in China and India also are including local manufacturing preferences or requirements. Such regulations could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our international operations and regarding global economic and geopolitical conditions above.

We are also subject to government regulation of the use and handling of a number of materials and controlled substances. The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.

We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.

As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. The benefits of any acquisition or investment may prove to be less than anticipated and may not outweigh the costs reported in our financial statements. Completing any potential future acquisitions could cause significant diversion of our management’s time and resources. If we acquire or invest in new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. Goodwill and non-amortizable intangible assets are subject to impairment testing, and potential periodic goodwill impairment charges, amortization expenses related to certain intangible assets, and other write-offs could harm our operating results. Impairment tests are highly sensitive to
47

changes in assumptions and minor changes to assumptions could result in impairment losses. If the results forecast in our impairment tests are not achieved, or business trends vary from the assumptions used in forecasts, or external factors change detrimentally, future impairment losses may occur, as they have occurred in the past. Increased antitrust enforcement and greater government scrutiny of mergers in the healthcare sector may impact our ability to consummate acquisitions. We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions or investments, and any such acquisitions or investments could adversely affect our business, results of operations and financial condition.

Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.

We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. In responding to shortages, we may source components from alternative suppliers and distributors. Quality issues associated with components from these alternative sources may lead to product failures and associated costs notwithstanding our efforts to detect and remediate such quality issues. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.

Lack of key personnel could hurt our business.

Our products are very technical in nature, and we operate in a complex and competitive business environment. In general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills. In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job market in Northern California, where many of our employees are located, is very competitive. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business.

We may have higher than anticipated tax liabilities.

We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate. The determination of our worldwide provision for income taxes and other tax liabilities requires estimation, judgment and calculations where the ultimate tax determination may not be certain. Our determination of our tax liabilities is subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact on our operating results and financial condition.

Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.

48

Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.

On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”) which made a number of substantial changes to how the United States imposes income tax on multinational corporations. The U.S Treasury, Internal Revenue Service and other standard setting bodies continue to issue guidance and interpretation relating to the Tax Act. As future guidance is issued, we may make adjustments to amounts previously reported that could materially impact our financial statements.

On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which includes an Alternative Minimum Tax based on the Adjusted Financial Statement Income of Applicable Corporations. Based on our initial evaluation, we do not believe the Inflation Reduction Act will have a material impact on our income tax provision and cash taxes. However, future U.S. Department of the Treasury guidance and regulations could result in changes in this initial conclusion.

The Biden Administration released its 2024 budget recommendations to Congress on March 9, 2023. The administration's budget includes significant corporate tax increases over a 10-year period. If enacted, the provision could have a significant impact on Bio-Rad's income tax provision. We will continue to monitor the proposed legislation and report the impact if the legislation is enacted.

The tax effect of our position in Sartorius AG and the jurisdictional mix of our earnings could continue to materially affect our financial results and cash flow. In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development’s project on “Base Erosion and Profit Shifting” (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.

Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, materials that we use in our products, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes. In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate. The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.

We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant. We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal. We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.

Our current and future debt and related covenants may restrict our future operations.

We have substantial debt and have the ability to incur additional debt. As of September 30, 2023, we had approximately $1,198.7 million of outstanding long-term indebtedness, primarily consisting of the 3.300% Senior Notes due in March 2027 and the 3.700% Senior Notes due in March 2032 as further discussed in Note 6 of the condensed consolidated financial statements. In addition, we have a revolving credit facility that provides for up to
49

$200.0 million in borrowing capacity, $0.2 million of which has been utilized for domestic standby letters of credit. Our incurrence of substantial amounts of debt may have important consequences. For instance, it could:
•make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;
•require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;
•increase our vulnerability to general adverse economic and industry conditions;
•limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;
•place us at a competitive disadvantage compared with some of our competitors that have less debt; and
•limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.

Our existing credit facility, our Senior Notes and agreements we may enter in the future, contain or may contain covenants imposing restrictions on our business. These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise. Existing covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test. Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions. The breach of any of these restrictions could result in a default. An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest. In addition, acceleration of our other indebtedness may cause us to be unable to make interest payments on our outstanding notes and repay the principal amount of our outstanding notes.

We are subject to healthcare laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.

We are subject to healthcare regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example:

•the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs;

•U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;

•the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;

•the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and

50

•state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.

Risks Related to Being a Public Company

Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.

Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements. Material weaknesses in our internal control over financial reporting have adversely affected us in the past and could affect us in the future and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence and could cause the trading price of our common stock to decline.

General Business Risks

Natural disasters, climate related events, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.

We have significant manufacturing and distribution facilities, including in the western United States, France, Switzerland, Germany and Singapore. In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years, some of which may be associated with climate change. These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, lack of fuel resources due to geo-political instability (such as Russia’s reduction in energy resources supplied to Western Europe), electricity outages, the inability to operate our production and distribution facilities due to power grid failures or lack of fuel, and strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business. Acts of terrorism, bioterrorism, violence or war (such as Russia's invasion of Ukraine), weather-related events, or public health issues such as the outbreak of a contagious disease like COVID-19 could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business, results of operations and financial condition.

Risks Related to Our Common Stock
A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.

51

We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class. When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors. As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company. The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.

The forum selection provision in our bylaws could increase costs to bring a claim, discourage claims or limit the ability of the Company’s stockholders to bring a claim in a judicial forum viewed by the stockholders as more favorable for disputes with the Company or the Company’s directors, officers or other employees.

Our bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders, (iii) any action arising pursuant to any provision of the General Corporation Law of the State of Delaware, the Certificate of Incorporation or the Bylaws (in each case, as may be amended from time to time) or (iv) any action asserting a claim against the Company or any of its directors, officers or other employees governed by the internal affairs doctrine of the State of Delaware. This choice of forum provision may increase costs to bring a claim, discourage claims or limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or the Company’s directors, officers or other employees, which may discourage such lawsuits against the Company or the Company’s directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in the Company’s bylaws to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions.

Application of the choice of forum provision may be limited in some instances by applicable law. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the choice of forum provision will not apply to actions arising under the Exchange Act or the rules and regulations thereunder. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, subject to a limited exception for certain “covered class actions.” There is uncertainty, particularly in light of current litigation, as to whether a court would enforce the choice of forum provision with respect to claims under the Securities Act. Our stockholders will not be deemed, by operation of the Company’s choice of forum provision, to have waived claims arising under the federal securities laws and the rules and regulations thereunder.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

As of September 30, 2023, $478.7 million of stock remained available for repurchases under the Company's current Share Repurchase Program, which was authorized by the Board of Directors in July 2023. Repurchases under the Share Repurchase Program may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The authorization has no expiration.

The following table contains information on the shares of our common stock that we purchased or otherwise acquired during the three months ended September 30, 2023.

52

PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsMaximum Number (or Approximate Dollar Value) of Shares that May yet be Purchased Under the Plans or Programs (in millions)
July 1 to July 31, 2023—$— —$500.0 
August 1 to August 31, 2023—$— —$500.0 
September 1 to September 30, 202358,478$364.61 58,478$478.7 
Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

During the three months ended September 30, 2023, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
53


Item 6. Exhibits

(a)  Exhibits

The following documents are filed as part of this report:

Exhibit
No.		 
31.1
  
31.2
  
32.1
  
32.2
  
101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Labels Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104.1The cover page Interactive Data File is formatted in Inline XBRL and is contained in Exhibits 101

54


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.
BIO-RAD LABORATORIES, INC.
(Registrant)
    
Date:October 27, 2023 /s/ Norman Schwartz
   Norman Schwartz, Chairman of the Board,
   President and Chief Executive Officer
    
Date:October 27, 2023 /s/ Ilan Daskal
   Ilan Daskal, Executive Vice President,
   Chief Financial Officer
55
 EX-31.1 2 ex31193023.htm EX-31.1 Document

Exhibit 31.1

Certification of Chief Executive Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:October 27, 2023 /s/ Norman Schwartz
   Norman Schwartz, Chairman of the Board,
   President and Chief Executive Officer


 EX-31.2 3 ex31293023.htm EX-31.2 Document

Exhibit 31.2

Certification of Chief Financial Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Ilan Daskal, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Bio-Rad Laboratories, Inc.

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:October 27, 2023 /s/ Ilan Daskal
   Ilan Daskal
   Executive Vice President,
   Chief Financial Officer

 EX-32.1 4 ex32193023.htm EX-32.1 Document

Exhibit 32.1




Certification of Periodic Report


I, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:October 27, 2023 /s/ Norman Schwartz
   Norman Schwartz, Chairman of the Board, President and
   Chief Executive Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 EX-32.2 5 ex32293023.htm EX-32.2 Document

Exhibit 32.2




Certification of Periodic Report


I, Ilan Daskal, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)the Quarterly Report on Form 10-Q of the Company for the quarter ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:October 27, 2023 /s/ Ilan Daskal
   Ilan Daskal
   Executive Vice President,
   Chief Financial Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.


 EX-101.SCH 6 bio-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets Parenthetical link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation and Use of Estimates link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Goodwill and Other Purchased Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Other Income, Net link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Restructuring Costs link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Use of Estimates (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Goodwill and Other Purchased Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Other Income, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - 1. Basis of Presentation and Use of Estimates Capitalized Cloud Computing Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - 1. Basis of Presentation and Use of Estimates (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Fair Value Measurements - Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Earnings (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Other Income, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bio-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 bio-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 bio-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Accounts Receivable, Allowance for Credit Loss, Recovery Accounts Receivable, Allowance for Credit Loss, Recovery Pay vs Performance Disclosure [Line Items] Proceeds from Sale of Debt Securities, Available-for-sale Proceeds from Sale of Debt Securities, Available-for-Sale Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] European and American Reorganization European and American Reorganization [Member] European and American Reorganization Research and Development Expense Research and Development Expense Underlying Security Market Price Change Underlying Security Market Price Change, Percent All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Accounts Receivable and Allowance for Credit Losses Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Debt Securities, Trading, and Equity Securities, FV-NI Debt Securities, Trading, and Equity Securities, FV-NI Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Deferred income taxes Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Increase in other long term liabilities Increase (Decrease) in Other Noncurrent Liabilities Corporate Debt Securities [Member] Corporate Debt Securities [Member] Payments for purchases of marketable securities and investments Payments to Acquire Investments Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restructuring Reserve, Foreign Currency Translation (Gain) Loss Restructuring Reserve, Foreign Currency Translation Gain (Loss) Deferred Revenue, Current Deferred Revenue, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Actual warranty costs Standard and Extended Product Warranty Accrual, Decrease for Payments Provision for warranty Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Property, plant, and equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Accumulated impairment loss Goodwill, Impaired, Accumulated Impairment Loss Proceeds from Divestiture of Businesses Proceeds from Divestiture of Businesses Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Net income per share diluted attributable to Bio-Rad Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Treasury stock Treasury Stock, Value Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Treasury Stock, Shares Treasury Stock, Common, Shares Other Comprehensive Income (Loss), before Reclassifications, before Tax Other Comprehensive Income (Loss), before Reclassifications, before Tax Mature in more than five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Trading Symbol Trading Symbol Restructuring Plan [Domain] Restructuring Plan [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Interest and investment income Investment Income, Interest and Dividend Noncompete Agreements [Member] Noncompete Agreements [Member] Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Net income attributable to Bio-Rad Net Income (Loss) Attributable to Parent Net loss Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Finance Lease, Liability, Payments, Due Year Two Finance Lease, Liability, to be Paid, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Mature in one to five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Revenue from external customers [Table] Accounting Standards Update and Change in Accounting Principle [Table] Leases Lessee, Operating Leases [Text Block] Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Property, plant and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities and Equity [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Stockholders' equity: Equity, Attributable to Parent [Abstract] Escrow Deposit Disbursements Related to Property Acquisition Escrow Deposit Disbursements Related to Property Acquisition Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract] Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract] Cost of goods sold Cost of Goods and Services Sold Reconciliation of Assets from Segment to Consolidated [Table] Reconciliation of Assets from Segment to Consolidated [Table] Executive Category: Executive Category [Axis] Common Class B [Member] Common Class B [Member] Common Class B [Member] Finance Leases and Other Debt Finance Leases and Other Debt [Member] Finance Leases and Other Debt [Member] Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Organization, Consolidation and Presentation of Financial Statements [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares Schedule of Weighted Average Number of Shares [Table Text Block] Life Science Life Science [Member] Life Sciences [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Name Measure Name Name Forgone Recovery, Individual Name Goodwill, net Goodwill Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Investment Type [Axis] Investment Type [Axis] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Investments [Domain] Investments [Domain] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Decrease in accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Derivative, Notional Amount Derivative, Notional Amount Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Net unrealized holding gains (losses) on available-for-sale investments net of tax expense OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Foreign Government Debt [Member] Foreign Government Debt [Member] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Operating lease liabilities Operating Lease, Liability, Noncurrent Summary of amortized cost and estimated fair value of debt securities by contractual maturity date Investments Classified by Contractual Maturity Date [Table Text Block] Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Foreign exchange (gains) losses, net Realized Gain (Loss), Foreign Currency Transaction, before Tax Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Reclassification Out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Document and Entity Information (Parenthetical) [Abstract] Document and Entity Information (Parenthetical) [Abstract] Document and Entity Information (Parenthetical) [Abstract] Europe [Member] Europe [Member] (Gains) losses from change in fair market value of equity securities and loan receivable Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss Investment ownership percentage Investment ownership percentage Investment ownership percentage Other Performance Measure, Amount Other Performance Measure, Amount Proceeds from Debt, Net of Issuance Costs Proceeds from Debt, Net of Issuance Costs Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Decrease (increase) in inventories Increase (Decrease) in Inventories Lease, Cost Lease, Cost [Table Text Block] Fair Value, Option, Changes in Fair Value, Gain (Loss) Fair Value, Option, Changes in Fair Value, Gain (Loss) Research and Development Expense Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Restructuring Reserve Restructuring Reserve Award Type Award Type [Axis] Anti-dilutive shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Goodwill [Line Items] Goodwill [Line Items] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Noncash or Part Noncash Acquisition, Fixed Assets Acquired Noncash or Part Noncash Acquisition, Fixed Assets Acquired Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, to be Paid, after Year Five Current operating lease liabilities Operating Lease, Liability, Current Prepaid expenses Prepaid Expense, Current Accumulated Net Unrealized Investment Gain (Loss) AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Finance Lease, Interest Expense Finance Lease, Interest Expense Amortization expense Amortization of Intangible Assets Entity Shell Company Entity Shell Company Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, to be Paid, Year Three Other investments Long-Term Investments Net Carrying Amount Finite-Lived Intangible Assets, Net Recent Accounting Pronouncements Issued and to be Adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Increase in income taxes payable Increase (Decrease) in Income Taxes Payable Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Beginning Cash, Cash Equivalents, and Restricted Cash Ending Cash, Cash Equivalents, and Restricted Cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, to be Paid, Year Two Subsequent Events, Policy Subsequent Events, Policy [Policy Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Restructuring Costs [Abstract] Restructuring Costs [Abstract] Operating Lease, Cost Operating Lease, Cost Common Stock, Shares, Issued Common Stock, Shares, Issued Gross profit Gross Profit Security Exchange Name Security Exchange Name Long-term debt Long-Term Debt Assets, Fair Value Disclosure Assets, Fair Value Disclosure Selling, general and administrative expense Selling, General and Administrative Expense Accumulated other comprehensive loss Beginning balance, Accumulated other comprehensive income Ending balance, Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Employee Stock Option [Member] Accumulated Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Interest Receivable, Current Interest Receivable, Current Finite-lived Intangible Assets Amortization Expense [Table Text Block] Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Common Class A [Member] Common Class A [Member] Common Class A [Member] Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Maximum Maximum [Member] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Document Type Document Type Other Nonoperating Expense Other Nonoperating Expense Goodwill, Acquired During Period Goodwill, Acquired During Period Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Finance Lease, Liability, Payments, Due Year Three Finance Lease, Liability, to be Paid, Year Three Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year One Income and other taxes payable Taxes Payable, Current Equity Securities, FV-NI, Unrealized Loss Equity Securities, FV-NI, Unrealized Loss Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accounts receivable allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Derivative [Table] Derivative [Table] Restricted Cash, Noncurrent Restricted Cash, Noncurrent Investment Owned, Balance, Shares Investment Owned, Balance, Shares Other current liabilities Other Liabilities, Current Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Goodwill Goodwill, Gross Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents, Fair Value Disclosure Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Other current assets Other Assets, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Foreign Currency Gain (Loss) Foreign Currency Gain (Loss) [Member] Amortization [Abstract] Amortization [Abstract] Entity Tax Identification Number Entity Tax Identification Number Goodwill, Foreign Currency Translation Gain (Loss) Goodwill, Foreign Currency Translation Gain (Loss) Inventory Inventory, Net Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Statistical Measurement [Axis] Statistical Measurement [Axis] Increase in other current assets Increase (Decrease) in Other Current Assets Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Other Investments [Member] Other Investments [Member] Financial Instrument [Axis] Financial Instrument [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Long-term Debt Long-Term Debt [Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Total Shareholder Return Amount Total Shareholder Return Amount Payments for purchases of treasury stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Segments [Domain] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Leases [Abstract] Other Long-term Debt Other Long-Term Debt Entity Address, Country Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Finance Lease, Liability, Payment, Due Finance Lease, Liability, to be Paid Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Operating Lease, Payments Operating Lease, Payments Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Proceeds from maturities of marketable securities and investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Payments for Acquisitions, net of cash received Payments for Previous Acquisition Basic earnings per share: Earnings Per Share, Basic [Abstract] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] PEO PEO [Member] Investment proceeds and miscellaneous receipts, net Proceeds from Other Operating Activities Cash Equivalents [Member] Cash Equivalents [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Equity Securities Equity Securities, FV-NI, Current Reclassification Out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Other Long-term Debt, Current Other Long-Term Debt, Current Debt Instrument [Axis] Debt Instrument [Axis] Goodwill, Period Increase (Decrease) Goodwill, Period Increase (Decrease) Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Operating Lease, Liability Operating Lease, Liability Finance Lease, Liability, Payments, Remainder of Fiscal Year Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Segment Reporting, Asset Reconciling Item [Line Items] Segment Reporting, Asset Reconciling Item [Line Items] Debt Securities Debt Securities Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Maturities Of Lease Liabilities For Operating and Finance Leases Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] AOCI Attributable to Parent AOCI Attributable to Parent [Member] Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Accumulated Defined Benefit Plans Adjustment Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Clinical Diagnostics Clinical Diagnostics [Member] Clinical Diagnostics [Member] Restricted investment [Member] Restricted investment [Member] Restricted investment Common stock Common Stock, Value, Issued Derivative, Forward Interest Rate Derivative, Forward Interest Rate Mature in one to five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Trade Names [Member] Trade Names [Member] Reduction in the carrying amount of right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Legal Proceedings Legal Matters and Contingencies [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Total current assets Assets, Current Finance Lease, Principal Payments Finance Lease, Principal Payments Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability All Individuals All Individuals [Member] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Other Nonoperating Income (Expense) Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Increase (Decrease) in Deposit Assets Escrow Deposits Related to Property Sales Goodwill and Other Purchased Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Unrecognized Tax Benefits Unrecognized Tax Benefits PEO Name PEO Name Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Asia Pacific [Member] Asia Pacific [Member] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] US Government Sponsored Agencies [Member] US Treasury and Government [Member] Restricted Cash, Current Restricted Cash, Current Changes to goodwill by segment Schedule of Goodwill [Table Text Block] Finance Lease, Liability, Payments, Due Year Four Finance Lease, Liability, to be Paid, Year Four Asset-backed Securities [Member] Asset-Backed Securities [Member] Net cash provided by operating activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Warranty accrual, beginning of period Warranty accrual, end of period Standard and Extended Product Warranty Accrual Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Gain on Disposition of a division Gain (Loss) on Disposition of Business Total stockholders' equity Total Stockholders' Equity Total Stockholders' Equity Total stockholders' equity Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Commercial Paper [Member] Commercial Paper [Member] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Finance Lease, Right-Of-Use Asset, Accumulated Amortization Finance Lease, Right-of-Use Asset, Accumulated Amortization Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions Ordinary voting shares [Member] Ordinary voting shares [Member] Ordinary voting shares Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Other Income, Net Other Income and Other Expense Disclosure [Text Block] Restructuring Costs Restructuring and Related Activities Disclosure [Text Block] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] Purchased intangibles, net Intangible Assets, Net (Excluding Goodwill) Schedule of Product Warranty Liability [Table Text Block] Schedule of Product Warranty Liability [Table Text Block] Standard Product Warranty, Policy Standard Product Warranty, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Share-based Compensation Share-Based Payment Arrangement, Noncash Expense Revenue from External Customers by Geographic Areas [Table Text Block] Revenue from External Customers by Geographic Areas [Table Text Block] Common Stock [Member] Common Stock [Member] Individual: Individual [Axis] Finance Lease, Right-Of-Use Asset, before Accumulated Amortization Finance Lease, Right-of-Use Asset, before Accumulated Amortization Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Earnings (Loss) Per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Fair Value Measurements, Recurring and Nonrecurring Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Treasury Stock Reissued at Lower than Repurchase Price Treasury Stock Reissued at Lower than Repurchase Price Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Fair Value, Option, Loans Held as Assets [Abstract] Fair Value, Option, Loans Held as Assets [Abstract] Minimum Minimum [Member] Schedule of identifiable purchased intangible assets with definite lives Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Exercise Price Award Exercise Price Acquired Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Total other comprehensive income (loss) net of tax Total other comprehensive income (loss) net of tax Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS: Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Liabilities, Fair Value Disclosure Liabilities, Fair Value Disclosure Foreign exchange (gains) losses, net Gain (Loss), Foreign Currency Transaction, before Tax Tax payments from net share settlement Payment, Tax Withholding, Share-Based Payment Arrangement Additional European and American Reorganization Additional European and American Reorganization [Member] Additional European and American Reorganization US Treasury Securities US Treasury Securities [Member] Income tax payments, net Income Taxes Paid, Net Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Cash paid to suppliers and employees Payments to Suppliers and Employees Developed Technology Rights [Member] Developed Technology Rights [Member] Retained Earnings [Member] Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Total liabilities and stockholders' equity Liabilities and Equity Amortized Cost Total Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Net income per share basic attributable to Bio-Rad Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment Finance Lease Obligations Finance Lease Obligations [Member] Finance Lease Obligations [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Treasury Class A [Member] Treasury Class-A [Member] Treasury Class A [Member] Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Arrangement Duration Trading Arrangement Duration In Process Research and Development [Member] In Process Research and Development [Member] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Decrease in accounts payable and other current liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Current maturities of long-term debt and notes payable Notes and Loans Payable, Current Restructuring Charges Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Preference shares [Member] Preference shares [Member] Preference shares Proceeds from forward foreign exchange contracts, net Payments for (proceeds from) derivative instruments, operating activities Payments for (proceeds from) derivative instruments, operating activities Interest Expense Interest Expense [Member] Termination Date Trading Arrangement Termination Date Depreciation and amortization Other Depreciation and Amortization Americas [Member] Americas [Member] Debt Securities, Available-for-sale Estimated Fair Value Debt Securities, Available-for-Sale Unrealized Gain on Securities Equity Securities, FV-NI, Unrealized Gain Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Short-term Investments [Member] Short-Term Investments [Member] Finance Lease Cost Finance Lease Cost Finance Lease Cost Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Restricted investments Restricted Investments, Current All Trading Arrangements All Trading Arrangements [Member] Mature in less than one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Less: accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Lessee Supplemental Balance Sheet Information Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Finance Lease, Right-Of-Use Asset, after Accumulated Amortization Financing Receivable, Allowance for Credit Loss, Current Accounts Receivable, Credit Loss Expense (Reversal) Additional paid-in capital Additional paid-in-capital Additional Paid in Capital Mature in more than five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Restructuring Plan [Axis] Restructuring Plan [Axis] 3.3%, Senior Notes due 2027 3.3%, Senior Notes due 2027 [Member] 3.3%, Senior Notes due 2027 Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Finance Lease, Liability Finance Lease, Liability Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] Municipal Obligations (Member) Municipal obligations [Member] Municipal Bonds [Member] Insider Trading Arrangements [Line Items] Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Deferred Revenue Deferred Revenue Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Other assets Other Assets Know How [Member] Know How [Member] Know how [Member] Other Segments Other Segments [Member] Entity Registrant Name Entity Registrant Name Other Nonoperating (Income) Other Nonoperating Income Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Effect of potentially dilutive stock options and restricted stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Adjustment to Compensation, Amount Adjustment to Compensation Amount Proceeds from dispositions of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Cost of Sales Cost of Sales [Member] Changes in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Payments for Restructuring Payments for Restructuring Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Payments on long-term borrowings Repayments of Long-Term Debt Finance Lease, Weighted Average Discount Rate, Percent Finance Lease, Weighted Average Discount Rate, Percent Finance Lease, Liability, Noncurrent Finance Lease, Liability, Noncurrent Accounts Receivable, Allowance for Credit Loss [Table Text Block] Accounts Receivable, Allowance for Credit Loss [Table Text Block] Treasury Stock, Common Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Reclassification Out Of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Purchase Price Finite-Lived Intangible Assets, Gross (Provision) benefit for income taxes Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Accrued payroll and employee benefits Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3.7%, Senior Notes due 2032 3.7%, Senior Notes due 2032 [Member] 3.7%, Senior Notes due 2032 Stock Issued During Period, Value, New Issues Stock Issued During Period, Value, New Issues Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventory Inventory Disclosure [Text Block] Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Net sales Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Money Market Funds [Member] Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Increase in deferred income taxes Increase (Decrease) in Deferred Income Taxes Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Licensing Agreements [Member] Licensing Agreements [Member] Interest paid, net Interest Paid, Excluding Capitalized Interest, Operating Activities Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Mature in less than one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Time Deposits [Member] Bank Time Deposits [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt, net of current maturities Long-Term Debt, Excluding Current Maturities Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Remaining Lease Term Senior Notes, Noncurrent Senior Notes, Noncurrent Weighted average common shares - diluted Diluted weighted average common shares Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Cash received from customers Proceeds from Customers Noncash or Part Noncash Acquisition, Investments Acquired Noncash or Part Noncash Acquisition, Investments Acquired Finance Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, Undiscounted Excess Amount Capital expenditures Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount European Reorganization European Reorganization [Member] European Reorganization Restricted Investments, at Fair Value Restricted Investments, at Fair Value Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Finance Lease, Liability, Payments, Due after Year Five Finance Lease, Liability, to be Paid, after Year Five Stock Issued During Period, Value, Treasury Stock Reissued Stock Issued During Period, Value, Treasury Stock Reissued Payments of operating lease liabilities Increase (Decrease) in Deferred Liabilities Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net Sartorius Loan value appreciation rights - Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net APIC, Share-based Payment Arrangement, Increase for Cost Recognition APIC, Share-Based Payment Arrangement, Increase for Cost Recognition UNITED STATES UNITED STATES Fair Value, Recurring Fair Value, Recurring [Member] Segment Reconciling Items Segment Reconciling Items [Member] Finance Lease, Interest Payment on Liability Finance Lease, Interest Payment on Liability Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, to be Paid Schedule of Cash Flow, Supplemental Disclosures Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Short-term investments Short-Term Investments Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) [Member] Finance Lease, Right-of-Use Asset, Amortization Finance Lease, Right-of-Use Asset, Amortization Segment Information Segment Reporting Disclosure [Text Block] Foreign Government Obligations [Member] Debt Security, Government, Non-US [Member] Lessee Operating And Finance Leases Remaining Lease Term Lessee Operating And Finance Leases Remaining Lease Term Lessee Operating And Finance Leases Remaining Lease Term Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Finance Lease, Liability, Current Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Work in process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average common shares - basic Basic weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Statement, Scenario [Axis] Statement, Scenario [Axis] Scenario [Axis] Entity Current Reporting Status Entity Current Reporting Status Marketable Securities, Unrealized (Gain) Loss Marketable Securities, Unrealized Gain (Loss) Marketable Security, Unrealized Gain (Loss) Segment profit (loss) Operating Income (Loss) Net realized (gain) loss on investments Realized Investment Gains (Losses) Allowance for Loan and Lease Losses, Write-offs Allowance for Loan and Lease Losses, Writeoff Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Lessee Supplemental Cash Flow Information Lessee Supplemental Cash Flow Information [Table Text Block] Lessee Supplemental Cash Flow Information [Table Text Block] Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Scenario [Domain] Scenario [Domain] Discussion of current derivative risk management Schedule of Derivative Instruments [Table Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer Relationships [Member] Customer Relationships [Member] Debt Securities, Available-for-sale Debt Securities, Available-for-Sale [Table Text Block] Reclassification Out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] EX-101.PRE 10 bio-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2023
Oct. 20, 2023
Document Transition Report false  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Shell Company false  
City Area Code (510)  
Document Quarterly Report true  
Entity Incorporation, State or Country Code DE  
Entity File Number 1-7928  
Entity Registrant Name BIO-RAD LABORATORIES, INC.  
Entity Central Index Key 0000012208  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Small Business false  
Entity Tax Identification Number 94-1381833  
Entity Address, Address Line One 1000 Alfred Nobel Drive,  
Entity Address, City or Town Hercules,  
Entity Address, Country CA  
Entity Address, Postal Zip Code 94547  
Local Phone Number 724-7000  
Entity Emerging Growth Company false  
Common Class A [Member]    
Title of 12(b) Security Class A Common Stock, Par Value $0.0001 per share  
Trading Symbol BIO  
Security Exchange Name NYSE  
Entity Common Stock, Shares Outstanding   24,059,355
Common Class B [Member]    
Title of 12(b) Security Class B Common Stock, Par Value $0.0001 per share  
Trading Symbol BIOb  
Security Exchange Name NYSE  
Entity Common Stock, Shares Outstanding   5,085,815
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
ASSETS:    
Cash and cash equivalents $ 457,850 $ 434,215
Short-term investments 1,301,143 1,356,457
Restricted investments 5,560 5,560
Accounts receivable, net 457,402 494,645
Inventory 775,818 719,316
Prepaid expenses 123,910 124,179
Other current assets 25,087 23,604
Total current assets 3,146,770 3,157,976
Property, plant, and equipment 1,538,545 1,508,020
Less: accumulated depreciation and amortization 1,027,156 1,009,408
Property, plant and equipment, net 511,389 498,612
Operating lease right-of-use assets 200,013 180,952
Goodwill, net 406,953 406,488
Purchased intangibles, net 314,187 332,147
Other investments 7,218,161 8,830,892
Other assets 98,470 94,599
Assets 11,895,943 13,501,666
LIABILITIES AND STOCKHOLDERS' EQUITY:    
Accounts payable 111,859 135,041
Accrued payroll and employee benefits 154,946 194,790
Current maturities of long-term debt and notes payable 476 465
Income and other taxes payable 103,978 32,428
Current operating lease liabilities 39,116 36,336
Other current liabilities 147,801 169,648
Total current liabilities 558,176 568,708
Long-term debt, net of current maturities 1,198,713 1,197,716
Deferred income taxes 1,369,556 1,770,481
Operating lease liabilities 167,179 153,597
Other long-term liabilities 186,121 195,912
Total liabilities 3,479,745 3,886,414
Stockholders' equity:    
Additional paid-in capital 439,455 447,454
Retained earnings 8,910,921 9,898,203
Accumulated other comprehensive loss (497,561) (466,822)
Total stockholders' equity 8,416,198 9,615,252
Total liabilities and stockholders' equity 11,895,943 13,501,666
Common Class A [Member]    
Stockholders' equity:    
Common stock 2 2
Common Class B [Member]    
Stockholders' equity:    
Common stock 1 1
Treasury Class A [Member]    
Stockholders' equity:    
Treasury stock $ (436,620) $ (263,586)
Treasury Stock, Common    
Stockholders' equity:    
Treasury Stock, Shares 1,104,644 640,492
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets Parenthetical - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Accounts receivable allowance for doubtful accounts $ 15,108 $ 15,029
Cash and cash equivalents $ 457,850 $ 434,215
Common Class A [Member]    
Common Stock, Shares, Issued 25,163,999 25,162,075
Common Stock, Shares, Outstanding 24,059,355 24,521,583
Common Class B [Member]    
Common Stock, Shares, Issued 5,085,815 5,074,130
Common Stock, Shares, Outstanding 5,085,815 5,074,130
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Net sales $ 632,124 $ 680,800 $ 1,990,078 $ 2,071,961
Cost of goods sold 296,441 308,233 929,495 901,728
Gross profit 335,683 372,567 1,060,583 1,170,233
Selling, general and administrative expense 201,199 211,113 634,576 615,598
Research and Development Expense 43,535 66,808 183,528 190,689
Segment profit (loss) 90,949 94,646 242,479 363,946
Interest expense 12,398 11,663 37,078 26,431
Foreign exchange (gains) losses, net (1,680) 4,364 (5,280) 3,133
Marketable Securities, Unrealized (Gain) Loss (36,425) 288,999 1,576,542 6,172,306
Other Nonoperating Income (Expense) 20,446 3,062 87,365 42,369
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 137,102 (207,318) (1,278,496) (5,795,555)
(Provision) benefit for income taxes (30,845) 44,510 291,464 1,340,286
Net income attributable to Bio-Rad $ 106,257 $ (162,808) $ (987,032) $ (4,455,269)
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 3.65 $ (5.48) $ (33.63) $ (149.41)
Weighted average common shares - basic 29,102 29,733 29,349 29,819
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 3.64 $ (5.48) $ (33.63) $ (149.41)
Weighted average common shares - diluted 29,223 29,733 29,349 29,819
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Net Income (Loss) Attributable to Parent $ 106,257 $ (162,808) $ (987,032) $ (4,455,269)
Foreign currency translation adjustments (126,165) (305,666) (34,342) (653,301)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent (342) 481 (72) 1,004
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense 1,808 (6,643) 3,675 (17,364)
Total other comprehensive income (loss) net of tax (124,699) (311,828) (30,739) (669,661)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest $ (18,442) $ (474,636) $ (1,017,771) $ (5,124,930)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Cash received from customers $ 2,007,482 $ 1,981,952
Cash paid to suppliers and employees (1,722,173) (1,800,487)
Interest paid, net (46,394) (23,974)
Income tax payments, net (40,966) (137,863)
Investment proceeds and miscellaneous receipts, net 81,828 51,146
Proceeds from forward foreign exchange contracts, net 14,119 44,016
Net cash provided by operating activities 293,896 114,790
Cash flows from investing activities:    
Capital expenditures (114,435) (77,987)
Proceeds from dispositions of property, plant and equipment 104 114
Proceeds from Divestiture of Businesses 0 1,360
Payments for purchases of marketable securities and investments (537,540) (1,807,148)
Proceeds from maturities of marketable securities and investments 260,849 292,727
Proceeds from Sale of Debt Securities, Available-for-sale 339,033 542,639
Payments for Acquisitions, net of cash received 0 (100,746)
Net cash used in investing activities (51,989) (1,149,041)
Proceeds from Debt, Net of Issuance Costs 0 1,186,220
Cash flows from financing activities:    
Payments on long-term borrowings (349) (367)
Proceeds from Issuance of Common Stock 14,168 13,218
Tax payments from net share settlement (10,118) (13,876)
Payments for purchases of treasury stock (228,728) (125,000)
Net cash used in financing activities (225,027) 1,060,195
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6,891 21,167
Beginning Cash, Cash Equivalents, and Restricted Cash 434,544 471,133
Cash and cash equivalents 457,850 517,943
Restricted Cash, Current 79 12
Restricted Cash, Noncurrent 386 289
Ending Cash, Cash Equivalents, and Restricted Cash 458,315 518,244
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $ 23,771 $ 47,111
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock, Common
Retained Earnings [Member]
AOCI Attributable to Parent
Total Stockholders' Equity at Dec. 31, 2021 $ 13,685,236 $ 3 $ 441,733 $ (106,290) $ 13,525,343 $ (175,553)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent (3,367,347) 0 0 0 (3,367,347) 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (132,303) 0 0 0 0 (132,303)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 13,521 0 13,521 0 0 0
Proceeds from Issuance of Common Stock (4,177) 0 (4,177) 0 0 0
Total Stockholders' Equity at Mar. 31, 2022 10,203,284 3 459,431 (106,290) 10,157,996 (307,856)
Total Stockholders' Equity at Dec. 31, 2021 13,685,236 3 441,733 (106,290) 13,525,343 (175,553)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent (4,455,269)          
Proceeds from Issuance of Common Stock (13,218)          
Total Stockholders' Equity at Sep. 30, 2022 8,477,467 3 430,547 (178,261) 9,070,392 (845,214)
Total Stockholders' Equity at Mar. 31, 2022 10,203,284 3 459,431 (106,290) 10,157,996 (307,856)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent (925,114) 0 0 0 (925,114) 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (225,530) 0 0 0 0 (225,530)
Stock Issued During Period, Value, New Issues (443) 0 (443) 0 0 0
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 13,571 0 13,571 0 0 0
Treasury Stock Reissued at Lower than Repurchase Price 4,267 0 (696) 4,950 13 0
Treasury Stock, Value, Acquired, Cost Method (125,000)     (125,000)    
Total Stockholders' Equity at Jun. 30, 2022 8,945,035 3 471,863 (226,340) 9,232,895 (533,386)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent (162,808) 0 0 0 (162,808) 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (311,828) 0 0 0 0 (311,828)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 15,735 0 15,735 0 0 0
Proceeds from Issuance of Common Stock (7,550) 0 (7,550) 0 0 0
Treasury Stock Reissued at Lower than Repurchase Price (1,117) 0 (49,501) 48,079 305 0
Total Stockholders' Equity at Sep. 30, 2022 8,477,467 3 430,547 (178,261) 9,070,392 (845,214)
Total Stockholders' Equity at Dec. 31, 2022 9,615,252 3 447,454 (263,586) 9,898,203 (466,822)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent 68,962 0 0 0 68,962 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 58,470 0 0 0 0 58,470
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 16,608 0 16,608 0 0 0
Total Stockholders' Equity at Mar. 31, 2023 9,763,716 3 463,402 (258,296) 9,966,959 (408,352)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock Issued During Period, Value, Treasury Stock Reissued 4,424 0 (660) 5,290 (206) 0
Total Stockholders' Equity at Dec. 31, 2022 9,615,252 3 447,454 (263,586) 9,898,203 (466,822)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent (987,032)          
Proceeds from Issuance of Common Stock (14,168)          
Total Stockholders' Equity at Sep. 30, 2023 8,416,198 3 439,455 (436,620) 8,910,921 (497,561)
Total Stockholders' Equity at Mar. 31, 2023 9,763,716 3 463,402 (258,296) 9,966,959 (408,352)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent (1,162,251) 0 0 0 (1,162,251) 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 35,490 0 0 0 0 35,490
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12,559 0 12,559 0 0 0
Treasury Stock Reissued at Lower than Repurchase Price (4,786) 0 (2,089) (6,919) (44) 0
Treasury Stock, Value, Acquired, Cost Method (207,407) 0 0 (207,407) 0 0
Total Stockholders' Equity at Jun. 30, 2023 8,446,893 3 473,872 (458,784) 8,804,664 (372,862)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Income (Loss) Attributable to Parent 106,257 0 0 0 106,257 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent (124,699) 0 0 0 0 (124,699)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition 15,952 0 15,952 0 0 0
Proceeds from Issuance of Common Stock 5,111 0 5,111 0 0 0
Treasury Stock Reissued at Lower than Repurchase Price (514) 0 45,258 (45,772) 0 0
Treasury Stock, Value, Acquired, Cost Method (23,608) 0 0 (23,608) 0 0
Total Stockholders' Equity at Sep. 30, 2023 $ 8,416,198 $ 3 $ 439,455 $ (436,620) $ 8,910,921 $ (497,561)
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Use of Estimates
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Use of Estimates
1. BASIS OF PRESENTATION AND USE OF ESTIMATES

Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.

Revenue Recognition

We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the standalone selling price for
each distinct product or service. The method used to determine the standalone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.

We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.

At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation.

We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.

The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements

Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification as operating or sales-type lease. The lease term used in performing the lease classification test, includes the noncancellable period of the lease together with those periods covered by lease extension options if the customer is reasonably certain to exercise that option, the periods covered by lease termination options if the customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term for reagent rental agreements, including the impact from any associated contractual termination penalties, is subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee to purchase the underlying asset.

We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and
consideration of any fixed/minimum payments as well as estimates of variable consideration. After we have allocated the transaction price to the lease and non-lease elements, the amount of variable payments allocated to such elements are recognized as income in accordance with ASC 842 or ASC 606, as applicable.

Maintenance services and reagents are allocated to the non-lease elements. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.

Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial, and we do not enter into direct finance leases.

Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and nine months ended September 30, 2023 and September 30, 2022. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).

Contract costs:

As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss).

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
United States$275.4 $284.1 $858.8 $848.2 
EMEA193.1 200.1 609.1 636.3 
APAC118.9 156.8 398.9 470.3 
Other (primarily Canada and Latin America)44.7 39.8 123.3 117.2 
Total net sales$632.1 $680.8 $1,990.1 $2,072.0 

The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).

Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2023 and December 31, 2022 was $66.5 million and $71.9 million, respectively. The short-term deferred revenue balance at September 30, 2023 and December 31, 2022 was $49.1 million and $52.2 million, respectively.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).
Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the nine months ended September 30, 2023 and 2022 were as follows (in millions):
Nine Months Ended
September 30,
20232022
Balance at beginning of period$10.6 $12.7 
Provision for warranty6.4 6.7 
Actual warranty costs(9.0)(8.8)
Balance at end of period$8.0 $10.6 

Accounts Receivable and Allowance for Credit Losses

We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.

Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.


Changes in our allowance for credit losses were as follows (in millions):
Nine Months Ended
September 30,
20232022
Balance at beginning of period$15.0 $15.1 
Provision for expected credit losses0.9 1.2 
Write-offs charged against the allowance(1.3)(2.3)
 Recoveries collected0.5 0.1 
Balance at end of period$15.1 $14.1 

Recent Accounting Pronouncements Issued and to be Adopted
There are no new accounting pronouncements recently issued or newly effective that had, or are expected to have, a material impact on the Company's condensed consolidated financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements
 3 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements
2. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•Level 1: Quoted prices in active markets for identical instruments
•Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)

Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2023 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $7.5 $— $7.5 
Time deposits— 44.7 — 44.7 
Money market funds120.1 — — 120.1 
Total cash equivalents (a)120.1 52.2 — 172.3 
Restricted investments (b)6.9 — — 6.9 
Equity securities (c)6,947.6 — — 6,947.6 
Loan under the fair value option (d)— — 290.5 290.5 
Available-for-sale investments:
Corporate debt securities— 590.6 — 590.6 
U.S. government sponsored agencies— 283.7 — 283.7 
Foreign government obligations— 10.0 — 10.0 
Municipal obligations— 13.9 — 13.9 
Asset-backed securities— 342.5 — 342.5 
Total available-for-sale investments (e)— 1,240.7 — 1,240.7 
Forward foreign exchange contracts (f)— 0.7 — 0.7 
Total financial assets carried at fair value$7,074.6 $1,293.6 $290.5 $8,658.7 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (g)$— $1.0 $— $1.0 
Contingent consideration (h)— — 17.1 17.1 
Total financial liabilities carried at fair value$— $1.0 $17.1 $18.1 
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $21.1 $— $21.1 
Time deposits5.7 — — 5.7 
Asset-backed securities— 1.4 — 1.4 
U.S. government sponsored agencies— 6.0 — 6.0 
Money market funds31.5 — — 31.5 
Total cash equivalents (a)37.2 28.5 — 65.7 
Restricted investments (b)6.8 — — 6.8 
Equity securities (c)8,530.4 — — 8,530.4 
Loan under the fair value option (d)— — 322.6 322.6 
Available-for-sale investments:
Corporate debt securities— 699.3 — 699.3 
U.S. government sponsored agencies— 230.7 — 230.7 
Foreign government obligations— 13.5 — 13.5 
Municipal obligations— 23.1 — 23.1 
Asset-backed securities— 333.4 — 333.4 
Total available-for-sale investments (e)— 1,300.0 — 1,300.0 
Forward foreign exchange contracts (f)— 1.5 — 1.5 
Total financial assets carried at fair value$8,574.4 $1,330.0 $322.6 $10,227.0 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)$— $6.2 $— $6.2 
Contingent consideration (h)— — 35.6 35.6 
Total financial liabilities carried at fair value$— $6.2 $35.6 $41.8 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2023December 31, 2022
Restricted investments$5.6 $5.6 
Other investments1.3 1.2 
    Total$6.9 $6.8 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2023December 31, 2022
Short-term investments$60.3 $56.5 
Other investments6,887.3 8,473.9 
        Total$6,947.6 $8,530.4 
(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.

(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.

(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023.

Level 1 Fair Value Measurements

As of September 30, 2023, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the ordinary outstanding shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of September 30, 2023. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.

The changes in fair market value of our investment in Sartorius for the three and nine months ended September 30, 2023 was a gain of $42.5 million and a loss of $1,556.1 million respectively, which is recorded in our condensed consolidated statements of income (loss).

Level 2 Fair Value Measurements

To estimate the fair value of Level 2 debt securities as of September 30, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.
Available-for-sale investments consist of the following (in millions):
 September 30, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$598.0 $0.3 $(7.7)$590.6 
Municipal obligations14.1 — (0.2)13.9 
Asset-backed securities347.3 — (4.8)342.5 
U.S. government sponsored agencies287.1 — (3.4)283.7 
Foreign government obligations10.2 — (0.2)10.0 
 $1,256.7 $0.3 $(16.3)$1,240.7 

The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2023 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$473.6 $469.5 
Mature in one to five years636.7 627.8 
Mature in more than five years146.4 143.4 
Total$1,256.7 $1,240.7 

Available-for-sale investments consist of the following (in millions):
 December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$709.9 $0.2 $(10.8)$699.3 
Municipal obligations23.4 — (0.3)23.1 
Asset-backed securities339.6 0.1 (6.3)333.4 
U.S. government sponsored agencies233.9 — (3.2)230.7 
Foreign government obligations13.8 — (0.3)13.5 
Total$1,320.6 $0.3 $(20.9)$1,300.0 


As of September 30, 2023, there were no significant continuous unrealized losses greater than 12 months.

Our evaluation of credit losses for available-for-sale investments included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.

At September 30, 2023, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of September 30, 2023.
Included in Other current assets are $11.2 million and $11.6 million of interest receivable as of September 30, 2023 and December 31, 2022, respectively, primarily associated with securities in our available-for-sale investments portfolio. The interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the nine months ended September 30, 2023, we have not written-off any uncollected interest receivable.

As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of September 30, 2023 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss).

The following is a summary of our forward foreign exchange contracts (in millions):
 September 30,
 2023
Contracts maturing in October through December 2023 to sell foreign currency: 
Notional value$701.5 
Unrealized loss$(0.4)
Contracts maturing in October through December 2023 to purchase foreign currency: 
Notional value$80.1 
Unrealized gain$0.1 

Level 3 Fair Value Investments

During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (the “Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in (Gains) losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss).
The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the three months ended September 30, 2023 was a loss of $4.9 million, which includes a $10.8 million loss from change in fair market value of the Loan and a $5.9 million gain from change in fair market value of the value appreciation right. The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the nine months ended September 30, 2023 was a loss of $28.9 million, which includes a $0.4 million loss from change in fair market value of the Loan and a $28.5 million loss from change in fair market value of the value appreciation right. The decrease in the fair market value of the value appreciation right was due to a decline in the value of the Sartorius ordinary shares. As of September 30, 2023, the €400 million principal amount of the loan is still due on January 31, 2029.

The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):

December 31, 2022$322.6 
Net decrease in estimated fair market value of the loan included in (Gains) losses in fair market value of equity securities and loan receivable
$(28.9)
Foreign currency exchange gains (losses), net$(3.2)
September 30, 2023$290.5 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill and Other Purchased Intangible Assets
 9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Purchased Intangible Assets
3. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment are as follows (in millions):
Life
Science		Clinical
Diagnostics		Total
Balances as of December 31, 2022:
Goodwill$333.3 $408.4 $741.7 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net291.5 115.0 406.5 
Acquisitions— 0.40.4 
Foreign currency adjustments— 0.1 0.1 
Period increase, net— 0.5 0.5 
Balances as of September 30, 2023:
Goodwill333.3 408.9 742.2 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$291.5 $115.5 $407.0 

Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):
September 30, 2023
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.2$104.3 $(93.6)$10.7 
Know how2.0165.1 (156.2)8.9 
Developed product technology12.2215.5 (128.4)87.1 
Licenses5.158.8 (41.1)17.7 
Tradenames5.86.0 (4.5)1.5 
Covenants not to compete2.56.5 (4.7)1.8 
     Total finite-lived intangible assets556.2 (428.5)127.7 
In-process research and development186.5 — 186.5 
     Total purchased intangible assets $742.7 $(428.5)$314.2 

 December 31, 2022
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.0$104.7 $(89.9)$14.8 
Know how2.8166.2 (153.9)12.3 
Developed product technology12.8211.1 (121.6)89.5 
Licenses5.859.0 (38.5)20.5 
Tradenames6.66.1 (4.5)1.6 
Covenants not to compete3.16.4 (4.0)2.4 
     Total finite-lived intangible assets553.5 (412.4)141.1 
In-process research and development191.0 — 191.0 
     Total purchased intangible assets $744.5 $(412.4)$332.1 

Amortization expense related to purchased intangible assets is as follows (in millions):

Three Months EndedNine Months Ended
 September 30,September 30,
 2023202220232022
Amortization expense$6.2 $6.2 $18.1 $18.8 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Inventory
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Inventory
4. INVENTORY

Following are the components of Inventory at September 30, 2023 and December 31, 2022 (in millions):
September 30, 2023December 31, 2022
Inventory:
  Raw materials$230.4 $228.8 
  Work in process244.5 220.9 
  Finished goods 300.9 269.6 
      Total Inventory$775.8 $719.3 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Cash Flow Information
 9 Months Ended
Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information
5. SUPPLEMENTAL CASH FLOW INFORMATION

The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):
Nine Months Ended
September 30, 2023September 30, 2022
Net loss$(987.0)$(4,455.3)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization108.7 101.8 
Reduction in the carrying amount of right-of-use assets30.7 29.8 
Share-based compensation45.1 42.8 
Losses from change in fair market value of equity securities and loan receivable1,576.5 6,172.3 
Gain on divestiture of a division— (1.4)
Changes in fair value of contingent consideration(18.5)— 
Payments for operating lease liabilities(30.4)(28.1)
(Increase) decrease in accounts receivable31.6 (44.5)
Increase in inventories(61.7)(150.6)
(Increase) decrease in other current assets15.0 (11.9)
Decrease in accounts payable and other current liabilities(72.4)(69.7)
Increase (decrease) in income taxes payable56.4 (39.2)
Decrease in deferred income taxes(397.4)(1,439.1)
Increase (decrease) in other long-term liabilities3.9 (2.0)
Other(6.6)9.9 
Net cash provided by operating activities$293.9 $114.8 
Non-cash investing activities:
Purchased property, plant and equipment$2.9 $3.3 
Purchased marketable securities and investments$— $11.8 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Debt
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Long-term Debt 6. LONG-TERM DEBTThe principal components of long-term debt are as follows (in millions):
September 30,
2023		December 31,
2022
3.3%, Senior Notes due 2027
$400.0 $400.0 
3.7%, Senior Notes due 2032
800.0 800.0 
Less unamortized discounts and debt issuance costs(11.0)(12.4)
Long-term debt less unamortized discounts and debt issuance costs1,189.0 1,187.6 
Finance leases and other debt10.2 10.6 
Less current maturities(0.5)(0.5)
Long-term debt$1,198.7 $1,197.7 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated Other Comprehensive Income (Loss)
7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions):
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of December 31, 2022:$(466.5)$10.0 $(10.3)$(466.8)
Other comprehensive income (loss), before reclassifications(34.4)0.3 3.7 (30.4)
Amounts reclassified from Accumulated other comprehensive income (loss)— (0.4)1.1 0.7 
Income tax effects0.1 — (1.1)(1.0)
Other comprehensive income (loss), net of income taxes(34.3)(0.1)3.7 (30.7)
Balances as of September 30, 2023:$(500.8)$9.9 $(6.6)$(497.5)
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of December 31, 2021:$(170.5)$(10.9)$5.8 $(175.6)
Other comprehensive income (loss), before reclassifications(654.4)1.4 (23.3)(676.3)
Amounts reclassified from Accumulated other comprehensive income (loss)— 0.2 0.6 0.8 
Income tax effects1.1 (0.5)5.3 5.9 
Other comprehensive income (loss), net of income taxes(653.3)1.1 (17.4)(669.6)
Balances as of September 30, 2022:$(823.8)$(9.8)$(11.6)$(845.2)

All amounts reclassified out of accumulated other comprehensive income (loss) were reclassified into other income, net in the condensed consolidated statements of income (loss). The reclassification adjustments are calculated using the specific identification method.

The impact to income (loss) before income taxes for amounts reclassified out of accumulated other comprehensive
income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in
millions):
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings (Loss) Per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Earnings (Loss) Per Share
8. EARNINGS (LOSS) PER SHARE

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.

We compute net income (loss) per share of Class A Common Stock (Class A) and Class B Common Stock (Class B) using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Earnings (loss) is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the three and nine months ended September 30, 2023 and 2022.

Accordingly, basic earnings (loss) per share is computed by dividing net income (loss) attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands):
Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Basic weighted average shares outstanding29,102 29,733 29,349 29,819 
Effect of potentially dilutive stock options, restricted stock and performance stock awards121 — — — 
Diluted weighted average common shares outstanding29,223 29,733 29,349 29,819 
Anti-dilutive shares154 541 229 541 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Other Income, Net
 9 Months Ended
Sep. 30, 2023
Other Income and Expenses [Abstract]  
Other Income, Net
9. OTHER INCOME, NET

Other income, net includes the following components (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Interest and investment income$(17.3)$(8.0)$(84.1)$(45.7)
Net realized losses on investments0.1 0.2 1.6 0.6 
Current expected credit losses on loans— 5.1 — 5.1 
Gain on divestiture of a division— — — (1.4)
Escrow receipts on prior acquisition(2.5)— (2.5)— 
Other income(0.7)(0.4)(2.4)(1.0)
Other income, net$(20.4)$(3.1)$(87.4)$(42.4)
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes
10. INCOME TAXES

Our effective income tax rate was 22.5% and 21.5% for the three months ended September 30, 2023 and 2022, respectively. Our effective income tax rate was 22.8% and 23.1% for the nine months ended September 30, 2023 and 2022, respectively.

The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of September 30, 2023, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $15.2 million for the period ended September 30, 2023 compared to the year ended December 31, 2022.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

Our gross unrecognized tax benefits were $92.0 million and $85.5 million as of September 30, 2023 and December 31, 2022, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions.

As of September 30, 2023, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $18.8 million. Substantially all such amounts will impact our effective income tax rate if recognized.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Segment Information
11. SEGMENT INFORMATION

Information regarding operating profit (loss) for the three months ended September 30, 2023 and 2022 is as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2023$263.5 $368.1 $0.5 
 2022$317.9 $361.9 $1.0 
Operating profit (loss)2023$13.0 $78.0 $(0.1)
 2022$51.4 $43.9 $(0.7)



Information regarding operating profit (loss) for the nine months ended September 30, 2023 and 2022 is as follows (in millions):
Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2023$887.3 $1,100.3 $2.5 
2022$987.5 $1,081.4 $3.1 
Operating profit (loss)2023$76.7 $166.1 $(0.3)
 2022$197.6 $167.8 $(1.5)

Segment results are presented in the same manner as we manage our business internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments.

The following reconciles total segment profit to consolidated loss before income taxes (in millions):

Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Operating profit$90.9 $94.6 $242.5 $363.9 
Interest expense(12.3)(11.6)(37.2)(26.5)
Foreign currency exchange gains (losses), net1.7 (4.4)5.3 (3.1)
Change in fair market value of equity securities and loan receivable36.4 (289.0)(1,576.5)(6,172.3)
Other income, net20.4 3.1 87.4 42.4 
Consolidated income (loss) before income taxes$137.1 $(207.3)$(1,278.5)$(5,795.6)
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Legal Proceedings
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings 12. LEGAL PROCEEDINGSWe are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring Costs
 9 Months Ended
Sep. 30, 2023
Restructuring Costs [Abstract]  
Restructuring Costs
13. RESTRUCTURING COSTS

In February 2021, we announced a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacted our operations in EMEA and included the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan was implemented in phases and is substantially complete as of September 30, 2023. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits. From February 2021 to September 30, 2023, total expenses were $70.0 million.

The following table summarizes the activity of our February 2021 plan restructuring reserves (in millions):
Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2022:$1.9 $29.7 $31.6 
Adjustment to expense— 1.4 1.4 
Cash payments(1.6)(16.5)(18.1)
Foreign currency adjustments— (0.1)(0.1)
Balances as of September 30, 2023:$0.3 $14.5 $14.8 

In February 2023, management approved a new restructuring plan to implement identified opportunities to further streamline and improve operating performance. The additional restructuring activities are being implemented in phases and are expected to be substantially complete by the end of 2023. From February 2023 to September 30, 2023, total expenses were $15.4 million, representing estimated termination benefits to employees.

The following table summarizes the activity of our February 2023 plan restructuring reserves (in millions):

Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2022:$— $— $— 
Charged to expense - employee termination benefits3.3 12.1 15.4 
Cash payments(1.4)(3.8)(5.2)
Foreign currency adjustments0.1 0.1 0.2 
Balances as of September 30, 2023:$2.0 $8.4 $10.4 

In June 2023, management approved an additional restructuring plan to implement identified opportunities to further streamline and improve operating performance. The additional restructuring activities are expected to be substantially complete by the end of 2023. From June 2023 to September 30, 2023, total expenses were $9.0 million, representing estimated termination benefits to employees.
The following table summarizes the activity of our June 2023 plan restructuring reserves (in millions):

Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2022:$— $— $— 
Charged to expense - employee termination benefits4.3 4.7 9.0 
Cash payments(2.9)(1.8)(4.7)
Foreign currency adjustments— — — 
Balances as of September 30, 2023:$1.4 $2.9 $4.3 

Combined, the liability of $29.5 million as of September 30, 2023 consisted of $29.0 million recorded in Accrued payroll and employee benefits and $0.5 million recorded in Other long-term liabilities in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the three months ended September 30, 2023 were $0.2 million, $1.3 million and $0.0 million, respectively, in the condensed consolidated statements of income (loss). The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the nine months ended September 30, 2023 were $3.9 million, $16.6 million and $5.3 million, respectively, in the condensed consolidated statements of income (loss).
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Leases
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Leases
14. LEASES

We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 16 years, which includes our determination to exercise renewal options.

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our condensed consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.

The components of lease expense were as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
Operating lease cost$15.7 $14.2 $47.2 $43.2 
Finance lease cost:
  Amortization of right-of-use assets$0.1 $0.1 $0.3 $0.3 
  Interest on lease liabilities0.2 0.2 0.6 0.6 
        Total finance lease cost$0.3 $0.3 $0.9 $0.9 

Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.

Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three and nine months ended September 30, 2023 and 2022. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three and nine months ended September 30, 2023 and 2022.

Supplemental cash flow information related to leases was as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
Cash paid for amounts included in the measurement of lease liabilities:
  Operating cash flows from operating leases$10.6 $9.5 $30.4 $28.1 
  Operating cash flows from finance leases$0.2 $0.2 $0.6 $0.6 
  Financing cash flows from finance leases$0.1 $0.1 $0.3 $0.3 
Right-of-use assets obtained in exchange for new lease obligations:
  Operating leases$36.7 $2.3 $49.0 $9.4 

Supplemental balance sheet information related to leases was as follows (in millions):
September 30, 2023December 31, 2022
Operating Leases
  Operating lease right-of-use assets$200.0 $181.0 
  Current operating lease liabilities$39.1 $36.3 
  Operating lease liabilities167.2 153.6 
     Total operating lease liabilities$206.3 $189.9 

Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions):
September 30, 2023December 31, 2022
Finance Leases
  Property, plant and equipment, gross$11.8 $11.9 
  Less: accumulated depreciation and amortization(5.7)(5.5)
      Property, plant and equipment, net$6.1 $6.4 
  Current maturities of long-term debt and notes payable$0.5 $0.5 
  Long-term debt, net of current maturities9.7 10.1 
      Total finance lease liabilities$10.2 $10.6 

September 30, 2023December 31, 2022
Weighted Average Remaining Lease Term
  Operating leases - in years77
  Finance leases - in years1415
Weighted Average Discount Rate
  Operating leases3.8 %3.0 %
  Finance leases6.4 %6.3 %

Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,Operating LeasesFinance Leases
2023 (excluding the nine months ended September 30, 2023)
$10.4 $0.3 
202445.5 1.2 
202542.6 1.1 
202631.2 1.1 
202724.7 1.1 
Thereafter82.7 11.9 
   Total lease payments237.1 16.7 
Less imputed interest(30.8)(6.5)
    Total$206.3 $10.2 

The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over.

As of September 30, 2023, operating leases that have not commenced are not material.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure                
Net Income (Loss) Attributable to Parent $ 106,257 $ (1,162,251) $ 68,962 $ (162,808) $ (925,114) $ (3,367,347) $ (987,032) $ (4,455,269)
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Basis of Presentation and Use of Estimates (Policies)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation

In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022.
Subsequent Events, Policy We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.
Use of Estimates
Use of Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.
Revenue Recognition
Revenue Recognition

We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the standalone selling price for
each distinct product or service. The method used to determine the standalone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.

We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.

At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.

Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation.

We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.

The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

Reagent Rental Agreements

Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification as operating or sales-type lease. The lease term used in performing the lease classification test, includes the noncancellable period of the lease together with those periods covered by lease extension options if the customer is reasonably certain to exercise that option, the periods covered by lease termination options if the customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term for reagent rental agreements, including the impact from any associated contractual termination penalties, is subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee to purchase the underlying asset.

We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and
consideration of any fixed/minimum payments as well as estimates of variable consideration. After we have allocated the transaction price to the lease and non-lease elements, the amount of variable payments allocated to such elements are recognized as income in accordance with ASC 842 or ASC 606, as applicable.

Maintenance services and reagents are allocated to the non-lease elements. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.

Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial, and we do not enter into direct finance leases.

Revenue attributed to the lease elements of our reagent rental arrangements represented approximately 3% of total revenue for both the three and nine months ended September 30, 2023 and September 30, 2022. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).

Contract costs:

As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss).

Disaggregation of Revenue:

The following table presents our revenues disaggregated by geographic region (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
United States$275.4 $284.1 $858.8 $848.2 
EMEA193.1 200.1 609.1 636.3 
APAC118.9 156.8 398.9 470.3 
Other (primarily Canada and Latin America)44.7 39.8 123.3 117.2 
Total net sales$632.1 $680.8 $1,990.1 $2,072.0 

The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).

Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2023 and December 31, 2022 was $66.5 million and $71.9 million, respectively. The short-term deferred revenue balance at September 30, 2023 and December 31, 2022 was $49.1 million and $52.2 million, respectively.
Standard Product Warranty, Policy We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).
Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the nine months ended September 30, 2023 and 2022 were as follows (in millions):
Nine Months Ended
September 30,
20232022
Balance at beginning of period$10.6 $12.7 
Provision for warranty6.4 6.7 
Actual warranty costs(9.0)(8.8)
Balance at end of period$8.0 $10.6 
Accounts Receivable and Allowance for Credit Losses
Accounts Receivable and Allowance for Credit Losses

We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.

Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.


Changes in our allowance for credit losses were as follows (in millions):
Nine Months Ended
September 30,
20232022
Balance at beginning of period$15.0 $15.1 
Provision for expected credit losses0.9 1.2 
Write-offs charged against the allowance(1.3)(2.3)
 Recoveries collected0.5 0.1 
Balance at end of period$15.1 $14.1 
Recent Accounting Pronouncements Issued and to be Adopted Recent Accounting Pronouncements Issued and to be AdoptedThere are no new accounting pronouncements recently issued or newly effective that had, or are expected to have, a material impact on the Company's condensed consolidated financial statements.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Revenue from External Customers by Geographic Areas [Table Text Block]
The following table presents our revenues disaggregated by geographic region (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
United States$275.4 $284.1 $858.8 $848.2 
EMEA193.1 200.1 609.1 636.3 
APAC118.9 156.8 398.9 470.3 
Other (primarily Canada and Latin America)44.7 39.8 123.3 117.2 
Total net sales$632.1 $680.8 $1,990.1 $2,072.0 
Schedule of Product Warranty Liability [Table Text Block] Change in our warranty liability for the nine months ended September 30, 2023 and 2022 were as follows (in millions):
Nine Months Ended
September 30,
20232022
Balance at beginning of period$10.6 $12.7 
Provision for warranty6.4 6.7 
Actual warranty costs(9.0)(8.8)
Balance at end of period$8.0 $10.6 
Accounts Receivable, Allowance for Credit Loss [Table Text Block]
Changes in our allowance for credit losses were as follows (in millions):
Nine Months Ended
September 30,
20232022
Balance at beginning of period$15.0 $15.1 
Provision for expected credit losses0.9 1.2 
Write-offs charged against the allowance(1.3)(2.3)
 Recoveries collected0.5 0.1 
Balance at end of period$15.1 $14.1 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements, Recurring and Nonrecurring
Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2023 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $7.5 $— $7.5 
Time deposits— 44.7 — 44.7 
Money market funds120.1 — — 120.1 
Total cash equivalents (a)120.1 52.2 — 172.3 
Restricted investments (b)6.9 — — 6.9 
Equity securities (c)6,947.6 — — 6,947.6 
Loan under the fair value option (d)— — 290.5 290.5 
Available-for-sale investments:
Corporate debt securities— 590.6 — 590.6 
U.S. government sponsored agencies— 283.7 — 283.7 
Foreign government obligations— 10.0 — 10.0 
Municipal obligations— 13.9 — 13.9 
Asset-backed securities— 342.5 — 342.5 
Total available-for-sale investments (e)— 1,240.7 — 1,240.7 
Forward foreign exchange contracts (f)— 0.7 — 0.7 
Total financial assets carried at fair value$7,074.6 $1,293.6 $290.5 $8,658.7 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (g)$— $1.0 $— $1.0 
Contingent consideration (h)— — 17.1 17.1 
Total financial liabilities carried at fair value$— $1.0 $17.1 $18.1 
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $21.1 $— $21.1 
Time deposits5.7 — — 5.7 
Asset-backed securities— 1.4 — 1.4 
U.S. government sponsored agencies— 6.0 — 6.0 
Money market funds31.5 — — 31.5 
Total cash equivalents (a)37.2 28.5 — 65.7 
Restricted investments (b)6.8 — — 6.8 
Equity securities (c)8,530.4 — — 8,530.4 
Loan under the fair value option (d)— — 322.6 322.6 
Available-for-sale investments:
Corporate debt securities— 699.3 — 699.3 
U.S. government sponsored agencies— 230.7 — 230.7 
Foreign government obligations— 13.5 — 13.5 
Municipal obligations— 23.1 — 23.1 
Asset-backed securities— 333.4 — 333.4 
Total available-for-sale investments (e)— 1,300.0 — 1,300.0 
Forward foreign exchange contracts (f)— 1.5 — 1.5 
Total financial assets carried at fair value$8,574.4 $1,330.0 $322.6 $10,227.0 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)$— $6.2 $— $6.2 
Contingent consideration (h)— — 35.6 35.6 
Total financial liabilities carried at fair value$— $6.2 $35.6 $41.8 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2023December 31, 2022
Restricted investments$5.6 $5.6 
Other investments1.3 1.2 
    Total$6.9 $6.8 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2023December 31, 2022
Short-term investments$60.3 $56.5 
Other investments6,887.3 8,473.9 
        Total$6,947.6 $8,530.4 
(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.

(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.

(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.

(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023.
Debt Securities, Available-for-sale
Available-for-sale investments consist of the following (in millions):
 September 30, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$598.0 $0.3 $(7.7)$590.6 
Municipal obligations14.1 — (0.2)13.9 
Asset-backed securities347.3 — (4.8)342.5 
U.S. government sponsored agencies287.1 — (3.4)283.7 
Foreign government obligations10.2 — (0.2)10.0 
 $1,256.7 $0.3 $(16.3)$1,240.7 
Available-for-sale investments consist of the following (in millions):
 December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Estimated
Fair
Value
Short-term investments:    
Corporate debt securities$709.9 $0.2 $(10.8)$699.3 
Municipal obligations23.4 — (0.3)23.1 
Asset-backed securities339.6 0.1 (6.3)333.4 
U.S. government sponsored agencies233.9 — (3.2)230.7 
Foreign government obligations13.8 — (0.3)13.5 
Total$1,320.6 $0.3 $(20.9)$1,300.0 
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date
The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2023 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$473.6 $469.5 
Mature in one to five years636.7 627.8 
Mature in more than five years146.4 143.4 
Total$1,256.7 $1,240.7 
Discussion of current derivative risk management
The following is a summary of our forward foreign exchange contracts (in millions):
 September 30,
 2023
Contracts maturing in October through December 2023 to sell foreign currency: 
Notional value$701.5 
Unrealized loss$(0.4)
Contracts maturing in October through December 2023 to purchase foreign currency: 
Notional value$80.1 
Unrealized gain$0.1 
Fair Value Measurement Inputs and Valuation Techniques
The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):

December 31, 2022$322.6 
Net decrease in estimated fair market value of the loan included in (Gains) losses in fair market value of equity securities and loan receivable
$(28.9)
Foreign currency exchange gains (losses), net$(3.2)
September 30, 2023$290.5 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill and Other Purchased Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes to goodwill by segment
Changes to goodwill by segment are as follows (in millions):
Life
Science		Clinical
Diagnostics		Total
Balances as of December 31, 2022:
Goodwill$333.3 $408.4 $741.7 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net291.5 115.0 406.5 
Acquisitions— 0.40.4 
Foreign currency adjustments— 0.1 0.1 
Period increase, net— 0.5 0.5 
Balances as of September 30, 2023:
Goodwill333.3 408.9 742.2 
Accumulated impairment losses(41.8)(293.4)(335.2)
Goodwill, net$291.5 $115.5 $407.0 
Schedule of identifiable purchased intangible assets with definite lives Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):
September 30, 2023
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.2$104.3 $(93.6)$10.7 
Know how2.0165.1 (156.2)8.9 
Developed product technology12.2215.5 (128.4)87.1 
Licenses5.158.8 (41.1)17.7 
Tradenames5.86.0 (4.5)1.5 
Covenants not to compete2.56.5 (4.7)1.8 
     Total finite-lived intangible assets556.2 (428.5)127.7 
In-process research and development186.5 — 186.5 
     Total purchased intangible assets $742.7 $(428.5)$314.2 

 December 31, 2022
Weighted-Average Remaining Amortization Period (years)Purchase
Price		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships/lists5.0$104.7 $(89.9)$14.8 
Know how2.8166.2 (153.9)12.3 
Developed product technology12.8211.1 (121.6)89.5 
Licenses5.859.0 (38.5)20.5 
Tradenames6.66.1 (4.5)1.6 
Covenants not to compete3.16.4 (4.0)2.4 
     Total finite-lived intangible assets553.5 (412.4)141.1 
In-process research and development191.0 — 191.0 
     Total purchased intangible assets $744.5 $(412.4)$332.1 
Finite-lived Intangible Assets Amortization Expense [Table Text Block]
Amortization expense related to purchased intangible assets is as follows (in millions):

Three Months EndedNine Months Ended
 September 30,September 30,
 2023202220232022
Amortization expense$6.2 $6.2 $18.1 $18.8 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Inventory (Tables)
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current Following are the components of Inventory at September 30, 2023 and December 31, 2022 (in millions):
September 30, 2023December 31, 2022
Inventory:
  Raw materials$230.4 $228.8 
  Work in process244.5 220.9 
  Finished goods 300.9 269.6 
      Total Inventory$775.8 $719.3 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Cash Flow Information (Tables)
 9 Months Ended
Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures
The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):
Nine Months Ended
September 30, 2023September 30, 2022
Net loss$(987.0)$(4,455.3)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization108.7 101.8 
Reduction in the carrying amount of right-of-use assets30.7 29.8 
Share-based compensation45.1 42.8 
Losses from change in fair market value of equity securities and loan receivable1,576.5 6,172.3 
Gain on divestiture of a division— (1.4)
Changes in fair value of contingent consideration(18.5)— 
Payments for operating lease liabilities(30.4)(28.1)
(Increase) decrease in accounts receivable31.6 (44.5)
Increase in inventories(61.7)(150.6)
(Increase) decrease in other current assets15.0 (11.9)
Decrease in accounts payable and other current liabilities(72.4)(69.7)
Increase (decrease) in income taxes payable56.4 (39.2)
Decrease in deferred income taxes(397.4)(1,439.1)
Increase (decrease) in other long-term liabilities3.9 (2.0)
Other(6.6)9.9 
Net cash provided by operating activities$293.9 $114.8 
Non-cash investing activities:
Purchased property, plant and equipment$2.9 $3.3 
Purchased marketable securities and investments$— $11.8 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Debt (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments The principal components of long-term debt are as follows (in millions):
September 30,
2023		December 31,
2022
3.3%, Senior Notes due 2027
$400.0 $400.0 
3.7%, Senior Notes due 2032
800.0 800.0 
Less unamortized discounts and debt issuance costs(11.0)(12.4)
Long-term debt less unamortized discounts and debt issuance costs1,189.0 1,187.6 
Finance leases and other debt10.2 10.6 
Less current maturities(0.5)(0.5)
Long-term debt$1,198.7 $1,197.7 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions):
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of December 31, 2022:$(466.5)$10.0 $(10.3)$(466.8)
Other comprehensive income (loss), before reclassifications(34.4)0.3 3.7 (30.4)
Amounts reclassified from Accumulated other comprehensive income (loss)— (0.4)1.1 0.7 
Income tax effects0.1 — (1.1)(1.0)
Other comprehensive income (loss), net of income taxes(34.3)(0.1)3.7 (30.7)
Balances as of September 30, 2023:$(500.8)$9.9 $(6.6)$(497.5)
Foreign currency translation adjustmentsForeign other post-employment benefits adjustmentsNet unrealized holding gains (losses) on available-for-sale investmentsTotal accumulated other comprehensive income (loss)
Balances as of December 31, 2021:$(170.5)$(10.9)$5.8 $(175.6)
Other comprehensive income (loss), before reclassifications(654.4)1.4 (23.3)(676.3)
Amounts reclassified from Accumulated other comprehensive income (loss)— 0.2 0.6 0.8 
Income tax effects1.1 (0.5)5.3 5.9 
Other comprehensive income (loss), net of income taxes(653.3)1.1 (17.4)(669.6)
Balances as of September 30, 2022:$(823.8)$(9.8)$(11.6)$(845.2)
Reclassification Out of Accumulated Other Comprehensive Income
The impact to income (loss) before income taxes for amounts reclassified out of accumulated other comprehensive
income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in
millions):
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings (Loss) Per Share (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands):
Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Basic weighted average shares outstanding29,102 29,733 29,349 29,819 
Effect of potentially dilutive stock options, restricted stock and performance stock awards121 — — — 
Diluted weighted average common shares outstanding29,223 29,733 29,349 29,819 
Anti-dilutive shares154 541 229 541 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Other Income, Net (Tables)
 9 Months Ended
Sep. 30, 2023
Other Income and Expenses [Abstract]  
Schedule of other income (expense), net
Other income, net includes the following components (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Interest and investment income$(17.3)$(8.0)$(84.1)$(45.7)
Net realized losses on investments0.1 0.2 1.6 0.6 
Current expected credit losses on loans— 5.1 — 5.1 
Gain on divestiture of a division— — — (1.4)
Escrow receipts on prior acquisition(2.5)— (2.5)— 
Other income(0.7)(0.4)(2.4)(1.0)
Other income, net$(20.4)$(3.1)$(87.4)$(42.4)
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Information regarding operating profit (loss) for the three months ended September 30, 2023 and 2022 is as follows (in millions):

Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2023$263.5 $368.1 $0.5 
 2022$317.9 $361.9 $1.0 
Operating profit (loss)2023$13.0 $78.0 $(0.1)
 2022$51.4 $43.9 $(0.7)



Information regarding operating profit (loss) for the nine months ended September 30, 2023 and 2022 is as follows (in millions):
Life
Science		Clinical
Diagnostics		Other
Operations
Net sales2023$887.3 $1,100.3 $2.5 
2022$987.5 $1,081.4 $3.1 
Operating profit (loss)2023$76.7 $166.1 $(0.3)
 2022$197.6 $167.8 $(1.5)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following reconciles total segment profit to consolidated loss before income taxes (in millions):

Three Months EndedNine Months Ended
September 30,September 30,
 2023202220232022
Operating profit$90.9 $94.6 $242.5 $363.9 
Interest expense(12.3)(11.6)(37.2)(26.5)
Foreign currency exchange gains (losses), net1.7 (4.4)5.3 (3.1)
Change in fair market value of equity securities and loan receivable36.4 (289.0)(1,576.5)(6,172.3)
Other income, net20.4 3.1 87.4 42.4 
Consolidated income (loss) before income taxes$137.1 $(207.3)$(1,278.5)$(5,795.6)
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring Costs (Tables)
 9 Months Ended
Sep. 30, 2023
Restructuring Costs [Abstract]  
Restructuring and Related Costs
The following table summarizes the activity of our February 2021 plan restructuring reserves (in millions):
Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2022:$1.9 $29.7 $31.6 
Adjustment to expense— 1.4 1.4 
Cash payments(1.6)(16.5)(18.1)
Foreign currency adjustments— (0.1)(0.1)
Balances as of September 30, 2023:$0.3 $14.5 $14.8 
The following table summarizes the activity of our February 2023 plan restructuring reserves (in millions):

Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2022:$— $— $— 
Charged to expense - employee termination benefits3.3 12.1 15.4 
Cash payments(1.4)(3.8)(5.2)
Foreign currency adjustments0.1 0.1 0.2 
Balances as of September 30, 2023:$2.0 $8.4 $10.4 
The following table summarizes the activity of our June 2023 plan restructuring reserves (in millions):

Life ScienceClinical DiagnosticsTotal
Balances as of December 31, 2022:$— $— $— 
Charged to expense - employee termination benefits4.3 4.7 9.0 
Cash payments(2.9)(1.8)(4.7)
Foreign currency adjustments— — — 
Balances as of September 30, 2023:$1.4 $2.9 $4.3 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Tables)
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Lease, Cost The components of lease expense were as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
Operating lease cost$15.7 $14.2 $47.2 $43.2 
Finance lease cost:
  Amortization of right-of-use assets$0.1 $0.1 $0.3 $0.3 
  Interest on lease liabilities0.2 0.2 0.6 0.6 
        Total finance lease cost$0.3 $0.3 $0.9 $0.9 
Lessee Supplemental Cash Flow Information
Supplemental cash flow information related to leases was as follows (in millions):
Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
Cash paid for amounts included in the measurement of lease liabilities:
  Operating cash flows from operating leases$10.6 $9.5 $30.4 $28.1 
  Operating cash flows from finance leases$0.2 $0.2 $0.6 $0.6 
  Financing cash flows from finance leases$0.1 $0.1 $0.3 $0.3 
Right-of-use assets obtained in exchange for new lease obligations:
  Operating leases$36.7 $2.3 $49.0 $9.4 
Lessee Supplemental Balance Sheet Information
Supplemental balance sheet information related to leases was as follows (in millions):
September 30, 2023December 31, 2022
Operating Leases
  Operating lease right-of-use assets$200.0 $181.0 
  Current operating lease liabilities$39.1 $36.3 
  Operating lease liabilities167.2 153.6 
     Total operating lease liabilities$206.3 $189.9 

Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions):
September 30, 2023December 31, 2022
Finance Leases
  Property, plant and equipment, gross$11.8 $11.9 
  Less: accumulated depreciation and amortization(5.7)(5.5)
      Property, plant and equipment, net$6.1 $6.4 
  Current maturities of long-term debt and notes payable$0.5 $0.5 
  Long-term debt, net of current maturities9.7 10.1 
      Total finance lease liabilities$10.2 $10.6 

September 30, 2023December 31, 2022
Weighted Average Remaining Lease Term
  Operating leases - in years77
  Finance leases - in years1415
Weighted Average Discount Rate
  Operating leases3.8 %3.0 %
  Finance leases6.4 %6.3 %
Maturities Of Lease Liabilities For Operating and Finance Leases
Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,Operating LeasesFinance Leases
2023 (excluding the nine months ended September 30, 2023)
$10.4 $0.3 
202445.5 1.2 
202542.6 1.1 
202631.2 1.1 
202724.7 1.1 
Thereafter82.7 11.9 
   Total lease payments237.1 16.7 
Less imputed interest(30.8)(6.5)
    Total$206.3 $10.2 
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Line Items]                    
Net sales $ 632,124 $ 680,800 $ 1,990,078 $ 2,071,961            
Cost of goods sold 296,441 308,233 929,495 901,728            
Deferred Revenue 66,500   66,500       $ 71,900      
Retained earnings 8,910,921   8,910,921       9,898,203      
Accumulated other comprehensive loss (497,561)   (497,561)       (466,822)      
Total stockholders' equity $ 8,416,198 8,477,467 $ 8,416,198 8,477,467 $ 8,446,893 $ 9,763,716 9,615,252 $ 8,945,035 $ 10,203,284 $ 13,685,236
Revenue Allocation Percent To Lease Elements 3.00%   3.00%              
Additional paid-in-capital $ 439,455   $ 439,455       447,454      
Selling, general and administrative expense 201,199 211,113 634,576 615,598            
Research and Development Expense 43,535 66,808 183,528 190,689            
Interest expense 12,398 11,663 37,078 26,431            
Other Nonoperating Income (Expense) 20,446 3,062 87,365 42,369            
Deferred Revenue, Current 49,100   49,100       $ 52,200      
Europe [Member]                    
Organization, Consolidation and Presentation of Financial Statements [Line Items]                    
Net sales 193,100 200,100 609,100 636,300            
Asia Pacific [Member]                    
Organization, Consolidation and Presentation of Financial Statements [Line Items]                    
Net sales 118,900 156,800 398,900 470,300            
UNITED STATES                    
Organization, Consolidation and Presentation of Financial Statements [Line Items]                    
Net sales 275,400 284,100 858,800 848,200            
Americas [Member]                    
Organization, Consolidation and Presentation of Financial Statements [Line Items]                    
Net sales $ 44,700 $ 39,800 $ 123,300 $ 117,200            
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Warranty accrual, beginning of period $ 10.6 $ 12.7
Provision for warranty 6.4 6.7
Actual warranty costs (9.0) (8.8)
Warranty accrual, end of period $ 8.0 $ 10.6
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Accounts Receivable, Allowance for Credit Loss $ 15.1 $ 14.1 $ 15.0 $ 15.1
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 0.9 1.2    
Allowance for Loan and Lease Losses, Write-offs (1.3) (2.3)    
Accounts Receivable, Allowance for Credit Loss, Recovery $ 0.5 $ 0.1    
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
1. Basis of Presentation and Use of Estimates (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Revenue Allocation Percent To Lease Elements 3.00% 3.00%
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Unrealized Gain on Securities $ 42.5        
Debt Securities, Trading, and Equity Securities, FV-NI 290.5 $ 290.5   $ 322.6  
Debt Securities, Available-for-sale [1] 1,240.7 1,240.7      
Fair Value, Option, Changes in Fair Value, Gain (Loss) (4.9) (28.9)      
Foreign exchange (gains) losses, net   (3.2)      
Fair Value, Option, Loans Held as Assets [Abstract]          
Debt Securities [2]         $ 400.0
Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions 10.8 0.4 [2]      
Derivative, Forward Interest Rate         1.50%
Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract]          
Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net $ (5.9) 28.5 [2]      
Equity Securities, FV-NI, Unrealized Loss   (1,556.1)      
Changes in fair value of contingent consideration   $ (18.5) $ 0.0    
Ordinary voting shares [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment ownership percentage 38.00% 38.00%      
Preference shares [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investment ownership percentage 28.00% 28.00%      
Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] $ 6.9 $ 6.9   6.8  
Equity Securities [4] 6,947.6 6,947.6   8,530.4  
Debt Securities, Trading, and Equity Securities, FV-NI [2] 290.5 290.5   322.6  
Debt Securities, Available-for-sale [1] 1,240.7 1,240.7   1,300.0  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 0.7 0.7   1.5  
Assets, Fair Value Disclosure 8,658.7 8,658.7   10,227.0  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 1.0 1.0   6.2  
Business Combination, Contingent Consideration, Liability [7] 17.1 17.1   35.6  
Liabilities, Fair Value Disclosure 18.1 18.1   41.8  
Fair Value, Recurring | Research and Development Expense          
Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract]          
Changes in fair value of contingent consideration 14.8 14.4      
Fair Value, Recurring | Selling, General and Administrative Expenses          
Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract]          
Changes in fair value of contingent consideration 4.1 4.1      
Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] 6.9 6.9   6.8  
Equity Securities [4] 6,947.6 6,947.6   8,530.4  
Debt Securities, Trading, and Equity Securities, FV-NI [2] 0.0 0.0   0.0  
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 0.0 0.0   0.0  
Assets, Fair Value Disclosure 7,074.6 7,074.6   8,574.4  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 0.0 0.0   0.0  
Business Combination, Contingent Consideration, Liability [7] 0.0 0.0   0.0  
Liabilities, Fair Value Disclosure 0.0 0.0   0.0  
Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] 0.0 0.0   0.0  
Equity Securities [4] 0.0 0.0   0.0  
Debt Securities, Trading, and Equity Securities, FV-NI [2] 0.0 0.0   0.0  
Debt Securities, Available-for-sale 1,240.7 1,240.7   1,300.0 [1]  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 0.7 0.7   1.5  
Assets, Fair Value Disclosure 1,293.6 1,293.6   1,330.0  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 1.0 1.0   6.2  
Business Combination, Contingent Consideration, Liability [7] 0.0 0.0   0.0  
Liabilities, Fair Value Disclosure 1.0 1.0   6.2  
Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] 0.0 0.0   0.0  
Equity Securities [4] 0.0 0.0   0.0  
Debt Securities, Trading, and Equity Securities, FV-NI [2] 290.5 290.5   322.6  
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure [5] 0.0 0.0   0.0  
Assets, Fair Value Disclosure 290.5 290.5   322.6  
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure [6] 0.0 0.0   0.0  
Business Combination, Contingent Consideration, Liability [7] 17.1 17.1   35.6  
Liabilities, Fair Value Disclosure 17.1 17.1   35.6  
Asset-backed Securities [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       1.4  
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       0.0  
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       1.4  
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       0.0  
Commercial Paper [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 7.5 7.5   21.1  
Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 7.5 7.5   21.1  
Commercial Paper [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
Time Deposits [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 44.7 44.7   5.7  
Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   5.7  
Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 44.7 44.7   0.0  
Time Deposits [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
Money Market Funds [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 120.1 120.1   31.5  
Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 120.1 120.1   31.5  
Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
Money Market Funds [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
Cash Equivalents [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 172.3 172.3   65.7  
Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 120.1 120.1   37.2  
Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 52.2 52.2   28.5  
Cash Equivalents [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8] 0.0 0.0   0.0  
US Treasury Securities | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       6.0  
US Treasury Securities | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       6.0  
US Treasury Securities | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       0.0  
Foreign Government Debt [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Cash and Cash Equivalents, Fair Value Disclosure [8]       0.0  
Municipal Obligations (Member) | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 13.9 13.9   23.1  
Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 13.9 13.9   23.1  
Municipal Obligations (Member) | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Foreign Government Obligations [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 10.0 10.0   13.5  
Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 10.0 10.0   13.5  
Foreign Government Obligations [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Corporate Debt Securities [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 590.6 590.6   699.3  
Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 590.6 590.6   699.3  
Corporate Debt Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
US Government Sponsored Agencies [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 283.7 283.7   230.7  
US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 283.7 283.7   230.7  
US Government Sponsored Agencies [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Asset-backed Securities [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 342.5 342.5   333.4  
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 1 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 2 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 342.5 342.5   333.4  
Asset-backed Securities [Member] | Fair Value, Recurring | Fair Value, Inputs, Level 3 [Member]          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 0.0 0.0   0.0  
Short-term Investments [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Equity Securities [4] 60.3 60.3   56.5  
Debt Securities, Available-for-sale [1] 1,240.7 1,240.7   1,300.0  
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 13.9 13.9   23.1  
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 10.0 10.0   13.5  
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 590.6 590.6   699.3  
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 283.7 283.7   230.7  
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Debt Securities, Available-for-sale [1] 342.5 342.5   333.4  
Other Investments [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] 1.3 1.3   1.2  
Equity Securities [4] 6,887.3 6,887.3   8,473.9  
Restricted investment [Member] | Fair Value, Recurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Restricted Investments, at Fair Value [3] $ 5.6 $ 5.6   $ 5.6  
[1] Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.
[2] The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.
[3] Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2023December 31, 2022
Restricted investments$5.6 $5.6 
Other investments1.3 1.2 
    Total$6.9 $6.8 
[4] Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
September 30, 2023December 31, 2022
Short-term investments$60.3 $56.5 
Other investments6,887.3 8,473.9 
        Total$6,947.6 $8,530.4 
[5] Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.
[6] Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.
[7] Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023.
[8] Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Business Combination, Contingent Consideration, Liability [1] $ 17.1 $ 35.6
[1] Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023.
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2023
USD ($)
 [1]
Forward foreign exchange contract to sell foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Derivative, Notional Amount $ 701.5
Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments (0.4)
Forward foreign exchange contract to purchase foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Derivative, Notional Amount 80.1
Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments $ 0.1
[1] Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] $ 1,256.7  
Debt Securities, Available-for-sale [1] 1,240.7  
Fair Value, Recurring    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 1,240.7 $ 1,300.0
Fair Value, Recurring | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 590.6 699.3
Fair Value, Recurring | Municipal obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 13.9 23.1
Fair Value, Recurring | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 283.7 230.7
Fair Value, Recurring | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 10.0 13.5
Fair Value, Recurring | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale [1] 342.5 333.4
Fair Value, Recurring | Short-term Investments [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 1,256.7 1,320.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.3 0.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (16.3) (20.9)
Debt Securities, Available-for-sale [1] 1,240.7 1,300.0
Fair Value, Recurring | Short-term Investments [Member] | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 598.0 709.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.3 0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (7.7) (10.8)
Debt Securities, Available-for-sale [1] 590.6 699.3
Fair Value, Recurring | Short-term Investments [Member] | Municipal obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 14.1 23.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (0.2) (0.3)
Debt Securities, Available-for-sale [1] 13.9 23.1
Fair Value, Recurring | Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 287.1 233.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (3.4) (3.2)
Debt Securities, Available-for-sale [1] 283.7 230.7
Fair Value, Recurring | Short-term Investments [Member] | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 10.2 13.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.0 0.0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (0.2) (0.3)
Debt Securities, Available-for-sale [1] 10.0 13.5
Fair Value, Recurring | Short-term Investments [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost [1] 347.3 339.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax [1] 0.0 0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax [1] (4.8) (6.3)
Debt Securities, Available-for-sale [1] $ 342.5 $ 333.4
[1] Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details)
$ in Millions
Sep. 30, 2023
USD ($)
 [1]
Fair Value Disclosures [Abstract]  
Mature in less than one year $ 473.6
Mature in one to five years 636.7
Mature in more than five years 146.4
Total Amortized Cost 1,256.7
Mature in less than one year 469.5
Mature in one to five years 627.8
Mature in more than five years 143.4
Estimated Fair Value $ 1,240.7
[1] Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Interest Receivable, Current $ 11.2 $ 11.6
Ordinary voting shares [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Investment ownership percentage 38.00%  
Investment Owned, Balance, Shares 12,987,900  
Preference shares [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Investment ownership percentage 28.00%  
Investment Owned, Balance, Shares 9,588,908  
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill and Other Purchased Intangible Assets (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Goodwill [Line Items]    
Goodwill $ 742,200 $ 741,700
Accumulated impairment loss (335,200) (335,200)
Goodwill, net 406,953 406,488
Goodwill, Acquired During Period 400  
Goodwill, Foreign Currency Translation Gain (Loss) 100  
Goodwill, Period Increase (Decrease) 500  
Clinical Diagnostics    
Goodwill [Line Items]    
Goodwill 408,900 408,400
Accumulated impairment loss (293,400) (293,400)
Goodwill, net 115,500 115,000
Goodwill, Acquired During Period 400  
Goodwill, Foreign Currency Translation Gain (Loss) 100  
Goodwill, Period Increase (Decrease) 500  
Life Science    
Goodwill [Line Items]    
Goodwill 333,300 333,300
Accumulated impairment loss (41,800) (41,800)
Goodwill, net 291,500 $ 291,500
Goodwill, Acquired During Period 0  
Goodwill, Foreign Currency Translation Gain (Loss) 0  
Goodwill, Period Increase (Decrease) $ 0  
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Goodwill and Other Purchased Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]          
Goodwill, Acquired During Period     $ 400    
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 556,200   556,200   $ 553,500
Accumulated Amortization (428,500)   (428,500)   (412,400)
Net Carrying Amount 127,700   127,700   141,100
Amortization [Abstract]          
Amortization expense 6,200 $ 6,200 18,100 $ 18,800  
Purchased intangibles, net 314,187   314,187   332,147
Intangible Assets, Gross (Excluding Goodwill) $ 742,700   $ 742,700   $ 744,500
Customer Relationships [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 5 years 2 months 12 days   5 years 2 months 12 days   5 years
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 104,300   $ 104,300   $ 104,700
Accumulated Amortization (93,600)   (93,600)   (89,900)
Net Carrying Amount $ 10,700   $ 10,700   $ 14,800
Know How [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 2 years   2 years   2 years 9 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 165,100   $ 165,100   $ 166,200
Accumulated Amortization (156,200)   (156,200)   (153,900)
Net Carrying Amount $ 8,900   $ 8,900   $ 12,300
Developed Technology Rights [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 12 years 2 months 12 days   12 years 2 months 12 days   12 years 9 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 215,500   $ 215,500   $ 211,100
Accumulated Amortization (128,400)   (128,400)   (121,600)
Net Carrying Amount $ 87,100   $ 87,100   $ 89,500
Licensing Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 5 years 1 month 6 days   5 years 1 month 6 days   5 years 9 months 18 days
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 58,800   $ 58,800   $ 59,000
Accumulated Amortization (41,100)   (41,100)   (38,500)
Net Carrying Amount $ 17,700   $ 17,700   $ 20,500
Trade Names [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 5 years 9 months 18 days   5 years 9 months 18 days   6 years 7 months 6 days
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 6,000   $ 6,000   $ 6,100
Accumulated Amortization (4,500)   (4,500)   (4,500)
Net Carrying Amount $ 1,500   $ 1,500   $ 1,600
Noncompete Agreements [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Remaining Amortization Period 2 years 6 months   2 years 6 months   3 years 1 month 6 days
Finite-Lived Intangible Assets, Net [Abstract]          
Purchase Price $ 6,500   $ 6,500   $ 6,400
Accumulated Amortization (4,700)   (4,700)   (4,000)
Net Carrying Amount 1,800   1,800   2,400
In Process Research and Development [Member]          
Amortization [Abstract]          
Indefinite-lived Intangible Assets (Excluding Goodwill) $ 186,500   $ 186,500   $ 191,000
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 230,400 $ 228,800
Work in process 244,500 220,900
Finished goods 300,900 269,600
Inventory $ 775,818 $ 719,316
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Supplemental Cash Flow Elements [Abstract]                
Net loss $ 106,257 $ (1,162,251) $ 68,962 $ (162,808) $ (925,114) $ (3,367,347) $ (987,032) $ (4,455,269)
Depreciation and amortization             108,700 101,800
Reduction in the carrying amount of right-of-use assets             30,700 29,800
Share-based Compensation             45,100 42,800
(Gains) losses from change in fair market value of equity securities and loan receivable             1,576,500 6,172,300
Gain on Disposition of a division             0 (1,400)
Changes in fair value of contingent consideration             (18,500) 0
Payments of operating lease liabilities             (30,400) (28,100)
Decrease in accounts receivable             31,600 (44,500)
Decrease (increase) in inventories             (61,700) (150,600)
Increase in other current assets             15,000 (11,900)
Decrease in accounts payable and other current liabilities             (72,400) (69,700)
Increase in income taxes payable             56,400 (39,200)
Increase in deferred income taxes             (397,400) (1,439,100)
Increase in other long term liabilities             3,900 (2,000)
Other             (6,600) 9,900
Net cash provided by operating activities             293,896 114,790
Noncash or Part Noncash Acquisition, Fixed Assets Acquired             2,900 3,300
Noncash or Part Noncash Acquisition, Investments Acquired             $ 0 $ 11,800
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Long-Term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Other Long-term Debt, Current $ 500 $ 500
Long-term debt, net of current maturities 1,198,713 1,197,716
Finance Lease Obligations | Finance Leases and Other Debt    
Debt Instrument [Line Items]    
Other Long-term Debt 10,200 10,600
Senior Notes | Senior Notes    
Debt Instrument [Line Items]    
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net (11,000) (12,400)
Long-term debt 1,189,000 1,187,600
Senior Notes | 3.3%, Senior Notes due 2027    
Debt Instrument [Line Items]    
Senior Notes, Noncurrent $ 400,000 400,000
Debt Instrument, Interest Rate, Stated Percentage 3.30%  
Senior Notes | 3.7%, Senior Notes due 2032    
Debt Instrument [Line Items]    
Senior Notes, Noncurrent $ 800,000 $ 800,000
Debt Instrument, Interest Rate, Stated Percentage 3.70%  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     $ (466,822)  
Total other comprehensive income (loss) net of tax $ (124,699) $ (311,828) (30,739) $ (669,661)
Ending balance, Accumulated other comprehensive income (497,561)   (497,561)  
Other (income) expense, net (20,446) (3,062) (87,365) (42,369)
Accumulated Translation Adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     (466,500) (170,500)
Other Comprehensive Income (Loss), before Reclassifications, before Tax     (34,400) (654,400)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     0 0
Other Comprehensive Income (Loss), Tax     100 1,100
Total other comprehensive income (loss) net of tax     (34,300) (653,300)
Ending balance, Accumulated other comprehensive income (500,800) (823,800) (500,800) (823,800)
Accumulated Defined Benefit Plans Adjustment        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     10,000 (10,900)
Other Comprehensive Income (Loss), before Reclassifications, before Tax     300 1,400
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     400 (200)
Other Comprehensive Income (Loss), Tax     0 (500)
Total other comprehensive income (loss) net of tax     (100) 1,100
Ending balance, Accumulated other comprehensive income 9,900 (9,800) 9,900 (9,800)
Accumulated Defined Benefit Plans Adjustment | Reclassification Out Of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Other (income) expense, net 200 (100) 400 (200)
Accumulated Net Unrealized Investment Gain (Loss)        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     (10,300) 5,800
Other Comprehensive Income (Loss), before Reclassifications, before Tax     3,700 (23,300)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     (1,100) (600)
Other Comprehensive Income (Loss), Tax     (1,100) 5,300
Total other comprehensive income (loss) net of tax     3,700 (17,400)
Ending balance, Accumulated other comprehensive income (6,600) (11,600) (6,600) (11,600)
Accumulated Net Unrealized Investment Gain (Loss) | Reclassification Out Of Accumulated Other Comprehensive Income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Other (income) expense, net 100 200 1,100 600
AOCI Attributable to Parent        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance, Accumulated other comprehensive income     (466,800) (175,600)
Other Comprehensive Income (Loss), before Reclassifications, before Tax     (30,400) (676,300)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax     (700) (800)
Other Comprehensive Income (Loss), Tax     (1,000) 5,900
Total other comprehensive income (loss) net of tax     (30,700) (669,600)
Ending balance, Accumulated other comprehensive income $ (497,500) $ (845,200) $ (497,500) $ (845,200)
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Earnings (Loss) Per Share (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Basic weighted average shares outstanding 29,102 29,733 29,349 29,819
Effect of potentially dilutive stock options and restricted stock awards 121 0 0 0
Diluted weighted average common shares 29,223 29,733 29,349 29,819
Anti-dilutive shares 154 541 229 541
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Other Income, Net (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Interest and investment income $ (17,300) $ (8,000) $ (84,100) $ (45,700)
Net realized (gain) loss on investments (100) (200) (1,600) 600
Financing Receivable, Allowance for Credit Loss, Current 0 5,100   5,100
Increase (Decrease) in Deposit Assets 0 0 0 (1,400)
Escrow Deposit Disbursements Related to Property Acquisition (2,500) 0 (2,500) 0
Other Nonoperating (Income) (700)   (2,400)  
Other Nonoperating Expense   (400)   (1,000)
Other (income) expense, net $ (20,446) $ (3,062) $ (87,365) $ (42,369)
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Income Tax Disclosure [Abstract]          
Effective tax rate 22.50% 21.50% 22.80% 23.10%  
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit $ 18.8   $ 18.8    
Unrecognized Tax Benefits $ 92.0   92.0   $ 85.5
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount     $ 15.2    
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]        
Net sales $ 632,124 $ 680,800 $ 1,990,078 $ 2,071,961
Life Science        
Segment Reporting Information [Line Items]        
Net sales 263,500 317,900 887,300 987,500
Income before income taxes 13,000 51,400 76,700 197,600
Clinical Diagnostics        
Segment Reporting Information [Line Items]        
Net sales 368,100 361,900 1,100,300 1,081,400
Income before income taxes 78,000 43,900 166,100 167,800
Other Segments        
Segment Reporting Information [Line Items]        
Net sales 500 1,000 2,500 3,100
Income before income taxes $ (100) $ (700) $ (300) $ (1,500)
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Interest expense $ 12,398 $ 11,663 $ 37,078 $ 26,431
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 137,102 (207,318) (1,278,496) (5,795,555)
Marketable Securities, Unrealized Gain (Loss) 36,425 (288,999) (1,576,542) (6,172,306)
Net sales 632,124 680,800 1,990,078 2,071,961
Life Science        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes 13,000 51,400 76,700 197,600
Net sales 263,500 317,900 887,300 987,500
Other Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes (100) (700) (300) (1,500)
Net sales 500 1,000 2,500 3,100
Clinical Diagnostics        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes 78,000 43,900 166,100 167,800
Net sales 368,100 361,900 1,100,300 1,081,400
Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes 90,900 94,600 242,500 363,900
Segment Reconciling Items        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Marketable Securities, Unrealized Gain (Loss) 36,400 (289,000) (1,576,500) (6,172,300)
Foreign Currency Gain (Loss) | Segment Reconciling Items        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes 1,700 (4,400) 5,300 (3,100)
Other Nonoperating Income (Expense) | Segment Reconciling Items        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes 20,400 3,100 87,400 42,400
Interest Expense | Segment Reconciling Items        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Interest expense $ (12,300) $ (11,600) $ (37,200) $ (26,500)
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Information (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Segment Reporting, Asset Reconciling Item [Line Items]    
Assets $ 11,895,943 $ 13,501,666
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Restructuring Costs (Details) - USD ($)
$ in Millions
 3 Months Ended 4 Months Ended 8 Months Ended 9 Months Ended 32 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve $ 29.5 $ 29.5 $ 29.5 $ 29.5 $ 29.5  
Accounts Payable and Accrued Liabilities            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve 29.0 29.0 29.0 29.0 29.0  
Other Noncurrent Liabilities            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve 0.5 0.5 0.5 0.5 0.5  
Selling, General and Administrative Expenses            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve, Accrual Adjustment 1.3     16.6    
Cost of Sales            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve, Accrual Adjustment 0.2     3.9    
Research and Development Expense            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve, Accrual Adjustment 0.0     5.3    
European Reorganization            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges         70.0  
Restructuring Reserve 14.8 14.8 14.8 14.8 14.8 $ 31.6
Restructuring Reserve, Accrual Adjustment       1.4    
Payments for Restructuring       (18.1)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss       (0.1)    
European Reorganization | Life Science            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve 0.3 0.3 0.3 0.3 0.3 1.9
Restructuring Reserve, Accrual Adjustment       0.0    
Payments for Restructuring       (1.6)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss       0.0    
European Reorganization | Clinical Diagnostics            
Restructuring Cost and Reserve [Line Items]            
Restructuring Reserve 14.5 14.5 14.5 14.5 14.5 29.7
Restructuring Reserve, Accrual Adjustment       1.4    
Payments for Restructuring       (16.5)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss       (0.1)    
European and American Reorganization            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges   9.0 15.4 15.4    
Restructuring Reserve 10.4 10.4 10.4 10.4 10.4 0.0
Payments for Restructuring       (5.2)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss       (0.2)    
European and American Reorganization | Life Science            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges       3.3    
Restructuring Reserve 2.0 2.0 2.0 2.0 2.0 0.0
Payments for Restructuring       (1.4)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss       (0.1)    
European and American Reorganization | Clinical Diagnostics            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges       12.1    
Restructuring Reserve 8.4 8.4 8.4 8.4 8.4 0.0
Payments for Restructuring       (3.8)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss       (0.1)    
Additional European and American Reorganization            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges       9.0    
Restructuring Reserve 4.3 4.3 4.3 4.3 4.3 0.0
Payments for Restructuring       (4.7)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss       0.0    
Additional European and American Reorganization | Life Science            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges       4.3    
Restructuring Reserve 1.4 1.4 1.4 1.4 1.4 0.0
Payments for Restructuring       (2.9)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss       0.0    
Additional European and American Reorganization | Clinical Diagnostics            
Restructuring Cost and Reserve [Line Items]            
Restructuring Charges       4.7    
Restructuring Reserve $ 2.9 $ 2.9 $ 2.9 2.9 $ 2.9 $ 0.0
Payments for Restructuring       (1.8)    
Restructuring Reserve, Foreign Currency Translation (Gain) Loss       $ 0.0    
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Lessee, Lease, Description [Line Items]          
Operating Lease, Cost $ 15,700 $ 14,200 $ 47,200 $ 43,200  
Finance Lease, Right-of-Use Asset, Amortization 100 100 300 300  
Finance Lease, Interest Expense 200 200 600 600  
Finance Lease Cost 300 300 900 900  
Operating Lease, Payments 10,600 9,500 30,400 28,100  
Finance Lease, Interest Payment on Liability 200 200 600 600  
Finance Lease, Principal Payments 100 100 300 300  
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 36,700 $ 2,300 49,000 $ 9,400  
Operating lease right-of-use assets 200,013   200,013   $ 180,952
Current operating lease liabilities $ 39,116   $ 39,116   $ 36,336
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other current liabilities   Other current liabilities   Other current liabilities
Operating lease liabilities $ 167,179   $ 167,179   $ 153,597
Operating Lease, Liability 206,300   206,300   189,900
Finance Lease, Right-Of-Use Asset, before Accumulated Amortization 11,800   11,800   11,900
Finance Lease, Right-Of-Use Asset, Accumulated Amortization 5,700   5,700   5,500
Finance Lease, Right-Of-Use Asset, after Accumulated Amortization 6,100   6,100   6,400
Finance Lease, Liability, Current 500   500   500
Finance Lease, Liability, Noncurrent 9,700   9,700   10,100
Finance Lease, Liability $ 10,200   $ 10,200   $ 10,600
Operating Lease, Weighted Average Remaining Lease Term 7 years   7 years   7 years
Finance Lease, Weighted Average Remaining Lease Term 14 years   14 years   15 years
Operating Lease, Weighted Average Discount Rate, Percent 3.80%   3.80%   3.00%
Finance Lease, Weighted Average Discount Rate, Percent 6.40%   6.40%   6.30%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year $ 10,400   $ 10,400    
Finance Lease, Liability, Payments, Remainder of Fiscal Year 300   300    
Lessee, Operating Lease, Liability, to be Paid, Year One 45,500   45,500    
Finance Lease, Liability, to be Paid, Year One 1,200   1,200    
Lessee, Operating Lease, Liability, Payments, Due Year Two 42,600   42,600    
Finance Lease, Liability, Payments, Due Year Two 1,100   1,100    
Lessee, Operating Lease, Liability, Payments, Due Year Three 31,200   31,200    
Finance Lease, Liability, Payments, Due Year Three 1,100   1,100    
Lessee, Operating Lease, Liability, Payments, Due Year Four 24,700   24,700    
Finance Lease, Liability, Payments, Due Year Four 1,100   1,100    
Lessee, Operating Lease, Liability, Payments, Due after Year Five 82,700   82,700    
Finance Lease, Liability, Payments, Due after Year Five 11,900   11,900    
Lessee, Operating Lease, Liability, Payments, Due 237,100   237,100    
Finance Lease, Liability, Payment, Due 16,700   16,700    
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (30,800)   (30,800)    
Finance Lease, Liability, Undiscounted Excess Amount $ (6,500)   $ (6,500)    
Minimum          
Lessee, Lease, Description [Line Items]          
Lessee Operating And Finance Leases Remaining Lease Term     1 year    
Maximum          
Lessee, Lease, Description [Line Items]          
Lessee Operating And Finance Leases Remaining Lease Term     16 years    
XML 71 bio-20230930_htm.xml IDEA: XBRL DOCUMENT 0000012208 2023-01-01 2023-09-30 0000012208 us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0000012208 us-gaap:CommonClassBMember 2023-01-01 2023-09-30 0000012208 us-gaap:CommonClassAMember 2023-10-20 0000012208 us-gaap:CommonClassBMember 2023-10-20 0000012208 2023-09-30 0000012208 2022-12-31 0000012208 us-gaap:CommonClassAMember 2023-09-30 0000012208 us-gaap:CommonClassAMember 2022-12-31 0000012208 us-gaap:CommonClassBMember 2023-09-30 0000012208 us-gaap:CommonClassBMember 2022-12-31 0000012208 us-gaap:TreasuryStockCommonMember 2023-09-30 0000012208 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012208 bio:TreasuryClassAMember 2023-09-30 0000012208 bio:TreasuryClassAMember 2022-12-31 0000012208 2023-07-01 2023-09-30 0000012208 2022-07-01 2022-09-30 0000012208 2022-01-01 2022-09-30 0000012208 2021-12-31 0000012208 2022-09-30 0000012208 us-gaap:CommonStockMember 2022-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000012208 us-gaap:TreasuryStockCommonMember 2022-12-31 0000012208 us-gaap:RetainedEarningsMember 2022-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000012208 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000012208 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000012208 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000012208 2023-01-01 2023-03-31 0000012208 us-gaap:CommonStockMember 2023-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000012208 us-gaap:TreasuryStockCommonMember 2023-03-31 0000012208 us-gaap:RetainedEarningsMember 2023-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000012208 2023-03-31 0000012208 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0000012208 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000012208 2023-04-01 2023-06-30 0000012208 us-gaap:CommonStockMember 2023-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-06-30 0000012208 us-gaap:RetainedEarningsMember 2023-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000012208 2023-06-30 0000012208 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0000012208 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000012208 us-gaap:CommonStockMember 2023-09-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000012208 us-gaap:TreasuryStockCommonMember 2023-09-30 0000012208 us-gaap:RetainedEarningsMember 2023-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000012208 us-gaap:CommonStockMember 2021-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000012208 us-gaap:TreasuryStockCommonMember 2021-12-31 0000012208 us-gaap:RetainedEarningsMember 2021-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000012208 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000012208 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0000012208 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000012208 2022-01-01 2022-03-31 0000012208 us-gaap:CommonStockMember 2022-03-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000012208 us-gaap:TreasuryStockCommonMember 2022-03-31 0000012208 us-gaap:RetainedEarningsMember 2022-03-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000012208 2022-03-31 0000012208 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2022-04-01 2022-06-30 0000012208 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000012208 2022-04-01 2022-06-30 0000012208 us-gaap:CommonStockMember 2022-06-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000012208 us-gaap:TreasuryStockCommonMember 2022-06-30 0000012208 us-gaap:RetainedEarningsMember 2022-06-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000012208 2022-06-30 0000012208 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000012208 us-gaap:TreasuryStockCommonMember 2022-07-01 2022-09-30 0000012208 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000012208 us-gaap:CommonStockMember 2022-09-30 0000012208 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000012208 us-gaap:TreasuryStockCommonMember 2022-09-30 0000012208 us-gaap:RetainedEarningsMember 2022-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000012208 country:US 2023-07-01 2023-09-30 0000012208 country:US 2022-07-01 2022-09-30 0000012208 country:US 2023-01-01 2023-09-30 0000012208 country:US 2022-01-01 2022-09-30 0000012208 srt:EuropeMember 2023-07-01 2023-09-30 0000012208 srt:EuropeMember 2022-07-01 2022-09-30 0000012208 srt:EuropeMember 2023-01-01 2023-09-30 0000012208 srt:EuropeMember 2022-01-01 2022-09-30 0000012208 srt:AsiaPacificMember 2023-07-01 2023-09-30 0000012208 srt:AsiaPacificMember 2022-07-01 2022-09-30 0000012208 srt:AsiaPacificMember 2023-01-01 2023-09-30 0000012208 srt:AsiaPacificMember 2022-01-01 2022-09-30 0000012208 srt:AmericasMember 2023-07-01 2023-09-30 0000012208 srt:AmericasMember 2022-07-01 2022-09-30 0000012208 srt:AmericasMember 2023-01-01 2023-09-30 0000012208 srt:AmericasMember 2022-01-01 2022-09-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:ForeignGovernmentDebtMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2022-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000012208 bio:RestrictedInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 bio:RestrictedInvestmentMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0000012208 bio:OrdinaryVotingSharesMember 2023-09-30 0000012208 bio:PreferenceSharesMember 2023-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2023-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2023-09-30 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2022-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2023-09-30 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2023-07-01 2023-09-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2023-09-30 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2023-07-01 2023-09-30 0000012208 bio:LifeScienceMember 2022-12-31 0000012208 bio:ClinicalDiagnosticsMember 2022-12-31 0000012208 bio:LifeScienceMember 2023-01-01 2023-09-30 0000012208 bio:ClinicalDiagnosticsMember 2023-01-01 2023-09-30 0000012208 bio:LifeScienceMember 2023-09-30 0000012208 bio:ClinicalDiagnosticsMember 2023-09-30 0000012208 us-gaap:CustomerRelationshipsMember 2023-09-30 0000012208 bio:KnowHowMember 2023-09-30 0000012208 us-gaap:DevelopedTechnologyRightsMember 2023-09-30 0000012208 us-gaap:LicensingAgreementsMember 2023-09-30 0000012208 us-gaap:TradeNamesMember 2023-09-30 0000012208 us-gaap:NoncompeteAgreementsMember 2023-09-30 0000012208 us-gaap:InProcessResearchAndDevelopmentMember 2023-09-30 0000012208 us-gaap:CustomerRelationshipsMember 2022-12-31 0000012208 bio:KnowHowMember 2022-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000012208 us-gaap:LicensingAgreementsMember 2022-12-31 0000012208 us-gaap:TradeNamesMember 2022-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2022-12-31 0000012208 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000012208 bio:A33SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2023-09-30 0000012208 bio:A33SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2022-12-31 0000012208 bio:A37SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2023-09-30 0000012208 bio:A37SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2022-12-31 0000012208 us-gaap:SeniorNotesMember us-gaap:SeniorNotesMember 2023-09-30 0000012208 us-gaap:SeniorNotesMember us-gaap:SeniorNotesMember 2022-12-31 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2023-09-30 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2022-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-09-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-09-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-09-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-09-30 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-01 2023-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-07-01 2022-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-07-01 2023-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-07-01 2022-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-09-30 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-09-30 0000012208 bio:LifeScienceMember 2023-07-01 2023-09-30 0000012208 bio:ClinicalDiagnosticsMember 2023-07-01 2023-09-30 0000012208 us-gaap:AllOtherSegmentsMember 2023-07-01 2023-09-30 0000012208 bio:LifeScienceMember 2022-07-01 2022-09-30 0000012208 bio:ClinicalDiagnosticsMember 2022-07-01 2022-09-30 0000012208 us-gaap:AllOtherSegmentsMember 2022-07-01 2022-09-30 0000012208 us-gaap:AllOtherSegmentsMember 2023-01-01 2023-09-30 0000012208 bio:LifeScienceMember 2022-01-01 2022-09-30 0000012208 bio:ClinicalDiagnosticsMember 2022-01-01 2022-09-30 0000012208 us-gaap:AllOtherSegmentsMember 2022-01-01 2022-09-30 0000012208 us-gaap:OperatingSegmentsMember 2023-07-01 2023-09-30 0000012208 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0000012208 us-gaap:OperatingSegmentsMember 2023-01-01 2023-09-30 0000012208 us-gaap:OperatingSegmentsMember 2022-01-01 2022-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:InterestExpenseMember 2023-07-01 2023-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:InterestExpenseMember 2022-07-01 2022-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:InterestExpenseMember 2023-01-01 2023-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:InterestExpenseMember 2022-01-01 2022-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2023-07-01 2023-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2022-07-01 2022-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2023-01-01 2023-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2022-01-01 2022-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2023-07-01 2023-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2022-07-01 2022-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-07-01 2023-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-09-30 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-09-30 0000012208 bio:EuropeanReorganizationMember 2021-02-01 2023-09-30 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2022-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2022-12-31 0000012208 bio:EuropeanReorganizationMember 2022-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2023-01-01 2023-09-30 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2023-01-01 2023-09-30 0000012208 bio:EuropeanReorganizationMember 2023-01-01 2023-09-30 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2023-09-30 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2023-09-30 0000012208 bio:EuropeanReorganizationMember 2023-09-30 0000012208 bio:EuropeanAndAmericanReorganizationMember 2023-02-01 2023-09-30 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:LifeScienceMember 2022-12-31 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2022-12-31 0000012208 bio:EuropeanAndAmericanReorganizationMember 2022-12-31 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:LifeScienceMember 2023-01-01 2023-09-30 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2023-01-01 2023-09-30 0000012208 bio:EuropeanAndAmericanReorganizationMember 2023-01-01 2023-09-30 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:LifeScienceMember 2023-09-30 0000012208 bio:EuropeanAndAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2023-09-30 0000012208 bio:EuropeanAndAmericanReorganizationMember 2023-09-30 0000012208 bio:EuropeanAndAmericanReorganizationMember 2023-06-01 2023-09-30 0000012208 bio:AdditionalEuropeanAndAmericanReorganizationMember bio:LifeScienceMember 2022-12-31 0000012208 bio:AdditionalEuropeanAndAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2022-12-31 0000012208 bio:AdditionalEuropeanAndAmericanReorganizationMember 2022-12-31 0000012208 bio:AdditionalEuropeanAndAmericanReorganizationMember bio:LifeScienceMember 2023-01-01 2023-09-30 0000012208 bio:AdditionalEuropeanAndAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2023-01-01 2023-09-30 0000012208 bio:AdditionalEuropeanAndAmericanReorganizationMember 2023-01-01 2023-09-30 0000012208 bio:AdditionalEuropeanAndAmericanReorganizationMember bio:LifeScienceMember 2023-09-30 0000012208 bio:AdditionalEuropeanAndAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2023-09-30 0000012208 bio:AdditionalEuropeanAndAmericanReorganizationMember 2023-09-30 0000012208 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2023-09-30 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember 2023-09-30 0000012208 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0000012208 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000012208 srt:MinimumMember 2023-01-01 2023-09-30 0000012208 srt:MaximumMember 2023-01-01 2023-09-30 shares iso4217:USD iso4217:USD shares pure utr:Rate 0000012208 --12-31 2023 Q3 false http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent 10-Q true 2023-09-30 false 1-7928 BIO-RAD LABORATORIES, INC. DE 94-1381833 1000 Alfred Nobel Drive, Hercules, CA 94547 (510) 724-7000 Class A Common Stock, Par Value $0.0001 per share BIO NYSE Class B Common Stock, Par Value $0.0001 per share BIOb NYSE Yes Yes Large Accelerated Filer false false false false 24059355 5085815 457850000 434215000 1301143000 1356457000 5560000 5560000 15108000 15029000 457402000 494645000 775818000 719316000 123910000 124179000 25087000 23604000 3146770000 3157976000 1538545000 1508020000 1027156000 1009408000 511389000 498612000 200013000 180952000 406953000 406488000 314187000 332147000 7218161000 8830892000 98470000 94599000 11895943000 13501666000 111859000 135041000 154946000 194790000 476000 465000 103978000 32428000 39116000 36336000 147801000 169648000 558176000 568708000 1198713000 1197716000 1369556000 1770481000 167179000 153597000 186121000 195912000 3479745000 3886414000 25163999 25162075 24059355 24521583 2000 2000 5085815 5085815 5074130 5074130 1000 1000 439455000 447454000 1104644 640492 436620000 263586000 8910921000 9898203000 -497561000 -466822000 8416198000 9615252000 11895943000 13501666000 632124000 680800000 1990078000 2071961000 296441000 308233000 929495000 901728000 335683000 372567000 1060583000 1170233000 201199000 211113000 634576000 615598000 43535000 66808000 183528000 190689000 90949000 94646000 242479000 363946000 12398000 11663000 37078000 26431000 1680000 -4364000 5280000 -3133000 36425000 -288999000 -1576542000 -6172306000 20446000 3062000 87365000 42369000 137102000 -207318000 -1278496000 -5795555000 30845000 -44510000 -291464000 -1340286000 106257000 -162808000 -987032000 -4455269000 3.65 -5.48 -33.63 -149.41 29102000 29733000 29349000 29819000 3.64 -5.48 -33.63 -149.41 29223000 29733000 29349000 29819000 106257000 -162808000 -987032000 -4455269000 -126165000 -305666000 -34342000 -653301000 342000 -481000 72000 -1004000 1808000 -6643000 3675000 -17364000 -124699000 -311828000 -30739000 -669661000 -18442000 -474636000 -1017771000 -5124930000 2007482000 1981952000 1722173000 1800487000 46394000 23974000 40966000 137863000 81828000 51146000 -14119000 -44016000 293896000 114790000 114435000 77987000 104000 114000 0 1360000 0 100746000 537540000 1807148000 339033000 542639000 260849000 292727000 -51989000 -1149041000 0 1186220000 349000 367000 14168000 13218000 10118000 13876000 228728000 125000000 -225027000 1060195000 6891000 21167000 23771000 47111000 434544000 471133000 458315000 518244000 457850000 517943000 79000 12000 386000 289000 458315000 518244000 3000 447454000 -263586000 9898203000 -466822000 9615252000 0 0 0 68962000 0 68962000 0 0 0 0 58470000 58470000 0 16608000 0 0 0 16608000 0 -660000 5290000 -206000 0 4424000 3000 463402000 -258296000 9966959000 -408352000 9763716000 0 0 0 -1162251000 0 -1162251000 0 0 0 0 35490000 35490000 0 12559000 0 0 0 12559000 0 0 207407000 0 0 207407000 0 2089000 6919000 44000 0 4786000 3000 473872000 -458784000 8804664000 -372862000 8446893000 0 0 0 106257000 0 106257000 0 0 0 0 -124699000 -124699000 0 -5111000 0 0 0 -5111000 0 15952000 0 0 0 15952000 0 0 23608000 0 0 23608000 0 -45258000 45772000 0 0 514000 3000 439455000 -436620000 8910921000 -497561000 8416198000 3000 441733000 -106290000 13525343000 -175553000 13685236000 0 0 0 -3367347000 0 -3367347000 0 0 0 0 -132303000 -132303000 0 4177000 0 0 0 4177000 0 13521000 0 0 0 13521000 3000 459431000 -106290000 10157996000 -307856000 10203284000 0 0 0 -925114000 0 -925114000 0 0 0 0 -225530000 -225530000 0 443000 0 0 0 443000 0 13571000 0 0 0 13571000 125000000 125000000 0 696000 -4950000 -13000 0 -4267000 3000 471863000 -226340000 9232895000 -533386000 8945035000 0 0 0 -162808000 0 -162808000 0 0 0 0 -311828000 -311828000 0 7550000 0 0 0 7550000 0 15735000 0 0 0 15735000 0 49501000 -48079000 -305000 0 1117000 3000 430547000 -178261000 9070392000 -845214000 8477467000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">1. BASIS OF PRESENTATION AND USE OF ESTIMATES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the standalone selling price for </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">each distinct product or service. The method used to determine the standalone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reagent Rental Agreements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification as operating or sales-type lease. The lease term used in performing the lease classification test, includes the noncancellable period of the lease together with those periods covered by lease extension options if the customer is reasonably certain to exercise that option, the periods covered by lease termination options if the customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term for reagent rental agreements, including the impact from any associated contractual termination penalties, is subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee to purchase the underlying asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">consideration of any fixed/minimum payments as well as estimates of variable consideration. After we have allocated the transaction price to the lease and non-lease elements, the amount of variable payments allocated to such elements are recognized as income in accordance with ASC 842 or ASC 606, as applicable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maintenance services and reagents are allocated to the non-lease elements. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial, and we do not enter into direct finance leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue attributed to the lease elements of our reagent rental arrangements represented approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3% of total revenue for both the three and nine months ended September 30, 2023 and September 30, 2022. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Contract costs:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents our revenues disaggregated by geographic region (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:34.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">284.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">858.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">848.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">193.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">609.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">636.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">118.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">156.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">398.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">470.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (primarily Canada and Latin America)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">123.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">117.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total net sales</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">632.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">680.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,990.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,072.0 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2023 and December 31, 2022 was $66.5 million and $71.9 million, respectively. The short-term deferred revenue balance at September 30, 2023 and December 31, 2022 was $49.1 million and $52.2 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the nine months ended September 30, 2023 and 2022 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Actual warranty costs</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Accounts Receivable and Allowance for Credit Losses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in our allowance for credit losses were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Recoveries collected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Issued and to be Adopted</span></div>There are no new accounting pronouncements recently issued or newly effective that had, or are expected to have, a material impact on the Company's condensed consolidated financial statements. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries.  The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented.  All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year.  The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div> We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Such estimates include, but are not limited to, revenue recognition, the valuation of inventory, the valuation of acquired intangible assets, valuation of accounts receivable, estimation of warranty reserve, estimation of legal reserves, the recognition and measurement of current and deferred income tax assets and fair value measurement of the Loan receivable. Actual results could differ materially from those estimates.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. A product or service is considered distinct if it is separately identifiable from other deliverables in the arrangement and if a customer can benefit from such product or service on its own or with other resources that are readily available to the customer. The transaction consideration is allocated between separate performance obligations of an arrangement based on the standalone selling price for </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">each distinct product or service. The method used to determine the standalone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenue from product sales at the point in time when we have satisfied our performance obligation by transferring control of the product to the customer. We use judgment to evaluate whether and when control has transferred and consider the right to payment, legal title, physical possession, risks and rewards of ownership, and customer acceptance if it is not a formality, as indicators to determine the transfer of control to the customer. For products that include installation, the product and installation are separate performance obligations. The product revenue is recognized when control has transferred to the customer, generally upon delivery, and installation service revenue is recognized when the product installation is completed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We recognize revenues for a functional license of intellectual property at a point in time when the control of the license and technology transfers to the customer. For license agreements that include sales or usage-based royalty payments to us, we recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Reagent Rental Agreements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our reagent rental agreements provide our customers the ability to use an instrument and consumables (reagents) on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we then determine the lease classification as operating or sales-type lease. The lease term used in performing the lease classification test, includes the noncancellable period of the lease together with those periods covered by lease extension options if the customer is reasonably certain to exercise that option, the periods covered by lease termination options if the customer is reasonably certain to not exercise that option, and the periods covered by the option to extend (or to not terminate) the lease when exercise of such option is controlled by the Company. The assessment of the lease term for reagent rental agreements, including the impact from any associated contractual termination penalties, is subject to an estimation process. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel the agreement, the period in which the contract is enforceable is very short so the lease term has been limited to the noncancellable period. Generally, these arrangements do not contain an option for the lessee to purchase the underlying asset.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We concluded that the use of the instrument (referred to as “lease elements”) in our reagent rental agreements is not governed by the revenue recognition guidance of ASC 606 but instead is addressed by the lease guidance in ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">consideration of any fixed/minimum payments as well as estimates of variable consideration. After we have allocated the transaction price to the lease and non-lease elements, the amount of variable payments allocated to such elements are recognized as income in accordance with ASC 842 or ASC 606, as applicable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maintenance services and reagents are allocated to the non-lease elements. Maintenance services are recognized ratably over the period whereas reagents revenue is recognized upon transfer of control when either (i) the consumables are delivered or (ii) the consumables are consumed by the customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as such arrangements generally do not contain any fixed or minimum lease payments. Our reagent rental arrangements are predominantly classified as operating leases and any sales-type leases have historically been immaterial, and we do not enter into direct finance leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue attributed to the lease elements of our reagent rental arrangements represented approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3% of total revenue for both the three and nine months ended September 30, 2023 and September 30, 2022. Such revenue forms part of the Net sales in our condensed consolidated statements of income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Contract costs:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income (loss). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents our revenues disaggregated by geographic region (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:34.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">284.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">858.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">848.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">193.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">609.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">636.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">118.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">156.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">398.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">470.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (primarily Canada and Latin America)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">123.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">117.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total net sales</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">632.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">680.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,990.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,072.0 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 11).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Deferred revenues primarily represent unrecognized fees billed or collected for extended service arrangements, including installation services. The deferred revenue balance at September 30, 2023 and December 31, 2022 was $66.5 million and $71.9 million, respectively. The short-term deferred revenue balance at September 30, 2023 and December 31, 2022 was $49.1 million and $52.2 million, respectively.</span></div> 0.03 0.03 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents our revenues disaggregated by geographic region (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:34.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.910%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275.4 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">284.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">858.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">848.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">193.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">609.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">636.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">118.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">156.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">398.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">470.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other (primarily Canada and Latin America)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">123.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">117.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total net sales</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">632.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">680.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,990.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,072.0 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 275400000 284100000 858800000 848200000 193100000 200100000 609100000 636300000 118900000 156800000 398900000 470300000 44700000 39800000 123300000 117200000 632100000 680800000 1990100000 2072000000 66500000 71900000 49100000 52200000 We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income (loss).<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the nine months ended September 30, 2023 and 2022 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Actual warranty costs</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> Change in our warranty liability for the nine months ended September 30, 2023 and 2022 were as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:67.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for warranty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Actual warranty costs</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 10600000 12700000 6400000 6700000 9000000.0 8800000 8000000.0 10600000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Accounts Receivable and Allowance for Credit Losses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. Amounts later determined and specifically identified to be uncollectible are charged or written off against the allowance for credit losses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in our allowance for credit losses were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Recoveries collected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes in our allowance for credit losses were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Recoveries collected</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 15000000.0 15100000 900000 1200000 1300000 2300000 500000 100000 15100000 14100000 Recent Accounting Pronouncements Issued and to be AdoptedThere are no new accounting pronouncements recently issued or newly effective that had, or are expected to have, a material impact on the Company's condensed consolidated financial statements. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2. FAIR VALUE MEASUREMENTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Level 1: Quoted prices in active markets for identical instruments</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2023 are classified in the hierarchy as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">172.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,947.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,947.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loan under the fair value option (d)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">590.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">590.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">283.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">283.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">342.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">342.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (e)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,240.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,240.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,074.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,293.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,658.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (g)</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (h)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are classified in the hierarchy as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">65.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,530.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,530.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loan under the fair value option (d)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">322.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">322.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">699.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">699.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">230.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">230.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (e)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,300.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,300.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,574.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,330.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">322.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,227.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (g)</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (h)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.6 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.8pt">Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">60.3 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56.5 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,887.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,473.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,947.6 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,530.4 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Level 1 Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">As of September 30, 2023, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the ordinary outstanding shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of September 30, 2023. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The changes in fair market value of our investment in Sartorius for the three and nine months ended September 30, 2023 was a gain of $42.5 million and a loss of $1,556.1 million respectively, which is recorded in our condensed consolidated statements of income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Level 2 Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To estimate the fair value of Level 2 debt securities as of September 30, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">598.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">590.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">347.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">342.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">287.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">283.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,256.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,240.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2023 by contractual maturity date (in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in less than one year</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">473.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">469.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">636.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">627.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in more than five years</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">146.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">143.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,256.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,240.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">709.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">699.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">339.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">233.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">230.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,320.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(20.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,300.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September 30, 2023, there were no significant continuous unrealized losses greater than 12 months.</span></div><div><span><br/></span></div><div><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our evaluation of credit losses for available-for-sale investments included t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At September 30, 2023, we have concluded that all payments related to our available-for-sale investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are expected to be made in full and on time at </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of September 30, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Included in Other current assets are $11.2 million and $11.6 million of interest receivable as of September 30, 2023 and December 31, 2022, respectively, primarily associated with securities in our available-for-sale investments portfolio. The interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the nine months ended September 30, 2023, we have not written-off any uncollected interest receivable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of September 30, 2023 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of our forward foreign exchange contracts (in millions): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts maturing in October through December 2023 to sell foreign currency:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">701.5 </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts maturing in October through December 2023 to purchase foreign currency:</span></td><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">80.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized gain</span></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Level 3 Fair Value Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (the “Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in (Gains) losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the three months ended September 30, 2023 was a loss of $4.9 million, which includes a $10.8 million loss from change in fair market value of the Loan and a $5.9 million gain from change in fair market value of the value appreciation right. The overall change in fair market value reflected in (Gains) losses from change in fair market value of equity securities and loan receivable during the nine months ended September 30, 2023 was a loss of $28.9 million, which includes a $0.4 million loss from change in fair market value of the Loan and a $28.5 million loss from change in fair market value of the value appreciation right. The decrease in the fair market value of the value appreciation right was due to a decline in the value of the Sartorius ordinary shares. As of September 30, 2023, the €400 million principal amount of the loan is still due on January 31, 2029. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.666%"><tr><td style="width:1.0%"></td><td style="width:75.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">322.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net decrease in estimated fair market value of the loan included in (Gains) losses in fair market value of equity securities and loan receivable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(28.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency exchange gains (losses), net</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2023 are classified in the hierarchy as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">120.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">172.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,947.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,947.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loan under the fair value option (d)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">590.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">590.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">283.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">283.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">342.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">342.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (e)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,240.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,240.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,074.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,293.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,658.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (g)</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (h)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are classified in the hierarchy as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial assets carried at fair value:</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total cash equivalents (a)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">65.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments (b)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Equity securities (c)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,530.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,530.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loan under the fair value option (d)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">322.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">322.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Available-for-sale investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">699.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">699.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">230.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">230.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total available-for-sale investments (e)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,300.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,300.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (f)</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,574.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,330.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">322.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10,227.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Financial liabilities carried at fair value:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Forward foreign exchange contracts (g)</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contingent consideration (h)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total financial liabilities carried at fair value</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.6 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.8pt">Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restricted investments</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">60.3 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56.5 </span></td><td style="background-color:#d6ffd2;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,887.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,473.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,947.6 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8,530.4 </span></td><td style="background-color:#d6ffd2;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023.</span></div> 0 7500000 0 7500000 0 44700000 0 44700000 120100000 0 0 120100000 120100000 52200000 0 172300000 6900000 0 0 6900000 6947600000 0 0 6947600000 0 0 290500000 290500000 0 590600000 0 590600000 0 283700000 0 283700000 0 10000000.0 0 10000000.0 0 13900000 0 13900000 0 342500000 0 342500000 0 1240700000 0 1240700000 0 700000 0 700000 7074600000 1293600000 290500000 8658700000 0 1000000.0 0 1000000.0 0 0 17100000 17100000 0 1000000.0 17100000 18100000 0 21100000 0 21100000 5700000 0 0 5700000 0 1400000 0 1400000 0 6000000.0 0 6000000.0 31500000 0 0 31500000 37200000 28500000 0 65700000 6800000 0 0 6800000 8530400000 0 0 8530400000 0 0 322600000 322600000 0 699300000 0 699300000 0 230700000 0 230700000 0 13500000 0 13500000 0 23100000 0 23100000 0 333400000 0 333400000 0 1300000000 0 1300000000 0 1500000 0 1500000 8574400000 1330000000 322600000 10227000000 0 6200000 0 6200000 0 0 35600000 35600000 0 6200000 35600000 41800000 5600000 5600000 1300000 1200000 6900000 6800000 60300000 56500000 6887300000 8473900000 6947600000 8530400000 14800000 4100000 14400000 4100000 12987900 9588908 0.38 0.28 42500000 1556100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">598.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">590.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">347.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">342.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">287.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">283.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,256.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(16.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,240.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale investments consist of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">709.9 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">699.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Municipal obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">339.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">U.S. government sponsored agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">233.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">230.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign government obligations</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,320.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(20.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,300.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 598000000.0 300000 7700000 590600000 14100000 0 200000 13900000 347300000 0 4800000 342500000 287100000 0 3400000 283700000 10200000 0 200000 10000000.0 1256700000 300000 16300000 1240700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of the amortized cost and estimated fair value of our debt securities at September 30, 2023 by contractual maturity date (in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in less than one year</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">473.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">469.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">636.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">627.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mature in more than five years</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">146.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">143.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,256.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,240.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 473600000 469500000 636700000 627800000 146400000 143400000 1256700000 1240700000 709900000 200000 10800000 699300000 23400000 0 300000 23100000 339600000 100000 6300000 333400000 233900000 0 3200000 230700000 13800000 0 300000 13500000 1320600000 300000 20900000 1300000000 11200000 11600000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of our forward foreign exchange contracts (in millions): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts maturing in October through December 2023 to sell foreign currency:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">701.5 </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Contracts maturing in October through December 2023 to purchase foreign currency:</span></td><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notional value</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">80.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d6ffd2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unrealized gain</span></td><td style="background-color:#d6ffd2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d6ffd2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#d6ffd2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 701500000 -400000 80100000 100000 400000000 0.015 -4900000 -10800000 -5900000 -28900000 -400000 28500000 400000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.666%"><tr><td style="width:1.0%"></td><td style="width:75.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">322.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net decrease in estimated fair market value of the loan included in (Gains) losses in fair market value of equity securities and loan receivable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(28.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency exchange gains (losses), net</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">290.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 322600000 -28900000 3200000 290500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">3. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes to goodwill by segment are as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2022:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">408.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">741.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(335.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill, net</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">115.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">406.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Period increase, net</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">408.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">742.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(335.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">115.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">407.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(93.6)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">165.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(156.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">215.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(128.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">87.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">556.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(428.5)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">127.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">742.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(428.5)</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">314.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(89.9)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">166.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(153.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.8</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">211.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(121.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">89.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">553.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(412.4)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">141.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">191.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">191.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">744.5 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(412.4)</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">332.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amortization expense related to purchased intangible assets is as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Changes to goodwill by segment are as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2022:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">408.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">741.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(335.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill, net</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">115.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">406.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Period increase, net</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">333.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">408.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">742.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Accumulated impairment losses</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(293.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(335.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Goodwill, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">291.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">115.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">407.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 333300000 408400000 741700000 41800000 293400000 335200000 291500000 115000000.0 406500000 0 400000 400000 0 100000 100000 0 500000 500000 333300000 408900000 742200000 41800000 293400000 335200000 291500000 115500000 407000000.0 Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104.3 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(93.6)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">165.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(156.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">215.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(128.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">87.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">58.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(41.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">556.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(428.5)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">127.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">186.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">742.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(428.5)</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">314.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Weighted-Average Remaining Amortization Period (years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Purchase<br/>Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Customer relationships/lists</span></td><td colspan="3" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(89.9)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Know how</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">166.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(153.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Developed product technology</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.8</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">211.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(121.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">89.5 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">59.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(38.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tradenames</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Covenants not to compete</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">553.5 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(412.4)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">141.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">191.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">191.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total purchased intangible assets</span></td><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">744.5 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(412.4)</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">332.1 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P5Y2M12D 104300000 93600000 10700000 P2Y 165100000 156200000 8900000 P12Y2M12D 215500000 128400000 87100000 P5Y1M6D 58800000 41100000 17700000 P5Y9M18D 6000000.0 4500000 1500000 P2Y6M 6500000 4700000 1800000 556200000 428500000 127700000 186500000 186500000 742700000 428500000 314200000 P5Y 104700000 89900000 14800000 P2Y9M18D 166200000 153900000 12300000 P12Y9M18D 211100000 121600000 89500000 P5Y9M18D 59000000.0 38500000 20500000 P6Y7M6D 6100000 4500000 1600000 P3Y1M6D 6400000 4000000.0 2400000 553500000 412400000 141100000 191000000.0 191000000.0 744500000 412400000 332100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amortization expense related to purchased intangible assets is as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.8 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6200000 6200000 18100000 18800000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">4. INVENTORY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following are the components of Inventory at September 30, 2023 and December 31, 2022 (in millions):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inventory:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Raw materials</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">230.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">228.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">244.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">220.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finished goods </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">300.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">269.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Total Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">775.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">719.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Following are the components of Inventory at September 30, 2023 and December 31, 2022 (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Inventory:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Raw materials</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">230.4 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">228.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">244.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">220.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finished goods </span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">300.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">269.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Total Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">775.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">719.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 230400000 228800000 244500000 220900000 300900000 269600000 775800000 719300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">5. SUPPLEMENTAL CASH FLOW INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(987.0)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4,455.3)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">101.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reduction in the carrying amount of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Losses from change in fair market value of equity securities and loan receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,576.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,172.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gain on divestiture of a division</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payments for operating lease liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Increase) decrease in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(44.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(61.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(150.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Increase) decrease in other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(72.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(69.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase (decrease) in income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(39.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in deferred income taxes</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(397.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,439.1)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase (decrease) in other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">293.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">114.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchased property, plant and equipment</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchased marketable securities and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The reconciliation of net loss to net cash provided by operating activities is as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(987.0)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4,455.3)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">108.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">101.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Reduction in the carrying amount of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Losses from change in fair market value of equity securities and loan receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,576.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,172.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gain on divestiture of a division</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payments for operating lease liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Increase) decrease in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(44.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(61.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(150.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Increase) decrease in other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in accounts payable and other current liabilities</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(72.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(69.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase (decrease) in income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">56.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(39.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Decrease in deferred income taxes</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(397.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,439.1)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Increase (decrease) in other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">293.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">114.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#cdffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchased property, plant and equipment</span></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Purchased marketable securities and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -987000000.0 -4455300000 108700000 101800000 30700000 29800000 45100000 42800000 -1576500000 -6172300000 0 1400000 -18500000 0 -30400000 -28100000 -31600000 44500000 61700000 150600000 -15000000.0 11900000 -72400000 -69700000 56400000 -39200000 397400000 1439100000 3900000 -2000000.0 6600000 -9900000 293900000 114800000 2900000 3300000 0 11800000 6. LONG-TERM DEBT<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The principal components of long-term debt are as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3%, Senior Notes due 2027</span></div></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">400.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">400.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7%, Senior Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less unamortized discounts and debt issuance costs</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt less unamortized discounts and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,189.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,187.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance leases and other debt</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less current maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,198.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,197.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The principal components of long-term debt are as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3%, Senior Notes due 2027</span></div></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">400.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">400.0 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7%, Senior Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">800.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less unamortized discounts and debt issuance costs</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt less unamortized discounts and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,189.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,187.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance leases and other debt</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less current maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,198.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,197.7 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0.033 400000000.0 400000000.0 0.037 800000000.0 800000000.0 -11000000.0 -12400000 1189000000 1187600000 10200000 10600000 500000 500000 1198700000 1197700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">7. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net unrealized holding gains (losses) on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2022:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(466.5)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(466.8)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(34.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of income taxes</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(34.3)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(500.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(497.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net unrealized holding gains (losses) on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2021:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(170.5)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(175.6)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(654.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(676.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of income taxes</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(653.3)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(669.6)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2022:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(823.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(845.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All amounts reclassified out of accumulated other comprehensive income (loss) were reclassified into other income, net in the condensed consolidated statements of income (loss). The reclassification adjustments are calculated using the specific identification method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The impact to income (loss) before income taxes for amounts reclassified out of accumulated other comprehensive</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">millions):</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss) included in our condensed consolidated balance sheets consists of the following components (in millions): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net unrealized holding gains (losses) on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2022:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(466.5)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(466.8)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(34.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of income taxes</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(34.3)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.7)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(500.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(497.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Foreign other post-employment benefits adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net unrealized holding gains (losses) on available-for-sale investments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total accumulated other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2021:</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(170.5)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(175.6)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(654.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(676.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effects</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of income taxes</span></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(653.3)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(669.6)</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2022:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(823.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(845.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -466500000 10000000.0 -10300000 -466800000 -34400000 300000 3700000 -30400000 0 400000 -1100000 -700000 -100000 0 1100000 1000000.0 -34300000 -100000 3700000 -30700000 -500800000 9900000 -6600000 -497500000 -170500000 -10900000 5800000 -175600000 -654400000 1400000 -23300000 -676300000 0 -200000 -600000 -800000 -1100000 500000 -5300000 -5900000 -653300000 1100000 -17400000 -669600000 -823800000 -9800000 -11600000 -845200000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The impact to income (loss) before income taxes for amounts reclassified out of accumulated other comprehensive</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">income (loss) into other income, net in the condensed consolidated statements of income (loss) were as follows (in</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">millions):</span></div> -200000 100000 -400000 200000 -100000 -200000 -1100000 -600000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">8. EARNINGS (LOSS) PER SHARE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B). Each share of Class A and Class B common stock participates equally in the earnings and losses of Bio-Rad, and each share is identical to the next in all respects except as follows. Class A common stock has limited voting rights compared to Class B. Each share of Class A is entitled to one tenth of a vote on most matters, whereas each share of Class B is always entitled to one vote. Additionally, Class A stockholders are entitled to elect 25% of the directors, with Class B stockholders electing the remaining directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares. In contrast, no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares. Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We compute net income (loss) per share of Class A Common Stock (Class A) and Class B Common Stock (Class B) using the two-class method required for participating securities. Our participating securities include Class A and Class B. Each share of Class A and Class B participates equally in earnings and losses, but may not participate equally in dividend distributions. No dividends were distributed or declared during any of the periods presented. Earnings (loss) is attributable equally to each share of Class A and Class B common stock and is determined based on the weighted average number of the respective class of common stock outstanding for the three and nine months ended September 30, 2023 and 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accordingly, basic earnings (loss) per share is computed by dividing net income (loss) attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options, restricted stock and performance stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings (loss) per share calculation if the effect of including such securities would be anti-dilutive.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,102 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,733 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,349 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,819 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effect of potentially dilutive stock options, restricted stock and performance stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,223 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,733 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,349 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,819 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anti-dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The weighted average number of common shares outstanding used to calculate basic and diluted earnings (loss) per share, and the anti-dilutive shares that are excluded from the diluted earnings (loss) per share calculation are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,102 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,733 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,349 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,819 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effect of potentially dilutive stock options, restricted stock and performance stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,223 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,733 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,349 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,819 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Anti-dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 29102000 29733000 29349000 29819000 121000 0 0 0 29223000 29733000 29349000 29819000 154000 541000 229000 541000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">9. OTHER INCOME, NET</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income, net includes the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest and investment income</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(84.1)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(45.7)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net realized losses on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current expected credit losses on loans</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gain on divestiture of a division</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Escrow receipts on prior acquisition</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(87.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(42.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income, net includes the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest and investment income</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(84.1)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(45.7)</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net realized losses on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Current expected credit losses on loans</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gain on divestiture of a division</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Escrow receipts on prior acquisition</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(87.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(42.4)</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17300000 8000000.0 84100000 45700000 -100000 -200000 -1600000 600000 0 5100000 0 5100000 0 0 0 1400000 2500000 0 2500000 0 700000 400000 2400000 1000000.0 20400000 3100000 87400000 42400000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">10. INCOME TAXES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Our effective income tax rate was 22.5% and 21.5% for the three months ended September 30, 2023 and 2022, respectively. Our effective income tax rate was 22.8% and 23.1% for the nine months ended September 30, 2023 and 2022, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The realization of deferred tax assets are dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain of our federal, state and foreign deferred tax assets will not be realized as of September 30, 2023, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our federal, state and foreign deferred tax assets increased by $15.2 million for the period ended September 30, 2023 compared to the year ended December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Our income tax returns are audited by U.S. federal, state and foreign tax authorities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Our gross unrecognized tax benefits were $92.0 million and $85.5 million as of September 30, 2023 and December 31, 2022, respectively. The increase in our gross unrecognized tax benefits is primarily attributable to an increase of uncertain tax accruals in various jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">As of September 30, 2023, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $18.8 million. Substantially all such amounts will impact our effective income tax rate if recognized.</span></div> 0.225 0.215 0.228 0.231 15200000 92000000 85500000 18800000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">11. SEGMENT INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding operating profit (loss) for the three months ended September 30, 2023 and 2022 is as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other<br/>Operations</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">263.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">368.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">317.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">361.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit (loss)</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">78.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">51.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding operating profit (loss) for the nine months ended September 30, 2023 and 2022 is as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other<br/>Operations</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">887.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,100.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">987.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,081.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit (loss)</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">166.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">197.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">167.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Segment results are presented in the same manner as we manage our business internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate overhead as directly supporting the strategies of our segments, and these costs are fully allocated to our reportable segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The following reconciles total segment profit to consolidated loss before income taxes (in millions):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">94.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">242.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">363.9 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(37.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency exchange gains (losses), net</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in fair market value of equity securities and loan receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(289.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,576.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6,172.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">87.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">137.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(207.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,278.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,795.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding operating profit (loss) for the three months ended September 30, 2023 and 2022 is as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other<br/>Operations</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">263.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">368.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">317.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">361.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit (loss)</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">78.0 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">51.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information regarding operating profit (loss) for the nine months ended September 30, 2023 and 2022 is as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Life<br/>Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Clinical<br/>Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other<br/>Operations</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">887.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,100.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">987.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,081.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit (loss)</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">76.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">166.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2022</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">197.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">167.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 263500000 368100000 500000 317900000 361900000 1000000.0 13000000.0 78000000.0 -100000 51400000 43900000 -700000 887300000 1100300000 2500000 987500000 1081400000 3100000 76700000 166100000 -300000 197600000 167800000 -1500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The following reconciles total segment profit to consolidated loss before income taxes (in millions):</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating profit</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">94.6 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">242.5 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">363.9 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(37.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency exchange gains (losses), net</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in fair market value of equity securities and loan receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(289.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,576.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6,172.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">87.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consolidated income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">137.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(207.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1,278.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,795.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 90900000 94600000 242500000 363900000 -12300000 -11600000 -37200000 -26500000 1700000 -4400000 5300000 -3100000 36400000 -289000000.0 -1576500000 -6172300000 20400000 3100000 87400000 42400000 137100000 -207300000 -1278500000 -5795600000 12. LEGAL PROCEEDINGSWe are a party to various claims, legal actions and complaints arising in the ordinary course of business. We record a reserve when we believe a loss arising from these matters is probable and can be reasonably estimated. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. As additional information becomes available, any potential liability related to these matters is assessed and the estimates revised. While we do not believe, at this time, that any ultimate liability resulting from any of these matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">13. RESTRUCTURING COSTS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In February 2021, we announced a strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The restructuring plan primarily impacted our operations in EMEA and included the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from EMEA to APAC. The restructuring plan was implemented in phases and is substantially complete as of September 30, 2023. The timing of the remaining employee termination benefit payments is in accordance with statutory requirements. The adjustments to expense recorded were primarily due to changes in the estimates of employee termination benefits. From February 2021 to September 30, 2023, total expenses were $70.0 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following table summarizes the activity of our February 2021 plan restructuring reserves (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Life Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2022:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustment to expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In February 2023, management approved a new restructuring plan to implement identified opportunities to further streamline and improve operating performance. The additional restructuring activities are being implemented in phases and are expected to be substantially complete by the end of 2023. From February 2023 to September 30, 2023, total expenses were $15.4 million, representing estimated termination benefits to employees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following table summarizes the activity of our February 2023 plan restructuring reserves (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Life Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2022:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Charged to expense - employee termination benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In June 2023, management approved an additional restructuring plan to implement identified opportunities to further streamline and improve operating performance. The additional restructuring activities are expected to be substantially complete by the end of 2023. From June 2023 to September 30, 2023, total expenses were $9.0 million, representing estimated termination benefits to employees.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following table summarizes the activity of our June 2023 plan restructuring reserves (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Life Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2022:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Charged to expense - employee termination benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Combined, the liability of $29.5 million as of September 30, 2023 consisted of $29.0 million recorded in Accrued payroll and employee benefits and $0.5 million recorded in Other long-term liabilities in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the three months ended September 30, 2023 were $0.2 million, $1.3 million and $0.0 million, respectively, in the condensed consolidated statements of income (loss). The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense for the nine months ended September 30, 2023 were $3.9 million, $16.6 million and $5.3 million, respectively, in the condensed consolidated statements of income (loss).</span></div> 70000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following table summarizes the activity of our February 2021 plan restructuring reserves (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Life Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2022:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.7 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustment to expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following table summarizes the activity of our February 2023 plan restructuring reserves (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Life Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2022:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Charged to expense - employee termination benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The following table summarizes the activity of our June 2023 plan restructuring reserves (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Life Science</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Diagnostics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of December 31, 2022:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Charged to expense - employee termination benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Foreign currency adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cdffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Balances as of September 30, 2023:</span></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1900000 29700000 31600000 0 1400000 1400000 1600000 16500000 18100000 0 100000 100000 300000 14500000 14800000 15400000 0 0 0 3300000 12100000 15400000 1400000 3800000 5200000 100000 100000 200000 2000000.0 8400000 10400000 9000000 0 0 0 4300000 4700000 9000000.0 2900000 1800000 4700000 0 0 0 1400000 2900000 4300000 29500000 29000000 500000 200000 1300000 0 3900000 16600000 5300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">14. LEASES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 16 years, which includes our determination to exercise renewal options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our condensed consolidated balance sheets. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our condensed consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:53.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">47.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="9" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="9" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total finance lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for the three and nine months ended September 30, 2023 and 2022. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for the three and nine months ended September 30, 2023 and 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:57.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating cash flows from operating leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Financing cash flows from finance leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease obligations:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">181.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Current operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1240">39.1</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1241">36.3</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">167.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">153.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">206.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">189.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Finance Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Property, plant and equipment, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Current maturities of long-term debt and notes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Long-term debt, net of current maturities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:60.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases - in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finance leases - in years</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finance leases</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maturities of lease liabilities were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023 (excluding the nine months ended September 30, 2023)</span></div></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">82.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total lease payments</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">237.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">206.3 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher turn-over.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September 30, 2023, operating leases that have not commenced are not material.</span></div> P1Y P16Y The components of lease expense were as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:53.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">47.2 </span></td><td style="background-color:#cdffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.2 </span></td><td style="background-color:#cdffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="9" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="9" style="background-color:#cdffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cdffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#cdffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cdffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">        Total finance lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 15700000 14200000 47200000 43200000 100000 100000 300000 300000 200000 200000 600000 600000 300000 300000 900000 900000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:57.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating cash flows from operating leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Financing cash flows from finance leases</span></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new lease obligations:</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">49.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 10600000 9500000 30400000 28100000 200000 200000 600000 600000 100000 100000 300000 300000 36700000 2300000 49000000.0 9400000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Operating Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">181.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Current operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1240">39.1</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1241">36.3</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating lease liabilities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">167.2 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">153.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">206.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">189.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt and notes payable, net of current maturities (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:60.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Finance Leases</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Property, plant and equipment, gross</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Property, plant and equipment, net</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Current maturities of long-term debt and notes payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Long-term debt, net of current maturities</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">      Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:60.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases - in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finance leases - in years</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Finance leases</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 200000000.0 181000000.0 39100000 36300000 167200000 153600000 206300000 189900000 11800000 11900000 5700000 5500000 6100000 6400000 500000 500000 9700000 10100000 10200000 10600000 P7Y P7Y P14Y P15Y 0.038 0.030 0.064 0.063 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maturities of lease liabilities were as follows (in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Finance Leases</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2023 (excluding the nine months ended September 30, 2023)</span></div></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42.6 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24.7 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ccffcc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">82.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">   Total lease payments</span></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">237.1 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td colspan="2" style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.7 </span></td><td style="background-color:#ccffcc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccffcc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    Total</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">206.3 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccffcc;padding:0 1pt"></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ccffcc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10400000 300000 45500000 1200000 42600000 1100000 31200000 1100000 24700000 1100000 82700000 11900000 237100000 16700000 30800000 6500000 206300000 10200000 false false false false Available-for-sale investments are included in Short-term investments in the condensed consolidated balance sheets. Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets. Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets. Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.8 million and $4.1 million in the consolidated statements of income (loss) for the three months ended September 30, 2023, respectively. The changes in the fair value of contingent consideration included in Research and development expense and Selling, general and administrative expense amounted to $14.4 million and $4.1 million in the consolidated statements of income (loss) for the nine months ended September 30, 2023, respectively. No conditions triggering payment of the contingent consideration were met as of September 30, 2023. Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):September 30, 2023December 31, 2022Restricted investments$5.6 $5.6 Other investments1.3 1.2     Total$6.9 $6.8  Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):September 30, 2023December 31, 2022Short-term investments$60.3 $56.5 Other investments6,887.3 8,473.9         Total$6,947.6 $8,530.4  The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets. EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

(S:>3PI83ACZ&N+IU7D+U)&[ LT:'9[9).1MTWD%Y?RIS7ZJ,S- U M1O&&]'H\#.:9S3&Q!G&ZX>KR*@6,A3GFX+@UAR,Q_+[ 5S;J&G33AQ?$'SN. M^<'\I#@9"J(05Q%7!' >:I,3A"Y+HS<35M]W0\T^>-C%L6P+I=AU19C>NKVU MY);ICIJ FI O V^R+>_[?9\AWXMW1+37FAJ(#HK?L6]R.5[:7X)MDMW MP84-N%FFQQ6N\N1X [XWUH;AA0V,_QPX_Q]02P,$% @ XX-;5R]Z_4FH M! DPH !D !X;"]W;W)K&ULO59=;R(W%/TK MUG15@82&^8 92 $IR6:WD9H0)6G[4/7!#!>P,F.SMH'DW_?8,Q"B)=FJ#WT MV^-[C^\]]\,>[91^,BLBRYZK4IIQL+)V?=;MFF)%%3>A6I/$SD+IBELL];)K MUIKXW"M593>)HJQ;<2&#RCA0&T3L*2:.0>+OK@[R5G[GEDY%6.Z:=--#TCN[[],KV_.7^\GMX>@Z*DEES/'1DH<LULT'\-+,C70)Y9D:=C'F&:#,,888>6A\2G.PZ'?BOT8AQ&;OF-_ M@Q:GD/G$\H$?6E$8M_=H_3CL8>BE'@M;>?L_1;F3B?+/.<@(SWP% _S,/.;>3APFW'8;[-]JJ(( MT 3ADB;F*T):^ ^G'#&&5R"&2PDOX//.+]#OF=J@H6X,>#,&PI:TY&7YPJR" MQ!,=,3ZG0KA;P'@"N3%. [L^3K*@D$V!5:P$+4YH>33-6L'E]/--T&9;U]D9 MCCJ2I6?<XZISA%=S1!'>=DO:MB<]*.NB'[!'X=9*XTW"^DH5P M26"516HT@OMP @D"1I5B[I%==-F,P!*!WT(A#I8_TW?Y]NC+^[B%LUN7S6^^ MO,WF$[GM,^5U]EVR(2LC7V7#GD^EI)Z*[]K%GXS=1P(9EKC\:Z&391C2 M/$PP))G+.]S'N&TE[D>M218O4"I67"*GEGB&F#JOR;0[3*)L8J1UJQ?VVJR/ M.FFEKOPO:W'PL.!"(T/T$R2WO-R0BR)]VPB+2!-.$%8T>5$J[CI"06+KXY1F M**U6,AB&D3.TT\^]=:VL$^?>^+IT:^IK6Y((*JX64: ]!@9Z[/(X9$V8FL(\ M%3O7SO*Z0),H=Z>X:NPDZ&Y]/^]W\F$?G)VZBKI'#X6*]-(_APRR9B-M_68X M?#V\N,[KA\:K>/U& M.=+7UMBPRIH8N],\#T7#K0HSU['%2>5\JR*6OLY#YUF5R:DU^6(^?Y.W2MML MO4Q[-WZ]='TTVO*-I]"WK?(/YVS<;I4=9M/&K:Z;*!OY>MFIFN\X?NIN/%;Y M'J74+=N@G27/U2H[.SP]/Q;[9/"7YEUX])TDDXUSGV7QH5QE\\ MYG,B>(4S(?VGW6![LLBHZ$-T[>@,!JVVPZ?Z.NKPR.'M_ 6'Q>BP2+R'0(GE MI8IJO?1N1UZL@29?4JK)&^2TE:+<18]3#;^XON9:&;KQKF NM:W#,H^ E<.\ M&"'.!XC%"Q#OZ*.SL0ET94LN?_3/06?/:3%Q.E^\"GC'W8R.Y@>TF"^.7L$[ MVN=XE/!.7L"[<&VK(SHI!E*VI O01:IL"\V!+G4HC N]9_K[;!.B1Z/\\YP* M0Y"CYX/(\)R&3A6\RC =@?V6L_7//QV^F?_Z2@K'^Q2.7T/_?V5Z'>)P,:/A M[_KJ_=DUW=S^>7%U=?GAC_=W]TP*Z2OJE(\/%!UME=>N#U08I=MP0";%5VF2 M!A$+UW8X3)IZ'<")M*78,#D/AAAPF/0^8%W1IH:M\$ ]OL-6WK4"#"A,860?2 ?JO-NHC>&!C++P!J *SF+W@3A$#6LN M9W2G:ZLK#9M(__9E+8T@")Z_]-IS*;PW+C:)?,D(@#E3Z'(3Z8IVG^X@?N,S@!3EEH\H:^VPRTK.!NHU*(]U59I(\8' M"/A G8N@KV%L]$3)LY%,)>X3F50(T!V'$]M)&&&TU4$$NF\T=$0!2D?6Q:D. M"!CA A!X8!4;K(4#+KP$\0.%(+M3M<1JT.X1FYTVAAJ5"BSN7K)0Y9:E2;BJ M<$^3:-[[$2X(!IX?GQ1!%U80&4,+M\X%/53(@P7J" T?#B0'E%ERJ+7$ 0T( MT'MX27?42EJS3CKLD\!+)4H_Y3LJIA,=9_H4#SUM2NFU?09072B//($^D4C>_FP]/[4?E:8ZX-5W"=SW[!3>J'YVQ81->E)P1C M@@NWJ0,*08 M -H2 9 >&PO=V]R:W-H965TC*9:J@*R-LE>?2+"XHT_/35K>U M_'"MIC/'']IG)Z6M\^[Q19_EO<"OBN9V MY5FP)V.M/_++V_2TU6% E%'BV(+$[9:&E&5L"# ^U39;S9"LN/J\M/[&^PY? MQM+24&>_J=3-3EN'+9'21%:9N];S'ZGV9\#V$IU9?Q7S(-O#B$EEG<1A;A6B#WN,)!'^5HZ>79B]%P8EH8U?O"N>FV 4P4G9>0, M_E70,'(EWNG S*RZ+E-)U M_38 -:CB):J+>*O!$961Z'7V1=R)>UOL]1HO>][>X.E>BM_/Q_B(JOACD\/! M7F^S/6;*L2UE0J&71)U&@LG!*9@A%HEG6(5>6 M@8 ACO(QF88F82#'_D]9(H#GOLP?"-IZ01 @TT1H3 5-E!.E7# (RZ,J[I2) M-JE/[5RY&2I"NLII%(RA3Y4R'K$-X\GT3S2IH V/Z3-F"\L#LPEX-2=#*PE- M*V*Q9":+*?G!?-8L8*/HO&?;D&+0-QS@M0IF@P_#@4QK)[,E(AN0[+SL1!WT MT2R#U>#!1&>8F3A&3HXSJJP%2'B:S U&,,D"[6$KPTM]MAT7"]!_=A(AAO)^HQZGXT"+?#^VT(Z0*E ML KP'LC2MPWN1@7F]0WD";TE<$>H%%5>W> K-=%N \__&Q5>(>7I$LW$LU74PZ6P7W4J%\J*NN7H$&G*9B[-0Z2=)XDIL(CO#8H!$^.)F!-D/CK3F=EV%43 M[SW!,JRB7W"$&[3J;IT$,"EG(UU9P>)E'$(C_"YPN2[+L:#'D-CC9H%7L,%; M"?9CJG6*]:7.$)@1-L2HN7TQ!4HC W29(L/*[P2P!VB*@/_"YH2D26;^):5; M+(]+WSZ60J"_!^MF!K[G86-(O#'<%-_ 0VZ"#0]WNLAG%6#NG<_\X(YF280'\/]':+5]X@.8XZ^QO4$L#!!0 ( M ..#6U>B50?SO0@ #49 9 >&PO=V]R:W-H965T+Q?Z@)3HF1A)5DHJ3 M/OU^YU"2)=OQI%M@%T$HD2+/_4I?KHS]YI9*>?&89X6[&BR]+R]&(Y%L;GTF-K[D2NMDBD?RK-1/![/1KG4Q>#ZDM<^V^M+4_E,%^JS%:[* M8S/$H M5F%OA,U)Y;S)Z\.@(-=%>,K'6@Z= V?C9P[$]8&8Z0Z(F,KWTLOK2VM6PM)N M0*,79I5/@SA=D%+NO,57C7/^^J,"2^YRY &+5D9)?>YM.!<_<^YQD3_[J9.V^A M^W_OXC& F.P&0?YPX4J9J*L!#-XI^Z &US_^$,W&;_80.&T)G.Z#OD?R^\]% MTZ'X^.'F[L.=^*K$4CXH 1>UTNOB7F2!:UFDPALA,7>@6ZA'KPHO%KJ01:+J M74<"/BWFEHA->V=P)LQ"1 M>%+2$N9HQJ\ N@+,I=!%DE4I !C 2A6= "WLE]BM'I5-M"/(A5K)# S1)S' H)07KP\ZZREE!OR%QD6LYUIKTFP9( -S%T-A ! M)(C$P'D*!XKPYDRF4^DQF#2'\U%/;%BN?+='BGXY$B7.^K[TUP8A@ ME0WHH:K,%/?')%C(=^X#Q1\WU@KD!&Q-M@'\-?HAQEI\4#![$LD/YUGH9 D M=*BV CB;/9',>#\;J%^JCITQH=L"[<,U\TS?M]:5RV\-A%(^D5!(AMH1FH4U M^1K#EMUT26?$'92D!JL2"QC;+]G,F<:BP<_3IE!R MR>NPZL' M&G.O,+,H'/P2Z\8U^QQ4!WLBCWSB T$0'3FLH2"V G6P:>E, 71/(D%8D;H? MHOU2^AK04=#\-B[8Y!K5#D'OQT;6_2Q&65/]4@X/#.#+W,!"X"U6)PJ)3MPG?8*^E(Z\ M;0:!Q#@O7HGH9'A*C^DPQF-Z&AX3/'JIC[=?B)O<6*__#-$*;/52=^UGK\1X M&'7&23W^4D#>"DAQ=#N+C($Q_,_X_XNAP+G8HJ$'DL;S>MS)W[KV :6 E<%, MTBHT)74 25#4A+27FRH$D770"&Z&($^V0?RJ3KS!U]RD>J$3E@>FM%';.LW! M.N09+9I4'LU([S(K-AS:2"6TGD@?D<@Z. M0=@.J4BCO]0446#^2/0J#6+3^;RRS&'B*ZB!$ANY*6*0H(H6 8,4?42YE2LJ MX>5C70[K A(/7T.\X"H,C2PDH,E(_BY;=U599DVN3J1;B@7

  •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

    S!0NVF 0 *PG / M " 4Z2 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " #C@UM7 MF!M:GOL! #+(P &@ @ $3EP$ >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " #C@UM7=-+&8MX! !:(P $P M @ %&F0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 !$ ),2 ( !5FP$ ! end XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 354 312 1 true 71 0 false 5 false false R1.htm 0000001 - Document - Document and Entity Information Sheet http://www.bio-rad.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets Parenthetical Sheet http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets Parenthetical Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited Condensed Consolidated Statements of Income (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement Sheet http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement Condensed Consolidated Statements of Stockholders' Equity Statement Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation and Use of Estimates Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimates Basis of Presentation and Use of Estimates Notes 8 false false R9.htm 0000009 - Disclosure - Fair Value Measurements Sheet http://www.bio-rad.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 0000010 - Disclosure - Goodwill and Other Purchased Intangible Assets Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets Goodwill and Other Purchased Intangible Assets Notes 10 false false R11.htm 0000011 - Disclosure - Inventory Sheet http://www.bio-rad.com/role/Inventory Inventory Notes 11 false false R12.htm 0000012 - Disclosure - Supplemental Cash Flow Information Sheet http://www.bio-rad.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 12 false false R13.htm 0000013 - Disclosure - Long-Term Debt Sheet http://www.bio-rad.com/role/LongTermDebt Long-Term Debt Notes 13 false false R14.htm 0000014 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 14 false false R15.htm 0000015 - Disclosure - Earnings (Loss) Per Share Sheet http://www.bio-rad.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 15 false false R16.htm 0000016 - Disclosure - Other Income, Net Sheet http://www.bio-rad.com/role/OtherIncomeNet Other Income, Net Notes 16 false false R17.htm 0000017 - Disclosure - Income Taxes Sheet http://www.bio-rad.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 0000018 - Disclosure - Segment Information Sheet http://www.bio-rad.com/role/SegmentInformation Segment Information Notes 18 false false R19.htm 0000019 - Disclosure - Legal Proceedings Sheet http://www.bio-rad.com/role/LegalProceedings Legal Proceedings Notes 19 false false R20.htm 0000020 - Disclosure - Restructuring Costs Sheet http://www.bio-rad.com/role/RestructuringCosts Restructuring Costs Notes 20 false false R21.htm 0000021 - Disclosure - Leases Sheet http://www.bio-rad.com/role/Leases Leases Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - Basis of Presentation and Use of Estimates (Policies) Sheet http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies Basis of Presentation and Use of Estimates (Policies) Policies 24 false false R25.htm 9954472 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables) Tables 25 false false R26.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.bio-rad.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.bio-rad.com/role/FairValueMeasurements 26 false false R27.htm 9954474 - Disclosure - Goodwill and Other Purchased Intangible Assets (Tables) Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables Goodwill and Other Purchased Intangible Assets (Tables) Tables http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets 27 false false R28.htm 9954475 - Disclosure - Inventory (Tables) Sheet http://www.bio-rad.com/role/InventoryTables Inventory (Tables) Tables http://www.bio-rad.com/role/Inventory 28 false false R29.htm 9954476 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://www.bio-rad.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://www.bio-rad.com/role/SupplementalCashFlowInformation 29 false false R30.htm 9954477 - Disclosure - Long-Term Debt (Tables) Sheet http://www.bio-rad.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.bio-rad.com/role/LongTermDebt 30 false false R31.htm 9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss 31 false false R32.htm 9954479 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.bio-rad.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) Tables http://www.bio-rad.com/role/EarningsLossPerShare 32 false false R33.htm 9954480 - Disclosure - Other Income, Net (Tables) Sheet http://www.bio-rad.com/role/OtherIncomeNetTables Other Income, Net (Tables) Tables http://www.bio-rad.com/role/OtherIncomeNet 33 false false R34.htm 9954481 - Disclosure - Segment Information (Tables) Sheet http://www.bio-rad.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.bio-rad.com/role/SegmentInformation 34 false false R35.htm 9954482 - Disclosure - Restructuring Costs (Tables) Sheet http://www.bio-rad.com/role/RestructuringCostsTables Restructuring Costs (Tables) Tables http://www.bio-rad.com/role/RestructuringCosts 35 false false R36.htm 9954483 - Disclosure - Leases (Tables) Sheet http://www.bio-rad.com/role/LeasesTables Leases (Tables) Tables http://www.bio-rad.com/role/Leases 36 false false R37.htm 9954484 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) Details 37 false false R38.htm 9954485 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) Details 38 false false R39.htm 9954487 - Disclosure - 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) Details 39 false false R40.htm 9954488 - Disclosure - 1. Basis of Presentation and Use of Estimates (Details) Sheet http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesDetails 1. Basis of Presentation and Use of Estimates (Details) Details http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables 40 false false R41.htm 9954489 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 41 false false R42.htm 9954490 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails_1 Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 42 false false R43.htm 9954491 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails_2 Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 43 false false R44.htm 9954492 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails_3 Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 44 false false R45.htm 9954493 - Disclosure - Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details) Details 45 false false R46.htm 9954495 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/FairValueMeasurementsDetails_4 Fair Value Measurements (Details) Details http://www.bio-rad.com/role/FairValueMeasurementsTables 46 false false R47.htm 9954496 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails Goodwill and Other Purchased Intangible Assets (Details) Details http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables 47 false false R48.htm 9954497 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details) Sheet http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1 Goodwill and Other Purchased Intangible Assets (Details) Details http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables 48 false false R49.htm 9954498 - Disclosure - Inventory (Details) Sheet http://www.bio-rad.com/role/InventoryDetails Inventory (Details) Details http://www.bio-rad.com/role/InventoryTables 49 false false R50.htm 9954499 - Disclosure - Supplemental Cash Flow Information (Details) Sheet http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails Supplemental Cash Flow Information (Details) Details http://www.bio-rad.com/role/SupplementalCashFlowInformationTables 50 false false R51.htm 9954500 - Disclosure - Long-Term Debt (Details) Sheet http://www.bio-rad.com/role/LongTermDebtDetails Long-Term Debt (Details) Details http://www.bio-rad.com/role/LongTermDebtTables 51 false false R52.htm 9954501 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables 52 false false R53.htm 9954502 - Disclosure - Earnings (Loss) Per Share (Details) Sheet http://www.bio-rad.com/role/EarningsLossPerShareDetails Earnings (Loss) Per Share (Details) Details http://www.bio-rad.com/role/EarningsLossPerShareTables 53 false false R54.htm 9954503 - Disclosure - Other Income, Net (Details) Sheet http://www.bio-rad.com/role/OtherIncomeNetDetails Other Income, Net (Details) Details http://www.bio-rad.com/role/OtherIncomeNetTables 54 false false R55.htm 9954504 - Disclosure - Income Taxes (Details) Sheet http://www.bio-rad.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.bio-rad.com/role/IncomeTaxes 55 false false R56.htm 9954505 - Disclosure - Segment Information (Details) Sheet http://www.bio-rad.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.bio-rad.com/role/SegmentInformationTables 56 false false R57.htm 9954506 - Disclosure - Segment Information (Details) Sheet http://www.bio-rad.com/role/SegmentInformationDetails_1 Segment Information (Details) Details http://www.bio-rad.com/role/SegmentInformationTables 57 false false R58.htm 9954507 - Disclosure - Segment Information (Details) Sheet http://www.bio-rad.com/role/SegmentInformationDetails_2 Segment Information (Details) Details http://www.bio-rad.com/role/SegmentInformationTables 58 false false R59.htm 9954508 - Disclosure - Restructuring Costs (Details) Sheet http://www.bio-rad.com/role/RestructuringCostsDetails Restructuring Costs (Details) Details http://www.bio-rad.com/role/RestructuringCostsTables 59 false false R60.htm 9954509 - Disclosure - Leases (Details) Sheet http://www.bio-rad.com/role/LeasesDetails Leases (Details) Details http://www.bio-rad.com/role/LeasesTables 60 false false All Reports Book All Reports bio-20230930.htm bio-20230930.xsd bio-20230930_cal.xml bio-20230930_def.xml bio-20230930_lab.xml bio-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bio-20230930.htm": { "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20230930", "dts": { "inline": { "local": [ "bio-20230930.htm" ] }, "schema": { "local": [ "bio-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "bio-20230930_cal.xml" ] }, "definitionLink": { "local": [ "bio-20230930_def.xml" ] }, "labelLink": { "local": [ "bio-20230930_lab.xml" ] }, "presentationLink": { "local": [ "bio-20230930_pre.xml" ] } }, "keyStandard": 302, "keyCustom": 10, "axisStandard": 20, "axisCustom": 0, "memberStandard": 52, "memberCustom": 16, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 2 }, "contextCount": 354, "entityCount": 1, "segmentCount": 71, "elementCount": 574, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1232, "http://xbrl.sec.gov/ecd/2023": 4, "http://xbrl.sec.gov/dei/2023": 34 }, "report": { "R1": { "role": "http://www.bio-rad.com/role/DocumentandEntityInformation", "longName": "0000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentTransitionReport", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentTransitionReport", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:ShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R3": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets Parenthetical", "shortName": "Condensed Consolidated Balance Sheets Parenthetical", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "longName": "0000004 - Statement - Condensed Consolidated Statements of Income (Unaudited)", "shortName": "Condensed Consolidated Statements of Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R5": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R6": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity Statement", "shortName": "Condensed Consolidated Statements of Stockholders' Equity Statement", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-65", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R8": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimates", "longName": "0000008 - Disclosure - Basis of Presentation and Use of Estimates", "shortName": "Basis of Presentation and Use of Estimates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bio-rad.com/role/FairValueMeasurements", "longName": "0000009 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets", "longName": "0000010 - Disclosure - Goodwill and Other Purchased Intangible Assets", "shortName": "Goodwill and Other Purchased Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bio-rad.com/role/Inventory", "longName": "0000011 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bio-rad.com/role/SupplementalCashFlowInformation", "longName": "0000012 - Disclosure - Supplemental Cash Flow Information", "shortName": "Supplemental Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bio-rad.com/role/LongTermDebt", "longName": "0000013 - Disclosure - Long-Term Debt", "shortName": "Long-Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss", "longName": "0000014 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "shortName": "Accumulated Other Comprehensive Income (Loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bio-rad.com/role/EarningsLossPerShare", "longName": "0000015 - Disclosure - Earnings (Loss) Per Share", "shortName": "Earnings (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bio-rad.com/role/OtherIncomeNet", "longName": "0000016 - Disclosure - Other Income, Net", "shortName": "Other Income, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bio-rad.com/role/IncomeTaxes", "longName": "0000017 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bio-rad.com/role/SegmentInformation", "longName": "0000018 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bio-rad.com/role/LegalProceedings", "longName": "0000019 - Disclosure - Legal Proceedings", "shortName": "Legal Proceedings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bio-rad.com/role/RestructuringCosts", "longName": "0000020 - Disclosure - Restructuring Costs", "shortName": "Restructuring Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bio-rad.com/role/Leases", "longName": "0000021 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-16", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Use of Estimates (Policies)", "shortName": "Basis of Presentation and Use of Estimates (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables", "longName": "9954472 - Disclosure - 1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)", "shortName": "1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables", "longName": "9954474 - Disclosure - Goodwill and Other Purchased Intangible Assets (Tables)", "shortName": "Goodwill and Other Purchased Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bio-rad.com/role/InventoryTables", "longName": "9954475 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bio-rad.com/role/SupplementalCashFlowInformationTables", "longName": "9954476 - Disclosure - Supplemental Cash Flow Information (Tables)", "shortName": "Supplemental Cash Flow Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bio-rad.com/role/LongTermDebtTables", "longName": "9954477 - Disclosure - Long-Term Debt (Tables)", "shortName": "Long-Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "longName": "9954478 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bio-rad.com/role/EarningsLossPerShareTables", "longName": "9954479 - Disclosure - Earnings (Loss) Per Share (Tables)", "shortName": "Earnings (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bio-rad.com/role/OtherIncomeNetTables", "longName": "9954480 - Disclosure - Other Income, Net (Tables)", "shortName": "Other Income, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bio-rad.com/role/SegmentInformationTables", "longName": "9954481 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bio-rad.com/role/RestructuringCostsTables", "longName": "9954482 - Disclosure - Restructuring Costs (Tables)", "shortName": "Restructuring Costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.bio-rad.com/role/LeasesTables", "longName": "9954483 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "longName": "9954484 - Disclosure - 1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "shortName": "1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:DeferredRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R38": { "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails", "longName": "9954485 - Disclosure - 1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details)", "shortName": "1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails", "longName": "9954487 - Disclosure - 1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details)", "shortName": "1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesDetails", "longName": "9954488 - Disclosure - 1. Basis of Presentation and Use of Estimates (Details)", "shortName": "1. Basis of Presentation and Use of Estimates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-16", "name": "bio:RevenueAllocationPercentToLeaseElements", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "bio:RevenueAllocationPercentToLeaseElements", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "longName": "9954489 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1", "longName": "9954490 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-134", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2", "longName": "9954491 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-225", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-225", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3", "longName": "9954492 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R45": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails", "longName": "9954493 - Disclosure - Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details)", "shortName": "Fair Value Measurements - Amortized Cost and Fair Value of Debt Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4", "longName": "9954495 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InterestReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InterestReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "longName": "9954496 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details)", "shortName": "Goodwill and Other Purchased Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:GoodwillGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:GoodwillGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1", "longName": "9954497 - Disclosure - Goodwill and Other Purchased Intangible Assets (Details)", "shortName": "Goodwill and Other Purchased Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R49": { "role": "http://www.bio-rad.com/role/InventoryDetails", "longName": "9954498 - Disclosure - Inventory (Details)", "shortName": "Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails", "longName": "9954499 - Disclosure - Supplemental Cash Flow Information (Details)", "shortName": "Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R51": { "role": "http://www.bio-rad.com/role/LongTermDebtDetails", "longName": "9954500 - Disclosure - Long-Term Debt (Details)", "shortName": "Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherLongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherLongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954501 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-257", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R53": { "role": "http://www.bio-rad.com/role/EarningsLossPerShareDetails", "longName": "9954502 - Disclosure - Earnings (Loss) Per Share (Details)", "shortName": "Earnings (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R54": { "role": "http://www.bio-rad.com/role/OtherIncomeNetDetails", "longName": "9954503 - Disclosure - Other Income, Net (Details)", "shortName": "Other Income, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:InvestmentIncomeInterestAndDividend", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bio-rad.com/role/IncomeTaxesDetails", "longName": "9954504 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.bio-rad.com/role/SegmentInformationDetails", "longName": "9954505 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://www.bio-rad.com/role/SegmentInformationDetails_1", "longName": "9954506 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:InterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-295", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R58": { "role": "http://www.bio-rad.com/role/SegmentInformationDetails_2", "longName": "9954507 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": null }, "R59": { "role": "http://www.bio-rad.com/role/RestructuringCostsDetails", "longName": "9954508 - Disclosure - Restructuring Costs (Details)", "shortName": "Restructuring Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-348", "name": "us-gaap:RestructuringReserveAccrualAdjustment1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "unique": true } }, "R60": { "role": "http://www.bio-rad.com/role/LeasesDetails", "longName": "9954509 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bio-20230930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and employee benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r165", "r198", "r677", "r890" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r745", "r748", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r770", "r771", "r772", "r773", "r786", "r787", "r788", "r789", "r792", "r793", "r794", "r795", "r815", "r816", "r817", "r818", "r880", "r882" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper [Member]", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r154", "r884", "r885", "r886", "r887" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r8", "r221", "r225", "r520", "r534", "r535", "r592", "r596", "r598", "r667", "r686" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized holding gains (losses) on available-for-sale investments net of tax expense", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r211", "r214", "r351" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS:", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Marketable Securities, Unrealized (Gain) Loss", "terseLabel": "Marketable Securities, Unrealized Gain (Loss)", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r131" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r133", "r659" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r572", "r578" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income and other taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r209", "r878" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r446", "r475", "r476", "r477", "r478", "r479", "r480", "r631", "r632", "r633", "r867", "r868", "r873", "r874", "r875" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsLossPerShareDetails", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r243", "r244", "r245", "r276", "r659", "r718", "r736", "r749", "r750", "r751", "r752", "r753", "r754", "r757", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r770", "r771", "r772", "r773", "r774", "r776", "r780", "r781", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r799", "r883" ] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest and investment income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r136" ] }, "us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions", "label": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions", "documentation": "Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r325" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r1084" ] }, "us-gaap_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInvestmentsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments [Member]", "label": "Other Investments [Member]", "documentation": "Primary financial statement caption encompassing other investments." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r324" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r118" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r206", "r315", "r364" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r113", "r514", "r1074" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r197", "r396" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r941" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "periodStartLabel": "Beginning balance, Accumulated other comprehensive income", "periodEndLabel": "Ending balance, Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r35", "r36", "r128", "r205", "r681", "r712", "r716" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r941" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash, Current", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r981", "r997" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r63" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r952" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r892" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed Securities [Member]", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r873", "r1016", "r1022", "r1023" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r906", "r914", "r924", "r941", "r949", "r953", "r961" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash, Noncurrent", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r177", "r982", "r997" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r43", "r194", "r851" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r941" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r892" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets, Gross (Excluding Goodwill)", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r196" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r591" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r142" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Cash, Cash Equivalents, and Restricted Cash", "periodEndLabel": "Ending Cash, Cash Equivalents, and Restricted Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r43", "r142", "r239" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r29", "r193", "r240", "r353", "r425", "r426", "r428", "r429", "r430", "r432", "r434", "r436", "r437", "r544", "r546", "r547", "r582", "r878", "r1049", "r1066", "r1067" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Bio-Rad", "terseLabel": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r130", "r144", "r173", "r191", "r216", "r219", "r223", "r240", "r247", "r251", "r252", "r253", "r254", "r257", "r258", "r268", "r283", "r297", "r303", "r306", "r353", "r425", "r426", "r428", "r429", "r430", "r432", "r434", "r436", "r437", "r570", "r582", "r685", "r778", "r797", "r798", "r862", "r888", "r1049" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r941" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r892" ] }, "us-gaap_NoncompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncompeteAgreementsMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Noncompete Agreements [Member]", "label": "Noncompete Agreements [Member]", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": [ "r81" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r30", "r439" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r27", "r240", "r353", "r425", "r426", "r428", "r429", "r430", "r432", "r434", "r436", "r437", "r544", "r546", "r547", "r582", "r756", "r861", "r890", "r1049", "r1066", "r1067" ] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents [Member]", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r194" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r20" ] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalanceShares", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Owned, Balance, Shares", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": [ "r737", "r746", "r804", "r812", "r822", "r882" ] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncome", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Nonoperating (Income)", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r229" ] }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable and Allowance for Credit Losses", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized." } } }, "auth_ref": [ "r59" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r933" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r933" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r399", "r406", "r782" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r406", "r782" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r934" ] }, "us-gaap_RestrictedInvestmentsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedInvestmentsAtFairValue", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Investments, at Fair Value", "label": "Restricted Investments, at Fair Value", "documentation": "The aggregate value of all restricted investments." } } }, "auth_ref": [ "r806", "r813", "r823", "r835", "r836" ] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Nonoperating Expense", "label": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r137" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 }, "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r137" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r934" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r934" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r934" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r934" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in fair value of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r542", "r995" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r934" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for purchases of marketable securities and investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r140" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r934" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r935" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for purchases of treasury stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r39" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r952" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r937" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r936" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r738", "r740", "r741", "r743", "r746", "r802", "r805", "r808", "r811", "r814", "r819", "r820", "r824", "r825", "r826", "r827", "r828", "r882" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r952" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r938" ] }, "us-gaap_OtherDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Other Depreciation and Amortization", "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } }, "auth_ref": [ "r12", "r68", "r134" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r415", "r416", "r417", "r418", "r474", "r481", "r507", "r508", "r509", "r634", "r658", "r704", "r747", "r748", "r803", "r807", "r809", "r810", "r821", "r846", "r847", "r863", "r871", "r876", "r879", "r882", "r1044", "r1051", "r1069", "r1070", "r1071", "r1072", "r1073" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r952" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r415", "r416", "r417", "r418", "r474", "r481", "r507", "r508", "r509", "r634", "r658", "r704", "r747", "r748", "r803", "r807", "r809", "r810", "r821", "r846", "r847", "r863", "r871", "r876", "r879", "r882", "r1044", "r1051", "r1069", "r1070", "r1071", "r1072", "r1073" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r953" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r952" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Notional Amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1055", "r1056" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r132", "r240", "r283", "r297", "r303", "r306", "r353", "r425", "r426", "r428", "r429", "r430", "r432", "r434", "r436", "r437", "r582", "r862", "r1049" ] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r101", "r103", "r104" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r50", "r51", "r52", "r178", "r179", "r180", "r181" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents, Fair Value Disclosure", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r192", "r210", "r240", "r353", "r425", "r426", "r428", "r429", "r430", "r432", "r434", "r436", "r437", "r543", "r546", "r582", "r878", "r1049", "r1050", "r1066" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r108", "r174", "r224", "r287", "r601", "r783", "r888", "r1082" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r903", "r914", "r924", "r941", "r949" ] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events, Policy", "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Trade Names [Member]", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r80" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1064" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r454", "r461", "r559", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r687", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r1024", "r1025", "r1026", "r1027" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement", "http://www.bio-rad.com/role/DocumentandEntityInformation", "http://www.bio-rad.com/role/EarningsLossPerShareDetails", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r243", "r244", "r245", "r276", "r659", "r718", "r736", "r749", "r750", "r751", "r752", "r753", "r754", "r757", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r770", "r771", "r772", "r773", "r774", "r776", "r780", "r781", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r799", "r883" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.bio-rad.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r607" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r36", "r1062", "r1063" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r1084" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r904", "r915", "r925", "r950" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r903", "r914", "r924", "r949" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r170", "r171", "r987" ] }, "bio_KnowHowMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "KnowHowMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Know How [Member]", "label": "Know How [Member]", "documentation": "Know how [Member]" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r954" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r956" ] }, "bio_AdditionalEuropeanAndAmericanReorganizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "AdditionalEuropeanAndAmericanReorganizationMember", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional European and American Reorganization", "label": "Additional European and American Reorganization [Member]", "documentation": "Additional European and American Reorganization" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments [Member]", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r826", "r827", "r828", "r850" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r959" ] }, "bio_ValueAppreciationRightsUnrecognizedUnrealizedAppreciationDepreciationNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "ValueAppreciationRightsUnrecognizedUnrealizedAppreciationDepreciationNet", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net", "label": "Value appreciation rights, Unrecognized Unrealized Appreciation (Depreciation), Net", "documentation": "Sartorius Loan value appreciation rights - Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r953" ] }, "bio_TreasuryClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "TreasuryClassAMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Class A [Member]", "label": "Treasury Class-A [Member]", "documentation": "Treasury Class A [Member]" } } }, "auth_ref": [] }, "bio_RestrictedInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "RestrictedInvestmentMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted investment [Member]", "label": "Restricted investment [Member]", "documentation": "Restricted investment" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r955" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "verboseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r120", "r157", "r682", "r711", "r716", "r723", "r758", "r878" ] }, "bio_DocumentAndEntityInformationParentheticalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "DocumentAndEntityInformationParentheticalAbstract", "lang": { "en-us": { "role": { "terseLabel": "Document and Entity Information (Parenthetical) [Abstract]", "label": "Document and Entity Information (Parenthetical) [Abstract]", "documentation": "Document and Entity Information (Parenthetical) [Abstract]" } } }, "auth_ref": [] }, "bio_LesseeOperatingAndFinanceLeasesRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "LesseeOperatingAndFinanceLeasesRemainingLeaseTerm", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Operating And Finance Leases Remaining Lease Term", "label": "Lessee Operating And Finance Leases Remaining Lease Term", "documentation": "Lessee Operating And Finance Leases Remaining Lease Term" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1029" ] }, "bio_FinanceLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "FinanceLeaseCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease Cost", "label": "Finance Lease Cost", "documentation": "Finance Lease Cost" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r960" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.bio-rad.com/role/LongTermDebt" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r153" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1", "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r242", "r285", "r296", "r297", "r298", "r299", "r300", "r302", "r306", "r425", "r426", "r427", "r428", "r430", "r431", "r433", "r435", "r436", "r1049", "r1050" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r957" ] }, "bio_LifeScienceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "LifeScienceMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1", "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Life Science", "label": "Life Science [Member]", "documentation": "Life Sciences [Member]" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockReissuedAtLowerThanRepurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockReissuedAtLowerThanRepurchasePrice", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury Stock Reissued at Lower than Repurchase Price", "label": "Treasury Stock Reissued at Lower than Repurchase Price", "documentation": "In cases when treasury stock is reissued at a price lower than the cost to repurchase, the excess difference between the selling price and cost to repurchase is charged against retained earnings (assuming that all APIC arising from treasury stock transactions has first been exhausted)." } } }, "auth_ref": [ "r16", "r75", "r118", "r157" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r958" ] }, "bio_EuropeanReorganizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "EuropeanReorganizationMember", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "European Reorganization", "label": "European Reorganization [Member]", "documentation": "European Reorganization" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r959" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1", "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r242", "r285", "r296", "r297", "r298", "r299", "r300", "r302", "r306", "r425", "r426", "r427", "r428", "r430", "r431", "r433", "r435", "r436", "r1049", "r1050" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r31" ] }, "bio_FinanceLeaseObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "FinanceLeaseObligationsMember", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease Obligations", "label": "Finance Lease Obligations [Member]", "documentation": "Finance Lease Obligations [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r615" ] }, "bio_Paymentsforproceedsfromderivativeinstrumentsoperatingactivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "Paymentsforproceedsfromderivativeinstrumentsoperatingactivities", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Proceeds from forward foreign exchange contracts, net", "label": "Payments for (proceeds from) derivative instruments, operating activities", "documentation": "Payments for (proceeds from) derivative instruments, operating activities" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r959" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r960" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r960" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r615" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r241", "r516", "r522", "r524", "r526", "r531", "r533", "r536", "r537", "r724" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r960" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Total Stockholders' Equity", "periodEndLabel": "Total Stockholders' Equity", "terseLabel": "Total stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r118", "r121", "r122", "r147", "r759", "r775", "r800", "r801", "r878", "r890", "r1000", "r1028", "r1059", "r1084" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Segment profit (loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r283", "r297", "r303", "r306", "r862" ] }, "us-gaap_RestructuringReserveTranslationAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveTranslationAdjustment", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restructuring Reserve, Foreign Currency Translation (Gain) Loss", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve." } } }, "auth_ref": [ "r1046", "r1047" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r151" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r525" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r21" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r11" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1029" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/EarningsLossPerShareDetails", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement, Scenario [Axis]", "verboseLabel": "Statement, Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r259", "r482", "r968", "r969", "r1005" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease (increase) in inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r11" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/EarningsLossPerShareDetails", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r259", "r482", "r968", "r1005" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r660" ] }, "us-gaap_PaymentsForPreviousAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForPreviousAcquisition", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for Acquisitions, net of cash received", "label": "Payments for Previous Acquisition", "documentation": "Cash outflow representing an adjustment to the purchase price of a previous acquisition." } } }, "auth_ref": [ "r991" ] }, "us-gaap_FairValueOptionLoansHeldAsAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOptionLoansHeldAsAssetsAbstract", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Option, Loans Held as Assets [Abstract]", "label": "Fair Value, Option, Loans Held as Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r572" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Foreign Currency Translation Gain (Loss)", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r388" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r617", "r877" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromOtherOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromOtherOperatingActivities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investment proceeds and miscellaneous receipts, net", "label": "Proceeds from Other Operating Activities", "documentation": "Amount of cash inflow from operating activities classified as other." } } }, "auth_ref": [ "r42" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r235" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimates" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Use of Estimates", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r114", "r145", "r146", "r162" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r11" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net income per share diluted attributable to Bio-Rad", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r227", "r251", "r252", "r253", "r254", "r255", "r263", "r269", "r270", "r271", "r275", "r569", "r570", "r669", "r689", "r860" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "totalLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r129", "r172", "r283", "r297", "r303", "r306", "r670", "r684", "r862" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r235" ] }, "us-gaap_ForeignCurrencyGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyGainLossMember", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Gain (Loss)", "label": "Foreign Currency Gain (Loss) [Member]", "documentation": "Primary financial statement caption encompassing foreign currency gain (loss)." } } }, "auth_ref": [ "r1057" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "terseLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r142", "r143", "r144" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r91", "r93", "r95", "r97", "r745", "r748", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r770", "r771", "r772", "r773", "r786", "r787", "r788", "r789", "r792", "r793", "r794", "r795", "r815", "r816", "r817", "r818", "r858", "r880", "r882" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r108", "r444", "r455", "r867", "r868" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Liability, Payment, Due", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r622" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r118", "r680", "r878" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r609" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r16", "r118", "r757", "r775", "r1084", "r1085" ] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of amortized cost and estimated fair value of debt securities by contractual maturity date", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r135" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r313", "r314" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due after Year Five", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r622" ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Elements [Abstract]", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, to be Paid, Year One", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r622" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r11" ] }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPeriodIncreaseDecrease", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Period Increase (Decrease)", "label": "Goodwill, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r1030" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due Year Four", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r622" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due Year Three", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r622" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Due Year Two", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r622" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1065" ] }, "us-gaap_SeniorLongTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorLongTermNotes", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes, Noncurrent", "label": "Senior Notes, Noncurrent", "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth_ref": [ "r31", "r878" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r891" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Interest Payment on Liability", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r613", "r618" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings per share:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": [ "r19", "r101", "r102", "r164" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r279", "r280", "r281", "r282", "r283", "r295", "r300", "r304", "r305", "r306", "r307", "r308", "r309", "r312" ] }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAssetReconcilingItemLineItems", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]", "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r609" ] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]", "label": "Reconciliation of Assets from Segment to Consolidated [Table]", "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r57", "r58" ] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Interest Expense", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r611", "r616", "r877" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r893" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r995" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r56", "r58" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r53", "r54", "r55", "r60" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted earnings per share:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r609" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r53", "r54", "r55", "r60" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r622" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings (Loss) Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r260", "r272", "r273", "r274" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in other long term liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive shares", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r272" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r609" ] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r56", "r58" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r90", "r94" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansPayableCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt and notes payable", "label": "Notes and Loans Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r221", "r222", "r592", "r594", "r595", "r596", "r597", "r598" ] }, "us-gaap_EscrowDepositsRelatedToPropertySales": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EscrowDepositsRelatedToPropertySales", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (Decrease) in Deposit Assets", "label": "Escrow Deposits Related to Property Sales", "documentation": "Escrow deposits related to property sales in noncash investing and financing activities." } } }, "auth_ref": [ "r45", "r46", "r47" ] }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments." } } }, "auth_ref": [ "r91", "r96" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid, net", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r234", "r237", "r238" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r16", "r76", "r157" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Common", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r76" ] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on Disposition of a division", "label": "Gain (Loss) on Disposition of Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r545", "r996" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock, Shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r76" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r517", "r523" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r365", "r366", "r371", "r372", "r373", "r375", "r376", "r377", "r454", "r461", "r559", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r687", "r864", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r1024", "r1025", "r1026", "r1027" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss, Current", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r228", "r368" ] }, "us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EscrowDepositDisbursementsRelatedToPropertyAcquisition1", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Escrow Deposit Disbursements Related to Property Acquisition", "label": "Escrow Deposit Disbursements Related to Property Acquisition", "documentation": "Amount of escrow deposit disbursements related to property acquisition in noncash investing or financing transactions." } } }, "auth_ref": [ "r45", "r46", "r47" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UNITED STATES", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r283", "r297", "r303", "r306", "r691", "r862" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r865" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r952" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortized Cost", "totalLabel": "Total Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r321", "r374", "r676" ] }, "us-gaap_AdjustmentForAmortizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentForAmortizationAbstract", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization [Abstract]", "label": "Amortization [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r894" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r184", "r202", "r203", "r204", "r240", "r263", "r267", "r269", "r271", "r277", "r278", "r353", "r425", "r428", "r429", "r430", "r436", "r437", "r457", "r458", "r459", "r460", "r462", "r582", "r719", "r720", "r721", "r722", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r757", "r779", "r799", "r829", "r830", "r831", "r832", "r833", "r967", "r998", "r1006" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r865" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r194" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r901", "r912", "r922", "r947" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r903", "r914", "r924", "r949" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r903", "r914", "r924", "r949" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r608" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Developed Technology Rights [Member]", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r161" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r221", "r222", "r592", "r594", "r595", "r596", "r597", "r598" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r892" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss) net of tax", "terseLabel": "Total other comprehensive income (loss) net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r16", "r22", "r217", "r220", "r225", "r592", "r593", "r598", "r667", "r686", "r988", "r989" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1", "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "verboseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r190", "r280", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r312", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r400", "r407", "r413", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r865", "r973", "r1078" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r900", "r911", "r921", "r946" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r892" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r899", "r910", "r920", "r945" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r892" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net income per share basic attributable to Bio-Rad", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r227", "r251", "r252", "r253", "r254", "r255", "r261", "r263", "r269", "r270", "r271", "r275", "r569", "r570", "r669", "r689", "r860" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration, Liability", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r1", "r84", "r541" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r892" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Purchased Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r149" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r284", "r285", "r296", "r301", "r302", "r308", "r310", "r312", "r472", "r473", "r659" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r902", "r913", "r923", "r948" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r880", "r881", "r882", "r884", "r885", "r886", "r887", "r1002", "r1003", "r1058", "r1080", "r1084" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r33", "r76", "r77" ] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Debt, Net of Issuance Costs", "label": "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": [ "r232" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in one to five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1018" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r187", "r221", "r222", "r223", "r243", "r244", "r245", "r248", "r256", "r258", "r276", "r357", "r363", "r463", "r511", "r512", "r513", "r529", "r530", "r551", "r553", "r554", "r555", "r556", "r558", "r568", "r592", "r594", "r595", "r596", "r597", "r598", "r627", "r707", "r708", "r709", "r725", "r799" ] }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r183", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r848" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r194" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1", "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "verboseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r280", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r312", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r407", "r413", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r865", "r973", "r1078" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in less than one year", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1017" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in more than five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1019" ] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Information", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r138" ] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Agreements [Member]", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r83", "r515", "r1054" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r738", "r740", "r741", "r743", "r746", "r802", "r805", "r808", "r811", "r814", "r819", "r820", "r824", "r825", "r826", "r827", "r828", "r882" ] }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement." } } }, "auth_ref": [ "r16", "r76", "r117", "r118", "r157" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in less than one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r328", "r672" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r11" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in one to five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r329", "r673" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r610" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mature in more than five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r330", "r674" ] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllOtherSegmentsMember", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1", "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Other Segments", "label": "Other Segments [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r280", "r296", "r297", "r298", "r299", "r300" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of current maturities", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r201" ] }, "us-gaap_OtherLongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Long-term Debt, Current", "label": "Other Long-Term Debt, Current", "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer." } } }, "auth_ref": [ "r115", "r116", "r755" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1", "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r296", "r297", "r298", "r299", "r300", "r306" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r952" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r621", "r877" ] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1", "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reconciling Items [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r58" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsAmortizedCostandFairValueofDebtSecuritiesDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale", "totalLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r322", "r374", "r666", "r1007" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "US Treasury Securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r859", "r873", "r875", "r1075" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r23", "r168", "r445", "r456", "r867", "r868", "r1076" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r195" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r621", "r877" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r622" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1024" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r622" ] }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOptionChangesInFairValueGainLoss1", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings." } } }, "auth_ref": [ "r105" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ] }, "us-gaap_USTreasuryAndGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryAndGovernmentMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "US Government Sponsored Agencies [Member]", "label": "US Treasury and Government [Member]", "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r671", "r873", "r1079" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Lessee, Operating Lease, Liability, Payments, Due", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r622" ] }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date." } } }, "auth_ref": [ "r160" ] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Related Disclosures [Abstract]", "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds [Member]", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1053" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Sale of Debt Securities, Available-for-sale", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r37", "r230", "r319", "r350" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year One", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r622" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Debt Securities [Member]", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r873", "r875", "r1079" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r622" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r622" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1065" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional paid-in-capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r119", "r878", "r1081" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r206", "r315", "r364", "r367", "r370", "r1077" ] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesBasisofPresentationandUseofEstimatesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Warranty Liability [Table Text Block]", "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": [ "r420" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r415", "r416", "r417", "r418", "r481", "r658", "r704", "r747", "r748", "r803", "r807", "r809", "r810", "r821", "r846", "r847", "r863", "r871", "r876", "r879", "r1051", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r207", "r852", "r878" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe [Member]", "label": "Europe [Member]" } } }, "auth_ref": [ "r1086", "r1087", "r1088", "r1089" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r31", "r73", "r74", "r106", "r107", "r109", "r112", "r155", "r156", "r867", "r869", "r1001" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Amortization", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r611", "r616", "r877" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r415", "r416", "r417", "r418", "r481", "r658", "r704", "r747", "r748", "r803", "r807", "r809", "r810", "r821", "r846", "r847", "r863", "r871", "r876", "r879", "r1051", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Provision) benefit for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r176", "r182", "r257", "r258", "r291", "r520", "r532", "r692" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r31", "r242", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r602", "r866", "r867", "r868", "r869", "r870", "r999" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r939" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r49" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.bio-rad.com/role/EarningsLossPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares - diluted", "totalLabel": "Diluted weighted average common shares", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r262", "r271" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r24", "r124", "r125", "r126" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r17", "r86", "r87", "r88", "r89", "r92", "r95", "r98", "r99", "r100", "r559" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange (gains) losses, net", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r587", "r588", "r589", "r590", "r796" ] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AmericasMember", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Americas [Member]", "label": "Americas [Member]" } } }, "auth_ref": [ "r1086", "r1087", "r1088", "r1089" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.bio-rad.com/role/EarningsLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofIncomeUnaudited", "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares - basic", "verboseLabel": "Basic weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r261", "r271" ] }, "us-gaap_TradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradingSecurities", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r111", "r200", "r853" ] }, "us-gaap_RestrictedInvestmentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedInvestmentsCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted investments", "label": "Restricted Investments, Current", "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions." } } }, "auth_ref": [ "r835", "r836" ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific [Member]", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r1086", "r1087", "r1088", "r1089" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes to goodwill by segment", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r865", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in the carrying amount of right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r996" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on long-term borrowings", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r40", "r722" ] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/RestructuringCosts" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Costs", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r402", "r403", "r405", "r408", "r414" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r242", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r602", "r866", "r867", "r868", "r869", "r870", "r999" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r12", "r409", "r411", "r1045" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r23", "r115", "r116", "r167", "r168", "r242", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r602", "r866", "r867", "r868", "r869", "r870", "r999" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r31", "r73", "r74", "r106", "r107", "r109", "r112", "r155", "r156", "r242", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r602", "r866", "r867", "r868", "r869", "r870", "r999" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r940" ] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase in deferred income taxes", "label": "Increase (Decrease) in Deferred Income Taxes", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": [ "r11" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Liability", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r609", "r622" ] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/OtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net realized (gain) loss on investments", "label": "Realized Investment Gains (Losses)", "documentation": "Amount of realized gain (loss) on investment." } } }, "auth_ref": [ "r690" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r985" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r905", "r916", "r926", "r951" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r939" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r405", "r410" ] }, "us-gaap_OtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermDebt", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Long-term Debt", "label": "Other Long-Term Debt", "documentation": "Amount of long-term debt classified as other." } } }, "auth_ref": [ "r23", "r168", "r1076" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalMattersAndContingenciesTextBlock", "presentation": [ "http://www.bio-rad.com/role/LegalProceedings" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Proceedings", "label": "Legal Matters and Contingencies [Text Block]", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies." } } }, "auth_ref": [ "r152" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r609" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r929" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Finance Lease, Liability, Undiscounted Excess Amount", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r622" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r929" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedLoss", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity Securities, FV-NI, Unrealized Loss", "label": "Equity Securities, FV-NI, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r352" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r511", "r512", "r513", "r725", "r1002", "r1003", "r1004", "r1058", "r1084" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r960" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r961" ] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNet" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income, Net", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r158", "r159" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r31", "r72" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of identifiable purchased intangible assets with definite lives", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r63" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGain", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gain on Securities", "label": "Equity Securities, FV-NI, Unrealized Gain", "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r352" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax payments from net share settlement", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r233" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r961" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r962" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r961" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r123", "r169", "r683", "r878", "r1000", "r1028", "r1059" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY:", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r963" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Discussion of current derivative risk management", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r17", "r86", "r87", "r88", "r89", "r92", "r95", "r98", "r99" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r962" ] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange (gains) losses, net", "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r777", "r888", "r1060", "r1061", "r1083" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Purchased intangibles, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r61", "r65" ] }, "us-gaap_DebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecurities", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities", "label": "Debt Securities", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r318", "r675" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.bio-rad.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r521" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r148", "r855" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r148", "r856" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r896", "r907", "r917", "r942" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r964" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r895", "r965" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r148", "r857" ] }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-Of-Use Asset, before Accumulated Amortization", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r970" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r898", "r909", "r919", "r944" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r69", "r70", "r71" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]", "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-Of-Use Asset, Accumulated Amortization", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease." } } }, "auth_ref": [ "r971", "r972" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r150", "r660" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r10", "r14", "r163", "r217", "r220" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "totalLabel": "Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r166", "r199", "r240", "r283", "r298", "r304", "r353", "r425", "r426", "r428", "r429", "r430", "r432", "r434", "r436", "r437", "r543", "r546", "r582", "r678", "r769", "r878", "r890", "r1049", "r1050", "r1066" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r895", "r965" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Fair Value Disclosure", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r101" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.bio-rad.com/role/Inventory" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r378" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r896", "r907", "r917", "r942" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Price", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r150", "r664" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r895", "r965" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r34", "r187", "r221", "r222", "r223", "r243", "r244", "r245", "r248", "r256", "r258", "r276", "r357", "r363", "r463", "r511", "r512", "r513", "r529", "r530", "r551", "r553", "r554", "r555", "r556", "r558", "r568", "r592", "r594", "r595", "r596", "r597", "r598", "r627", "r707", "r708", "r709", "r725", "r799" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant, and equipment", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r970", "r983", "r1042" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r7", "r14", "r128", "r163" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Less: accumulated depreciation and amortization", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": [ "r971", "r972", "r1043" ] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets, Fair Value Disclosure", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r101" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r187", "r243", "r244", "r245", "r248", "r256", "r258", "r357", "r363", "r511", "r512", "r513", "r529", "r530", "r551", "r554", "r555", "r558", "r568", "r707", "r709", "r725", "r1084" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r518", "r519", "r679" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r972", "r1041" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Defined Benefit Plans Adjustment", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r6", "r15", "r36", "r988", "r989", "r990" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Translation Adjustment", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r5", "r15", "r36", "r222", "r223", "r594", "r595", "r596", "r597", "r598", "r988" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Net Unrealized Investment Gain (Loss)", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r211", "r212", "r213", "r215", "r222", "r223", "r988" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, net", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r196", "r381", "r665", "r865", "r878", "r1031", "r1038" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r899", "r910", "r920", "r945" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r903", "r914", "r924", "r949" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r404", "r405", "r406", "r407", "r411", "r412", "r413" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r897", "r908", "r918", "r943" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r15", "r36", "r553", "r556", "r627", "r707", "r708", "r988", "r989", "r990", "r1002", "r1003", "r1004" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r393", "r395", "r396", "r398", "r660", "r664" ] }, "us-gaap_MunicipalBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MunicipalBondsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Municipal Obligations (Member)", "verboseLabel": "Municipal obligations [Member]", "label": "Municipal Bonds [Member]", "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r63", "r66" ] }, "us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForLoanAndLeaseLossesWriteOffs", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Allowance for Loan and Lease Losses, Write-offs", "label": "Allowance for Loan and Lease Losses, Writeoff", "documentation": "Amount of loans and leases that have been written off from both loan receivables and allowance reserve for credit loss." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Divestiture of Businesses", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r38" ] }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BankTimeDepositsMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time Deposits [Member]", "label": "Bank Time Deposits [Member]", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": [ "r175" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r223" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r223" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r78", "r79", "r483" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification Out Of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r223" ] }, "us-gaap_RestructuringCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring Costs [Abstract]", "label": "Restructuring Costs [Abstract]" } } }, "auth_ref": [] }, "bio_Investmentownershippercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "Investmentownershippercentage", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Investment ownership percentage", "label": "Investment ownership percentage", "documentation": "Investment ownership percentage" } } }, "auth_ref": [] }, "bio_EuropeanAndAmericanReorganizationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "EuropeanAndAmericanReorganizationMember", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "European and American Reorganization", "label": "European and American Reorganization [Member]", "documentation": "European and American Reorganization" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r12", "r62", "r67" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements Issued and to be Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "bio_RevenueAllocationPercentToLeaseElements": { "xbrltype": "percentItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "RevenueAllocationPercentToLeaseElements", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesDetails", "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Allocation Percent To Lease Elements", "label": "Revenue Allocation Percent To Lease Elements", "documentation": "Revenue Allocation Percent To Lease Elements" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r36", "r222", "r592", "r595", "r598", "r686", "r988" ] }, "bio_LesseeSupplementalCashFlowInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "LesseeSupplementalCashFlowInformationTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Supplemental Cash Flow Information", "label": "Lessee Supplemental Cash Flow Information [Table Text Block]", "documentation": "Lessee Supplemental Cash Flow Information [Table Text Block]" } } }, "auth_ref": [] }, "bio_MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities Of Lease Liabilities For Operating and Finance Leases", "label": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]", "documentation": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r36", "r222", "r592", "r597", "r598", "r686", "r988" ] }, "bio_OrdinaryVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "OrdinaryVotingSharesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary voting shares [Member]", "label": "Ordinary voting shares [Member]", "documentation": "Ordinary voting shares" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r185", "r186", "r187", "r188", "r189", "r246", "r247", "r248", "r249", "r250", "r253", "r259", "r275", "r316", "r317", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r401", "r511", "r512", "r513", "r527", "r528", "r529", "r530", "r538", "r539", "r540", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r579", "r580", "r583", "r584", "r585", "r586", "r599", "r600", "r603", "r604", "r605", "r606", "r623", "r624", "r625", "r626", "r627", "r661", "r662", "r663", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r446", "r475", "r480", "r574", "r632", "r867", "r868", "r873", "r874", "r875" ] }, "us-gaap_DerivativeForwardInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeForwardInterestRate", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Forward Interest Rate", "label": "Derivative, Forward Interest Rate", "documentation": "Stated rate on an interest rate forward or futures contract." } } }, "auth_ref": [] }, "bio_A37SeniorNotesDue2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "A37SeniorNotesDue2032Member", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.7%, Senior Notes due 2032", "label": "3.7%, Senior Notes due 2032 [Member]", "documentation": "3.7%, Senior Notes due 2032" } } }, "auth_ref": [] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Reclassification Out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from dispositions of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r139" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r446", "r475", "r480", "r574", "r631", "r873", "r874", "r875" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.bio-rad.com/role/EarningsLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/EarningsLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of potentially dilutive stock options and restricted stock awards", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r264", "r265", "r266", "r271", "r484" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from external customers [Table]", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items." } } }, "auth_ref": [ "r48", "r185", "r186", "r187", "r188", "r189", "r246", "r247", "r248", "r249", "r250", "r253", "r259", "r275", "r316", "r317", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r401", "r511", "r512", "r513", "r527", "r528", "r529", "r530", "r538", "r539", "r540", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r579", "r580", "r583", "r584", "r585", "r586", "r599", "r600", "r603", "r604", "r605", "r606", "r623", "r624", "r625", "r626", "r627", "r661", "r662", "r663", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717" ] }, "bio_ForwardforeignexchangecontracttosellforeigncurrencyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "ForwardforeignexchangecontracttosellforeigncurrencyMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Forward foreign exchange contract to sell foreign currency [Member]", "label": "Forward foreign exchange contract to sell foreign currency [Member]", "documentation": "Forward foreign exchange contract to sell foreign currency [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignGovernmentDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignGovernmentDebtMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Government Debt [Member]", "label": "Foreign Government Debt [Member]", "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity." } } }, "auth_ref": [ "r1009", "r1021" ] }, "bio_A33SeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "A33SeniorNotesDue2027Member", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.3%, Senior Notes due 2027", "label": "3.3%, Senior Notes due 2027 [Member]", "documentation": "3.3%, Senior Notes due 2027" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r446", "r475", "r476", "r477", "r478", "r479", "r480", "r574", "r633", "r867", "r868", "r873", "r874", "r875" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r64", "r151" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r394", "r397" ] }, "bio_FinanceLeasesandOtherDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "FinanceLeasesandOtherDebtMember", "presentation": [ "http://www.bio-rad.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Leases and Other Debt", "label": "Finance Leases and Other Debt [Member]", "documentation": "Finance Leases and Other Debt [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r904", "r915", "r925", "r950" ] }, "bio_ClinicalDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "ClinicalDiagnosticsMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails", "http://www.bio-rad.com/role/SegmentInformationDetails", "http://www.bio-rad.com/role/SegmentInformationDetails_1", "http://www.bio-rad.com/role/SegmentInformationDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Diagnostics", "label": "Clinical Diagnostics [Member]", "documentation": "Clinical Diagnostics [Member]" } } }, "auth_ref": [] }, "bio_FinanceLeaseRightOfUseAssetafterAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "FinanceLeaseRightOfUseAssetafterAccumulatedAmortization", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization", "label": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization", "documentation": "Finance Lease, Right-Of-Use Asset, after Accumulated Amortization" } } }, "auth_ref": [] }, "bio_LesseeSupplementalBalanceSheetInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "LesseeSupplementalBalanceSheetInformationTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Supplemental Balance Sheet Information", "label": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "documentation": "Lessee Supplemental Balance Sheet Information [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignGovernmentDebtSecuritiesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Government Obligations [Member]", "label": "Debt Security, Government, Non-US [Member]", "documentation": "Debt security issued by government not domiciled in United States of America (US)." } } }, "auth_ref": [ "r1053", "r1079" ] }, "bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_2" ], "lang": { "en-us": { "role": { "terseLabel": "Forward foreign exchange contract to purchase foreign currency [Member]", "label": "Forward foreign exchange contract to purchase foreign currency [Member]", "documentation": "Forward foreign exchange contract to purchase foreign currency [Member]" } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "In Process Research and Development [Member]", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax payments, net", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r44" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r208", "r379", "r380", "r854" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.bio-rad.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r127", "r225", "r667", "r686" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r573", "r574", "r577" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r404", "r405", "r406", "r407", "r411", "r412", "r413" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r573", "r574", "r577" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1", "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "bio_PreferenceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-rad.com/20230930", "localname": "PreferenceSharesMember", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Preference shares [Member]", "label": "Preference shares [Member]", "documentation": "Preference shares" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r614", "r618" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesMember", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable and Accrued Liabilities", "label": "Accounts Payable and Accrued Liabilities [Member]", "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Principal Payments", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r612", "r618" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r446", "r475", "r476", "r477", "r478", "r479", "r480", "r574", "r631", "r632", "r633", "r867", "r868", "r873", "r874", "r875" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r903", "r914", "r924", "r949" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesAccountsReceivablesAllowanceforCreditLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Recovery", "label": "Accounts Receivable, Allowance for Credit Loss, Recovery", "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery." } } }, "auth_ref": [ "r369" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.bio-rad.com/role/OtherIncomeNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of other income (expense), net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for warranty", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued." } } }, "auth_ref": [ "r423" ] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillGross", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill, Gross", "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r383", "r390", "r865" ] }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrual", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warranty accrual, beginning of period", "periodEndLabel": "Warranty accrual, end of period", "label": "Standard and Extended Product Warranty Accrual", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": [ "r110", "r419", "r421", "r424" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated impairment loss", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r383", "r390", "r865" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r620", "r877" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r929" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value by Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r573", "r574", "r575", "r576", "r578" ] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_4" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Receivable, Current", "label": "Interest Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r986" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r619", "r877" ] }, "us-gaap_ProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualPayments", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesWarrantyRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Actual warranty costs", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty." } } }, "auth_ref": [ "r422" ] }, "us-gaap_IncreaseDecreaseInDeferredLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredLiabilities", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of operating lease liabilities", "label": "Increase (Decrease) in Deferred Liabilities", "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle." } } }, "auth_ref": [ "r11" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r933" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r932" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r141" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r931" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Issuance of Common Stock", "negatedTerseLabel": "Proceeds from Issuance of Common Stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r9" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r930" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r930" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r931" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofStockholdersEquityStatement" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock Issued During Period, Value, New Issues", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r16", "r117", "r118", "r157", "r725", "r799", "r830", "r889" ] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve, Accrual Adjustment", "label": "Restructuring Reserve, Accrual Adjustment", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": [ "r405", "r412" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r933" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r932" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331" ] }, "us-gaap_InvestmentOwnedUnrealizedAppreciationDepreciationNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedUnrealizedAppreciationDepreciationNetAbstract", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract]", "label": "Investment Owned, Unrecognized Unrealized Appreciation (Depreciation), Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails", "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Acquired During Period", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r384", "r865" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue, Current", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r984" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r906", "r914", "r924", "r941", "r949", "r953", "r961" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r932" ] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://www.bio-rad.com/role/BasisofPresentationandUseofEstimatesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Product Warranty, Policy", "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r1048" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r932" ] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r933" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r200", "r581", "r853" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r184", "r202", "r203", "r204", "r240", "r263", "r267", "r269", "r271", "r277", "r278", "r353", "r425", "r428", "r429", "r430", "r436", "r437", "r457", "r458", "r459", "r460", "r462", "r582", "r719", "r720", "r721", "r722", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r757", "r779", "r799", "r829", "r830", "r831", "r832", "r833", "r967", "r998", "r1006" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r28", "r878" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable securities and investments", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r230", "r231", "r1008" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r933" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r928" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in accounts payable and other current liabilities", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other." } } }, "auth_ref": [ "r995" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r620", "r877" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r927" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r45", "r46", "r47" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1", "crdr": "debit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash or Part Noncash Acquisition, Investments Acquired", "label": "Noncash or Part Noncash Acquisition, Investments Acquired", "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r45", "r46", "r47" ] }, "us-gaap_PaymentsToSuppliersAndEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToSuppliersAndEmployees", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash paid to suppliers and employees", "label": "Payments to Suppliers and Employees", "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided." } } }, "auth_ref": [ "r236", "r992", "r993" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bio-rad.com/role/DocumentandEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r966" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r310", "r311", "r739", "r742", "r744", "r805", "r808", "r814", "r824", "r834", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r849", "r872", "r882", "r1052", "r1078" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25", "r878" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r85", "r163", "r218", "r220", "r226", "r668", "r688" ] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.bio-rad.com/role/GoodwillandOtherPurchasedIntangibleAssetsDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships [Member]", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r82" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for Restructuring", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r405", "r994" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.bio-rad.com/role/A1BasisofPresentationandUseofEstimatesOrganizationConsolidationandPresentationofFinancialStatementsDetails", "http://www.bio-rad.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r310", "r311", "r739", "r742", "r744", "r805", "r808", "r814", "r824", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r849", "r872", "r882", "r1052", "r1078" ] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.bio-rad.com/role/SegmentInformationDetails_1" ], "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense)", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.bio-rad.com/role/FairValueMeasurementsDetails", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_1", "http://www.bio-rad.com/role/FairValueMeasurementsDetails_3", "http://www.bio-rad.com/role/FairValueMeasurementsFairValueandGrossUnrealizedLosseswithUnrealizedLossesDetails", "http://www.bio-rad.com/role/RestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "presentation": [ "http://www.bio-rad.com/role/SupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Gains) losses from change in fair market value of equity securities and loan receivable", "label": "Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss", "documentation": "Amount of unrealized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI)." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromCustomers", "crdr": "debit", "calculation": { "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bio-rad.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received from customers", "label": "Proceeds from Customers", "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services." } } }, "auth_ref": [ "r41" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "30", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481108/505-30-30-10" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//230/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "610", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//610/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//720/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "b.", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r967": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r968": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r969": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 78 0000012208-23-000072-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-23-000072-xbrl.zip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

    FSYD$,G[;I P\K21^U0]+L7Q A,P' M*8QAA'#*LRC3C6*X)F1N"[W5T]LKNCW7T0]BN IH?Q2#"YA&7NT6"!D%,?1! M8!7%<'70R<(8^LPZC&/H?=8^D.%^Q=EZ]5Q8Q3$,1)P]?N&C0I>B%RP^:IZS*<;:9 M[74!U[:V2Q*0+$0I S$-.8!,?HR)PHR0%'-(N1PGT$U:O2QB;JMZKV53>=FF M7LX5,+N7M1N(1E[7(Z*CG[XZ'*6)$EC/T'*3N-IM?T?JZI47)TM>[5;\,'VU MYTD+?MOF9HER]:(BM#FKE&[RY?Q5_@I>>;ZOY5FV!ZN8RG]IXGI8PM, ,B[W M(DDBMR:4@"Q1C3LP#A(4("C"<%'PQZ:%IAX?#E-)Z_>.FM_[F6)C_N8;4YHV MM=*VVA.0_Y_GCX7'?](GE>?DR5_+>B6-J6Z\HJ/@LO-YU.#@":9E(K+>6J+0 M]WYY.9R87[V]/=Z!03?>SB1O;]-TTV/P$9ANFJ;Z6HP^769?&3< =WV.!DJ8 M[KOE!HJC#YRC(6W#E*4KS:OUYY^JRA#?>F 1#!D5B?RRP8P ",,48.&'\J\J M/"-"."1&S:DN2IF;O]\JZ6VU- T6O@2DWB'[8'A&_GR<(C-*RF$'!,["<"_) MF#B\ML/,\[#9KH=MJP<\U,G)@AWV6EL(7P0D25) B.IBCA %. Y\$-$8I2EF"/E&/4OZ!,YMJ1^J6@>$ MX -E#8,:^[#6^XJ[1'!D5F@R<,X@O-6!T#R44!,75R&"?>*F#?W3-/XLI$_W M/3-ZJ5;KQ>VSW%I0W)ZVPBRFTL$/ &-!#.3?8H SS$#F4T@CSB*>:$7FG0\] M-\IHM3,\J;Z 63[N6M'SK8#G+O^V7\H4!)UFTUPUI MEV?'$W;?^=,N]OL.]L?][!4X$%0(+B*C?#1= MP7-;Q'6[K;UZ-][.$"#*%:BP:>BL]@RD J4B8P)$$>+2XPHA0#S%@ D44!\E MH4^2Q5KU&'_'&=B)'V\&/E?K_%E=(GA?<+ZJ:]R/!;F>XS4&D".S<,^O^$?7 MK]C8 3/%QY$CIBUV4H?,%(Q3Q\SX?9&7>=>Z[$[L+?*J\TZ79 W'JE-\Z1MPYPONTFV M\\Q&G[KW=]MK>ZF7B?O M[8OM_%'WBN#LKOBNU%)9/O*!;Z749/O7#[C*J]_S@G]=\^=J 8.8!TD:@80G M4%5P" &2&V$00D)]GXH@R(P*E3G5;FZDO]\OWWB-?4TJZ]Y"KS71JU-;ME;5 M3QV:Z=5V>G\I2[W:5,,Z#FY_!'H?@W>;VI$_"N\RJ\:?AU'0=_29<*O;I)^+ M46 ]_6R,(\2RGMI3N5JKN^ZOQ2MOVENWMR*A(&$LOP<@1CX%,$,I0$G&0$@X M9 $248BUDC;[1N"YJVQ%BOP6=5Q/K?&-:X_F-9K1=$D(33* ,PR*2KF&8IP"A+0(2RE+(T M1@%#.O1=>LIW(F/= M0_[0=,VV\?4K[](I_E#9:\WACYZQ#7EG7.1%ON:_YZ^+C,=QG+$4P$CQEN]#@..4 DI#3E&:T8S$9L'P1O+GYNOL MU0=+I;^W-Z#=_ORE]#;N\F,V*WJNT(A8C\R;!S#_;@>S10R^%5C.HO/-I$\< MMV\%S7E$O]TP=D3W:9="]'670O0]K_ZG7C^41Q3C- 8!3@6 <0Q!EJ$$!)+2 MXBQ .(R-4GRZA,V-PO:Z>GMEK5BK$V(]BG(%W.A7'Q:8&5.0#AB.^*93U*3D MHF/T*9-HO6-'&^JDJ0DY7B[+OY7G]4FEX*\X>\ _:Z+Z6&=N?RUNGU41_P6+ M<8R(CT!(4" W=I@")$(.PAC1$#(>9)%1;4]3!>9&+SO]O9T!-UYK@KKT:S[@ M-]Z%IADW7F.3&0T93YD>-8TY$2/3U:AS8$QKMD ZHCIC\9/2GRTXIY1H/@U(Q0TUL'#94W3:Z*FKVW:8_3%&J=] M[UB405PNM\FX![FX[<6.;C7$CC'F1@-25^]"]K$F$?0BUDT"+L$:F0"NX>3P M*DP7#;LZB5T#3U\N"OX?W.\VN9V;&+K7.=0?(I6J.OI:> MG5<6W'N3BKM,1M*:+CV'9-I)&/TX2"<2ME6^OMVZ\;8VOMW4FS):1\BJ(*@? MZ?ZZ(4-YXRWY,P3)4(93(#DZ1(:2DTH^0I$P#-TJJ,1K9C[?N5*JZU M?KN7/_/U;<%4LL6+^BC(/Q]>0'[/'Y_6=^+/JCFS/XC9[:H@$2=^'$9(-5UMZ4T_=SMCZ;\=!$;7!H!1 FMP>V!VF5TQ4P622^7'T21E7 MUTF_-I/ ?OHAFD:HU?'!+?OG0_FQ?'XQ/C0X>7-N!*^VP%+%31L$NBX]I2PO M*@-"OP*2UCG! 'PF.!WH@,;](<$5*&R/!DZ'F_) X(HI)\< UYZR;W3R*:_H M[YK),5??F]-O\+"%AU)R6:J, ]>9*KU0#&KC<3SBY&T\+AITJ8W'Y0?-?XQW MFW6UEBZ1G+/OG):O?/6F?N2WSVO=[\;U$>;V_3AB1)/[\QZ@^I>N&XQ&7K\' M2GJMEIX)9D9+N!\2JW7<,>QDB[G?M,,5K?&T>5:%V@MS_F/S\K*LCZSQ\@-> MXKH[!N?K@Z;O#^HP9=?P?1$A'$493$$8^K$J%YJ!+$IB(,(01[XO,AQJQ>@, MT&%NK-&8X1W:X6T-\6I+O -3]),6;&>HFVPFPGUD)C*"W/NKML-3AGBU)0:M MA6QG03_#9(+9F"@19;19,4I;&8AG1W:+[%3:WO5 S'=L# IZ_*N?@9A\Z7S51GBJ.?S:5Z5.0!W[R'2KTA&>+31U#!8[PJL24P3 M$G&YF9 ;!Y6"A@&FD((LX3X- HJ3B"SD0B/EA, >RIL26N 46CU>=@#7V)2\ MQTFIJ$)'/_;@9!Y@V(V"JZC!*U*F#07L-O4LOJ_G\7%#K6^52_DE?^4/3ZMR M\_CTP L5/UCM"JLM2!"&4#(P2$+I <(L@R!CDD!01.-4I%B(3*M5GG/-YL;D M^\#K9U7"M@Z\%BHK7$5>&V9YN9L^39)ZCTD9F=:T K$/2U2:!6$W.^HZ%#OV MMG!X@3]]3+;VG$P,_-B*NW5A\WOFFZCZ ^3,;?%'_SOZ?VZ\1ENO M5M=C&^XIA?6O(;IP[;_Q<836R!30 91AH=[>7Z+VY8PCY":Z@+'YJ1E=K6C MT7%]TO7V9%QJ%LDD I*N20UG*D6B4D,,A3X( Q(2$2,_4 $)BU;+TJ9>131 M3D_##C$7 =4CH\$PC4PYQ@B9=UOI0L!5UY2+,J;M?M)EYED7D\Z'[9;]1UP] M?5F6?Q\&/!YD*.WC>C,2I7X&(8A\5$TTVV75MNQ* M:G[](27+EFU9(FE*)1S,GG1562+7^FA^7"37979V3=O)5RD!E!;FGN[& Z#' M'&/ .C*9'$!]H=SLI%9F"< MO2G6K,EEEB81"X+ @UPDB[+* MOU?44X+?:F&O.T/I@\J\F$*JA-8/2:_%:R16?N(4B7?"'6G^@!PQ,2=74S*NGU*GC-L[[/F M ."8 MO6UY?<2_5R5%^),*OJDS&*QI+M_XKIA0=GW_Q#=8??2P*42^55^5/Z2F^Q=5 M2IUU6:QRIAS,CDLS38@G1!9!$L0$HCB.(4ZB&":OVQ M'_MN[-6'W?QB;=Q!<74!-Y*4TU[4C0OUQ87>R-W9%KFK:[RH.+KU3AK/&$5I MEJ0P\N7:@L)$0,*9!T.YS 3R$Y%DF5E=NY/VY[8P'$H:[>4S+5]W"IX>[]X MR3&"!&" MJT0#N)+-C*_:@.GQD"4,(_-+CN?C3?A,/)<= :!?HB(-103!854D/S0@<0H%*13[9[@C]/G)POW MZ!2S'>#1_8#U]6%%8'NKHO''B%*?))QRF+& 0Q1(DP"S6$ ?QX0%$0VHKQ7X MUM_-W-BH7A8;&8VO_[J U+[NNQ&>20R&1KP1/%OZ$7!W;]?5R=3W=#V*=MS+ M]3UM-N<9SY?OU]M\^_*%?\]5B,1Z^UD.^I('L1]@CZD<)00BGV"8!AF%(DJC M(,910HA6EKIK'XH/J=[C 21? MK>>U_.$XG:\V.,E$'E*GF<*#S]VP9_]5J&&8HHDGL$[/DA1!1S ME:!"94*FD5!Y*@1/EFO^7=V3?#/JO[46G8R]3;7'!;[7 AMZ_ MUU VV/1;@C;E>GX"5"VCX]. ZR"X/!GHZ&7Z4X+KJG:>&/0\;NZW^FF[6BV\;=K?9'&-D- OS7&]A;HOW)TDFFQRO0"6N.B'O\&75+]73 UW_9'>' MVLAS70LPQ^%$>N!8^?[V-#N9[^^P:FW?7XVG[0O#?>+;'P4SGN]77I_;9#\I M$U?+:E"Y\0I$P_/: 3HC3^H.8$:8P@,XW%0\[[S-RM4?M3'BY MW&_VT8!OB\?'8OWU!Y;?C;OM=I.3W;8JHE)4?WN#2\X>\$M5*[85J;%,@XBA MB&'(D7)Y#5-IZ+,T@$E,(Q8AN0401FX+MXLT-^9X+P2G5?Z/IV(K!90+X.H% ML'RUVZHT(.56CB,HGNI(-I6K3'6'V(U^(:G@ Z&5F^+,>V C4QF M+65 K0VHU0%M?92SZ;MF_([#6ST)*RW!7LV3J"9W.QIWF#O:_#@0:-)]DCL MS[=4#ENV,,6::K\&A5#;[\R-.H^UH<]+0R^,*Z&>8*-A>%G",K:U=141IV5. MN[2WL[':#4UG6'6(?V)-=7UN772'!CXB19Y-!WW.;V8WH=1 'R\NG MHLQK$T@92GLU%N!)*5)91;Q1Q;@JC_;XZ!D\(Z$^,G&< J[D5D _'("N9%]4 M2+\?1-JF:(\I9NYJ^&CW/'5)'U-(.BK\&#=AF8FJ*+?W0O71N!-X,<A>9FZX^:#>3W^S*?,W+4EH_)%]7EN/;8JWN M?B1+J! VE1RB^G-[3_+VA_KQP[JV,>_%E5<.B>_\99H(+Q0^A2S#(43<4]6K M4DD74>9[B1"ISXULG8GDGAWK5 J4JB*-4&5.GE5Q"37OZ$$3]>-1%3-FFNK; MH,=W,QSCD5FTT1BT5%Z HP;@1(63TR3Y6*6X^FK4JM>MXQ!.-;EKERC.C*ZJ[0/G[DDJV_XUZ&* 0H2["%! M(<)!"I&(4D@H]J'@/*$1(I&(C8Q=2SGF9KRV2]77?GZ=%1#J="X+(-6I?(+P M+^OR$[8#J,=,$PS+V-<'8XZ(>:C%;7BZBL6PE&+:8(W;H+J(YKBQ.?-PCW?[ M@+T'OLD+]G[-5 7.I4ABYGL"09]Z6!I>F, 4,0;CU(O#$&D:G)&!FCL(]>[:WB/KI;G"SPHU>A=N1' M_X/F/@;5M:DTMY07DZIV_5^*)6K*,/;]U&EK;C/X],Y]+WQ==/VY_/=JR1P( M8+"#=-AEP36:H]\@: (Y@CNI"516?@]:'4SF#V&B;MM/PN@];<:**1S6!UOP+)\,2_#8V1IWE7B(<>.$8S^CH&5O.WH[G)9NMU M5=ISL^_I0ECLY._Y8&Z_E/4W,;6XJ44$E*]@+NP!_%,5V M79A,U3[,AN>L([C&/NCL06J$95D#%*O9W-?N9--:0[GV_-9YW.Z4\PM_VA^? MWHN/Q?J[B@A[Q\EV25D_/5;#UCAQOPFX:CCB*J,X*E9!020F4F.[. M"H> <'08>+6;24_[AI0]/\X;?/[VLK/_X/GW'W(&WCWS#?[.5?$X=6G[1<[* M!RZ_2>OM,O"CD&4A@Z'O"X@R@B5S1%S^X^&(T2#!W"@4S*S[N1D99V58&P7 M7@/0J "4#@NPU\*^C*W& .E1SGBPCTQ$CA&_J2RN/G CU,O5Z/S5"NGJ ]-7 M8=>@%8<5MS]+=7>;C9I*(DB9M(H\B+GO0\0%@6E&"611%N"0$)0@8LMU'?W- MG-P.$B_ 468'%;E;@)MSUXTP3DM69@BZJ=A]B]+U;7J>7>\ M9NUHEBG\_"C.NNPZI'9T[ &OV"J@NG$4+:!L%P M1#G7^YF450;5/2>.X1=LLPR_E1;;!J\^K!G_]9_\922#VB:IJ@!G, M(F5628L*)=*.BC)LEF;XK(>Y<4$M)-A+"2HQ@933--/P.9#]+. $GI%GOS$R M%MF&KVA_0[KA\Q8GSC=\1:'+A,/7'K2]N*(K7):YR&GE-72_V]X+#5?6_9(5 MX)"G(:508)[*W9.JTQM&,:2QH('<0"5QS$PL@=O$F1M%G&L#I#K@7@ ]EW'3 M2[&;!E+WZFRJX1G]@NUL9(I=Y9:OZW?TY: M=5-*O54A[N.AXG42!)PA)&! 8P21[Z<04Z$*7"9Q)M+ B\R21.IT.C=^[:V> MZ+!*>>< Z#&F:UA'YD4'B-Y< +P/HI&J>7=V^:JEN?M &*JSW?NNN2/CYV+] M9;?BOD1ZR(&_E=B.W!D'8;%R9KS>ZF2NC(.*M1T9AQ^VOJ+/M_RC M-&?8A_56CF6NCIJK\I=_;HJR7'J>"%'&0ACB.(1(<%_N]T@ 0R2"%!&:$A$8 MWM'W=C@WAGB0#?W )0._L9>JL[7VJ=J1B[WWI$++_GFF9=+X4>( MJX+9L4 >1'X00^*+&*8<"9KX)$%A8E848[#/N1D?C:3@NQ+5E!B&(=8E":? MC4X8>VD7X !?)? A$TLCM$OZT$;(&94,]S@QK6A#<$DQ^J_:TEHJW]..?HO6AZKX'SS7RK+L JJ6!7E3G['CEZLF=I[9&D( MA4KVCCA.)>VD%$9"X-A+DRB-O>4SWY!"^U2EKS^3Z='N=42[1F5AKN0%GRIW MI8':3A88:QZMN,)M['.5(V M21T'CQN!XNI(I;>O:<]3=-2^.$S1>LDVJ\N' M-:N*T1LE=-F_-#<#H[?Z_(#^PY< M(7!#VI:FI8DSMIPI<)FLY?P!NP5:)V'C@[I<+=:G5><><&6YIDB$+" 8>DE( M(0HB#V8X]2#./#\38>B'@5;.14?RS&VR&Z5%78"]9A?U(6OES,R"6T=6SW"8 M<+Q&9JAIALK8"'$$L",SY59I)C5D'$%W;NJX:M:,L$E>+._"Y"M?Y\7F<['E MY;L=#[PPV+NQBB@*(S^62QBA,42)NE9B#,M?<11$B+$HU(I,&NAG;@0;_GOR MOQ:@EA94X@(F-P=*8#VZ',*UGP8=HC4RO?4 ->S4:X08V^>(K=RPID#NI,-Y M?=6TZ5X3CIK&Y<,5-7M9Z%7T//3V)+2KJ4)#I[J/6WH2J["O*MD9>U<5!019W,5K=3[3F_E* M]CH_'P.U]/LDVHOZX$6903_K!PP/JO3&1,_N= ?Q1.[%3F U]S V@Q484:OW(J.U4G\A\/#O@< M!TGL!1ZD22IIRXOE?IL@'_H9P0)%-$PSLP@(D][G9@&JU'3@*.<"''2 HMC M4A4GOB$@PFA@-+EK++A'YK !I+]J(VU.8S:(N:(SH[ZGI34;6"[HS:J1&]V= MCK<$QYLJX3,?"88@"CSY3T(B2**,01*PT$>)QQ@WRH+6U]G<2.P@JZ5O4Q>> M>F3D"J61N><@9NO>;Z1K/QU$7'LO=77U.FY+/4I?]5?J>\?R6N*I*M>Y_MZ5 MH/$+?\3YNOE0A=OX2TSC$&'DP3##F600ZL,,B0C2, QPC,*4)V;W$(8"S(U0 M#O)?36!Z4*)^H@I;,KQA,!TDS2N%$:$?^P[!+>KFEP66T+FZ'3#M?MKK $MP M+L[_;=NQS5,B67;'_Y#ZJ)+&JG+>/_+MC[>[3)#2+&,<0^Y]"+>1PG'L\2S\B4LI!A;H2H[N[47M XX[XY M^GHT-S*F(S/=7GJ@IAEHY <_I0*@T6 !#CJ 1@EU=^HR=8@UA,[RA9A+,'&2 M$&N(+C.#V#?EHC+@V^(K7W$JN7;O*^F@0N#U-N?&7P,%[M3'>/T"&G4:?]); MZ@;V -Y/<6-B/3*O6<(\257!80 =51?LZ>@5JPP.J]]?;5#C?3L+315)V>Z+ MI'R33=S]RLLE"V*$&)6&%X\01 C+#:E@\A\<9TF2>2AF1OGANCJ9&T=]/!0X M4E(N@)(3_*TD-3QU[T14SZRZ%:>1^>6THI$>1,9V41\&C@R?SBXFM6SZE#PW M77J?-<\#>_?(UTQYG%09;0*&,BI"#^*4RYG.(A^FRHD@B0)$ IP1*E+=_*\G M+<]M>A^$ THZ_6ROIW#U3^.;0!AY[FKJ;Y33M5-7JURNIRU-EL.U4X%V[M;N M!YQGZ9'[^SM25KN2)?-#'* @A$S.1HA"3\W-@,.41[[@7HP\SU6NGE:WMN.JCX5:_[R"6_^R;=_[-:LW#O')M@+,?$]N2/(E,3DD2_ MHN>D,/"T'0F\Q>6/NS53_WG_KUW^C%9B0R(8+K76L%9'!3T0Z[&"&^#&/I:TQP1K*WQJ)?U>H-D*#8QY"MXG##%!REX50H\^I\O7W*BABR4)*19!@F/JIW.D$B%1EVR'%04!QG*81-THBIM7K;,T< MJG[@1[F=V#=GB-]DZMCC^%I6SP+@+6BDKN.G1K> NE$:UQ@ZZW,.=E$W#)HF MTI671_ 1[BCBODPX1QF)&>0L3>66BW.(29;!)([].*9>2 .C8V%3 >;&4,/> MJHT20&FQ 'L]''H)=PV3'I>-"?[(M.8<=[=^PCW@3>$GW-7]?/R$>\ Q\A/N M:\?2"R6G*AO)^OO=]PVO\P@V9\XLS' 8I:I6EC3'4IY"+&(*/9YX-,Z",(V- MBA9?[6EN!'<0%!PEM3QXOHZN'ETYP6QD7K*#R]P[90@*5RXJ5_N9UD]E2-T+ M9Y7!%VQ/E^2<-]YMNE'T2(<&G_^)PG$"&Y2TO#2, X3#!-F/!B9'>. M=-+-;$^,:BG!DQ1S =;(Q]F 6) P2@I*(XSBA MJO9Q(;\VFN<[;N4S,D,.4HYXC*&;4_"@[-7L@J<*'R:DX9&2XZ^#YN'3ZPWR MV,=4KS>^YH=;XXR"JV,PQ])->V V#K071VLC=6.WM%S/&:)\K3_A[?XW%2F6 MK^_7_/]RO#DD"U^&(8X]FE+HQYQ"1 ,$4YQBR!!-4$ P20*C*(G;Q)G;_K62 MM[K47/&R!-L?> V*-0]U>Y).K MBH.EL:SN+;[*B2:)O?D8O*N.\Y3:0*KOCM7=(.^(Q&\49E+.=@/<.44[:M6. MD=_@]3^_Y8_\'7\JROQP3$4$C@,4)M)FCZ7-[B$5I4)B&$O.12S*@B@Q8MKN M;N;&H$I"T(AH>?1W!5 ]3KP=II&Y3@D(#&$RYJ=^%!SQSI5.)N63?D7/>6+@ M:1=!\U6R#S8?.:!\!T8:]XYWHS. M9\'PK5N'/6Z?AG&SBHZ_#HO#^/B.3B:/D+^N:%>,?,_3U@&[6,JJFR PX#R, M$ ZAP+X/$<,1Q,B+H9]$ :8T"@C6"J6WZWYNG+*7?L0,CH;#HT<[XX$^,ATY MQ=LFN-<"-G=!OB:=3QWL:P%,1]"O32N6Z?RKHB8-HU;%398HB:,@BSP8)EC: M10$/53Z"!#(_9BS,8L)C9)2T_[*/N1%8NU;. AP7%<,4_!U@ZC'1C1"-3#?& MZ)BGS;^NOZOD^!T]3)L"_[J*%XGN>QZUF^9G//)YIXYO[L6[?+63?_WZ \NO MR_UN6V[Q6EFURTBEHO;C" 98VC@H\E3,;T)@Z&/*(H8SD?DF%_]SHX;# MXOT"2XO'QV(-RDIP &K%3&C"]-!D;SKBU#N4F-"$XA2+X!9@!&,48P3%@6;Q3B&/(K#, AB'C"CJB^=OI'&"?1'X0A"C2&\+&>;&&GNI)?1 *0&:WUMJ* ?U@R*@T<2,4FQ&2X]P M1AZ#D>G(/?S&A'4#@([HS$:"2EQH"YVJGJ=SSM]M48D(L]K7D+ M-H[[9[6I[AZW^E[ZE^_.;?=YM6Z:B?5T%:CA _5;,1J9,FSA,?2BOXZ!I?^%2:+S._ZC>R@E-A]:;U(*K]T]LE5B-/\RLP M&<8E#N+%"KI3ZU'UMTEP.^EQ/E\S;7K4Q:*F2?ET181>%GH5&0Z^/@DIZBK1 MD*/V\[9UR\OM)E>\VS[KVAZ3"L0X%M0+ YA2GT/$?!]B#PE("8N(*JC'N5$I MG*$.YT::1WG;![]5:N-C;@'3:N4#F.MMNUPB.3*EW@:B1<5Q/62J5C'#^O].49CDF$NTDS$D"*/081H +-0")A0 M&OM9ZF6$&"4_[>UM;A1S%+8*UH7YNLGG9YD+H1]K/79QAN#(U'(+>.897'1 M<96@I;>O:?.OZ*A]D5Y%ZR7;["DK=6;]]0?GVX]JU%0:+55,*A0Q(S[FJM9. M(JV5&$$<$*1H)>326*$$&[D47.MH;A2REQ-4@H)&4JM275>QU>,-%XB-3!EV M8%FD4^E'PEE"E2O=3)Q2I5_9RZ0J \];6AE5?=!E&L1IDJ4IS%@00X2I@"0, M*111'"=4)3_-N$FT2-VLT:2?( BDELK0-*@!TK0!C-4>>['OU]A\/3]1T-7" M73"^01ONW[$JWG'7JH-?>K[W;\3L@I6.5" MS)_Y,O'#A#*,H!>D3#EK!!!'PH-1Y/EI[$' +>WJ^.BM]*.A/C(I70=<,A/A^SH)NG"[\4L;@FU,O[2K?;^^ M7]H0+%I^:8.-6&8"V1;TGQ_*;FF[Q@U;GGMTUU(?U2/?.%Y]53 MJC X9L03T)-["H@R1-1!@P>]5##D1Q3QV"A1J[$$IG&TT,\XP8#Y4> XXZ ".SX C8FV?ETD\\%/B40YQF!"*.!4R)G\(D"%+.O8"01,NEQJC7N5'@P:6T M$* XE%Y:55G(5D>Q754Y;^.OQW'.41V9UX:JG'_4 -5AD?,.D$8O9"!%B)$%:!UPNA9H;K55Z =P2&&PJ MS53LSU$W<%0.M+53D_?X6UUK2=^%SME(]S/D:XW?R 3Z_\?0Z7M*OL803N15 M^15OY+J5[TKPLCTN/?Z:RKR7Q!78/3 M]AMUWK:MZ]=_[_;^9-^**VXA5;(M(DT%UJYB\(77H=C\*]\\YY37>YTOM?3J M@=I?4GA9FL4\@CZ-J%S%XP1F@C%(DR F"<-IE&BMXE,)/+<5_N[AP]M%G=0. M5BHUQ]7@;K.1#U;EC:O"B+4Y+HH->%N46]!2S-1#;>2OA.8%]XP&>NSKN]88 MOW$]QA:.=-, [\P7;V1Q)W;GFP;\2X_ B?HU6Z:J,/?-R_*OK\LT] 3#F0]% MBC.(A(=@ED4AS))48,("''"MA>38Y-RH_J_/'[Z]?P>^?KO[]OZK'F>W\.EG M53NM1^8]/86U">Q2QQZG@_W#-C-!.WXQ-)UH D6V =Q M5G/]BZJKJ$ZJ]_[G(@L"D? $1J'G26LM8C!#408%DY8;27E",C./ 8U.YS8- MVV5)#Z(:N@'H8*UY^^\8P;$O_;O &\';WP065Y?Z.EU.>Y=O ,+%%;[)NW:, M\PG+Z9KCE;(%UC1?J9K96_[8E/^D<4RH%Q&(4Y5B$*O*U0@Q&%"F_N(AE!$3 MKNGO;FXL\Y5_KRS\EK2@$M>,:08PUN,8=\B-?9E^#;01&$8/%$?<,M#9I*RB MI_@YGVB^=;O;XX>U[(B7V_T6^7Y]<$!:>C&.,Q]153@QALCWY>X@I QZ,?6Y MER0)38RJ@^AU.S=F.?.[:P0_G"D4ZZ,OGKUW8\\P:!HVSL$=V[1Q@>M-;HS# M,(W@O]C3Z:LY+@X#T>>QJ/&V'4U5-6);M^BM>J.!B%.1BA#R!!.(O"" :9)B MZ(4Q$C%#/@V-\JQ?[VIN=%27-EX=JKM:>]OTH*O'.&XP&YEE:KA:4HY3V&P8 M"T=4TM/1I/0QK/ Y96B\81ZM]5E=VA6->:X9GG7RTMSFMQ0.?GY_KSF9+S'H MG[LWJ3_R5&TT=[CYN*JN5?C4:4N3Q4MU*M .D.I^P+*&.B]+SN\;E\ZK(0G+ M$$6()"H@ $5V0S N:KF;OF\9W$1_ M<+9;\7NA:A+]L2I^?MT]/:VJTUB\:D7N?L-DQ8\%T+ @?A)D&+*$J+)-"8&$ MB S2F,5AZ'E1XAGY]%O*,3=;I%%#>?E719Z4)@O0UJ4=#FT8W60Y5GI$-\$( MC'TX:P8^^+O2!#@M6^<(35=Q3Y923!O]=!M4%S%0-S9GR:,_BLU6%:5NY<=; M4LI(@CT$?2_U5*89#RH_$9A@DH9IBJFAZV%7)[-C0"5C?="2'Z4T)+HN,#59 M[$:(QJ:H"ATE7SO7I4/:Z5'?%:=T=3$M8?0H><$&?<_><,@J=Y"'*+X/:UH\ M\O>JYD;)FYR57H1I%A/HJ?07B%,*"15>%/B1\7'K0*=SHX+Z)+$M M-*BE!K_MY?[=X@!V"'F#HUB'>$YR*-L+Y0@WT"8@N3RM'>IR^G-;31 Z3W!U MW[W]9KJ*X+@7?Y6\2NIU]RBY;Y\/7&[8XB"@L31#0B^4_R ,,S].(4D8"Q+, MY(?6J7AZ^IT;)YW=H5:2PT) *3NHA%^ MOCVU]-]8V%^/^T(X6DOJ*W!O>F. M6@.J$2ZI^WI]M5MJ#2CZKJEU7K?<+=5N5%_XDVIR_?VX*SN>6GAQ*F(6,R@X MYQ#Y1!)6''C0"T6JBEL*@HT(2Z//N9%5XVWV82V*S:,%(>G@K+FOV-NL M@YO>7MS6N0_X>YP#'WV 7&W$-'J<=E^F#\'%-LW@54L[J=CP_/OZS^*9;]:J MKW><;+\J=^/J;GV_>< L"F,6$AC%G$@K*0LDZ20IQ%F :91YJ0@2(RM)I]>Y MT:'"4&MR35?Z](B"-R^8;\->TC%RC.C(=*?' 7KZ710O7RK5&/C)&?(() M1JX,(JT^IS6'3&"X,(:,7C;/5'-VQW>W9FWSJ_S"'W&^;B[_U"'6DG&?\X"E M,$M4"0-/4E.6H01Z(DPX]5F6^%HE#*QZGQM/U0JTKKFE"N!D#U*"@Q;U'X#2 M0S]+B?D ]1/8Z+!/XEDP+\3U$\",BOQ$F5Z^<>B+/^0<+XMUM(6V,F.]G9!L2[?<"&WF_5SW_ ON;W,UX4Z,&BBQ:0Z MIZTH=;8OG_CV1\%.W([BA&/"8ABF@D,4$0+3-*.02?6Y; MS/TE.ZGT WG]VU9I:)RH>;+AUULC9SJH(R^0C=.$DOAWH)@-'%4'1]V;$:\U M K5*I^6)]TU5R-0A7KJ\7*7OWHRR:?.@CWUD'3DTIY< M!+L%\#/?JB7X85,\YXRS-R]_E:J8=+T75OMBNLV?JV/5.R+7;*RVEAX/LH0S M2$DHMY8\I#!+XPB2E 6,)R25?S=9Q\Q%F-MR5-GI8E7\+&ON$HWH !]D_]]F M*Y/%N.@M,..B/?(Z(86O-T6-^("\@-^4!M((^!T;#^WOP^?V]43#V"13] M['(C"F/3QA$ ]S'973K;1F6?M#5E7':7$F>1V9V/V!D=M2FCDL46:W5]6ZBS M]B4.LS#.&(*1CU.($A9!C&,?2FN#H4P@CR5&J5 Z>YG;W-SO9 Y2@K]K.0W= M.+H1U;,(;L9IY-EK#I'Q>MX+@:,EN[N/25?E7C7/%][^AQV6J7V[3]9#DL0C MG 20IYF<_PP+.?]9"FD:91&2.PQ#S]*^SN9& ]=KHKX=R/!CCK,>*[A";V1R ML ?.3>'8MZ,D1^KMZO7+PK[M3Y"D]8Y%07OVW]\*Q4=WO_)2NX)]^Z6YS?IC M_&%EWSSS,MEPJD(LD! [I$( M(FFG0R(M>6FW(Y%Z7"57,EJW-?J.45N]$N? MO;0+T."WE[BJ8Z;2A312N[ROT8;(V3W+<(\3WX]H0W!YKZ'_JM7IVY^REWWB M^7>\I)O\22T QZ@H_0.Y@9;FQB#JB.K/N[L'L)<9M(0V.K0;0E#K',\A>!,< M[5W#S7%(F1DVMD> 0\U/>2JHJ>K90:'N6W86B8KU^+ NMYO*K?MCON95.OEE M$A+*?80A#0)IA80$0X(R!B,<9+&7,2K,K) K_J:' [A&9@HKI(SMBP$<'-D4UWJ9U(X84/7<=AAZW(X._L%5-#QG=\]\ M@[_SSSMU/7$OJI)TY?UN6V[Q6GD.OL%E3I<)81AQN4O)(B8@HD$*L?P;S-*4 MQA3%*$IC$Y(PZGUNU-$(#W M/:#%XZ-<-@ !45*;D8CA<##E$JGJMV.5 M 84''*8X0C"*1)1A$@7R_Y:R)5*\^H"TI1AO2"JQP,_S@=F/2'&4?\Q1T2/\ MT9 >>1DX?.OW@H-:$7X$WO'#!>'JQ0<[1HF/4]Z5)B!5$=O*:()4F2^9"$*9?V)\-RD4E]&"*!*&=^ MC#.MI>5J#W-;/@Y"+D CYM!!K2:4?N#%C&LN"$S"GH?[QX.SG M_O*'X\P?;'@2 M!5K^$![>=M"[UN_LFW*I_W,3O+7^L-QZO\?SC[$^=K%=RP M#+D7"L0%E-L^50--)!"'@D)&(BRP-)V\S%^N^7?)5^R;2=U7G=ZUOOU9_>V_ MD&&\F7 4'ARE7X"C_. WI<'O0.E@6AI6:U0HI;$0/H9>Q#.("&40!R7Y/G)ME''0VXZ[1W=DJK\$]L485HO:O28H.:OA MJ]7IQ+5\38"XK.EK]+9E/O?3Y,S57$B3Q$,Q2N1*(01$"1$P103#V/<%HVD4 M9$WO>=1NBG_9,\8QG%5Q1ZE:YJ6JVBVD"1) X;,0 M(A;ZT@ A$<0I0Z%/>9KXV,0 Z>UM;G:'V$7C7^#VFH\'LARJ4O,L99ZL$8X0"BR*,0)[$OB0:'%!$O M\./08L.IV?U,=YP'Z8$H-D#)7Z6CJG,5UBHL0*4$+*069LRC.S)Z'.02Z(F< MV[7!E=BZ(R9#H!Q1E&ZODY*5(13GM&7ZNKGWZ\/S4U7Z3M?'M7E^;I;+ WX! MSZ7*5%=51U#?^6/:>'U7U@,<_91@B\3(\[T7A'V%2T?:6SF>'AJ9S+WT M7.RV$^G%9Y;E3)H;KC>[,E_SLMSOIIO;)&UD,[IBUL-5[M-H$$F[*HU3=7L?2N,J\+&TL%*6AB%& M<9:8.74Y0W:BF_SQL-4SCYSA-3))Z@)E7O1%!P!7Y5YZ^YJVT(N.VA MNI& /QZ\R7& 1:H*W'D\D%NO, D@P6$",QZP.(Y23E.C0YW++F9'M8V$-_CF M=P!I2 56\(P]_\V0L:>!"^5=S_V/K^.!?UW!J[/\\DG;^BCM\MU-2>]61;2S M8O=1E"8BR@C,$(^EC<48S$B4PBA&Q/,9S9#>;;)E_W,CA7V]B+8.=6([I85Y M83G;4>DGD0FP'IEAM&'>;\F 3L"@$^1-RZ.,-@+3%DAQ.Q(615*L+7])09"3 $4RJ M8ER)B"&.PQ#ZGLAXZA$>1,+$Q+Q%F+FM.XW3K_=<)9OJT/IOGH3 M]N?_Q@-J?BDPYC"-?5,P_@C==(U@"^T(=PO&HKS:A8,M:'VW$-9M6D0\[2,$ M_EJ73YSF(N=LGV$R3'#D4^1#JD[\4$(]2(2?P3##!*$T\YG'M*.>KO4R-Q(] MAJ,8Y>KL1[*?Y)SA,_:67AL:LUB=(=5OB=>YVO9T,3M#ZIW$[0P^;'E81W]P MMEOQ>_%.\L>S-.J>^3%>OVQM75(?95Q.Y9" +J/66$''< F+_\)'O$:?Z_,9L,C/]WAT#P(' 'D MT;FD%EFA>Q2ZE<*C'&6O:(N8JS-%W6ZG/6DT!./B_-'T?7/_"6D2?2_67)I! MJB[TR[L=_U;(*?JO'5Y)DJ35)O5>?,._WO U%_FVO'OX^'I6!J>^Z8342_30VQ2",3&>CX6_D+7(+B%:> M)58=3N:%<@L<;8^5F]JQ2(7\$V]8^795E+*?3^NG7-DB1MYCUUN8&V_5DH)* M5)4C]%O^6,V;3Y\?/K2@ET4I1-B+Y+8L M""%)_"1%1$0D-MJ6]?0U-XIH1 4GL@Z7^C'&6&^OY0BYD3G"%C3S>M'#<+@J M[MS3T[25F(=5OBB;K/&*?<;48YSNW3/.5XJ*I,GR%:_XV;VT%Z0X0P&"<1 S MB(( PU1P 9$7QX123%!L5(3)I/.YT4J5,;0=]7\0'XIB TNI@'F*5>V1T..: ML? =F7P&H%6RCWJX8P.;P]RMVEU/GM#5%)2N+*_&;=A&#],5+LOC_FJWO1=W ME.X>=RL5-'>__<$WJ@[&AO_@Z[(Z<5*!R\W5541\/\Q\&+)$,IV0EA,1H0^C M-/,RR77(#P,S/_7;!#*9G=,XLI_KHS)CJM.)EDJ@T@F<*-5$X]M5LKMQ5/58 M<[J1&IE'+X:H<#M$%J'0+I!U%BM]DS 3!U.[ .XRVMI)J]<(NOV]^2A_^H]_ M:_XB_R&XY/_Q;_\/4$L#!!0 ( ..#6U>XOZCQ^)L $4I!P 4 8FEO M+3(P,C,P.3,P7W!R92YX;6SDO6F76SF.-OB]?T5.S==!)?>E3W>_QVNUSSC3 M'MO9]$"VNJ2)9>D<&;TKQ]0L3I"$=;"&Y?AK,6.1;X7RT,0 $'@W_[7 M'Y]G/WW%Y6JZF/_[7_A?V5]^PGE:Y.G\X[__Y;K0+E(H.06(:H,!?T^?<+/ :;SU3K,4WW!:OJOJ\T/7R]26&^D M_EVZ?KKS$_4[N/@8U!\!%R#Y7_]8Y;_\Q[_\]-.9.):+&;[#\E/]^[=WK[YY M99PN8!GR7]/B\\_U]S]?J#C,\XOY>KH^?36O^MP02PQL'K@^_8+__I?5]/.7 M&5[\[-,2R[__I3ZN*IIYR2H5_^>]C_OYBL8O2US5C]6?OZ8?G#^UDM2*7OQC MC?.,9Y*Y>.]LD;[YT*SJ9;&\^)>S$'&V^>F$WCRY>-F3+2][&Y;TFT^XGJ8P M>Q)7ZV5(ZXG6RMCL''AO+ &W8C8*"8DQ48IE66CU'1$>].(SV>[/Y5('UC1]"G.&$,:5L5!F,CG7]F0+1^@2H4X@Y2HS:?\M&U=F*E+9!; FK MN('M^>-_K@S^C+/UZN(G&Y8W[&ZGX%M^KJ/ER3+]M%AF7)(!NR A+-,MY'R[ M=,X_\?.7C? @?9K.\L6_+LO%YX?2^7K13.YGJB7&_O(3R:?@/+'=#61R1?+E0,=DP:5R%P[DP2H+$-1 M0&[P'*4N#O S77ZGR\^A^E\8B51F;(')JP#I80%9XL" M7XHH/J2@66@,F-M4=(*4X]2[:"KK'M"R^/QY,=_P\>07_!QQ. B7A\,#E$R!W Y-+*4MB!K^C+U<0%U"@%@YRY M) Y"@"!8@F)-3-9JY\I@SLHE%>/"9 @OY3 !CPB1C--+]__#,LQ7TRK^=_AE ML5Q/&+GSA3D+T2A.(L$$P2"27)@5*1@3S7T.R@K37S\NOOY,[SC#!WUQ!8O[ MWMR)4W*@-A>-13LR/,Y"PFKB57%H= 6/,ODIH5((6&( M!:R.+H=2: MU1T'DOK=W8C^.ATDS$7EI(Z^E7?![6X9RMB60Y&54" M%*,B^58I0*6?A$/K0!*Q5A]G3>Y[^TY0D8\&*@U$W 54WG_"V8P8SI9$OU< MQ _3-3EC6BG'A2\@C"':4R*;1RX8V)S(5W=<)G?U9"<#Y"X$$I*86Q01R%@6]>MQ, S", MP.%"[,0(O/@C?0KSC_AK^(P3SW-@4260(C,*W G'WF,!HAZ=RX*;>^/4W0W! M];?NA 7["+!PM$A'AL0SHOW)$L.S1<9)]7.MS!*EYX)RL=TX*!%\\;6<8/#A+$I') M4B1D2PGL.(-PQXMW H1_!(!H(=@N8H=7\[18$ND;)6P$]&QQ,E\O3S=09T$( MJZ6$+)P#5>MO@J$@VK+L@C.(QLFC<+(#$;NEL=@C $UKB77.81,NT"$\]( M%LLP>S7/^,?_C:>38DSQC-@W(7(R;B9!M%81QHTS3B>,-K7(Q0Y"S%^G*Z2F'V_V)8OICGYR2>22:G*7(CP2='/K6R$5S0 :S"1$)Q MUJ7[ZC)V"$ON>/-NX'@,R R9S&,EVDD ^X$^.T$5E2B1/"$N$J@@ M:?^+&B%K7F05 ZKC_,OK;]L- H\AEWFP##O1_5M<3A?YPIJ%8%72Q@#G*=:2 M1MKMI"L0$X5.3&/F1R:TM[YV-S0\AFSF\5+M!!97&]U+^LEJHJ)CF@L!B=>, MK,XD$!D0HI(NI\A=SFWJ;&Z\>#=H/(8L9PO)=@6.,XR?,5&*K= /*8LI['27=DB#PA#O*&BUGX.+$VR1B0"*]U M'BH0K$DZY! Y2P(JSK*(1\'BF]?M5FOU&'*9ATNQBQ#CK!QY4]S\_A/);O7F M9%TO7]9#WXF4.NN($3QZLG=!>/JJ1! BNHBZ("M-TA3WT+ ;4!Y/9K.9O+M MS_O/839[>K(BX:Q6DT08CTDYP!P$*)$]!$=K@27N'9E"R76+ /6;E^Z&C\>3 MZ3Q>>3*:G*>ZL$?)^85. *4:]X M) >+LC=GOU_TR^;*A/RJ*.7 MC ,3A79,K%<GB$HP4+DL,'$2]7:F<+Q 2:K >!?U82"5;A#%;7[X;.AY#]K25 MA)L!Y=]^OB53XO(?!S8$>[:84W"VPDQ?K!:S::Z-WYZ&6>UH]OX3XGKUVSR< MY"G]]%M.=NH/ML_36[0+.YB;([N'W<+=F_)R.J>W3LFR+,YN/U\VD&(J!H<< M0=:B'W)<,] /!&#QHC ;I72MVU3L0E?CGF)1QB)5$9 E_:$";:;!1 D8#<\J M"R?-?<[*8^TI-A@2OM-*;!]Q]]26XU;SHR*L%[;ZYM58JUP2Q?SDN9<T#+[2Y7Q8@LC=QX@,2!%;Q6Z&M F:4@5S]8U[KY MSR-H);:77K_?2FP?(1\,DZ^XC(OAFHFQI*35-@*JD$%%1SQ(I2$+3F&A$*7D MYF:E_V9BC8!RB)!'!4IM%?MAB6%ULCS]%NK,RMKD&J*LE9G<,/ J(O#$O&>B M!.^_%R3=]>QQ^[8T4GX3P76PE5SPL)''&9+/&;$4Y[-@!!BF:(O%0GY9UHR^ M9<8XFXS'UH'.G<2,V].EL;UH(_*NL8/2VTS_!RLW]T9S+<\DEAAMD2%EH66Z M[W1P0.P<$=)=Y=QL4%X95>_!;KS/R.L-:P_6UM18"E&E/UFGQ29!W&$"[F A M/%FM<+VZ3'\HX[SP4H#+(M9;TQ%BHZU\O_GDR_1IF))C5D_6SL%R>3NY/']BNL+7E3D(1$SH(O(=P-CL!+2EB[(P6+M8HM9?,'E M^O3M+)S-0:3 _\OY3,2SVB5\C6&%[^J@US?EMQ5NV'V*9;%$5Z\*-KYX4 -J82R-'PBM]7 MF_V ZZ'A2ABNW>OX2V$ O3_B15"(A!TE8NK<;5\H+,_2@[(A@8^^0);!(E.2 MA]++2MB=JY%;W':P' 9"0 ?NTAN21Z@SJK;Q78=.Y)ADJ M<5-^/%G@H'+PT M+&I&!+'6D?F]!(W<7+=E\-5,[AT8UK\M%OGWZ6PV2=QIATX MT@1@BB)9!,Y M"(6:>V[HC]:C;2_>/7*'W8;0.$B:':#@%;">A*8RRZ!$RM+T3L0M?(+7B;IH<;:Z$#9+U>S#_> M/(PML=BPV6)54G4>DH808@")C MGL!31NE!Q"QDC-^EMB)MC9=P!3*XE-"<^ M(&.*(Z1L#=%? CAM$$SDVN?H3-*MX7'M]2,W[ATF2;R73#N PSG5A95HA:F# MO051;8A@7VL6(R,0LO$VG-9ZC>X23-=D]PE0UJ3[?4)& NU!%&3 M]15& OGR,61CG6@>/GV7J'%MU(/ JZUB.D#:KXOU1EZO%V%^<]'D(%')[""Y M.F>8D\/GR+"#YL0A#U*$TOHBPSWDC%L9^B#H:J6,#G#U(?R!MXTP9QPU@YPD M@A(A@W/D,D2'+(LZV_S>9EX'70N[3<:X!:(/@J-CA=\!?KY-BU]([?2"FYH$ M]]9ZX%'(FA-6E3X(JAJJI > U7S&EOV;EWHT MERWDS4!EBQ3;.J; U2J/6M"AFQ>/W4'*N%6H#P.I!DKH $M;."@NZ5Q'YUI7 M6VUF9R!F42")(HUWM!;*@*F$+BI4'P1!1XJ^A^S4>;[].<;UKXMY.N>"Z>!X MR@6082*A)$(_DP4LXX8G'6JJ;J!CC6\I&;>:]6% =+P*.K!"S\]?6V=Z?T;R M :_)KEX1B9B9BI;3MAPV65L+/@8!I@05LM,BR-9G\M\A:=Q"TP>!5DNE=("Q M.WS :XNF,&=R\0ZBR8KB#%:[33L/,@EG26 LJ_OF%37TS/+:J/;K5TY#Q1T!T!Y MDO.FJ7J8O0U3BAZ>A2]3,FV3(H7,&C7P'#:=!^M8;"Y!:RV+5YIDT[RYV'92 MQJY(&00V+<3> 7JV=$,\FW0ZX4YY[9%!\K+VN"H:O/.)),0$S\@M-N]#?RBDR(5#3A&DI0C2ENA#+L(&WGJSNDW%N.>W M#X&:_86]/US\&5SF^+'6L7QHV&ML':9SS"_"8'9L=C:!'V?JG'/;P="56-E=&"4KG&PR4G4D55+_(3S MU?0KGN587R]6-;/ZIGP(?TR29BF(+,$*;TEZFH&O[?J\-M+(&%S$ 4HO]R%Q MW%/>H=RH =74 0IO2VT2>*(E@PZ\U[PVS"%I*66 !QNB1:Y$;GW?^S85XY[W M#H2E(X7=02KI>SF220ZFL"P3:%;G10CKP2$&8"98+;-7WCSTO8-Q3WT'@E)3 M130#UD-//GR[4<$G7$\31?'?<--H^N&W;WB8"8CW<-5H"N+UUYW7?S^?KM)L M08X[7MVOXFA+BMP"2JR%NH6PZ57M\NI2LI@02^OL\&Z4-9Z$*%"R6'2$8#)Y MCI;'.B74 N.TASO'Q8#S'CN8A#@ &KXS"W$?@8_H)*V6ZRO*WR>^ND'+GR\=.K*6F&BR\6Y%MBX MBX!Q\-%(J8O6$NXBQKIK^*-)RJD2%#CM'9'/(G@G"^3 G#,,D>76][B/&Z7Z M4%-X#C$K;<7= 6ZV3.O*7'.G>OW^ M*-5]A-P73"YF?#HEM)%9 Q>A=D/VDLPNDX 9>:X]+WGS\.<1#%)M!)-#A#PB M3.Z(XX06+-MP1\8AD<;.'0$$\2(\)/3JG=.NKRO?1TTDL/!!^ M#A5\!R"ZNR1-D)_EFK IO!I(_(.L/-D M-EO\7@\Z7BZ6SQO?8^684)LJ[^NB#KZJS2%-:Q*!1:94/K M-N%[$3AV[6!3C VGF@YPM]O$7D94%R3O*4?M6J=N*^5PQ6/+$S7XVJ M)\[>0TK@^(A:>:YH* M7'""%D0QX(WGD'*@G\3(,>YTVOU(ZR-:Z/L[!1'[2'CL@^^MA[QUW+-))@(: M74 IF\&KI"&GP)+*O$2QTTGFHR^(V$N3WRV(V$>L8^/BSN-ZS52QC*(#@8:8 M0"%JG(!@5:V(1J>-VZF/QH]2$+&74G%X;, BEF-8YE-0Z=WA@COFA2B .,22-!-P!1-[A5YR?X$N2$KEZF_WV[]/U MIVK%]E+;1ER8*HF1)%V9F=9 *81N>68]P>0 MVULJU ]#)0F%BL*.T/SN^BIA/CU097C83> 7S^MERL5F^7BS)=3[()6HJ$ M4+0DB3 *&'QV!9(J(4?!G+2M#=2UUW>7E3X&((>*M8,[5.]Q-JN#RW".RS"K MLS;SY^E\6H/*]?0KOOCC2\UP3"2A.OLH0-C$:S6;A:BB@836*/I5=*)U-F$W MRL;=P Y6_$T7J;T6.K V[T@91$!-;6?2DBN):W V+KCRKT$C;MEM4)2.YEW *#+WHM75YLG*MLL*+P$FQ1"_8XB M$9')?XO*FBB3BH--S+TBH[L#KV.VKV/%W,$V]FI.J,/5)=#1%Y&4)'&(ZI'GAXLWPX,RC(^@..TLA"3M=QRXV5K_WHWRL:-TUKC;0!M] .U34>87Q?SQ;="NPP> M9+$V%0%:5=\O6%H_CF>(W%#P$+-!T7RTS[T4C>M#M8960^EWL&%>">4BFSJ= MGQ!3YU);S,\-\V7[?5R]^(.B5=+:=!Z6IQNGM':SKGG8Q2:XO7 A:'4)9[PP M(#VKL]$E2:&V3]>,JV"$,$6TGL Q(#OCEB2U]_/ZT'L7(<4YB^=+^"G.L4;G M2DGC:HUI(&<7E! 18C0:&+)03\D"VF'@>XN4<5N<#0.]X^3=SV;\*ZZOR240 MP3K7N;C&UB-QDI#GLD!)Q(_A0HG4NF;I&P*ZJYL\)EUQN&@[L"H7+2/?XG)3 MN/XTK*;ILHBKE$1(5QR$-K4[!2V=*)P HTLV3!DM=.L;]?<2-'83Q::X:2?Z M#ARTKN8YTQ)WE@6F8)T41.VZ]#<"PY4%(' MY346D5O70NU%X+@)L>&@-IR6.H#@3;$]G\Y.*J\7@B,NA%/DZ3DGR.=+M7NR M+)GDF#V&$$EPK=-AWR%I[!:P@^Z$QXB_7S1-BH[6%8HU$\FCCN:FY6%= G2R M=D[0%(RT-EUWD-+7?GB4NG>#TEZR[P!"=UC;Y6[<[QXTN MVEV^_,WYO;YZ=_,V$9<0=U%Z+X("8YTFB)L +AE!?AEMT=P[5,V'NNQ)8N.+ M>3QIYZQDM;5F(&\W,XA<.T 5ZBA>2VS_R(V+A\3'=R[L[2/YL2]F;;^$%(PG M[\ #X[5MG8X%@HT!6-$A>,ML,#L5=3WZ"WM[:?+[%_;V$.O8N+CS.IGTQA2E M"G E99UA4L!+94@DSI>0,Z)LTMWZT5S8VT>I.UW8VT?"'?CJ6X+AP"@'VVM==7M@[Q) T$G '$/GVB"@RBUQ&!44;6C', M90BU0[? H RC"(2^&_WT[2$OV>VES7M/W_81;0>XN&]HUMVUB.3(;;Z;G>DL M__?):ET%>CEF*^=$\M0"0K(<5$Z*%EL@>^H%2H-,"M'ZV&X83CHQ86V0VH&R M.X9\'50XQWQ>9?%V1BS?9O;M8KF1PGJ]G,:33>'DA\791*!)V!2MJ0RR=CE7 MA2,X]!R$*YK"FAA*\T:L0_'2W67$(6#_H KOIQ#G+G%UP4^6TQ7]ZCE].__X%LE[SI=VP,K,4U5*<)J1'YY];;5.7K-P/FAI."\[ M-1)I@/]C>>GN-M,0^']0A7=L^+\9$!H9%Z4P#;Y0'*ED$1 U"P0]%);[*#5_ M*".^]_#6AZQ7&\H/.4@1'92Q;6'G@A7Z[JS-QM:]Y([:8"U5CHG5(4J.V+<% MP:/VD )BD,H(85L;T\8L=%CE;_+X:]N#M]EL> MYKCM.]RU/V2[?./EB4E.&*UGM3,XX5AEQL%+X\%;K[F-B2,$%EOY :^ MFE]>[WN2UM.O9\F1B^TX2"ET=>>]KM5[QD6(MO8K8D%G:YTPNG7KN/VI[&2O M.A 7MT_=AE12!S DUA)B/KMW?-ZQ JGF]#UP^+]R9^- 8:ZB>?@Z;+A)>;\.T MGAM,O'>2!U$ HU*@2%X0ZN%9$H73-]+RW#JM>8.$<8\V'QA4QXB_)Q!=]M:X M8"1*[4K<#/:TM4LU;JY+6 @F.IML,66W^MB]<'23BG%/"1\<2DXQX(A>5Q-%C3RX M^V*'+XOEEW/6JHQ)9].OFZ[&TSE)[>3L?.&"U7#%JE3D4IHD:?/7@J)R7Z\T M>P>6L>P8-YEL^'=.4QJ0,>ZQW@-!\*'5U8]UW%W $Y);+M+1TBN2/%+BB#8" M'<"B@[PN M,WV#X7(@M?5@)Z^Q]GRZ$=_Z9$D\,%VX4,5T^>^^TM8G]^4>+O$+^>\;H;8SV:K-^7) MUS"=U9J*EXMEM?57%RLF7DN*P=" 0,Y 99X@B(QU$E'2*F6I;.NRDR:$=YF# M? A+^3"J[L&6WG)0[N;M.4:2,"=5\$P[1)&PR;?EP'F9#!?8 T//%1\S04OPZ79RL-IO+:EH5.M&:2>ER *WJH;. LI^;56/=3U&4R$Y2Z%")B=9U%L]RH#+3(*W M.M7L:KW -EKJ<2<0NA\$A ,IK8.,^#>Q&]GNS36T5ZO529@GK(.95Y,L+?+H M:74E5J9G =RE->+^8?*:C?++!)U!R3]1&\]ZKV>X]U.25(FA6352DAM,YOWT5+EXKC6YIB:'B65@PH7HH2'_$P@,8I.6%Q@:3F_MY!]+:Y?'*8 A]"(5V M9#.O G[:#4Z6Z1,Q]NV*S-P8'4,D[Y9[4$YH6I'D4&MNLD0MK&L^>.+[5'5Y M##,T)ALIJ1_T[2['273)\% *A" KEPHA&(N@'281I%&^N;WA^T =\1Z'TXU1V,TR^; M5I/$]W+=#*V;L_IO>'E"V]!R>4H[SG^%V0E.!!JNI(K M;>@/)?@<[UI&ZS1 M.6D54^N^U3L1UE\OO2/1UU85'5C#;Y?+61OM]00E1T9R@L0HJE/9DTL=>9]D;HRGK81T-ZSQ&/P<+^KN\%*[1)[SX;C3HD0.KM3>.XXY" 7)%2BI M]E,R@GSN02%S1N1 MUUDT-F%9%E:,AJR=!V5S!F\PDX1R;5/ O2ZMRQ ?EL/=3A;9GV$Y#(N.Q]IR M>9/(K<<,M-U48:U/+W_[+6MM>B_?][H':<*\,[_MNS'??O5E9I3B$^4-12W, MU1E0.1<(# ,@23

    FJR5G%*#\]S4\2<^T];D M)&L=+'?:G[D1%K[3J'D?>7?@J%Y2?R:1>M"YF&\B_=J(5@K!ZSST,U];94,; MAR"['++3/!(_V:BAP+.-H$ZP=("F[P+-T6+O $,W>#AO.1PR)J98 8U!UY.G M6D)>+'D>SFCDF(1KW0-S*R&=8.9X1=\\W#A:ZAU Y]K)]B_X.>)R8ES0K(Z] MMR+70F_&(=AZ8"E+RCY;:W?K!;Y/>'"3B'$ATT"QM^>B'"'E#F#R).?-O90P MJUWM7LV?A2]3$R,JV* JV1F#%*4\R=&"1KL]#)I,);7^BXEZ!Q"_W: MPZ>=]#N TH<:@IXL3S>KX6QAG#/BL\%HD:1C2FU2YR3X6#1HD9![&Q,V;WEP M)S'C5N*UAU ;J7< GW>X#G4>Y8NPG$_G'U?G7 B6N+-60SW=J%4!!5S-7;!H M-)?68?*MNZQMIV3<^HWVP&D@[PY0\R2ED\\GFSK3N\;JG3.6*7@(1D@(Y V2 MK#QYA,$P<"&J@*Z@:MXR=V?BQJVN&&!?&T0K'<#M;FL;E?5%< ^IU&N44CIB M20I(TG@5I&29M3ZWW'&/.R)U<97HYBBU9CR#P'KZ@@G)+-C:KH3LA?<.HQAL M&-GK+H?$-$E2'";@#A;"[9.'VTG =XO9[.5B^7M8Y@FY'#DK7H!GSVLC+P51 M)0O::R$<"XSSULG2/4GL))MQ(")N=RL?3#T=H.\V,Y,L2OT?@\AISU(A)MI( M:,]*QJ-+R4<,K4/5VU2,BZ%!E7[+@AVE@6[J(G_%]=7PY4DTS BN!12M22*) M9!,U.2>2R4*KT!8T US9OB)@W WN(?%SN-P[,#^[#/#>.@WY[48/D\23B(&, MNHVBSK+A2(*CY9(B*H=(,1=K?4!Z),GC9DT>$I@/J=L.H+P19+U&C/GYR;). M\=X8V$T-\J_X^^8WJPEF72P1#B$',NTH%7@4Y(_DJ$229-I9>^]_!\+&S//&\#L\:ZR%[W'Y=9KP3"CO,"T^ MSC=/.:NE+]'D;*,#0_L)*!\%1"3!<^LSXP:%%:U/OH;F:=R,T4,BORMT=&"Q MO]__0>=0CQD52&FJM'6&R$J!E)3%D&-P[5OP-VG1,=@-GH?$:UO]]&.EO\DV MOL/I9B]ZLGZ]^!V7'SZ%^=6U^K=+6FP3$Y"Y6O3%= VY)B+CJ)9.N#*[7JOB1PZ QX MIND73)*T6K?>/S M.=@MHK'3DGMHH)-[0_<%>UM-^40(S964 80E]U41R^"X M3I D1T?!H&9I$)CM0V0GIW=M#EB&55&S,*/M_9NG835=+K M-%O0D\N'7PZTT?\^8ZM3\OPS3Y6:#^V6SOYW) MX@![O_TY+0S\#A0VLNB7;[K"PA4P+1:M(OD4J4A-6[UC$).*P"2JG(.3P;5. M?=Q'S['V=]NSKX#-M5<^*E,;WQ50K ZT<#Z M$:(Z%'FT#J@OI>@<2U;,US< M-%CME'"P=?F*R[@8T+[\;;'(OT]G,_+)-J>P;\]S4OD5/7O^<1IG^&2UPH-L MSN[/;F&'#N2DD6VZ>#MM3C??=VWGN@"E\IX5C0:X5!27:%4+> B>R%ET/G*K M>&MG9R\"C[5>.[WL:B4)RXE>)VJZ0-NFP1M0;YWZ5W4:RYS ?'J ?;OZMRWLUQV4-+)/ET_?@IBBK1>!$V*\(34& MK#=X9>T$BBQDE:)H[CK=0\[Q5=*W'GV%6$Q,^A CE,CKGFT9..49Y&)]85;1 M?UI?X[Z/GK%K5]M@XG8A=",-=&HSWI]\(>-0XYPPJRV"7LX6O[^:E\7R\]G< M@?TMR?>>V,*^[$5UJ]XU6][Y8G8CI5!RS(X<<>"B>NBJ2(A&*F )E>#<A:X6C^N M&YO1%)X-;Z[)[&\S=GUR"W-R$!>-+,V.[[ZX MR7!UEN)\R@(%2,7KF)&8P^ \DM4%CI)NO^76QOIY)J)-- M2Y @#9,UE[J9X2? 1.GHQ\EGT[KCQ/=H&M>"/02FMC16:J>E3JW=1>>-*KRW M>#84[0#3MO4Q+>S8]^EK9+0N7G3QDDL$"A6?C>>>X7DY*QRW$60HLZ]<6@ANMJ85V?),\^I-+]<=2O>#+/+_ZH5WZNG;,Z M;2-:3MN-3ZHJML[>+1DXKT/-OV'H4DI5Q4C/B M5Q*NB]+@ZU"0VD$_"::%%8-<+]Z5P)%KC]IA9^O=X4'4U*GY.>.5?+Z#ZCZO M_^LVIU9W4-/LW.K\^5O"^3I3V:@@P)<:SB=OR!U5#)CF.A3#*3AO'33<0TZ# M[CXW'WTMSZ!JA3YR4)@M_6$+K9!(G&N,V7-+OG?K@I_[Z!G[W*H-)K8T\&FC M@4XMQWO\6'/<1QY5W7Y(D].I[]#6ZD#J[#7O\$MM)S'_>(F;I*W)PG'0L>HX M: >1*0\Z<*4-JTT\6Y>@W$7+T3=9;CQW&YIUD5R&Q.ORY7S;O#[D#6R,=-+;!QZ\Y*8V5T:EI>X\C0&YIK7 M[NY%X-'G4E7DOX1U!=S-MUTKS8\HN#8!4+M(:\HD"([KVKB,,9*"C;RU%'8B M;%P3-!R2;AUG-==2IY9I,\WK)*TW%P;K;>=#;-.6A[2P3M^CK9%]NOV:J^H) MJ3EJ%D!(D\FK91:\J6.6C2V%5)V2'F3RYU9JFLPWO7CR9I#;YOSD25I/OT[7 MWZRA*XA''XKV=89<%A(4CQR\$AJL%U@$"UF6UH[?(72.:Y<:(6CK?-0A%=:I M37I=K^0?YB-M_F$;S^@V#8WLS=FC+Q%"^Y"*,B&8$&@3T5: $Q;!%;2V6,5X M\\SPMQ0<[]&L5HAOON RU$WR[.'7 &F"LE<0="^@';.>"27/C5O M8'H_1>/:BB.T?]M):2;X3BW!+K?C+^ZU'F O]GK\0]WVW\Y/5[?^:7NI)0T1 MK*%@7$G:7ESR&:Q5F0N6??OFA5W<^M^H[TVY<:?Z].S/:PNO1&^9H+" YT!A M@32T!2=R 82-(0CO;&X]]'@WRGZ$&_;[8.^FP1Q ?QUT7WQ_$E?XSQ.2THMZ ML62UG2F9C,L>'226=.U,$,'EHD!8PT*D3 M(:V,$ZS=2VLBKDKC[]/UIV5DF./D *=(+HB<13W(TQ!,O=//'4/RE43!UA'[OC2.VQE\?#P/JM-.TY]/^"X)PUT^LYD/ M>= EQ=8D-+G-.*A+C,GSY-$U/:F/CC1:O!0P!I<5ZJ\]*\MI8I-V* MQ @QY9RLX)9%-5P N"^Y/T)2=A^4WA,-#JKI#OR2]^D3YI,9OBDWPHW7TQ"G ML^GZ] 9_%']HDB,")Q\+E JN3F[3P$4NQ!I)6[;NQ[0OC3]"_O88^ ZJTPXP M>W^\\(P(FJ[K;=P;7#+/7217"[QC=52[JJ/:1296513>, RQ=)!NTF>]/&GM71CO*:[.Y9W?S&F)G"S/:_%^72F=I+QU/TR>DKQ722,7)G6V<4VG/1<=_J?1!X9]_J<=3=P:9>NS2] MK_QL6'[R-4QGE1\R^.\#L?4M;\DQ9YU,D'6RH((@46?M(:OB4RK!I-(ZG-J' MOG$=T,% .IB*.H!?[8!Z/C_UV2RL5M,RQ?ST].(P\&1S]:)R?OJH $EAR4SJ+%AK.!Y#[[C^Y6#P?# 5=@#7JQ#O.2[)1UYO M^C_5VOPS)^R2K^R)>)8],$FR5)%'B$YY0"&Y#\5B:3[(<5?:QJTY& R&@ZBF M \BU<%'JO]]H^ .F3_/I/T_PIM>B2NUW9NLD56?JM#E+\9N58*+QUFJ7VH_H M>Q#&QBUJZ-IO;0N*3B/[G6>='!SM[_N&!YW@,F!68+]9&UYP*PW2QAYMK1U( M$4)FM2^T9)(GJZ)[U'-.WZV,EI-:[R$VA\NUJX(5EE(1L@<'$./ MS5M(W$W.8YK0L@]J[O8'CM-(!R[ %2L7PZA?3N?3-;XF%^>6&)^>_A+^>['< MN.+7JL9504?.#1B2:1U9+<"5L*GX559YJ6-I/CK@:*K'C>?'@.J#Z+<#1-_# MWY//M?_+V3G(>7^Z&VZ)85X5GC2Y[1M1EP+!*0&B8) F>B1OI;6O>@2]XX;] M#X?B!]-IIZ[FY3"?@UW)FT]H.BQK0%?POO%(.==TI&<$(>M!:4=;K789,!2I M!3-*L=:!Y8 CLZXL]>5+GE%(15_=S&O)8(Q+!DP2K*9AZSELX" 9,N5M%%P/ MM]_>3]O8+0G;8.7N/;2A9CJU--\94'6P_=GMN0\P8FM 6[73J"2IN&(5?BX2 M4!2%!1"#H/B@)!D4]XJ[QSAHZVJ-?&^>TXT\D%#*:%$OFOK:/L):B,D'$-IF MR8+63 Z7S-Z+U$L)E$D MH_VL5ETI"4HY!2$P"]:RQ#S33)36EUR'F=-U_00GKK>>W6AG M0MP,;4'A?<98O8C1*@LI80ZA:FE1,1!>;?E'>PUW#/PX::FC>@/W#WS#0ON'1H2-.U[D]LNM0R@H!)17)& M4;!LW?QDJ-EY5];^[SC]^*FVY27$A8_XZ\GGB,LW9?.VFS:>1Q^\DQE$3L2V M" )7&NM+X5\^MBOKAH M%7SVSNV'LEHR8ZV50#ZG!L6U@6A\!$&KRP832VR>63J,TJYG]NV#IKM-U6"* MZ]16W1YS=?BQUEV/&F8 M%1AJ*-__+:_HQ>9B,%@5P5VI\5 Z=\ LX56J-3 MI'8ZO&L?#-UMIX936@=E:Q3U+N9I.IN>W\2_;+C_=KDH9Y?C:_.27CYCD&0>X(*NUTQ[T] MNN;@'??.1PTS"VK '?>>>3Z*>\^=8R!0ECKL,()C=>*I$@ZSR%XV+_$:;B+4 ME0&_8]30F: O\8[!"1Y9!.D,>9A.U9Z\6H!-7F-1TEK>O'GM?B1V.P=J']S< MO<^V5U.G9NE\ELW!)1_7_WF[<5 #FIP;8X$**E%\(;B8VJ'=6E.OXVF(!;E MAR[SUK>'6@^%HJ=57-[*_1OR_(P!6V&IZN6%J*2"4+ 6@QN%_\)\5;BYAJ+M# R:H14ZI4491 \(YG* MH)"I(&.1^B!4[?3Z<6\-#8:L]J(?&5WGO4VFN'I3-E*[=A'_Y6)Y&4Z&>3[K MVX?7'(AKMQ(P*E1UQE1.B22<-+A(ZXES'FQTR%P(.X"M#37C=@AIA+T1%-.I M![U;C^P[^T^&;_M/+K;UGWR.ZS"=#==5O EQ#]=OO+TLN^I$[AEB0A& R^QI M86#M7"($4&2;4C'T&]8Z^.^B$_D]@P?>+)]]"O./^&I^_1-3(N3+>8NV20DZ MI"0S9(J^047'(%A'P;^J%]*BS\6T#N2.(OA'Z$:^#U+W&#/16-LCNC"KY7IR M*;>K#NMA]N2/Z6K"6,*0T$/.RH'2DH'SR*%8S"ERP9+>Z4R-WG(-KO3=%53O M)6!<"#X@ !:MM3$VI,Z.2ZZS\'SQ.4SG$VLP>EDGL/":BBA6@3?<@4XR"96L M#&:G?L'?@]1=!(P#J8:*7;26\LA0>7&R7'S!7["6WDVRIO\:6B_%6@N*60D^ M.@O%1Y.%40733B>CWT'']7>."(@VZELTD.7(&'BRFH:W(=5J\@OBG:H&5$/A MM:E\<($V;EUO1.@<6"VYE#N-G/L.$&Z]>)R$WC!H.$ZJ(T)BLZ,N3R>_O9]$ M96-(%'Y'G6HF2"0@]!HPRK"4LN92W7PD[7@;YG M [YYZSBYKX$,P.'R[*#8ZE#W^_5TCJ_(TUI-9)!"LV(@JLQ 6:/ %;000F', M\VRM:EV_?#31XYXH/7S(,XZV.X#W=T9?O_@CS4YRK>U8K>HI2OX0_IAHZX12 M*0+GL@Y?50A.)@F63+Q@WDK1_&+" 60^SJC]0"#M-]#\:*UV -Q:7W#65+7V MG7Z/RZ_3A*OWBUF>")E3*=J"TP)IHXH>G#$)2*!66ZXBL=08GW=3\S@M:1L8 M-M)1!VA[?O[:\X4UL9Q8]W7J],87"H%#T.00*1YKL6^Q.K2>@GJ#A'%/YL?% MU3':Z !,[^K1VASSQ;72:Q?6B;-IFJXG2F7AF(CDOA S%"U5.>D"9**UL3PF M,<"L^^]1->Z!_-@[:E.===$O8\^.#9,:3L1YO M%K@]='N<<>=LC(O0(;79@=%\OUZD?WPBUX&>^.*?)]/UZ:0XR1*Q %G+&N@% M#0%K=8ZW-G@3B)O6I;NWJ=@)ZC39<^ZQ[S%9:KW A>; M$JR+EID3E M]<#:.TC9"7#NQP)<2^UTX.5$@$ M?")^GI-IGRV^5'E>,*-Y]#88!&UK-Y(B!<3L-'#+D\JR1)9: _%>@G9+%K,? M$X#M5-4![E[-Z5FXNB0_,9NML0C)%W)#N22CC@$!"TM8=/#:MPX2;I"P&[9^ MT).(8]31 9KN[WRT2A#T=<:9UUY;ME.P&M3_' M"<0ARGG4U[3^'I;+,%^?OEO,9F6Q_#TL\]"7K^YYY<-=J=J5[ZXN2J7 <_*U MMX>(=O5JL3S)-0/'I=:).)D63&,^TY3BK@C NEA>1:M^XMOQMEXY:I M](K%H_3716)P.U]OP^E9-IU)+8TD]X>%A'4,F 1?6 &1O;+9,.U3Z^CX?HK& M+6OI%8<'Z6M__/DS_,WQ8SU%'A!_$\>+I]7#0?K:U"#)0NLH,3#1F5(L,:9: MU[<_"+>1XYF#D_]9G^#^9GL\5)KI43)YO6GE4H'Q^F MM\1>1#Q08@;[PH%R=2)=R!&F"XTKD[%QKOZMA"#3&HCA/ MG:S>8<+IUTV?P7HV_WMM44.1[S-:Y&=]:8=>&'L3\G"+XS@9=;5 :*<(.==1<0- NT7^0<^;Z72!'U&= MEK5"ZCF>_3UQQ6CO:E# .6UX&!SX4!2),RN50["6MSZ4.H;>'R'S,#R"&^BZ M,UR_7H0JY+.F>(MZ$>WOR^D:WY2RFAB>E6.RWA%/MO:Q9^!=UN'=;PE=8CKB;),2YLXL!T811<1$5"51;0 M%HRH=,B\^<3@/6G\$3(K>U[M4*E)0& M8DX! C>,%65U;GX -&J;O +/U M18O.(Z=]T'3(98M]--*I*7P9ILO_"K,3_(4X.UD>F\R]]W$M#-WN]#:R:Y'XS)V?@9'D^T>;7Q7QY\>UF"SIK,A,#CX))24N-/ 65O0&? MO8#LA#9&2.%]ZP.L9L2/:_F:X>VFHS>.8>%AJ+ ?34*=[.>\1Y(6-@+M6^;K1^ MI3'@0O!@O1&%4]PO4^O]XFYJQL5<&VWO *$#1-\!B"Z*]=-9Z?0WZW'3)S!$ M;5FD]25<]3T%"^ TTR"$*DF;)+0;9/SY/33U!ZA#='_'K8DFBN@ 6.\_+9;K M#[C\_&K^%5?KC?]\SHG0GIL<*(CQFY87.5,X4PP8(S'X@%[;Y@TC[J1FW'./ M@<#42/@=P&BS+&YSX7W.T>L$)495(V(''C.#F*0)%":B#:V+Q[=3,NY!Q)"V MZ#BAC]Y4A"*9:5ICOF+CG LFM,S..C!<.U I28IRK 8FO<>H72"_!N961C2^8?0ZL"$]X3C6+1Y8Q8BAD&4EV\\O$(,2)X&SQ7.41N6GMF]Y S+N[&P\A-B]I( M81U@[Y>3.8GQ2Y@]7;*&FP#6!58+$S($"F?(LRF%L>2=XJTCRFUT MC+MY=X.VHU74 UQLVG/QNY% ;,G(F MC&38ONG^/02-&PQW@\1V2NL @;^]_[#>!K2/S#?6DS*^BAJ5RF4 M2/YL0 7!2@F2K'RP)F RS=NCWTW.N'VINT%?*X5U@+UG855;--:_:K/MKV&V MJ06L^002B9<>ZT V4Q/D/M90JH 5%M%Z+U)NG4:\FYIQ?< ^,HF-=-4!ZJYR M\-MYVO[3\Q5FA92)EBDP64=B9+3@M:XC W-R.3 6L/6MTF/H'3=ITPHSM[N[ M/HP".P#K_;X&U\+G(,F]98[B+5US30X#:,N-RX66>6Y=#G>\@S@8W!X.%WLY MA/LHJ0/$W>=?:*DB.HKOLS:U+SY]Q67WDM^$++B_RF\E[3)CJ$+W: BC[FM_4H,EG%IAL8+[U'KN5 MD''=OM'P=;Q2.D#6UL1Y4$)%RS2%1XI"$1?:2EI/Q(5PQ(N7)U?&FBLT6AL'T7L#RJA 03N7 M$+07R%#8TOP"PW9*QATI-]X.>KQ:.@#777)A% X7"]+6\M? $*)S$9C2G-C+ MD=O0VND_.&,VV/"X\9S^HY72 ;*N\C"W=G>4Q0N?!/B<50V,'81$JP5YULQD MRTAP@V7*#O+#!IL-UT&:["CU= "T^XH DRE>ACIU!>OE,I8L1%Y\C6VD#E%Y MUSQ[<735YF!CX/KR^0_04 ]@NSC_>WIZK8/&RR7^\P3GZ71SG*),]I("9[#& MNK.N>3%1&(.!.]K]2UU1K4'W?;+&373T<6[:6GM=SUM+EDJ7S&@?+]>]#EFCVW MZ++89'BPH%'6CNC*@JL5,$%;(YT1PICT %B[25D+;T]/+ M+_]SBDLBZM/IZSI*=K-&IRL;- M\':WX[;284_(O+[:;O-WOJZ508R"-A&2'Y[=+P^AWB_/47"9/?=F,']P%P([ ML8P-$;*+<6RBKIZP^&K^Y62]VDB,7YP36Z4##P9*G1JJ!,7T(0<)Z"1SGL=B M9>L2D7O(Z01G[4%P%]R.U$BGX!(7D7N*WD55@*&AR+U4=X58 V^R=$YSP4SK MTZU[R.FDP< HX#I$(YV"2UZLDYA*KD/'T&I&Z\05B(8\5QN$UYQ7=^0AP"5[ M*#X:%UR':*0#<%VU=*DW0#8NA%5,DM(5R*(M+0_4X"5]2P$]:DPBIN9C'VY3 M,>Y1?!]!P9&ZZ0Y=S\(:/RZ6Y_VV+XRQ34HJ*T&BDK0.+9* K(""Y*DR9;V5 MK<_GOT_5N"[8L7J_%T9'*V'DUEYOEGDZ#\O3_UK4^8?O/Y%$+WL,9"V<"AZ4 M+0I4- H"LP4,XSP+3"RI&]?QM[;VNOL-/<'B>#TNF@MU9&B\W;P3-^W/KG%@ M8V""J=J4OTZ=-!C)W;,!N#(IR4B;M78[P&+[T\?UIP>$1 -A=K$!I<5GO)S9 M\/IZ!V!NHC(UN1MH6Z:M64?P05H* Z3+,J8<1'L_YTYRQBT/Z\7A::.M?H%W M'GP$J4RLO3-+KI;54;@00Z@=J(7T(6EG0^M4Y[T$C;VQ-5+[;G Z0 <= .H= MZ:3&K[3RGM=X<_&E\O3BCR\X7^%%*QLCR \4$33&VM-<%W"V:!"6:8E.!^9; M^]([D-4EN X!P>TKO4TUT@'(WN.,?O7Q;SC'99@18T_RY^E\6L>"K*=?\9RW MRXM[(K""PD..J.I90X&H9(9@8I*):6]]Z^337@2.[9L-!;SAM-0!!%MX(J^G M@[)8S:"U0).V1BB31D8M[*[#Z]P/$1TL!QJ MA>GZ6NWQRZ^_3G\CYL)L^C^8_[;)9,LH,+C:-J<6O)M,$9[A'B)G10FGL\/6 MTUZ^3U4GAY@/#YG%H/KK )';RY^WS!.;I!)9SM( Y_5.(D\U5V D)*XUBY[6 MOFU^)WY7XCHY!QT=G\-HLP.8;IM:L'JRON1LHF7F3GI:;-ZQ6E&?P!5RCI(S MQ7AO2HJM:WV_1U,GYZ>C@[*I[CK XK9-8,*YM\JK""RF DK2'Y'S #RG:$H1 MAH6'V+8?_WV'X3;JO734 73$PR\QPQ%R ?NUX62@)B'2)LBY,L MVB*%:&WD;A'Q^.M[VR#L..UT *\G7\-T5L.YEXOE>W(4KCCYMCG%1!!]*5L% MW#):-D9G\(G89)J<"%ZOR+7OP;HC;8^_KJ0-& ?190<8/;]#^6PS1C&=/EO, M-R.--_+>YM7:%(/QVH.T/)%7*QDMP:# 6NFDT_0;W;R ;C\2'__!8!O$#JG9 M#H![)M]MC"B-RKO(06/(H H7X)C7()3E5BM!GG!KB-Y)S.//1S8RGTVTU0'L M[EA5JPO!GF[C40>/,2L/!26'VOH;O*NCE+,/%(9)Q^1 0Y[VHG/ XZ XFNBW;8F8PZF2%F@!!4H7N0! M7)$&3'0LJV!K7\K&@+V?HMVP^2E^P&JA_X;*:M&CHP:YAC.OK!3'X MGSC+3U;GLH^K3;@W\3'GS7EI2;J6'/):;<@04*=(TC76Z=;W'7:E;3>T_@G. MB 919@=F]<:A0LG&%RT1) NT*7C+P%MRBK6WT5A4Z%SK@*^ MXVS,0\2-&Z&6NFW%Z6XI)+4=^XF!(5&BS2)EDJ66]J\_"0XUL$C6(HE5"R7[ MP;)44F/E\"&12.1PE*!N@/TW>#JJI[8&#/!=F.+=GU-(=YG-K[X@27&\+GF! MN]__CIMUZ\,(1[-VT1$J'"_;KO3AL7@U5%%H(:F1U4,F+(B 2J"-X&D".J!'$KWZWJZ);V#I MQQ,T) ^)7XROOTS@"4_EB07_ZX[.70XVZS["Y$4TP[*!$:M,V.J6QZZ\*YAYX62O#79=^<:>D-U=_43!6L0W4L%\*=[ZJ*8_7;D-.+X_^8E?=3,#V&DQ)!37 M0AN\AXI4>K1P$JQFA%NO(\3@T);7]@<.T-((YIX7&H^FD5;04Z-XVS1_@6#_;CJKN/AB"Y4(9PEM!+9L"(<](2X"IR)B$F7_M1_RF:V@/4.;J?]:B( M!H#59:J70:\^6Q,(NANE! #YLH8K$K12"9PP4M9^I:\UH*_I.^[E9V1M[;V8 M 7V.&9L]RHO;4M3'?22!QQ)VS4%$K61,SS$CZ,4-Z#L)#&<,Z#M%+RU9OV-C MX)(,@@NIRB&!G$23B(,L"B!_2=!(9S!O2=HIF6T%8E+FJ2 MCI3G1'@RFD@?2C5;AO:9H*I0J7F*AE_B4\K.@^OE M3RF\_Z>4'9J?XRF%6YFBXAZ5K]%1#<$0)SDG1FL%C$GE'A$9LU*6Z/YQ5>;J@&S@3[\A_ M.T5IW)1M^&&\^.=ZIBL7T9G5E$(>D)?,B7<4F]6=V'M/3 M"H(NU?I!.%VH@H'S7C=YZ7E=.0G?XBHO)FYX6LX6,)EL_C)NRBJW07!.I41+ M38#'XC0R(#Y3W(Q14BPAH!5B7ZG_VW,IH''%?;N;XHP7L9]2" MU,:#(RE:7>;416)C]H0* R HC7ZW ?Y9J#M*Q+"O$H,@KYY2FCH^[QJXW+L, M0W3:.4"995IZGUMB(5O"G(X._0RAD^_M_-Q#4"MHJ^F"72KWID#T^ZPHPT_6 MJ:0C@*0"H'!\U&6H^"*0+9-\ AK9= M*=Y-=SI7['-;%\CK&UC@ORJI^*\6?X5T-9Y>W?L'HQ!HB*Z46MG2>LHR1[Q! M&>1LH^5@ IX*E:%7F856C%UMQ ZIZ9<80=W)I+\\@BKZCZ#NT/P<$=0L,LUE M+B]3QI?B'T5"3(;8) V7/&83>WL?["6">K]!Q6[;\K4#HI-TX&7I[5S>#@KR M;7D>%BE3':F)QM#,[9)!DZ+/B2=-0.(O4BI# M0IE&R[P-RH:LA>LM\^C"9+@>O;G*4#@CS>T4O;0$M2/Y,T(HE2F+Q"AMRVGN MB,,[/'$07%#)!AUZ:]3UDI/<3H+"&4ENI^BE4:@]3J4*.0>0I8I(Z4UGVI@8 M7N YWMV]M%ST]M[ZHI/<3@+#64EN)VBF ;0=+.0(3,F<,E+/F<#[-_(1 E@2 M/>4)()B<:Z=17E1>U>--LM_3LHH&&D729M.9I+/U,9)8RL%E:2-CE==$1W#( M8.G P9X!2RTH7F5)! %<,] MIB/Q(5NB?0I.NF!"J VBP]2T!Z)S]+T[H+Z.\!N T:KLZS$7(3-&*9[[(4F. M9S./962S*$D#U/$@?):U8RS[*1GV1.L)/A6$W@!T?AE/43AC/[F+T:[L,UIA MXPTW)$N(R(9-Q(+)!#U&H7-"XQU5;8][/RG#9N+W'CRH(/\&8+1J6(Y?+OG< M'V'^=1SQBO N[^%N4=[\%_O_:GMIT8[*$"QQEIF2U,V)!UJ9Y<=)6A8O[ 9Z-536@.F;I-B M+%7,8LDXRU[R9=".N$R-Z&&36#R/I* M;!69VTU61HXXF@G5NC35R9P$:12)/'&EP:(_4?N^ ;(;@.E%6PW <%=P.WOZ>C9? ME@$'KV>+Y:I5RX##&F^N;22G-^,M\MEC,H11X_K4HD/_EO(VJXT8Y;0FUF9::! M0K83RIA:H,B:XE#;@%8A?-B(4#,X[D'+[1O>@TR7VJ4[IH45BKD8"2MM)B4- MLKS3XY'#HJ<^Z*AL[1D(50@?UG%M']KG:[F=R4*'9;LS_C9(IT%X23(#O"-( M4Z8OEB'+5";-3.23R_*O+D[_96/'F9!)ZCQK+$,:/&JU4JL):0 K%>:L*H8U(X_&O_DKK4'=]S MO_GEYD]_'R\_CZ?OIO#?X.XOA5QF\BPY\^SV4-]Y]@NH=Y MX9,-"B^GU* &)!><6! M!YF)#Z$,%V".N"0%\4;&G*422M:NR.\E_MM;<.'9<%I55>=#<;;TDV3*#0[FNX1/<8 M%Y(JAYL8/)3N\M$2CW< 0C,/'J2*>+=MS.<]#=7FQT9U->4VC^I[0>Z,>U,Q M]-Q]5HK(:"GQ,DG"N0)F@G!*/Z\I/O%!POY@F#Q3-=5\VF=X?[C]H9_N>PN$ MQ9_H+NW^K/);Q$4T]/8N44\RS_%& 5*CF),@49;3GBF\_GM 'Y8&(8 FR7/U MW/D>WR@^HA97:EAG.$LNS(IEY;8.C*:?:+S /*6CX[> 4 MS3_*=#U?S VB&*D"15(G6 MS^C9>(H*6D+5L9FG6>#I;RWADI5^)RH3KZ,AR46CT>-0EM?.[/LA>C:>!(5S M!A.?H)=&H?:H,R!CW@)G@.ZMC>AY*B#..$>4Q[M.]-DE7KL6Y,?HV7@2&,[I MV7B*9AI V\$>+!6$78 MC8)FL[^B3XDRXTF,I1-.R$"\D)%0E965QJ7ZTRU?7'O&D[3=O3WC*:(?$$2+ M^?)N3WV,,/7S\6PE%R4+IJ"2PQFY,.G5R>I]!QB(!AC$DEM9IUGC_2;DJG(1"+2 M:T6"!$VT"X)GS5*JWECQ,14#EY/4T$3]X81L&7.!:2T\]2]IP-"]*,5]_^HO\]G-%[S9K7>2 M$$9D'C,1008B<^#$9H>,*VNUX335;[_0A:Y&KMR7HN1(#+&.2AHXL.[Q=/O; MOXYACD1]_OXK?(7)^F!GD@E6^I=D5EK;Q4 "2Y$802D>ZRZJ7#LSMQMEC4"M M&B(.0ZZ6>EH"W=YGS%O^-BY@3E%3="-)AE*4'U@IX N.Q$QM&6@B;/7J]),( M; :"U1#2)<9815TM8?'M],O-.>]FLW'_[-2T;:O')/""C3AVH$C MTBA&G!*EG4?T1F8MT97M%4C[J!K61EVJ]Z,PNE@) \(*+^^C=_,TGOKY][_- MEKC)/GY&B=ZV9A7!9T8]R9JR\CYHRE24A$)2SGL?0=$=F_0HX'#\"RW!XG(] MSJH+=6!HO%]]$U:&^!X'P4#PCDIBLH:2DQ^)%3X2SAEN)&&Y5[D#+/:O/NP1 MU",D*@BS@0/H[HS> M5H[)0?!624V-OD/_939+?XXGR%5:3;M\?S./G_T"$FXT/[T:XP9;M;J_H+#J MY$_4>*N^C*]*K]=;(EY-'W_V]J7RKEB0XV7#0"+4Q8(FH4A@NE22EH0ZXRCH MVFU$3B*PWIR![6?7'J[U7.B4+-$REM<*)0K?N(M" (^N S!5O8)J/RG#>G#] MH>7P%('S-=' $7IK\G^Z6:"Q7RP^PM6Z;V.) [H4$WJ?E.#E79"2>4KP!A4( ME2$:3:DUU:1N=J@^<^ 8U4X5VNV%W(G"WE@<,+K_&'X^@G;\;^:CI;+,?Q=M2H ML$8Z+Y%TIY )'DFPU!,F!;4:4%"Q2RC]X <&AL+Y"IO5EM[ $/AUG.%C')9RRY1I4<+#UQJ5$7EETFK@0-A>T[> MW2.]R\JRQ(@SW!%93LU@%1 ?+5-,9$BQ=CO61T2T,LBEGA=QF9P; LJJ$\?( M WY#QTPL73T_(]ZMIH%XXZ0Q$"3S?=WB5@2T<8SP#4["$,>F!.F\RKYW7T9FX8>U-/W"J MJY%VIHML^1MI+V,PZ))#+@T-O%>X4X0E'%C (UL$9FJ_56R_/6RHN!^\G"3/ MABS/J_BOFX+S-S>E,\![F(]G:806,PAPG(3,:)T-IICY"[;S^ M8_0,6Z;6#UXNEGM#&-K,6%X_LL7OJ_F[DY5^RJBQE;'4&B_]7@AB\/I&T $T MQ*-C3XP2FM.0K6&U\SZZ4S=L1^%^\%59)PVA;;U7WD[C'/P"WL#Z_T=9X\4Q M<$5RZ5<@@4MBA8NE08^(R8"RL78H]SA%PS;W[0=5%63_@[QQCG8.\UY>.?$C M0[QS[O(VR$LG=QY8DI3056D2^D_$,:6)2$:@=^6BAMKM609ZZ=RZ K^,I^,E M_#K^^D@Q/WW_S?]C-G\]\8O%9CXX-8$)SPE Z=V$XB!>@<3-S#5D9$S6?WNX MA. V(@[UD7=D]GK/6FW@1'Z+1B$?9&]QG[_5HY!.3"2&]V24+BME6H;8Z"4! M+Y2/GFN9:F_I$TELY?VU=_ \RF#J3Y/M _6.N=_]-6S>-$1FW@B%5D"SDI2J M,_$NH8LCK N* ?Y:.Y!_!IE#E]#T")O3('JQ#IN Z?OY+,)B\0'56.IF\;QZ M4^I<9U]*U'%;@4*-"3QX0HUP)=E?$N>2(5$YEY-RP'LH%>U 6--0O!P>C^!8 M6U<- /#PN<(W/:^NIC(T\D<>!BH+Z@TAV2 M%^NM 5B^OEDL9]6.Y9#<1XT^A*AQ&]9IH0)FC-5 M.8>\DS2R-Y'LP:(#%XD] R0NDV,#]F7C5)8<@/AY.IO,KKY_&%]]7F[Q[$H> M@C"9T%P*EPREQ$4TS=GFTL$I"4YKVY@G2!JX$NP9[4Q-W30 M5_'$::+\?3J MU=4UG[L7:7AH''"#\CC"Z2 M?@/H^7TVC;/K+["$1_L@&Y49CXY0CDS($%$L'*5$/4T1@A,L0F4<':9FX&F^ MSXBH2AII %M/QV?NU8AKY35>>-%?I-3@U2'B<>X%)8I+P\&7']1^$CB%OH$' M0PP6\^I-APW@\PA/'Z#LX^(=7,_FRTV7JG6"#AMEB%R6]%.O T=Y)D:\LYQ8 M9K61-"7T2)\O^'6,U&&C$OUAIWL4K)HB&\#KT?16%22-&=U4ZDH%$.4>><'? M&>M*XJ&VC-7NQ7]Q6G%OP8]G0UXUE30 KR/"^AV6MQD\+N'-6VA&&') 9 1/ MD)=($NAD&#Z3, MSK3T):O91HA;(ZJJE!9S=X^%=WA7;B"83M1&9 MQ)C1;5":$V=5)DY!#E$(IWEM7^XX10/'2>JJ?Q=<]731 +*>2$7]^5N834V$^*07V72]7._"O@?J%K@8U^;_(K::.)A UO!SMGI%6"5]M 2QS:]7*Y_O5'=?V#Q2W># ]1 M1*V)!I/+?':\R.F$%[D4\ #"#+6WHA=Z+HXF1N6;TOR,*Q;T$5KP$E)4H(R MCXM98J5R!'"3^2R9<-4S)AX0,'"_E]HX>)2G?;:PSS8\7V$>9I4.IE6SLC> M!,3Q6BG3AP_H2;IHK''$* FE+!G=N,0UD<@E).I%R+7WR%,T#=QXH&]$555) M [[/NR\P]V5(\Z^ED>&J>.]=_F.Q#H#=9^SG;U]@NH!1S"$R[_"&2L$0&;,D M ;PD5 H)V0D#IG;;BU-I'+@.H'<(]JFR!B"YFAOX4VG/^+K4V$P7ZXTEF9$. M(EXE? GL<200$&%7P,.M8&WGY*AG71>X=7!?$W *+?_/R?Z,&&"7R$ M>#,?+\>P^&,Z!S\9_P_>633?J'?3CL';"#J;J=E,0MD^^F'WVI0-N. M)!M1R6T [@E$'LOP54U">:\"'P)#7K57M0L!#M$R[!MB[RBLHH)V$+4E'\^ M,)ZNU/1Z-BU>!TH,?[<8IY474K0W]_C3E21??RZ_?3M%+^1FBE[)@?_DU[$/ MX\EX^9V-0"M-?11$,1&(#!SO9):KDJ%)!<-S18K:N1;/Q%HGO)L7B_<6 =* MW[';&O[M],V6D U/>#J-K#69.V91W((1:2 0&[0C(&PV7.$U$6IWK^Y$6"?, MVA>+V?K*:1)QKV(LNVOQ 2*,OZ[*RR5/0>HB*\YD:<1CB T;3]E".27CI##$"4G7/%D)BC#/& _:2L;K M)_0>(:A;F)O^0$ [5QLM(VQU

    X\B??D#H5AS*"X=%8*L0 M^)"HZ$4KX.T$<%48=!J?QG+:IK$&./=D!@Y![W"N"(U% (?.(@\YL_AAY"W M*PB8,Y_$ :W3BF+@%P3 0SBO@)D&XHQ&C%1" S'X"![2B,R? J;5\8 U^%\Y MKAA!2L[G)M#!P3A.)8LKP4>%(+92B-5O\6+A"LA [#3_P?6?/Z;H@)N@M]KC MDV();V5@=0D@VN',F,(B,AB'A+C%")-7\JP9;D/\6B&W7%(!-*B3PST-6\.] MX)Z&S7Y_/Y"@'5 _K6)0/^5&[?6/ :'4:E<_ZJ@Y*@BC=2A:R>!"\5M*@!U= MZA*/BV!TJ50IAF#T\E9W EBBRX- .0@\YO*66P1(Z 4M]ZIW]QJNM=%9,,#U MM=R2/[=2PLJYRWQ!46&2Z%-?1$="_)BQ!WLA5-%ME6E*9V:V;N[Q>L)IQ->.>&SYI*]]V;NZZK69/,ZYFW#ID9Y?@W"XXD:/#JZHKY-QK M<&&+.0/9IHT:4N1J*F7W* H40O[@_2%"',M<<>]54NQ5;=FX9N07R\A[E"H6 M9.2^9F3-R'7Q% [@XT$EA7&:CS4?'ZNLLR C#^O&R-=VJ<#WKD(_0H<)+EW: M2_@17P('F&=ANENC!=5 L.DPE^;?JMV'8OP[UORK^;>.7D,A]NU6 W.FV5>S M;]7.0C'^;=>-?_/[$@S.U9?@Q8]Q#3X985=FT> -?Q*9\" E)[*?ULST'AEE M+WKP39Z:Z$]@ZKRT;[_4Q%-V"CCG&-=[/ZCO :\L6K?#?U]!R7T02N:C]UZH MF ]^D$T%V!K"ZV(6R^#P3I4Z&*W9NPKWOFKVQE276H%$:^Y^R=Q]6N;NW=SU MQLV6YF[-W76(#53-WGU,##\XO_9TMXL290$FR[8[/_5[,@O+0T 4_\A@>QP/ M!^2-Z6)(Z=N,L:@ %DAWP/G2\6)FWT?RE_B56D*$3/CRC!#7=R4P(:/FJ-O: M!R9DT&KV1X/*03+:HV:O6<5_>^M\Q M2RR_3M>B5-OZY];-1<=99P7$@ZF$5\[H.$=JX"=E0;T_L@-Z.DHZ_FC MK+JGZS5[-Z5*L5=E!-6/PB#6K?/S=N;8 M-O->HZ+JM8YXTB?DF(I-T0>^YO6J>+U]1*.@"*_W>,+ M^I7JV7G]A006]O9>=?/=XRG_SSX'I-\@$UVPE ?#VC94U;N^GQKL]V/5^ MMU:8:]=F^V_J9UFA+["U7PJN5#?\J8Q +T?A['?,Y*J9/L81\RRN(_3_*;5= M1W1*M-!IH3O5*9\K= .,?8Y/TW3K)$*7D^!3SP91'S+ !;S!D0+S_44T16H8 M"Q?;.6'7(O;OV%E@NDW#D,' N1G% 9WW! 3N>X^\WY3-)A'O#?5'YG>\5Y(? MP?,+(Q1Q:WW(;8DYJVE3ZSW.E-0=L?)>ISG$S)J%'SKXS&M*#7*> MF$BH$:*@O"@XJ96^8DZ :>)H\RMY>4'GV.!N:X5@RG]G26A_83ZRVTG S!^W MYA0F^]ITG\UE>/./;.J3X]VNT'!U^9M9/,E<4[='JH#V>'S;N=GX9YYQ]H+3 ML'K=8HE-)=.P^L.>3L.J61J23L,JGX:UK5Q8IV'5-@U+&A45W\_]X$&?Y/9ENOC#<'':S=' M-4IOT:S]@EF[!+#5P:P](M:N*GJA;V?+'VM8Y_3:,-,]@\U?!+#_W(VD[M3* M+E[9C>VKTYP)941F?'/7S\%!^$U?WIZ= ?;7G"48H-]"!ECO0W06!K@V)V#3 M?W$MSX;C (N+MV@""B*740?MF[M!:=C0$UZ=:@9_J0R^ MX;BKFL$[R.!EX15.V.]WU^UL=,[R6P$H)_[!(AGN_BXBU M!S%N+=7-^Z]NLC?2K+1QC2B*XOY'5NE;\_6[Q.:V,$XISK( M5R,UN&/',8>S7IT_KLURWUZDD6E1I4LT=+9X_<^87#TS)#U355_2\Z>*:XG3 M$E>;,SY7XD8D<54UGCR_Q.U1G+$MJ__D:>:#46_/-//!<'B,-/-NZPC##IO# M=C$049UFKM/,=9KYM01__J(?F&W>M3\LJ@9L-1Q4 4##I !#T:$?"D,N*%YY1KJ6@7M*S\E MV9L/T\Q%-?Q&;6]J>K:ZS^&F;I:#87W:5G[*UE>L9F49SRQ@+Z(]Y;@YZG?W MNK >- >C\_VE-O^UFD..T< <>LTQ_UBM^L%K\$+VF+ 0&?2-O_- MS,!X[^%D#?46]^3WUZ<@0?[E]3[]"T]YZ7P!)-R"/?9"6WU>:A+!.4Y@8A%, MBC%>L9\(=XNR%LV8X<%3QAQ>G84&\Q %-TFDX>:>S*;Y+7L"[V/]O;1DS+PE MUMNPK3"!F7=:WP!Z_<5<(H1&R*^,0!X?IA\<]#3^F^Z&UG,N!SSGLB9.;Y77 M$UI KE1 20TJ: +UP,Z;* M[FE;5?*?GBTJ4IC]_J<%C][/\:=<8>E@:_><(MGB#;2T/7S!C)2K8$LQ4!>+ MF@YIP*9-X4J0FLD@WO-PTXBP)R!0O95*A3IEP[&4JSUZ>+E075'D^4%A3Y3> MK 57"^[YP--'_6K TVLCM1MJD55DK5W0SN>I_OT^8\:3Z<8,BW_].##\+ J1 ML?"#: KT\@TG-!:!XUG.PG3=)2*,&5/32LJ$G6A&W=E88-AQ0.77H1'-8$E8 MS^2BPQ&(3SVQF6/!;QK4O\V'OP=I?U<^4CB#[\*OL:-.2(_-8-;XBSCP;GW8 MC.8&"M:*O/=45+VA=*NQ2FRB5V3,S">&7>U ^.9 $0M<7C/@OYF;0!#'=%<6 MOZ7N_=0K-M8KPE'JG>&HV[7;DTEW-+%ZX]9X;-E6K\,F_6GK^JD57Z$_30Z3>.3Z9F/#-GV?_U?HTY[^,^0@-7B,)3MWN\] MTUV&#O$!UX^P?<9;'URDI"7\5Q;&;D2/"-L'9**-)(O67-9% M]="(KQWPVQQK.].V^UC-#5KSR6'/:0]/@I/R+D4XSC3EP/FP/,@KL M#XP?PZ$"2AY4/>[)LQ^X]K-C,^3!*' F<03[)L^J9\]PG2D#"\-!/0DL&0*O M6#-ZU8*OXX$-;YJ/GA_"Z8TGF&_'5A0V#>,!1IC$(4P18XL@?<&CZ<%2*,#H M&]&S#^/A\<=A*M@C\4W#^ ._^$U\$3_T5G[H7?JA1BH*TN_) 4UNN N;!;3TS :@@C4GE1Z.I6^HHY 5F,H\VO MY*&#G$/9==LKYZKRWUE2J+\ E7\[ ?7WXY9R,UZ;[K.Y#&_^D3VYX)!:H>'J M\C=KC9K:-"3"?Z$PN""K?L"X@=?N-."3*<\A=X:H:RPT:7R0+!5(%C_YTRU!7F49@@M^ ; !"]6=C,$%T ,(X\Q&("]JWY%GM;UH AC_0 MG\4Y/P;^0$[.O!>P1_L'IGOU+.EUZ$V8!,@/[X)G\ZI6^Z(K-LI!2(;*V MV G\?,/X]@PFC_$!I-IJ&/]I G/"OAO_S;R&\7;F\!] &].*WR#V6#@#(K MF.R19,\4@M-8]Q12DH+ !1A5H%G9"!<&,=(? MI+F:)7:J(W&[P%J2,1%EL.P;:<0 ]0VX.B$==K"?,4P.=XN[:IQP,]2K(=)' MZ!RN3/F;8#E&[-$/'/X$C[3 K$E2Z57\#,@!2+T'+_'1C"!A5O4E4W+$$G8H MC@*8*IR'#BS'F>(YC#9T V44/NZBZ)*3.%_ XM,W9\!%H$ZXCB3%6??#3FI" ME!>^&F!'T#&K.LR2_CZGG*^Z'L\F6NF/9)C !JK#()'@@$!%I@X%+ @DC&C; M4*#,Q'#PO4FXF)E@^@CC@LO"')[&/T4,1!G/07"$ M!&D0D" X1,7&*XNVOKR"X5?&T_?@1M$5' *Q(+%)@;R$?D M7M?E_"ON7Q,?E GCU(J!\13@\([$)MS?G2'8H]1DC[YOAQ@WMQMX*H9DS8+6 M:RA6$YV)J^JI 5HL#*46%"H$V'9J@LDD6#")/Z.-%2W!OK,D(B5RI^N;'DF! M\\2U",5JX#T<&0\>TUAPU%23&Y')$;&.3GERT,E^<]P:[ ,ZV1LU.^/-?SX MQ[';[E4..MEJ]@>=RB<[:HY:^T%9;O]B>[COFUL("W\<]R^$L#398I0]M*GE MN CP9PW[-E(%J<&!2Q %E-D%P"]?+#4^8VA\(S&NE4HYGLT: [U'M5\C[K-OH9,.B:%?U>N^:\,N[/?;;8U+F;-]ZA76DGK M/3J]')4U=O0>G7J/!J4/4@WB6HK"WYB+B_1Z?=(!WYJOD>=\3F#"M?@L'Y5B\ML]L1HJMV75_];CI> M^%OE-5Q7YN>^ZC='&@^YMMO3ZS1[VGVJ]QX-R^MZO4G-99TLYL6?.FTVV.B]LWVDTZ]?[TQLV!WI_Z[D^GW6^VSK)!.;C5 MNR!*"L+YCMLW14>L"W[+6W18$=SJWJ+F)0AC\L6'=Z47^SZ,")KK(D!=[CW# M3->QP'4L$4/-9FS.X=(FS+#DDITI0AL*E#MY2Q6WCR#\P*J-_)!^ ^>'HA!J5HC'*/R,, MGQGZ'K KPO4A#C%A94\8\XP8YM,P_ !?58"O,L,G,U+&<9T?"%<$2_,MB]#& M<%P)'9@"&>% >4#"$M$VA8*&^;@.>Y+@C@AOSI2)>KX1@B0BUJ6)^)5BKC8' M =L3DACG3Y!:\,<4,%*"7]H(DT.(8'*_5UE#LGA*:J!=NJ3_NSI<:QP8IW+O M>3&\\95QV$#/^. '<[ZH=NOV?R?XS%,'^P?L!H&6^U!.-J547B7:;2=+CKJ@ MW9Z:#M]S!#2>(-)GA#RM*!/D6U5V\Z3H,#GF@%J@HNP40'KG%UD(C?GE:]=9-VA)$^_&WF&&C=Q;6;Y_$1Y'2-X M(#Z5A]JT\4.X)0^[88$P9C MIC7+8O:"(1[*$TIB+HNWZ(0"DQ>.P@!GM@'\E1\BIH+<2OT62*#XR"8!=:^, M3G.J.Z)KNZ,"CABOZ']^4[J%.(&-6/+4G4@ EH*I#3OSRZ#;:;8-F([+NYXD M^@7^-&HU1\F?A%N2-U:G@6CYS JH^1+\;MAL_RI-V[^KH98:9E>?L36/M\_UF_U?RF3>@):?0 MX!M(_4V=QQ9>W((G+.%Z,4=NSN4V!12F[Z<8P3G@P DBOIC$&J!PBC?,5R^0 MTC-=4T0SE02VV&;H;?L2.E9"'3/OR0E\#N0NH8X;R@>27D)%6K(D'5PN0@,A M)&\NR02F> %UU!ETFWTIPJMJI8UZ9:M4N8C/C&Z"U#X/F_EVG=-A_-'Z^-GI MEI-;Y$(.6P^"MU$35J/[^LUQ,=UWG%9*G4(L8ASGX\7XLZ3B:W>;P^V:S\86 M!QXJJ?2M1('\^\O;KPVL1<5>TN"0@Y8R(_\Q,!6VI]E CW<$HM6H0?#LY%DF/X+Y6K4;2:#TH;#2 5/WG]7.6TMRHJILY@^84D M4J5L;ZM JCU9-E*3>A>D'8]2&5:X)+$SD-EXEZ7D2,8>.60I+$.,6S>4L:AG MC.L#!T7+!97/P7L3)GM/P/*QN:QL^:(T=KL$\7RK=C3A>/ISX<<2$V$!^J\[ MI%-E&BR&WOY\(A^_9[XF7\DU-;9_?XO%W@/708'D7_BIBMVB'KZ39A:,!;RN MTF4CHXEM!QGYV9 M8N7=#74OX"? ,W770L:%]R(_6%(KHN ))2-/['GK%>PC MQ=4FC=0T\HFW5=%N)V(J)&M$;#6'>Q(QD<-;6.[Z:](7J)&-$'3:;0DZD9RU M_)U6^LXN$9?336=;^-S!IW@$B:X&!&<%;.HR\AXYC[#YPO67C"6G2]*%Z!*V M?&.%V*NO1+=W);>YISA8N%D#C%1LV-_!0 D P;-CE1=V!5A65:.8;F7;O*(8 M>"\?4TGUIXM83/=/\OQY&.&1.C#":>;8(C8KTOTO@EDJ"453X^?V/XW/OG>; MM+_1E]"%;]9Z^A*:.HKC'F"C/MF=;;L"0BFC6QT4W5_:G68O42[XIU_@-!FN MG"8P.K;RHJC@FA_W"YH;>:'K7(71--:F*QJVJ1:\['L'3DP'_&@^]C?FX6"? MP:NNC1[8NC$?5H+8Z67(JT=>'<4U'E5(D2H,([4+['H8G-_:F+QC.HVA#N&+ M)H&\#=N2NEFEE5/"UC*7Z0\4U,T6925:&LD/GW\V WO],H=\)Q,[TF+N%&[V MG!)^Y%L;EATXX0_I36PF#JVK0;/GA^4J0Y9P;S;/A=.,?P:YN"8I\!$_6 MWU?)CW=L:T>ADD0F@DL4B'*\&4]0D\>O,\<_P^C2& YGO&VM;)BH[*O-)A%N MI.@J+NOH?%3UZ-HV]X)AB8DAS1:2-] MRG1/=^FIU>WC\EPH$)]=IK*\]E@Y&+>NCF3&F<11>NSQR5Z$##U@DBD>Z/Z< M<6VXPW]!JZ'36A6(C,?27?%'=^K2]4EDPAMTI[SRP76GP\N$+QQI9G#U^03_ M%+>!^!')DND?PM5POV6&,_%W5< VFB2&$X8QCQ)_(E>1KRT35L%4X;6EFF[H MKTBRYQOP!@@$5S$\4+T2[35^2>58?9BT4W;%&]+RZL6-Y&<_P)ZPZ90K1+E7 MD?F3TD>(]V A_5^Y_FSCOP[0L^F'DB\$E/B8QOHWRT#*?R8-(P)QGA%[L-.M'^4^@4GH+DG[4IR-B 2)6WDO,F$-GT>>&^1\:OSBAF.7=^ MTHEJ!AX<#6%.[]TC)0U>?*[A6D_$%YYJ6'2].M.P-MI89QK6>'-V9!I.G0#L M'K5P(!M\;C?'X\2$R5XE-%O#Y"_2_]@PVEJ^8:_9*IUOV%TWLC?/?LME][BO M!*%63]"-*T#+)O=0O? ?%,P]W$SI M2Y"H@IESN\1K-!JFJ1=KV7.MXV;/C?/27K8)P)9:&S.P9;%G%"/.(\7 M\BD)+0WC>>:X+)L@$YK/F\;F)\FV=+S.N@._GVKHK"?";"%(R?0TVLYBV6D\ MKK$A%4T,OR[%)+^V_>7MUTUGTU7? ?7K>0=4.[U6(J5OM_G0;DDCX=19?;E' MZA9IWI;MNQ8&W4N]E+!@RJ?:=7=HE\-2[5)K7B;(-582Y[;FRS4,"JF(4O>- MY1$V/.5$P 3Q8H'%]S,,BJ@)M#/S"0F"C"3J/Y"2\.>8F--F+DPX<#:;Y:>6 MITU>:@US ;N_%A#K3#[@0 VJ;>'D$MF ,MA5*-MM\S2WI@V.\+MM$,_U MOZC!P(.R"\-BZ86I1,.FQU-@; K:<7-KEZ-.H2$]G(BOT#4N)2PE"F M4[?7'*BI3@A/GY/#5HR5?QFT^]GA$$F]Q'!)YNMJ#'\]66X3%^ -1!"O;'>: M5)KD1.+M'E>"-L9+@"]KE_)467Y<*L>X2>W12BK4]7KPBROBRET2!NH=2?:E[6;=$^;HDX=4L[6LS M;V93O[K#U6M:RO_JK"8[[,K_:K>:@\V7P1NRP++WHKDBP8]DEV5O5&4EEDX- MTZEAQB])3]S53(-B"KIX>MC&E(9ML36=(G9VP^3(*6))!EB[V1=0LQ-5F0Z: M[6'VU\6U]&K.0L6I83P4#33O MO=1V;PR++1H+>K%I8UO"AVAUC-8RN3(6?(JH7T;1[L@?^Z777TW/W)4^QI/# MMJ:0F1'?/^*D32/4,KW,A/,L853A+0 G@5OAB2=4LJ7?4% MR*">%R"U3!P__6K:!H]?L"3,0]$:8X*I5.A1/+K^ M!$-%*EA"- O\^'%&L*5 !3-8[HI*%N <,C<%&\&!/_N EJ\2@,=T?P)?B&1X[-0F;D(WO:&$7& MLY8, M-"'X8,*<: &X F\&B^10F?J(-8ST4<@2LNH%JV; M@;RX9O"(]P)^\C<4=A 3A"'C60YTRJ9O<'O"8OE(";@L$1:'4<,8QW+PM(/E M@5?%&!ZB 9#&2.)/"?Z 9_,1I[!,_#TJK6!3K!4HZ@%#90!L9*09"!6A(H+_ MF8+=S(/?EF!VBB"!",!.A8VLV0/*C25 U8KU+4U6DP/&\H/SB7&S!K\@BOB2 M%6%DXHEVK9$, B^ZB?0YA-%MDPI\,AV7S*HGQTSC0!C'G8&&O87YS;.V%7*/ M16XSVD!8.=AIM11K//9(6S*L2P"Z<:#1X7IH)US#\C;M8@Q)"9+-GC'@.? M@"3N&S\(_&?4O@:ESO(KLRU3:A!GI;2B>^)T>3S]A#@=--*$*?&8'W3--7,[SQT!R;!W.$2R:_DS0!$*B!# M^Y.Y--I]VLMD]O@+.O5!F?"[3@6X?0V+'KE)(48#>.F1$4L0WG2^Y!-3/3L( MAP6\:H/I(KH!S!E&UA!87B3@^I-_<8.*ZR;U_4T:KY&RJ- H_-WL)2N]I!P@ MZO)-@SYB98Y3(RF9@NJ27,D]$I3 X*)WT-!>Q/ST&U]RTB M2PEUX]3%6S+D2R4BFX9;*5ZTB)(@N11G>LP/0,-QJRD.^(5(8F\1X\6*6\[Y M!?-\8EQAF&4H?#S5E%S7X/6>#%[YWJ-/(:?48,784R@H]XP.R&,,U@O0"_P- M)Q(.CK#M$S4HU#D/?$NA#8U7Y)F %-!/^)"T%7Z["%;]2)HP,;0XMP+=^#_P M"/:D>(*C9H(ZP!V75F 2YA8>4!*8YR1=OF>$VQ;QNU9'NFW<:'5- MH"/L@0*\'\24YB5B[WAZ<]PWM6D 17-P3R5&DDP$.8I/!J[]Y77;0:;]P*U8 M/&K2V]R:\RFERGQ6SGX,N1''I*>=*+ ==V5#Q+PPZ;;WR59H]V3GN]4P:O&^ M,)O"'SDY,:B14]\EU2FY][H\;*^$:!:F8\MH/E\9_ *?I)1!!TTU.JL%*%#8 M6(U9AJD=A0_.G= "M\?TF!^'6?4M7J2O\'L &1--4#JWP;IES;4M=Y_*MQ)W M"E=5%TUZH,1]I",;-_L^<>MJLK*M9T0B>[&HJ7&2A:3^*9? ?D=Q'SDP3B-[ MPU.=1*UF'16;8NY%7R@BZK M2O@O>7<7_/9 ;D@:E*"H0FH7X5AO85H88%AF,D?%9<'6'*B\",<+D4'1.NL M&;SJ>Y/AU=^;Y&O$:<)6JQJQT^DKVF^K.9(["!DFC=:@M0IP65J1-K9=S3AA M1I=N7(]RX[)RD;L]\2RCV+BONG3 OV1V3EB'K[D]&B@!*L4V2+Q))$&BK.E+ MN( 8_$JP2JP?EZ>RR-3]+A?Q;0:L4G<+@>X1WZD]V'*P/QI&N]UMC%LC(Z0U MT?'D@B-NW*_L&8^*83O,Q\< FVHP$0E"IXY#%/45 "7*9P-[DI^4F)L6NU., MFST&)G((7A9( UA$4?&$5QQ/_E5@/7AC+ASXP'@O7C*^T9^_""8SOO#G0&3^ M7%#--'Y9+CU_18TM;0,Z/?S_8Q;=W*>7!FA)WX+2E:<[BK.,WHITCS2_@0Y+ MVBRQ2)-:?7!EL%2;[HFM/F=SA!P0E8L4$@I&285F&_U1HS?,$QDX14#A"]9% M)?A+1\6M3_F<- CV)5SGW[_0>,9.AU0'!9,*LQ\77P4>65&J.Z/YO\"D,[@" M6 3-U) GOX]+-7=ZO;%QPI>PP1\]XS]C1# @,N!R)CYF^V(8T0&_.?+1)X^C MF1_0-8M)%X]2R)(E2UU$*BS1+2)%5;P>+45$3KS4X/=8V'\V8"3OL%^B&C1> M4(Y8OY6:(>)05F^;4BY3/D=I_L-_AAF.J_M>M(9980NQOU'>D31L]#I5G$@# M)17R; =2\?/(N#_3B40;4_P\4IN[E3Z.ZLZDJR?")B9=/1)ZX\9HT"UV)K2& M2I5UD4-A_S.!'PG_&8,KDAX$JM[".R]U*%,($<.)XBH9=/V+,Z++/&(5E>*+J-.K2$E*=A/3&2FWS=9[\Q*>-06M*:][AAND;Z9J_RW/- MQ1V]7+W(C$HC&+N-5,IH=3&Q3S6#,TZ[\,Q-3TWM74G!Q>S=.CG=I=$#\+[* MN$^3>8 \'OS;8CR$?V_["]C,FJQNJS1\ ^V&]Q=&.ZD\!)% $ '>VC0!%1*7 M)P@IA>ERZ5U%P*FAI#8MLM0P.36.4TC2;G7/G[2TE5L^ K&,[I&:_!;;Y!,U M^(7<> ?.%FOF1"NI,,[)[1&K M^Y&^NE^Q:4K>)XC]1I_3,5C!07 M4\!FB84UZ,GV/]&&I\1Q7NN R2E3ND1$=#%,!S?:7?.VW7_%..9/NV^+GQ3+ M/$W,>R]S3>\M\HG;XVY/+9HR7HD9J@^*J?S6X&%C-/.Y]\$=9S#\8BJ]-*-, M%4R 11LBQ6>2* /N,\8AAPQ#40^3VK@I%4<&F,\^=R)E!9EI4Z6?Y0=4XR7@ M;O"?83S'C)R_985F4D^-@8$4!4=B- )=$7X4*SH)*22;O9A\$1R6.?BQM*!8 MPAOA(I-$?)G:KZX=BYTL*YZ+-@:B=\ \1@!+@=B!*F^>E$LU1($795_"7][. M'#:%6<"LZ/!_P+)/H,:KF[?O'V[X7O-G/B1&MO+,!WB&[RO6P2RH6*&1>F*D M3X$4F/P)- @I\QN#)@%-(-FYE$\Y> K?=ED5Q1 9V?-A$!SSSSXE1X5N1A4P2&ES#;#:K,$2<,G"6$:".KK1I4/?T>-4RBX!42K8)UDL[*N6*K#/+&X;'D,=YMAD/OJ22 M91(LK@-2]*_8?I0P&,K6:[_S%D0'I0/[(V^_.Z9)1V! M<3%TQ81@404H@R B(!,3V8R "I-BC(3)"AKZSL)0>SHME2%2$(*E5,XP0?\,*':TO_# W(@"^L&Y/\!OGU#K(<%7,@74CZPG)/"4NF* MN'&+:@7K;;ERDK7$I.=MTJ4%YTUA9@7L0U2N9G0,KYJFFUSX_9*_DYRPBEHS MA'92"D=3?J=KW[HP9=GD=.$Y 'D^\F)W5UI\Q@/LLW+(\=V]$)!-,/VPPBCB M5@9B'8F%R@Z#'MU/\(4B0RLALT NE'.L;U&ELRU#Z,A_,@B]O6R$7B>FEIZ: M A/3,&2C(QZR%XRUY)IWR0O^5]YJI/!61>:_I;/;5<8?QO6,/QSJ(H]K[B)_ MN?_ZW?CX,4'L??C^'^^_&A\_?WCX^NG^^\>'S\<)';0[)T$MVAT=:#>-/\#" M=[GWS-#0OQ3WF8!*R!0AA?0$EC"69EJNZ: ;YM*R.':M!"^:+US>'@*>I=NK MW07W3>,O0N5_70;"38Q MKN&1A]"7BJ60.GI(D6018'/SWK:K\Q5VMD/3027+"WABUT:C.UF!\&G32EXY M>31O< ;2T7[-=1<7X/LFA?J- M#R9=T]9<>&4F^$J4( -O\3SC"# $A?1$:#2>E!G"PDF",@UCZ<<(^X%<9X%" MF,8N=^JYSS'U,;!!7(NIK2W[#B,0'/)CL6!:8N>F%:"4)M) M3Z?I2]>!$-0$=C_9 M:E9*B;Y+Z0-3[,V9HRB97C8V+-4Z15J2T@LA62($+3#B;UW?1SPQ&1!74@G$ MFLA)5Z0V!V>.BV%:U4'=L]IC.))@ G.!:I.>W1SJ$,%?Q'PP]F ![ISH" X:<'T M<:9+#.)!+W7BR_(0Q9I,Y'J16_T@)KLJ"2X8\O M8K])=<$>\=X8<43^GX+WE,LD#7'F2-Q7;O_B6:0Z[MMUV0X%IDC'BKZK&0=M M:6"X)EL8MYR9XJ[(F2J17;!*D7 =..YQFH%LI,=)<7L55* M4@+__4:-33X.XG($U"TNR53$"!F;2\Q)>;L@ 4TD6&L*5P#?2-)P<_5OB&Z( MA 0@BS)M;C3G0">KG^$FIMQ'!3*D6I)VRK4;/(O]GY$KV:Y2]O619*: -_Q2 MD;MD>RV!GH9YWX3B3>T@E?-5?N\RJJ0?N#H1?2_1I".: M8"PD87N.]2O[<4TPP<:W$R"M&:A^1N'FY#I'C(:PA.9S!EVB/?Z-DJ*431"G-B4NS$B6">(B.K4FS55QMT".T);']HR<_C0:AY^6 M,P$M!RDL ^AH*'PK',4A>6G. RFU/;&+Y(F/BR 77E#(LR1[@$D]6 M4TS=#N X:!H?X@#=%6D0/..YPWZ0.2YZ7BSYM'A#DQQI2%;?4"TN[,&.UTTA M6:V"=MOI9L)'7)80@"-;KI]Z:!!%Y.>1E9?@@9O"#BTNNO0%(%/R.MB0K@^\ MP"'I2UNW(A9CF3&'=M!F[5I'$1E^>FTL;V9A V#&L+<$ @>V!XLNT%PXU&EEPL," +5R3E[PEXC6E M_&$\HYQG\D*\\/I-+DS"3 U#^_A\HY.N=VK?PE7OQUB M$"WKDF)Q(J6;TO5Y>A>XGM)N%T163HQB!%F,F[W,S/6=AUR;DAE%D7TF^U:*1R4^_/-A$^584< M]"S;A@JO7SWFDIA0YERWK_B\"$CFB&XOF8!R0[2%*%^[E6W'B^65^"'>\ #' M[P]_E08: I%R*].@@FW7H;P1?B@2UM#/9"2KT#A(=IK?FE.:DJD MAVQDT_1$X 86!VVP??6*6I[7B04GC\:(-AEX:0H"0R=4[G1$$YT&FI-H:*/A M R2US?XOK%.]Y8V\'%'UDGRN(2X_ M>9 >NYPE80K^YPBLPND4)Q!SZ^'?L1^9XFZ1)T;06Q,S"+B;C+(<1"MS3,FO M7A3)-MAO?3H.C"\(+>^@1L%)/Q;-,R4V=2>*9=\:D,WRKO& MXW$J[J;E]^Y#O$P7V;N-A$_6YO?G_S;>@#2@J8\3ZK3:+2/I$I5YBZL@4/$S M9^)$V#F*%I2@WP)G/:((>:+M!6G,L[V5C*BD28L,7JN%&(GAFKB/\"&N16JN%PG,[G=J M"TG7-O#;-(M+: LEB%6UWDA,-SA1\#C"'8&W,-*!-@O:OA11"M,&9>PGWI%3 M(A_O7C@-S-B.78J*T06"ZSSR%E:@OAUN13EP3#TY-E:H*ITD2*>:CAL'(KPY M7TA73FD-@\WY;-^*B3_5VCC9M4BP_;,3KD5I,QD\838RFEBR9-KGI/&@>16F M)2"F!(XFNXBV1X8\FL8#692\"QY/R^/^'%Z\-.39KMA>J/FH,$3ZFFEN#:\D M$;]6O"A)[X7OHEL?-C(5'IZ]EE,.W/\?LDO;,Y/V!TC8 NT.>X4II$?S:'K. MWZ*X0YB[:,DGQZ\O[KJP?D>5>02BZ>*)S?'Q#;G M*/4\;7D11V::^S8)X(U&C@P N8&#D#PB4K7F7B*Z/E!;+)'OD:)_@X- M8EC,792$%T^F5DAV-]9R0"SU5KQ6J5@E'<_OU,:)4K D7PB(AY ])IWN5L,M M%'W H\A=&HGMS)-J["020_GWAHQ0R%ZY20"A=$++55\1M>MY171J.GRG&M@I M^.\6O[8F10;/.;Q-=-H=2#:JIG0+M"37V?5<63VG1"7:4%4L(LKR)@0)XE,4 M&53B(T7GLY6 ,I8(EI#'ZVL0"N"'T*YS$'0JZJ=VJK)S-S^!TUZJCF(C@D&) M+3==ZIO*L"Q()/ED\M\"#NO(-P/B_L5C$]4 MYA1/@'F!<3UQM4)8253-),RHE"'$;45J.(0&^DI 7R_%;IC/'=%'C=O)3K#Z M#0S#XW:!P4EW,DG1U/K+QNS*(7MU>_F&T35> MMEI#%,8)6M\N>=*2("V1%X4XKTS7C92:F":FW(9@0=B,Y[)AFL'^1/QK@299MT[7DE" MQ%6KOC+WGJGSLV)B2'N%GF&9RWJZ;Q/31^+7[91.D73 M^#A=O\'=]1:_T\^?,3=O..!(0\Z]D;G851R[G:M(DTNXO&8N@OFU;^,0X>-9 M ,C :Q?'FS)&R+3AM^76#$,(:F67FK*AIED(>BE,L'-;P_STAX1<9NPA@$R2 MQL'3+<-(T'>)A>>(E*1F6S:5>DJJX694"IL$%>7@2020XK=I*D@F!2B3^Y- M?Z@K0-9*U\;SA@@IB4D&$ D,L+*F\2%5#6)QRO"985-MD83!:BYZ5IDK.>P(=S#'5M\3[N?'$>_9C8':N01"F)G6#V%RP_/P Q<\ MYK$HX"@* 8C"DK"I1&'L,KG.:%#R$@FWQ"_%B\^Q\78Y01K3>!P-D9*JV!-F M#;K+;'DIH0$,Y:YG85.S> DK6*D&ATEMCU%/1\HA,B6O($.V0H9UUUNB)Z03VH#I M ]5<$;R>^[(?@8B=2W<:M A+TLN?V<0(G8BK30KMRMQ#)8*LSIB#S6WH%2]5 ML<;*4E(L^UD*FRZHOEG& MD8R%"\Q)H"[9*Q99+HW?#$")_IU!F1,A^ P%TH]GKPV)Z5%SJNHAD_5#.2.) M@//K9F%^B!8'CKB'42Y@%S,GG,E D\ATP+MG(P0]/F>26;@7D]Q)/X$4^X$" M($IG&3F.>(O%0MD!6*8XT#&7OI_H-6JZ()*1U.P)VH\%EBR:W@^)RK^6I9KZ ML&KZ,,?,B3(=SA+\?H/JB.2"I75BI6AOQ.E'2 V_F98FI\(X"-L<^")3' M;08!+BNY],#.TKX7)MFHZU8I3\P+US/SDNMYY50@MR*Q6IN&&IX@-G:0$WCE M7GJ="<11VFP2A1LX#*T6B\W1:;"95+D4ZH0_^I@,G=H0' EW2LQ&V17$OE.P M^,D+09G=S)FICN],BBQH8;'B6? /T-*Q)C$)'N#RRN17$A8%3*3VVZ>8I)[M8G//X2O8%<@W$93P7 MT% T"+D(DZ#*$C7O M=OFCG/"!Z$,]Z**@A MM4>4R=Z*DL4*B-0;4 K$1/:DR*Q8RLM@? J="^7)"1/BQ-.W"1E,1((28R3Q M GDN7>H(('\Z42Q2+(020$@5&STNWW)D]D5J%Z0*G!_K0AU*QQ[/&"SF?$TF(J^/U''DSF['(#Q\NN[P&FL],6OE86T"B M2]&#A_6,-,7%E3HZ6ZZ0(G=A0I9B.N89C H?I>EP!,H=*OBFPK#:: 8#KV 1 MC7+BZAM=]4:W<_4WNN3LT>)L_]EK4-0B#DGWJ<5\#27+K<'//)[#I9B&B>6I M ',0=#2*V42XV8VJG>E"V2>KCOVZO9P<0UM-9?ZP\>K]UR^_K=K-EYR!\G$] M]I%'HB"CB3 814%4#&V3Z:C&+!/J2+SZY-[Y,3GZ-WR/;[8$[DW8ZI!H9Y)8 MC%&NTBVQSA=AWT"A5Q^__Y;9%M.3I'5%\'T5!H>.*#11J80R-8+EDQ^_)P.^ MXA9^VK4.MY,[X%AH&=NW'()>/I_TH.$PXL(:6DJ+[K>3%+[P=GYX R%'4E:D MG,GR-!9,B4!L'ED://E Q&B$MT*N-]@'8%WS,U\9DX=%J!.$2%25=;;N,B-?IYFE;>4N0?LQE-UOWTAV),C7/(7ML^R ML< T,QALK;P0I<#9G+"E+RPWZ6I?LB$F<+J5:*$ZT$*]+4-)+M90) 4\ MI4M,+_)V;ZN>O4]:T(B.+-EH,XE">L:M+%I'<))-HL2*,55C2F #;%:RP8S@^>7)5!D,NBB;JK!"Y_4[2=X6.&1RYBH M,F0*Y90KPR4E=[T@.J61BV%(0AK!5'S>0AFO7'R+(FYRLBO!*HI11X&2G"=I MK*Q!8L]Q)\*4%>N9IKA)<2W2+F#R4D^E+O7Q$T1H<&V\^J5G<'N9)UR+)'"4 M7V?D1"PMKUVI+Z/L-JHG<461'M]U9=,X+L+*PE;9U6XOH>&&K/5O_B'B@,!<[IS X?=(]@I3G[_>:8U9VAOLL01>P;[B-UBM"XA@II9*W'04SQQG(Z7 MJHX*)F2""??D\]L^03>8&.ID01_'XZZX@,BCDFQ^;Z*8GBR@V(:7HK*GIKCQ M;K6G10JX%U$C-$Y=7E88>)[$K MTA-)-G^%83O[&T[@E+KX;=W-T*6[6[/^*&5 MW#/WVPV0 $6T08 #$)+9OWXKGY4%@-2CY38E<2,VIBV20#VSLC)/GL.X!*]: M^]Y_** %E=U]O+,AL0SR6?OKF<]:%\N'R_:@[E"E7'CZ0IJY=[J#(]]S(?_3\3S>DH@%0E95I; M92[FN^W?B,Y:34DS%]$X7'A?%J8+0^C"!>V78@B^\'*K_V6;A@J9JM2N$^+*&R MFKCKW <,_%(4EP1!A-R!H%& :D,9&\1KQB'A*#X6A87F_ U#9VF_0J>P:@M+ MTV: <= T0_<-/MN+\+,98G&9Q6&48U9:X]:<]/(GORQ8>"?>/?N6,[C"0@Y] MKKQB@?X-)C<,U_L\'H^EN2=O#V5JB(%]"E4!Z 9K,D3L!@*5F$D:&/FGJ(V5 M8U6O*F3+%A$D5X4T?SV;B[3?:".DWU+2>+[XE)0)4+@?B>*&-@O0>P3_39.> M,6,0E'2"(K#GUTKB8UT$_512#HH\CI=9(&:#K$,19DL-L=KT, NB50/&]W(9 ML*DFAII$=#^AW+F&4(3:G?8Z(Q/R7B/FB!J.$66-?)5@CTJ]G*&>(&*.^/Y9 MQ9SM\\Q#%O!*^5.,_F=SAH#!XF$U64G=*%E6:T+[YI#A@M,R$2K:I=Z:39BX M:UZ6]"R :])&K&<(!=V"?PD!%N#)^,8-\5<*6;&G?ID[>(B(JQH*"?QXYRP0'V6DT8G <5;5<7FZYUHSS -KGT044">+';_O-RA]#5)QS&X MB1611K;NOT'4!4UQON"<&D)#/7K4&1M%HS(&W1V%%%P#R"*&C@:1T )3:CQ6 M@L,)7](Q-$T6HQQ"-A)/'FZ]LRE%+?*MJ'.M@VIC5!1[AU8+F[:P6/KF^N\S M$S:,ROFD]')TA:B@BI]C/*M[*]-S0KJ:YZG-IP.9'B]-O^?@H[B>+ -Q(R$O MI[O-'@07 ZML3.0I# T*3B))A_-^%4P4B3A7G]CMO\;S6ENA4,5%\_(2:NU; M5,)V8*7Z/(0!N_JIG%/MQ&$)\2?XQJ&-^GIS=:)A7:PI@A]&>UBS647_1 OP MD<#R_!WODTU2&F2^['SGI;GTN.L?G \(I=FW_?#^4_TCMQ'? 7ES)*DDI=PB M=3]P5V]G_IW7\K:I2IQ!]5VV?DVK83V/7CM')+0='6&L$$DGE[UJ8-ZJ;1P8KU?1>Z*#P0S\ MD&3$JU&K[LOM2PR2LC>_["BE0;D5UD9J![ON52#89"%\$I5NR:M1,145DU7LX3P+. MG2K&X$"?\8'FC!I7]?"/V7:XMUW2"-OB,-PH12EE-AA5(I0L7XI+>J&^2556 M@/V'S)[DDOH7[HJQAW90]*+0S*^=/2@F2[EDB8* \<06UE^E2*9D5OL(03<%A%X)7$^>A4PTXG" M,AB=<*:X[>=I//6-Z]RO&9[I+3=K M+[2_0 4SB+QXK5?E8)8]LU*Y/LF=UN[+"=LAW,2U861T\PD@?2@IR,L%!S': MQ706-P]?%5"Z3QW4PM+>71O:+[P+,>LW[;-)WGU&'(O0Q-&&Y6S!?9VP"I1=>I\ MR#F _.:R2O$#N%MZF0BL[S+-P&PM M[_D J3X0?U"0+.TT $4+:@%5P]QLW M>G05,HSJ!LB:LSKD4A[*$+W:UV/GM%0H58Q+<.#7J+G0K)QZN-G9YFD-1W#Y M:^K5#>TC2!4^^>"V0(Q(AEK-%*HW' FQ3)2&.0 )6J@N$%M.R1. 02B1C1>1 M4::;8:HR+)#98;'@I;@L/(_\YGJ')/?.P. X95/2+<78[12"Z+SPJ,0?1](<2% M0J:?&O8[MUE33@VA4+D<4:@ M%3FY_Z""[[TD=\-V,WFB#,7O:(,-3$Q6X9F M("G?#&SGY<=N[+*86>=J=(]J=@Y_^PH\!2F7]K;ET>B'3 -2$?DU@H8N.^94 M<5FE71];0NB&DXY?1]'7M'960\,6GT?SDK/:^SZM0R*N( IS#OOM?5W%*!MC(OQ4*O;;/4*WA#[?!BAE M!N?_UZ(\+Z))>1ZAA'RL!TRKA6'P&4&YDY3@9PA6;'_5:H?4X";V:$1R=-,H MM&OOF>(>@=MP$6X)E:F"H.O6X<0=7-W@N#'D!O]5(LBY*50%CR8/).(6--?( M)LKB ?B-CP@AQ\F6_*^7;3!5R/PP^#UZ08CL_A,SCNA(.L+9X^-4:V\UI)Q:L$"E,@:W"3%)?\\AB2N.R:GEY-BNB M(29-9GT#BL-6F!295#;+PI:%-**SXW$5I&B%J?SN'HG MV'YY302IUF"B6U?V/F8&)GSPPJ42!:7C +[RWJV(>,!.L0 @F,A45,QA$PKN M# 7%[N^H,R#/<)[J.!#C6L% MVTEFI>J5DE]UQ77;:IRI9\2*2WSZBW)9$$*]=Q/\)V1CV9M-1VF#8<%!-,S*%BTN*%QPR-"7(7ZY:(?[6A(A:&>V4WZ&;'=[4/J=3DBF MWMN%>_D)1]=93*9*F3$$LVWG #^SQ64QEQ>W<]=R60RR1R< W6<_9NXV1E=QZ*E@2N:+&:%64%I7L]=X M69*+OS]G9":03\Q9/+RW)Y288)7O!=Z^W"=D(ROTR>$074W&.:Z'+,R_VVWF=L M#-42QKUZ9.=NYR'<(J0B7:$1IMMDMNV96MPP[_&:#-I%BN&5"?X/O%!(6)XY MZ 7(K!A83.PR(DQ(BD%& 7)@9!@-0 S"!46IUMY.IZ_W'_J^HWG M=(99WY=;N\^_9RWS2BHG+)AZ^KWKRU8TX54P-KN/MW>?P&!\P;HD2(?.2X@T MU0S_@? C OC+4XK88A;(3&^5$B10J+[R#%-$#)'FY="]@AM@(#\A*QCU1$D1 MVEB4D/91,1O_,HU@\'05J)2(MC.7P2Q;EGXE0KD)GRPCDM.1(D.,BJ.8V]*7 MCGJ^?+6&M'L]3L\!5H)1\%GI_AN0'*=5V#YJL='PC>B4!,= J 8# M0K!EXXS.42#DKMR48BS=\V+AL8H[OJ9L7]SJBYM:ZQPQ]V3G.\/<7>FILGE, M]!_D$-<"2O,C7A'U5I'8^S6EP)%9>T0*+L@\361N,&9(*$Z6%CJ2YZJ)3 =\ M<[7[D!O)&E8YD!RPFI@1!,72(X"9+F=^N2:MPL8V7=TV>9F"6;Q GU0B=A_3 M)!O%K'5(_\B27K.C7I MNN7G.4\VJR>$(='A&Z?IEOO-%G?068("*R28%Z\F2*S>%C!S*+_58?@@9F(1 MO4O3Z 34T!K7JX>'']Z=/()*//<:5/[#/P.5PC"GMI";^;LS$((2LJ@?&;]# MLBC8N_Z9/^$)/((KCR0231)/!H]O/N<-EX(PSW;M1'+):55?.%IKQ(B MF-CVG16;2/.6@48"XK32$5RHL%"W9)(6E,5"MD1=9GT&AB8J&[>GG;E_\= 0 M$)_R3S'V< 9ZA\BD0^=U=^60,X=BV!8*:+N(58S8B 82E']H\:O1OL +'Y\T M,KJY%RP[<^?,!^ +REOJ;##61^YO\)XCCTN$7AR 4T ES8?0RP,HES$D:CQ3 MOY(:Z*%,_EL2)7 /.8:4SLBUF/X)C$(/CXX.#@\>Z260\]V'>>RVZ)?XF_M- MGJ5C_/SOY3 Z!#E1^;';J7L[NWOBD:CE\),1;-C_;"&M^IR% #@T(T](JHU>?%U:GZ5=1IZQP(B9!';.JN0!]?3J=:BB#W5A1 M8S3KO21%.OBE+S7%9:FK$B:5P@+*8I3;S>-6/@J'2A"F:) ; 4#1X6DQ3 U= M+^&$,0A#-*<7G#S8Y#EQ$MR(@%-?X."]A+B67QFE1'[I[8$N"GHA#>&F'DKI M'IA2# SU)F/421(W?^!1IP/#*,ON).V&MMU;E\5^Q5*"KE"%!:'VYEI8@ZI8 MV&GR'\.Z.LM*0^H6I&D6GGWY GT2-[)4^7+-M,0Z6YT34Z*J)^=#SUU9]KN0 M^MU' ZUC*8M6C9Q'3+=F%K.KXQ104?F >,X9#8)1:@X,HR2 G6T?X^5#]MV; M@^7[+Z.3C\0NP+*D%7@8=-7#GPI+7WUA+\%&BJ^=I'P$&>)&NVK-66=D1T=Y M&E=$F5#R5C^#*#TZ*<@R<'$;-&S ".L6D]H [6/Z+8;JP@$7;G]-TYG8"Z_= M8Q\0>CUN7!2Z&/8X^+G?1^&#L0*FJM*1_7"*7?7CCK=X9^H2.T 8MVZ3M M;-KNZ;U/VZ&IA'R-6:!"C5A,=+":F/8\K1''E*58NH*HQT?3\+G7# RIR M)+:72L2+1]E9EAM98CP&(9U4*R= 'B_ 0ZOK1MCLU9I W7[V!X8>,0G$BMTA M?&]>SHDU$,-KD.&;-'-('QF^80*PNEV45/%YG B^\@FA1LK7 M$I&SJXX\V#IA^2-/LM1CRJXB2Q(QD3UQ3V*'\FY,YC1.AZG\X6D5-R9/%IT%@NQ MA8-12])6TAG'DTHAUO&>L]*>?(3;B7BA%CZ LR+$ME63I^(L^7T;@M:XU)+L M!)%<5_PO=SE.Z;8(.&JM3&T-\38A*P2I0*)N8.+8^P%BH<"Q5.FWT ;*[H4% MMZ5LVWXB^3PH PJMH+YSB57P;K ^#)U["DTP.)/*?=7)1=J/W]SWMLZR>54& M0>YCOW>MLH'[^OM_OCE6*0/.XHI+*IO?C[YK!#W<1#_%Q.,U)[P8D)_;HOB M\FCE7>,6($_"QQA9$?:@*UBBR5\X!/:$C.IKCH Z*,9MR=1-<#I!O'&JH2*B M+-*(K9"$D:PG49 F;EYR\IY%9QCS=AB\AK9]*N?NYN*^^;I,>$I0$13#4NX> MCCF^:CYVQTX)J\MU(C#1V'0AA:#I9'(G[K#*S:Y:24B:%-B%MEB4/^8D+__. MV_YIF@J'7[":+U$\*G=)U]S JGIF"V=0.=S.#0QVH@8UW0/LNUN'/-=YP2W( M^7F8>J$JHCG6PD)91IC6"5Y"%V7>\>%!3LAP^URBI'>],#^P]Q^^PG*=TE+( M^>LJ_H/7(F/.YVHVL.G6;!$-:H!;[HX4K0N^M/_#-2PIIS_5UN644]2O*/=M MJ&J1!#1OS:[3T[[F00%\"=1[4A]*N.[ *\-P&@D8VG "MXR/;[/L8'=_\SSE MO/O:"L/XHD&K8 )Q>6X1 C=0[H8/]9BEJF[)N[OCT%I3R IGX&B)<[_-NB0B M>F2+<[NCSPTD0A)P_L"L ;U92H[9=O2F$650<"%%09H.;$I:AXL*]85' &CT MUHB6@'I=Z,K1E<@,*QHB#[SP%_J!D(M*E&)6SIG]?&SDDEE,E)#Q>./"CXNR MP,>@T@R,FZC0&\J)K)YZ@DLM!)#C$:K=V\<5H0*8Z(U52CV$,CBD^HE#%7(Q MQW(K'2NZ02(13F4*-57QAD0#I0L:R@\D*#0]P]%R>M:8J.(9HBG:?_U0^)K]7+2*;WRQKH]-]HVGVW:XGSC\%QX.Z);9K?@C1;.75T"$ MM0]78"# VHE;X:US#@+'R81T>Y,/2BY=D\UR;F.2 JFTJ24NIN7)FL M14]S =$%P2=E_#STWSKQWU*5L6<[V]9!LS%:X30'>\T916%$ZFX(PP5M,D/. MK'NCW*#38N-E6)QHV;S\DAZHP:0#L&B;>.<6X<$O?@RU%;'./K 27(T07VZ3 MW7W0;;Q: \N*J)L8C#Q+1J_+;KDZH^\2=JGSU/,W\?D'EN8464&5!UD/IT$0 MCVE1(PEVG?6-W!$'DSQN,"Q25DN.6X"I Z\C9IH+.7D3!A%Y#!,WIV[16*RS MV3I +NBYKG!&'NJU!HU$>DJB3;AYPTX2YWXHWLTJHWR'1*+=-W:CGZQWP>AW'@*9\L?)-S<^64K-6H:,1=]1;P-Z610K0K08\B+N@T? M1/)2.A'99!(+(:N3=Q" MS &-4["R\X;&N)4Y?+;)'(*!-@D%W+ S0X*2%2;C(#MZUN_WF,V@*A)C0]A" M@(=13*8%W?F^=8L']&@"2J )D;8I0SNAWL^0SD'/0],BH=^3]U!N0(7/Y$[! MN:LD=>X5'B!X-K.I[?0"#1LJC WX@L](HQ!=[/Q83P6M*C(( M<:P2F50#64YW%CC+-46HO[LZ$H2ECU:Z=Y@4Q?.6?_-[W#S7Q(&Z MHB=[Q!&K?S>QT"V8FP9*NG:.#>>(-',?H[V35-T7DE+#9A3 -BP@!JC*./+( MM2.R'8(AKY>837PX+(,(0\>$4:>\ MER?VT5>6U9(.#%#=0X0IT"!Y =+@5JIB%G0O#>[3Z+]BYINTI3UX#+(2L2= MI39O1_\33JW1KZ7T/ QE'C<%/8I*/LQLN5$ ']@/=A#7;@]04RA.H&'F_RX3 MK-8=1(9'&>"?GJV:_,3PI^W3UB0T#TUSCUKN)@UB8VTDRYA3'*>\S\=G_K#8N[>&D M S<85"8+@#G(TSAAIFV<:F7*PT/4/YHVD3ONX1VP>S2$:LI& ;&HDM"T?YB M(%S86GYXP<$R8.>)_\SQ,5!NP9YJ8B?DQM,']9#7X_U3OAWRA?TE!]A?73]X M^S@!L-D?0'S'#30H#/CD(:^3IKJ%)/J? _0/B!!"23;&/#"! +&1&.X+FJ46 M$:&,:??AD.T4Z.I5QM M^S1DOM )"1-(?>%\]$PP0XQZ'W5J>22-Y"00GC&-2MJ#N/+!%F#E8RON/(^_ MV6CJNO1TY?'6K:+*"HHRQ-_2%<5J4XM3_-T9I3KAO!CN5HJQL]?1=^IKT35\ M1>HT@CRIK^ZCII3G=--23B0WVL&+X4-:F-[V4X*A\WQ6Z)*<:4G*'TD@SDK3M,?^;X_?Q#:V6F2P41Z3I*MG; M_G:#0$C:SR+ ^=P*852)_!3*H-S/+-IWU8AN8RUQ!QOL+A$H,F/NXMIQ$WC3 M/(Q\GU.X>G2=IX0C#V0_6F MN);73* U#K _,#^$ZA8J#&>B1UR=5A-$HF\, M CH-<5E;K)R=@/ZM#;/ 'G]K01<><2&T,S7O>B+H@D7 P/1@<81;#:85D]>0 MM")\%R[GK'8W#[@8 %/6UF6 V>]9EUP0NVS-P2^L'Z2W],EB6&6 ML1O.!QJ68-@=^EZ4'0). :QO0787C)]ZYA5WS&<5[B589P/+?2,6#OP3..%H MC1(5!@@+9Q/@C&$K)FO2KVISI33+4F]_6*]&!A"#$@'T?8F9 GUJ1@.?0SHU MATB]CA$;*/8O8);+@D25<-=AV4W7 N-TP !I,%A&V&O"]'*K*130>V#@)[IY M)2]=FNW[PZ\8C:H&ROXV_)B73I<]OS?ILC]!B0?G)-PJ(+E-G#FM(GT%N@:K M7W[3^K*U@P#;R[X9P5ZHX5N9%/%'B*PV2?UW?:1;<;9\+J(WSI;C;0&*$O9V M=I\Q0SG TP17#A>3*IU XON,=K]A@D"N%;QE(^I1D0KX&/! #ALV0W\OAX03 ML_49\ WW-ZW/D#JT) UP=8%$E4^?@M!'U\4EK'IMS17X9VC"Y:HZ*JM9&<+3 MMT^B+Q4";!<#=S_D).8_6\D%S"@FIW:<#+K(Y[XMQ M+E0]0FR@[#;P$%J16C?D>G9@@LD?LR*;-E.A>B*^ MBFI+\MHD'&L*L12K22<;*5SZJU">@:6&A=>Q%;*RZV% MYG4[G8 ,X)>YM?68N7,1M36% B_O3!XZAQ53J:4H]KS 1;U/MBJL^/BIEB?I M*@T3@+2N:&I5D(.07G&TN[,%GCRCL3!*Q8:?C@*_%H++5[\JPNNLW#J.DY_J MWM6$OG>'N-6='A#?DY>14(,]83SIA-1&PMNR,1/8^2]F6@NU]B;K":\4]/'9 MQ>";@O@6;B>WIVC#GZ^[:0!%'+Y\@Y+43(2,5,/.]' E6 MNU^4A1*3W+1JN (5*Z3%25 ,?HCG#D'=1YQJ\5%Q%1);D[UTQ5O$6Y\2@D00 MH;XHG4(5ZFU>FZ!>'E E:8*;Z6(=Z[L([_D<5$^TX\PAG=. RZ LE5-JA[^_ MT(,6)6+V!*RF"Q8N$!#:T3)X&%JNL/1%-I+3(FGF5A(NG69UK3LGJP1#(9!H M]]=S>%( '-+"'OZRL\88;9-:222E Y9A8&#\PWG_I0@A5PC&:>QG%A= MTAT.$3!$5JI.MWHGT(I>P;'!V6U@^Z/07][,*& J%[6$&A(#J2T_39 M5HG'+QG MU4B1@C,=<#@"8@9L7,.<*6Z=&IBM1()-O1>7;1CW&&>9U-H*0CA[C?>>/C%] ME(V)AVM=!+*Y]-EO<:KAJUE*7%>S/H96\9_>U\!+ >N,LF*"*.#-21#S&//; M6_ ]4T$7_@#+ZWI?.R;6)-QI_4AK4+[A>RC:"#P]9%P85LUC6@YS#GAW5D0X MK.YGWKWI(Z_H9'WVK$YT^M.@0_:&ARUG_-R9VSO@[[(( M*96NXQV$Y^GVV"1.O=,J-H%)[;5"B RF@NR5R8'"M[W_>W]G9W_< TI,B*' 6*(!MTJE0Q^IE>+_>UG M%WU[?R\R?,U>9ARQ-SKJ"YS.*)2J@I*#0+DB,<> M# 0K8Y!M<0[0IG:KE8QZ<6^242NW]=_V=G:V=V@3RN9R"W985E5Y+EP9(RR\ M_]O.]E[X1;>>/5$Y"I<05WU*RF=).4V13@KW*?!GIWQ@C7G1NN5-Q0=D4D=I M._4AH7VD'1S./:J)^<(PVN>VTK^;E*@&,'(871&CC1;(=;5 M, 63S5NH"3(TQ,KBK$;-#(C>J!F_)-2S*S%LY)-"Z+ ;XPX3_VHS?S..A(!&@I =MHW>+$)^==4;ZSIL)TYV9-W-R:4$ 5S,U9DP.8W+MR M#"[W*DX6HF54^X039S,S-S'2 D$\&C$>9T,U\W-E]^PQD+6 ZQ ,'<9MFQ\9R3&'%" MLNSSLOIJE6TIQ=A#E<3I S[@Q,KZ]+6<=,ZM77>"TE.9O@_HQQ M6X#)4F*0$3ZI\ #X..% 57^8N\"+ $F4!2%0#('ND%YI-8 8B%EWS*9$SI)]C0PSBOYBZ'"!N>J*7S>!Q@A8LA3;D=O=?BT:V1 M5I-Y!9!?"/47I_7+_A#,*\_4$_A51*C#U#9<1L1,$E@;S)+2KWRF)74G/0&R M#,G"*YU & _(:(F2 )$Y:$+W%=61T0M?:5(ZIM)Q:P#!+\T2TL$;1*=-C%S\ MJ;=^H#&0Q\0]-$,(/\0^"B0G31.WOH :#BH,*VIN*1$:98FC>PM\:5+F":*F M5RWF)95F0?2=27H,X@ \YN#N \BD;XBF"@)!HA)*OT!F$]HK0*?2_;KZVZ.R M\SOJ1HO74YI(P?PP4CE,52<*DD;(!@]W^T4)"8=&.?-L-P!WY_QU^$_Q# >F MWTN<1&;3 J]E(EQ:JKT>K/8V4@??:!HB*HB@N >,7K!G09O.?&",>J!1B^"Q+G,F&5#VB2[4-V!;J\#>%*%F8KA\I0A+8Q),Y>#$NR*X$&5D#=S/"KA5!&4 HURC6,R<*6%!F0/_$XN.F9B%4B+D(TZ; M(A5J62J=RA=$KB+_XL(OYWX2; _PFB6>8\X6I!FW*N4B !81*O ![BT-<7UMT[]K_*+LV3G O$ #0_)# 4TBWH'?/R9O>ZK%<[*Z!KJTC+2.)75B$61TFU'Y&KL%.($J M;D"7NFC[1ZN.%+S N5M$Q5HA,370.*BPJ>I@5[4A3UY)4Y*T*ZT5.N!N$+%Z M-.YK/[=A3#QU=1Y-%C;KBT1$O^),&B(D*%LBF M3:CW0=6O]QHA#4'\'A58>7?F15,5K56E$I# M51JRGMT5=>0N_^[7UM$(@CR4\T/=$7J,$/=+-O",:\3Y2ZX7#$++?/-O*J2] M*<+N;(PG.^N&>]D8D^L:$U*6!K>#+\]0X@EGD#L_8HE[-%)X>K7]/QM!Q*M0A='"#,QB6JU] MI$3T5&N..72J_$1UV50NGF$F@Z.Y7K0I7HJ&3W1A$] 0F&^3#P! M\-H%%0(*^[BO &R1V4%W.T4D>%DJ49 7+V6HW6@ZZV/HM"B3M!Y5V1!"T+#3 M0P)N?X5J*>K2A,GF;@)U!A,4U"!HL)-1X1G7MXHD^^\Q1E\%H]-O7.KL!V1U MB$*K$ "$[19Y+FJNF#!H#.MNN[R(A\9RP?6BV2_(_]WNRK=.:'P'K-@Q$@&?[7QL3W/0X0Q3FOPD.&JBCFYEXTL%&5:%IQ-Y629&_$U6^7+M(IIKC%- MJ=-M*+1YPO4.,TH316FT5T6]?%F@!(4RJ7I4+-5I(M0U(VAC+][_HZRB<^=] MU"XNO32I1J!EWI!4O$-Y%PA;^\]%-XBMK35Z3>6%;/PA9Z@ZA(2K@"@X MTG(1<2?L/2:&F"&%="@!K9-"*(GQ%?NL,!SG<)YP >#CG<=R'I[$U3!V3][Z M_"U/%Y[Q9&>/:/GL+A2K0!+O)!*%A7'T!R)H[RR)@1ROBHG60G2%MAB9BSD* M[>*[(/].PNVAKG*7M-U@.:;=A3*XM#6ZL/#$V!I:OD+%NMI$05(_JWN\)[11 M+/YI3)5?@7?"\O2S6__"P*[7@@"B W=-FGY%JNY/0+T,4**LAL)O9"G.B2)4 M:M\(-#*(W*=5Z>X64$(Y=S=*\,)&9$3.X\JG!I:"3 S>@3S'B HEJV8F9>9< MC!XP$P\$I\.^J0^+\57(RTGZO[@V)"63*B]AC#>^_[V@1=AY9NO^S,4G9/<. ME!K0EP]&7Y,P=+"Q"]JZA@Y\3=/_](J]P]=!#]DE;(W MO.''/ MB)W%27NIK'N?2EKAAN;;$JRE[@F3?S?Q5Q2H<'?G,83N!U#D@)P+T((ZSY* M5K=H+_XN.ZC BGR89)AV-1MXQQ!*6V")K >%)<&TXLRJA_M-R34U.K[F+49& M"TX8WB*U%-0$^$76I<*CR5W!(() 9ZU$I 5)UKYSY\S3/V[2W"L (@P*RP3* M+4_8BD58?)EZ*!$F$GO6"W&EE%W@@SLK>;HPC^4\"%Y)_L433"RKCP8=F!.@R"D_YFIHJ\]S= MM9W35U -3,"$0'7D$"AS$PWW>'88X_#(#$U<&!4X8 LJQG6*Z23S+P@(I.Q. M@)EMC3TR59W%(O/XVU<4!'@$=_P8FK_5MN*8P<1S6P+UI.)A<05N C!:3.K MB,X]138'UQ,L*P&JV>CP\S_?O]G:?6%%=-CQA(<0%?T2-J)@#;=,*PN NA9" M301$3HYT%?(TM$"^)*5N9,E!;!C#!-(KX*)RO7)==K\^J($+'Z,369(XU_VM M>,]O8[LLR9/4H!.?:W=7=6SEQ;L358";^"&Y<2?@QJU).Y?Y83\^=''0.G1_ M+]%E85MR5I)8%7K$&1"GY)H1/!E-W-:?_Q%12T,W1B2 P UW#:%%I[C4#9_Q MI5-IN^N62OMA;#7$_W".=$,U0UWL^GP918?P27006 !.1\,'KX,/MJ-_(7XZ M&KLF@H_(?$C5Y70+?K_O' M&_]B]& [3V[UBMHOJH#IE -OVGZD^[5T63UFZR>0T0"E&U 8ZMWT:P/I)K& M2Z-3I^*. 35CR8244+T5+V'CF/)85 Z(UK MEB6;^_+G1M7@J6:B-4P46OH&^5.(#,_K,%8&-^01@(@8RR>6WN#OVB3X7'C M(6;VUND6,K1_T4?1N@TO91@&*L!"FP273B>,(N]!\K25V<&' JFH(X\7"N!% MCXIR$ZS!2X1?U-MQ,%1KXB-=\DE6K>!6;W6-%(2K>5 M!&Q8\1!!VAXYW-PWL3"($_E(H@4U,):RA_<@)WOTBF:+HCH/IVJ5 M&@XR)AZ<%/P^9JV-<7Q65KK 58=#JI*D$8*>;K?)[-P20JU,@L71) D#?6>\ MQM*)[?<6MMO+F80(BO1%%AO3(48-4OG@,2\(7+W"Y:@\%:"$E?& M@"<3!?WD3KPF]9JPQ7&0>CNJ_D-Q;EU7\*!WG8"HLCIG##:,Y/9!TX=ZX*,YA_TB/P M&/(<#@(<5W>?IUH;RI;+<.(S'F:/*.>0 K0.QSI6Q\&3NJID*\@JI>[IX]9^ M'[@G\:,$5(&0:KO9X>SRY7KN8IHT;MO#3#1@/\X]V$4V811H(O#TCGCTGKBK>MK#A\/ D"*O9X#1CVY(!#_ !-2 M\%(>!%WURMTFH\G"W:U8N=?L4LID]H2P_Z$$W&TX8UD!PQ:;K-Y"PY3V \T) M)AB$X0R9?2U1+R/*(%*P<( MLK/B%).E;T@EW).RTN/5K 2OYA5>-;G6'UO8F5NE6- 67 X'%XR0)R<5Q)IB MT?DTH"*YZS=&QW-/32&E#^':9D<4[CO,#1H,)1@;&6,*6*MKP4"2/S?&K>9< MLF,#"^:+=8EIN(7H=3E SN(#F!@"XDJ\>O- ;XODP!?DNW5'0E/P[X#WPU\+ M_9\?S_9'0[WGP]'CU_LO'@Q2D:/]]+AD^'3)T]V]I[__]W= MYP_6Q6SVWXS?0V7LWG;T6P')&DB[0*(7$SENQ-_^NX&-8>86"Z&(3.2(_.#Z M5IP.J^EQ__;X68L'EQ( %&*#''= G5>E4GEL=P OW)]JW8(G&*(\UF_#D '@ M5BGZ(%!*$B)_>+O3C0["_OY[X_8Y2?<<][Y^VYZZ5O"$0 N@8@)R]3S8..[T,3?NQ8OMYT_VH7WSROU_ M(B_FIF]CTW^>)SV?/=]^^O3)TH]WMG>7_W3U8Y_C=KO7CWVQO?_BQ:4>^S/. M&\V=6QVPJ/[KP?Z#5N7?R[W9MVA7ZO[LSFLO$5H=WWT_=JLE8#2.$/NL6X/[ M?NN[]:6$K-=T,EP)-;_SG7X@,G2CA!F?(151J[KV.\[U]F+9A?N74W,W@8'&8/OGX4#.4%EA+JV7T8X__=*B=!1._!3>#__E.. MPL5#< =L4$\G[YJ9Z>OB>EN2ZQWM_>OUNQ[@FRVRV2*WY["]P0URW>OX;3I/ M-4-#1ZK_I^1J_LSU>\5 K.%B>SYX_.SY59VZNVPP^KJXWG.X__3Q]M/=Z[GG M/^!.O-D?F_WQE_8-X2,_;GO@@?HS9H*O@5':V^UBE'X(#&E_.WI#:C-U]-L, M:L](U\K#C]8<+()=^51>F4#GTC/U>$UFZO%V]!$P["\W5LS69JR?;T6>$?1HFZ]LP2V^N@X :1/^9?7M9E,6G9NI>BZQ88$N/T[%K M^=;NTP=1$4]=+])1\M+MU.,F3W=WAD]V#ZKJ("G=,Y-W>7SZ(**AVMU[_M3-[[7?]:6:%O-+O^K9E5[U)_KT_-HONEJ'7CSX M[Z+4$@R$P$E%4UB_%%/[$7?(];[N7U$LR&EH0@1MV-I5AK.XJ@"-+ARQ *%V M/^(Z@V C>#/CK)!U+"0=9P9WG#V/,6Q][^::3K7_\Y\_! M&/[W5?_= S>^STB]_7 XVD3GE[3'^SMJCW\DC<0%4$PW2*,M-_!5/)J_K)OI M-*X6?SUVPQ\>3T$[DZ2C;L.9 =N1#H3;U.H07IR4HX;)(J&F.\L)1S1C'!%2 M !!+Y!7%UFX/P-1=IG8NAX&\TE-?;.^\6/[3FX%6KMVUFS<"+HE/Y?8EPHY7 M[-V\G/VP7$3GPLT3USHO2=AA613I,NGC'1B)U=&HWJ_>[$+Z<4.]O[N]^[V6 MSBJ[.QY_MTY1XQ)0@D+/[266TL"W7)OBW@,YI;WTZH0I]_V=W=? M[$/EQV3N#,SA)$O'[L!.1PUR%GQFIUI*+=TW3;4]W@/CMKMREU9M?T3NCO7H MKDR6,S%[&Q.SCB9FKV-BWBE[YL;$;$S,K>G:_M[&BUE+$[-W&2\F,"L!&='N M?3N[2;'V9>-(P#=Q["LUX-DMCD:4B*L"8!=+B>8RQ M_6B8LO;?+A'"^DPSD>" M@/B0%5^'0$"U658WOZS>O'UWCY;5&T#<9/=A5?W0'#$LK \'K^_1POH0#].\ MONN+ZL>:JJ/CM_=H11U5:2T*LY=95QVX_@WWZL6EH$=]\@E_.4KH,4J@7@,E M]/C)\^^!$MI_?#E>M[NS61]_C[S(#SW2X&:.M,H18#S=O=G?O=_ W?L=W+VS MFK'*3 )NMSCJD]WX[4G/27 A4G:M8+1')DA.^FC(I4M8VB[%?,A:/XYV M7^P_'O /@0F[@D+U?SKLC47? MA1X_/%:C<"5NR5OC!-Z+5-JF1^O?H^MOJ-Y*^1_7-W?/2%_>I -.]VJVW9CXW/5K_'D%V)DL G(42]_T(\\V&NQV3N>G1K>S1 MG=E1FXO=+>K;W=M:<+%[G[OWOHGKKW%^4W[B>G7RGMT)[MXJO6<3"!N2NDR[ M_/DUB] ",$YJ<-]H' MK0:")*0124;GC>_WE\%)X]?W;]Z\^T<0_/'A]@I]I&$Z@42@"P980(0>B1@C M,0;T.V4_R0-&-S$60\HF0?!>BUW0Z3,CH[% G5:GFS?+[[*SX?#H,(S@*#@) M(0QZIYV38# X/0FZI[W#HU;W^*AWU'T[.@N/3T]/6V$8M*/C7M [&;0"'+:B M8-"#:'C8.3WJ]0XUZ!,_X^$8)AA)UQ)^]L3/&V,AIF?-YN/CX\%C]X"R4;/3 M:K6;?WR]NM--&[.V,4E^+K5^&K X;]]MJML#S"%O/B!TJ;7\'# <'81TTE3. MMDZ[K;RM0B(5V"3A B?A'#L2+!#/4^#M5=^46E*:2;A^H M/X-V1[+KH79=3KKKEI^"7&X;-BSZG)\-N=P+;2CM9NMRP2:I/_.7FC'OL]YF MS"2]S-! ',*#$7UHAC1-!'MVZ1)E(OD'G\ZP!!8!\=&=-U=_;*P3PLA'9]Y< M_5&B$R<)%5I>79E=FTY),J39!7E)I>Y9GK^W,,R?(,;3J620T/^=818R&EM& ME.:4T2DP08 7GVP:8,Q@>-Y0PW8^7/^(\>! &I*W,/"7^Z"ZW90B$%\M',EE M5?Z=-[B,?PQ9:';8[RD#7[^E")=/2DWS_[K[(8Y]W9RE" M$K*!\TKZ7MY')#IOY/-LG$2?$D'$\Y=$3:IU4!M(-?U^^V7M'$L;4@F1J\Z5 M+ZQ^W]+_VBA83/8+?THTE,&A MZ[YBK*"G[*(;I.WNN_5[O'3'C6I$)P);&< MY98I*16;7)3AHU_F&OZUI[(0^!O,I'MC$$0:O#4ZEU&M ME'8WHG1)2=U)G8>/T^&71%(%6^FD5;!66GMNM"YT(#I$F99]?RWGX().I(=C MV88\P"OQ7*G#2OKA)J0OJ=RG0#4]F(\O8_JXG:>P!=E*]]%&=$M%2&O:DUQ. MQ9V@X<\QC2-@_-.?J9R,SN]NB^TJ%5;:CS>AO:CQGRC3N6A2(_H_8$XD S<% M)^2JXSL'.OS$!9$K#N".-#M!6>D\40L@PL.8\I2!_*!A%6=%8+TTDM#J^AR\ M1K1=8L)^PW$*7P&K..G$=N2I7-9*S.DJ,0H':2!41*H1"Y\IC1Y)+)<"T;6< M_;.;E(5C+,&^J$K B QBZ',.SLRXX]G8:K=6V,J>'4E:M+>2T%XE82Y;H_C>I=-I]C83Q_FTSK_ 9D.Q4 MNSXR7-&L!/56"2H@SYX7Y4MC!5^G!=,GS!*2C+CR^P;8W1@S<"2K5-3*S.$J M,SG,+/9(0B&-52,6=$9F*?@-7(>L%2%KY(]6(Y_U@PSA+9(8-8IXYO4]?G)> M$!8EK+$^-N=*>GS1XC4*\QV,U)QD@QF2*6@-NK'8GH'4=18$(QS?,!H"J$V9 MKGENB%GC;JRE-00J8-0HZK? !4M#D3+I^ 7ESLOE$D%;Y#O&NG@)!&F4&L7^ M"N3ZWSW/=6-KC(UE;R98H["ZE$)O:$Q"LM7JZARR@J+3T\->[]B@R+W*BG[) MU=1IUM]ONQ#@TN8>#V)GUK>NUIH91IVD?>"3'#YYE)E4IRPJ+;U[)405@I5; MHPBSIH1?1VJ<:^]>=/FB6BDTRC1^=?TZ,CLONGLQMRIE9<8HT\P1ZAAT2[W> MBPHW+"M!1C7'_@:@CLP5Z_I>-)4(6CDQJC[+KP7J&'_'BK[?--(+T\J:43;R M>E=01U++*O]>#%8 6.DRJDUK7R#4D9KEEP)>I)2*VN@X,4I0QEN%.M)@EJ_] MY@CKQ*UT&*60DAIX'0DQJZM>A*P5MQ)B5"!*2K1U)"2KHOI-R8HBUL";>S2T M>!UC[59WNV8CG)"_],W%9N.L95&0#B^)O!82'"^V(7\$@4F\W4+@5@RRYHE1 M@_ K$1:-?(N6S-0"2PA2?2*MY5.N\M5OBO!;"($\Z#E!/X[IH_HF MK.R&%PPB(M2*\C62R5NY-:&,VI-?0N4&H8)%:&X2DC:AS"BDK-JGU5IF7R-; MG)/ *&7Y)4$=62U]!>E'8B6$E3/7;R+MV5D)[8_V%OB1(#:&3HT2UYXA1X8Z MVV"H8V?(J'KM&7)DJ+L-AKIVAHPRV)XA"T/]"65"KS:H^DW$:-Z(#M7+Q#L( M4T;4KU%MX6'EKMBJ)Z9%!K+"8I^=[JP89\B>?#F%V7,/C,Y M+_^>,,A6A6J6#ES]Q.[JM2VDRXOT6E/'*,BM3YW"'94VVA:T4(PRS=DO#9N7 M]WFT,H[WMO$PZ-D9-BIF^X?!!EOW_#JR-ZR51:.$Y;MY;T^NE07G-L[I-LX84..ZI]*QN^X%:B3/*/)X[-6O(:]E.2S\2JQ"LC!EE MGXK-FC5D9WG+I1\OY;)61HS"3,E^S1HR4?AU!]^9FR%HY<"HX!F\7WC67SY_*/B^= M4:5.J)H=_:?)D)'^<<-@" ST@19RUL^_PF0 K('P0"8L#L5Y0^8M-/316N>- M=:T35>DJ@(YSTDZ@_D9I#G-P"+6QSK^;,6?SU2'3F M\!8>($E![7/,CF:[R8)T3W4G_A3G/T6]ADUG^==,6&=BKX!S )?OG]_#D_@@ M??JYUO.-L%XS"B)78X_#5RQF6PFNAYJG*X(')-97+BF[E@9AM9-:;830W]: MPC>/[*'9%OR.1.N:1=)*]OP;54:[C-I5$KLP[QW>0$,J^4;6Y-H5.J]NI M=JE29!=\NLR^."*['I!1 D_A6'T'(*2)=D90#OK+)>IFF#+U2'VN]O@%@+L0 MCWZWNTI8Y]C&<87(+OBT-%KD+WK5&PL+DS:Q7?#M0DXQU7%C'PD>)7*Y0D++ M(%,AL O^%(-^J\XPOQY^Y]DK>#P4P IO+F;[WV8&K7FH;(SG,:/,;@VRP^"D MUS @KO/,[,J$)M(<]KS)5*1XS-TVIB..>#ORD+6-MM/9-HNM#N$6T%WH1O]) MZ.._Z6.UGRN-=L'N?A3I-36.7[B:V@!H!]95>BM??SIE$!*M20]9>IMH2$>) MVH2YV(Y9;/<1%G_K7T)?T]^WI\ G6G_C 'G/]#[(YXL8<]ZOSI'RMKO0#709 MDH1";4/+ZQ[5OE1)[()'^6G&_9*CD9?.3>W/W%OGZ 9 6_<_NZ("GHQA4_5TIYE:UG!'AY@K,H2[D*CJ M:G6?+&FX"UTQ?R!N4IS\NY^Y:78P M !\R.HFD$0]2]0.H90A+LS,TYR6R4-[1A;.UW>W%N"_HG:'^1OR+NZ=^=<+# ML1SVWK_Y+U!+ P04 " #C@UM7Y?OT1P\> "')P$ % &)I;RTR,#(S M,#DS,%]C86PN>&ULW7U9Q+15=/>"G7.,)5=MBNVW.? M&%@.K)RB2$V2E.WY]7- 2K)V2R222G57ARQ*%/,#S@?@[/C[OW\]G#XYQG[1 MS6>_/.4_L:=/<);FN9M]_N7IGY]>@WOZ[__XV]_^_F\ __GBP]LGK^9I=8BS MY9.7/88EYB=?NN7!D^4!/OGGO/^K.PY/WD_#LLS[0X!_K/_LY?SH6]]]/E@^ M$4S(T[>=_K;_N12C4T8#+F$"Y86#&+T#Z94V3%JCC/R_GW].UGO/4@*>K0+E M(H.06(:H,!?WXF&)//3M_]].3M7Z^\_XM5+__?/#FPN/C-T<^I!_2O/#9_7WSU[.9QEG"\ST MS6(^[7*5\XLPK0/X>("X7/PY"ZO+KK#HRF>_NR@Q_++ MT_KI5>[,2U9!_9_[?/JS[R-(89I6T_6$O:77)\^H> <:#'Y=(OWI9A9/44SG MZ<*;IE6&\_[T+Z-H+TYB'>""1KB6?0F+N"; R2.>U>E]AM/EXO0GZPE? M3_;-*#9SN_VX?B51S[\AL6I:9_2:81I;F#,902KE0+$4(03TP TS08JDC$N- MA_E#4!='?8Y3S_OT9-YG[&D/?/KD"];]ZF0[W" ,?;I"MHM+\>0=SQ:KP\/U M9P*1ZO#T[TL_/VS*C.5\2(%L:$!#VI4GSU.:KV;+Q?OP+<0IGF+A:'P*Q@#7 MD79SF2V$Z!AHZ1,K+F2.H3$YKD=R%T:(Q\F(!E/?C ;OCK"G*9A]?HMT4)T. M]-LIIJ"*3S8$T)H74 $S>$0+//#,!)ILG&],A]L1W846\G'2HJ$HFM'CC_D2 M%\]G^>T\S"[SU="^):*Q(*04H%1)$)GR8+G@(3AFC,#&W+@%SEV(H1XG,5H) MH=VF069%?\T@O?5.1E8@IDQ@:,S@A=:T@T7I; S>%=9ZM[@>REW8H!\G&UI, M?C,F? I?\3(E2Y;>UW%Y;211DJQ"CUJ \\E)PUQ1PC5FP34P[L( \S@9L.ND M-Y/^Q^4\_74PG])D+G[][Q4=5A/NC;>6!D*6/^FR62GBHY3 HN3&*1.C;6U# M74710#=>':[6ZOIZM;V<'Q[U>$#F:G>,;V9DP^+;^6+Q!R[?%1+&Q""W5DH- M/K (2F@&,2H#&%V)F1NII6JO--\'XICLJQU9ETJ_[;>NS_ M+TQ7. E)T=)E":,0@%$Z R.0J-P35WP%S&,"8SJK'8=YKN9D+_@,O0 MS3#_&OH9F72+<[O4*RQ=ZNC(#L0_31N1,(5PQ1@A9C+HO%%!:%FL5KHQ#7Z, M:DQF5&-B-!9).T] G M2]F4* M[SC7[=@[GWW^A/WA*XS+/^:S=((E>5^TY@Z*IIU4"4G;:=".S-,B,R4@C"KO)?O96N<&2=;7)"?'4M :4"0B9='U7+6D M@?OH=>0Y,=DZEO #2&/2@ELQHJ44AHXRG6-LP**S3 [HX*6!E!U=8M6X(5HP%/6_M'KI1\Q^-AKP[$VY1F^\U MY4-&3Z2,1O*4P"JD]<:CAFBR)[T=E5/*%&-;,_M'7!Z-GMR> 3L*X!(1_O[L M\GR]I=>#I7J^#W6'/L!E1T\<)-WSXA/VDO)YRZ :I7T^7RSH.1.6-#,L2#"L MYEIEKL!GC57G*=H(9WPVK7UKZR?O["QCP#@ZFLFH-^!D=K1Y M.3JBE?>&MPZU7P PIL-B"\E><09N/;D#64H?ZKR]*W\N< UM(D*PQ9.U)IBF M,SCU^3,Z2%K+>Z+;^]I_-O28O#P-*-9< M%,U#1F]FQ[A85M8O)MZEZ&S)8'4@MEH,X URT 0DA%1"=*UUVFM@C"E]M $% M=IWH9A(_XQLO)B=CB66:>>*;)L5:2@3IT 3,BNSMUF*^S_*VCT>V6TWI8U)C M:K:FTBJ E4F0>E8BJ6=:@!<(OJ(K21 MRD)$EFJ(1$!PJ$%ILB1S*D[)UD?#+3[G+=+QP^* IK7^4R5T'*95&WZ^?!GZ M_AM91"=)XR9:YDD#2\I;4*1 0:CIXR63,B:X1^M:ZQQW C8^C_LVO+B2L]]< M)LW[)'S A 2,C&@RG\^J^(S,4B0)3,9:6L M!&L=,.XBG6_<*=_:?W$;GC%M MUNW(T4P"#=4)/ I=_O7K40UGGD(14F8C,((HFFPXYB.X)#48;AF9VB')YOF- MUP(9GZ.^!0MVG_-VB1L'=")?]J:D(@0/U6Z7CI#X(@B)RV3&,ZEUS)*QUOZ, MZW",SSO>0O@[SWA#M_8Q/7S>?ZNYM+;PZ&LIF?6.@Y*\@).DG#'K18RD1N8H MF[NOOS]_?&[J%K+>>H:'B+F>#H@IS90@FOF:#:28*Q!K3[?H77$"DY&AM3IX M%<7X?-(MY+WC;#>LV%PL^RXM:^K\V29SAHC^EW1F0$]WH&Q4X'16-%ZEBR;; M,)C6.9FWX1F?![L%$YI)8.^9>1^7]'4-=UXVA1?-.S'>]HBA>F=:%TV=N[QNV\F=(BM\#6M M%IK091_2\I_=\N#E:K&D6>S/PJ]U\=#_\..)QF2;G?,4X"*:').T8DJM4': R$ M5"20=FJ3YLZHT-H-?@V,,>W&8^'CC5F]6TJO94K<>C0G/JP)S\D8F3C(4DMQ MA=2UVPB"Q!)48C;$YD'V2Q!&M4^/E3^[B*T9=U[3P+O/LXTUE+Y]ZL-L06H* MSCX^^A_PN7-1;S$=.J7Q?H_3GK,4R[_\%\"G+"?98JT0Z;677?13+? M?1 #=D8W*3CY6$ \BXK8N6QCR_>+:?;M&V1%\4:?C:&<)D MZ* /7!A(RF6KM%=.MZZCO1W1F%SU8^5;0YFVZW^.RW-:8S:\!)XS&..P-MDM M$'S44(N&B^4IYN8=V2X :&,QDD1/YO0%SK!:Q0RE8CJE6OY>K>+@P9%V#!A5 MX*$&5%5KW\$-4$:5I[F]\*^JD+M/_./P&[!$FC&7('EU^M?>B3'H!!:]IBTA MTA'1OJ!G3WZ#A\VG:4W&AY=_^YKIN#$@\K".IEWE M?:6 9LM9;I=0A.M5]!N="GV8UIS??-C-NL6R#O/X3 -26?J(V8/UM/*581*\ M=G6@1I"2732&YKWU[X1L5&ZDUNP80#@MQY4 *BK1[YFA9$!I6#) 7-%4^T!0_2(K+Y M2$:E9;7FZ;7^GH6^%#LWBLC!N?W M]WC ?\RGZWXB)V&!=[/O08/G?;>@7[VBE[//[['OYOELBITIF?0% 2I'4HQ" M=N"%,L L.Q]T2.'E8O>HAN7;E9MFMI33XR7)AIU+%E,AL!G2,QJ@2Z72, M1X@ZZ\((:0ZM"ZU:W:JXK_C F&C57*8/ZQ()BX/7T_F7Q;".D*M/V8O[XP># M:^3TJ!7;]*3W_?RXHT][\>W/1:WRV;3%J)GU9-L=;WJQ.Q.C9EI!4K5;(5.\ M;D 67#8N:)&B;!Z,OCNZG2O'P[?UQ'_ =:N/3W-:";74X&"C+)'9^_& U/P7 M82VRP^H\/&F;4[+-U@D0$3GI1E*"=]Z!-O15QQ2T:MX#:TNL8XOA#T&\*]7I M^Y!KN_X%)V@)U@<\6O7I@'"]*^=NSIRH8"(Z+\&*&L[(]%UDB+7&13,K';+8 M.I#_8U2C\B#LF5F-9-6RI59"S.L<@O7M8_5B\+_$EM-$+H-L-*>DO;C_11:" MK5?:26L)EJVP.#I(& S3V7O7O/3QAZ#&E/#[ -O,[H)JY]NCH5]J+/:]TI<\OL+-OV<&]:]?Z3B>?<8/I/3]6@HF6B-.Q\:S?(QS;"Q!.%&$ UGTNM)*@;?T MG5%16\6S;M]UX^[H1N53'"_'KW$Y#B'^EAG_U^';="2YB,]JYPU/FG;'>C\F M$P)B;4_(;6$,K:!I:-WQ]>[H1N6;?/3TW%7\0]/SNK/<^'K[9V)@63UM52TN MR,E"9E+2RD$4S9@<8QI@J3A\1X1^:4 ^A5\1L-;",D("Y&&>RS2P,>!')A/2>4+2U$ )&VKEY@" XAZQ40L&PN-#\=+T[ MO#&IR ^V';817O-4@4_SM0;0X\WX%&:9A4YD859\IV:+U:+;E9[\]819RT"SY!#+J"4R!#6]]I& MPZ05CF-NW?GA#K#&U+'] 1/,[K:X% M,J;XZD",N6W%;">0 <[FCZNCHVE'0*K"<'@TG7]#&B;+SI;$&=AU=NA_08DD.;$Z:AE)JW.7X?NEK6-XDE:F^= EUKBY2Q"8(M M'#SG-F#6%DOK+(Y+$$;5>&1/U-A%"HU;S:U;B)WB0!6D4ER#]Y&!TL3+4+@! M+,PE&A8=_*VCTE=1/(:LSO:$V$D6@^CPZT*QZP8:/-.1UWL:(@^@7+WE36MES5#&#LXF4JH(^A$NN^2L5?0U@/ :G M0BL^[5MJ0Y:,O@Y=O[Z2^'<,"S)I-Q&"S3W=M;YKL0RS?/:F>:F!K/-AK67H MIHN+0.]41-KFN0W*2@>8@$:%II>C,Q>?? 'BB[#H:L9[=B*28AQ2JA?6&0Y! MZP@N8'(Y*J9U:WWDOAAWOL+ZU@CK]W!7+5CL9N]F^/\Q]!=@3#1*JUQ,('*D M#9Z,!XA"."B:*Y6"D:YY+N'NJ,?D01B4EU=NS-ZOP-O=M7Y'W,\+V38$^]-! M/U]]/GA-)T<=P<5IG)BDK:Q) ]K)&B_3J9X6!8H(#(5(.I2'XNR=!C"F[)!1 MTK<]#1Z&R17XR1@^X>R:(2 &XQ*2B294[<41.#CO)"3)=;'>%6%:AS2:#F!, M"27C97)3&NR)R>>27P+9 J)@(?-/SCNAGC,BE,3_C51F+83\&B4I>_P M'__5FM@YWG'0IK%D/0 >;?YO-\"5@,J?"0#$B4M<$U ML3?(6(\RFVU014=L?T7>#V&-22-I3Y-&XAA2G_@U]+-N]GE1>^2^QTV[R.U5 MB]L^K8&6<6>PC12.?ZYIA_GY,?;A,_ZQ.HQDW)17W715^]G6QR_>K9;KL"/A MFBBF;5110DI(IHUH(:38LL4ODU\/TQ/6KFM MP5WL(?Z]N>U)BL?SOJ_=&C:E(DFXK$5A@%CO5(Q<08S90$+'#=H:2NT]7.6N%O?YA>_SD-CM$[ &QYZ=S-=ZN;'(S3B/4^0D&J M#P:(12:(HN@BHT[!-[\M]U9$+13Q3:7:YF-/LZ'K[8Q=S6^;Y8EVQ7I3%!3' MR7@TQD)PUM-+Q;*LM\W;UH.^ ZPQ'84-67.=:MY20&WO(SD_YM/1HK0ELD*6 M!U^;!X4,D90C1&\P&>^UR*VC)#=A&56IRX D:2*+=KW-%C0Q7U[AT7S1+5]U MB[CJ%WBQZ_]I@?6Y;CE\HK@29+?F6JTOZD4G#$** 9AF3*1(AV5L':C8$NJ8 MG #TFH?@AR&=50.:T"I3P" '1@#?1.$%J6+:MB^7O@FM4 M93;[(E0+&;4LMCDF_LYGK^?]J_DJ+LMJ^CRE^:KJZQ+"YLO&[4E9O;5Q[]ZJ'E)FB-9ES MKO8052&O#UL!64FME,2B3&O%YU9 ]ZR:>:PT:2>4(6WLM[7YYPXE+1?_OH%- M?0N@1K;TV]JZ L_JHM8/?-N%V$V[Y;?3$J=7*YQD94L0+$!.)=86*0&\30)L MBNAU3(;[U@OGKMAVW3'N^IQU/L"NB8;/!!V'9YKQE>G,W.JKM"7:.RFTIPKWS[ ^RVSY]P>DQ_CZ?+0\6$Y\< M2MJ:(3M&MF_4!GP1"FI:N$1T7-G6V3W;8AV3KV)4S-M)J$U:R&SNS,$UP@]U M^M^5/Q?XG. O0S5SGJ>T.ERM7;DG99CK29X(X:+G(0$7]8K$["RXXFB+9C*G MX+*1EV/EU[:.V?+QNRZZ6Q[[ LN\QYN&G4D+0HP6;"!FJ$+GD>.T3VAI.$.> MN2NM0PS;8AV#^;XOAEU>?WN1;[,CX!:T-^(,]?:_G"%GC: 4G5=1205,D0G( M:.J":]U-\/XH1Q&@'R$%6PAU$/)=>PX65Y03B99$DH3*&=*/F)/T!9UARBO$ MUGK&CS -/>8SATN6JECK(G#)$ND /(*K[6=UU#4QWKJ,K9,6[HIM#-O[(!RZ M;2$U$];>EL]W=XI++NIL!127:KNX4.]QY87V%LZS28(7W_HZ]SN#&Y/K]<') M=']Q[8=--SA'A)59%CHJ8JU?E\+01"@!,AOMBIGDI*2P85B@3Y7NGKS!>VN>]ZZ[AVIW);,&5/U1@CK05DFP#/& ;.D310C4W9(D_BQ^4$?E%D["6]8BDULB!E- MK1,3JEX1@!$B>B3R"Z%9\<8VSR*^%L@@HWNYZOMZTYG)B,B"!D\F$RAT#%PM M+XED-C'OBA:R=8C^-CRC-V;OQ8H[K89M)#$L\_^8S]()J! T>L\]L-HC5,G( MP3N>:-MWAMOH8A9[\7M\AS1Z"[4]0[:41[L:L.O#5Q,E8M"!GEYO-:CM9FQM M06,@&^.D81EC:.W(N '*0",\-_&HD[;99M LU$N^:>*=4@YHC(DS*Q(W>QKK M_9;"WFHC&W#D2KU;4ZD,O1S.]G&I$TN)0:K7ABK&R-A2!)%6IV29MH:<6V^9 MMR,:TXZY1YIL(X_FD?1-\WA=?'&V@)15I]7&0:PGNXVJWHRMD;/[ALBOMI%N M&VV\$/SB)F;%,W@52#&Q,H)'6FFYJ& L6A8'U8-O@3:!GB=\G7KBM6 ;1 M%T]KU$^K>YP(I(3H""R&#-4N!"^R!\,D(NW'RC;O]W8+G#'L>H-R8Y?IOV,) MU,G/ZY=(3_S'W_X74$L#!!0 ( ..#6UOR(GYW6\,O:EK*NO44MFR:XR MI9&4W7?F!1:+AX1;(, &0"WUZZ_'(<$5(+'$ 4FPK"J5XI(X7_CG)\+=PY=_ M_Q_?CT<_?<7I;#@9_^UG_A?V\T\X3I,\''_^V\]_?OH5W,__XS_^[=_^_?\" M^%\O/KS]Z=4DG1[C>/[3RRF&.>:?O@WG7WZ:?\&?_FLR_LY2 9ZM N<@@))8A*LQ%"V^4TMV'CH;C?_RU_A'##'^BY8UG MW9=_^_G+?'[RUU]^^?;MVU^^Q^GH+Y/IYU\$8_*7Q6__?/[KWV_]_C?9_38G M#+]T/[WXU=EPV2_2Q_)?_M?O;S^F+W@<8#B>S<,X73Z 'I_G%__A533ZE[,? MTJ_.AG^==?_]VTD*\XZ@>Y?PT\K?J%_!XM>@?@NX ,G_\GV6?_Z/?_OIIS/) MA6F:3D;X 7C\R_GO_!)&(T+?9\/AD MA(OO?9EB68E^L>0*2E\'6S^N[K#,2]:!NO/CKF D M91B.A_6[;^G+\\^L@%JAQ>]S'&<\VV463QU-TK5?&M4];G)!RBA$''7?'9S. MX',()X./C.)/EYNO*.!PLA/AI&DC5J^@^X,ED M.A^PQ%AASD(TBM-Q1T=C,(@0+;,B!6.B"7>L;(;I+Y\G7W^A9YPMBOYRN9:[ MGGQ]-9>Z<31=K.O\9=KR;2O3R7%37N>3QN(\XXT6\?-/DVG&Z=]^9KM0?/9R MO#R=3@G8&1PRKNJB3V<#JXI#H2UXEC6H$!WX$ M8'5T.I2B3W4XTW_7T)TUU M,['>IIOO3O>;\1RG($AXOX:3@?X4 KY;CP!80QA"4EVDNB M1+ YI: =E\GMMD7??.*3)G,G\=VF4NU")5D!-8[Q\<=QG(P&I#8Q>H.@9;1T M)E@)P?D(@0>EI!3&!K$3C]<>]Z1)W%YPMQG4+5[&U]_3ES#^C'^$8QQXG@.+ M*H$4F8%2I%O>8P%"@\YEP^<% B^>-KJ,7APEE8HDR6+VY82V&XOYHH'/VE26PCS-K^NA0N3 M)E."T@5TN@6_G)R.Y],?G?JQ((354D(6SH&J\?M@R.&R++O@R+4V3C;Q9.X M\:1Y;RWDVSK@=]>!7X(E)Q M^<0#8'=+\2V)2#2(0'W S\/9?!K&\^[XY\X+QR.MS&:RZE0V$)UP@"S[$*W0 MP<<&?%Y_Z@%PNH,8E_#:(-3TDA8W#:,WXXS?_R?^&!1CBF>T'A,BITW#)(C6 M*E(\XXS3":--+4**UQ][ ,SN(L@EU.X45CJ/;/TZG*4P^O\P3%^/\RM:[R"3 M31"YD>"3([-/V0@NZ !68:)5.NN2W\U:7O'D)TUP$W$NX7BG2-/E&3%]25@^ M3Z8_!N@];1^!/.Q"IKU*U2E3DD-(GI>48TFJ-#IE+Q[ZI)G=58A+2-TIYG1Q M T6_.T 5E2B1CGHN$J@@Z7"(&B%K7F1=%ZK=;*:K3WO2-&XMMB7\[11Q6@!Y MC]/A)"^VB1"L2MH8X#Q%TBA%1X%T!6(B$YUIS'S'V.'2QQX$H]L+<@FU.T6= M%H@N3X%?Z3NS@8J.:2X$)%X#83K3"F5 B$JZG")W.;>Y:K_QX(.@=Q=A+B&X M25SJ#-.9XIVA*L4YQ;V%Q HYTMIR\-G16:\"XUJA0K9;M&+EHP^(Y&T%NH3F MG<)31P0I=[!&X?/ VB1C0$)2KWU5(%VCY=*)[RRMN#C+XI*LK@VHO?:X)TWG M]H);0F&#Z-++R?%QC7I-TC\^?@E3G+T[G=<\V7KW-)!29QTQ@D=/&TD0GOY6 M(@@1741=D)4F;NP=&)XTV8U%O"1MHD%,ZN-Q&(U>G,YHM;/9()'BQ:0<8 X" ME,@>@B,%98E[1WN,Y+J%\W/MH0? \?9"7$)J@X#4I_#]3:;U#@=\7C#X#H%H)=0GF#_*>CG&EOF9W_ MJZZ7#SSRR)759!W4RPM.UD$HQD%AV7L6;-#.-*![R:,/@.I=!;J$Y@:QJG,X M]1[ZW?33Y-MXH&@YDC85VF@B5E<]@(O9 ";RX#DM/_B&)%\^^' HWE*82PC> M*6YU#5.WUG?3]]/)U^$XX4 8[AR3"EPA.(I'LA(YN>XL,RV,H7,EM;C[6_[T MPZ%Z%[$NX7NG.->ZMEB^D]4-!TNB7S_+$-10RN"O FFH7[<4;U]A[YL0? J7=E) MT VKRA; KN)YU>V2:R$:W"@D;Z0"M]&T/ 165<'?P?QN=$UZD?5^M,!*>GK* MGJQ+ZT I8<'9HL"70N9F2$&SNRXP'S/[UWH*/"#YFXBX#]*[,'Z'Z^CWSC(: M9$[.8\(,@M8#RF0.SO$$R2FA,#LG5&M3X#:*_=M]NW)SD^K=!-NP5'P)HA<+ M1&AI+3*#TJJ0Y>,4!!T2.(8J9:4E^KL01^_(,YG?X[#:1[2=Z_C6JLAR":? MOGM_D*W7TE^[$!N45T;5 @KR(U2.O%;7>+"V.G)D&M(YT9>E?(%BUPWB:#8C MV1W%FH2>Y@-EG!=>"G!9Q%HC$B$6D8 SK9)0,1AQ5_[#-FNZCN!1^/Z;,'MS M8]A!H'WL_V'VY6B__?I\&L8T4)G1_.783K],1Q__L\P.L4!CXB$Q4+P MO&Z$.H*/)8!T.3H9(T^&M3X2U@&V?V78A;V;)T1ST?=@"G[\,IG./^'T^,WX M*\[F]368#;*V*@^X"\^3 M)K^9H!MV([E89DJU)G3V 1/2IA1'^ ?.%]A4Y"$1.-!%Y-H6,T.4]#<3>+ Y MAIQ1MS[^[\#SI)6@F: ;]C%98*MJ.:9?^4&0!IIEE9.6X+,B%U4%#M'1UA1C M-J2J*3C6VB&\^OPG3?+6@FS8VF2!Y?T43\(PO_Y^4AVEBVY6QB.&D($;S7?1-NQYL@#U;OX%IV>+7""RT>M<0LW\ MB *4EQ$"RP*,]MPG*8(M=Y5A;T/V;11/FND=A=JP-\KUQ2W )%VTL.*K%2BI6BM#^A#X;<[479L"?*Y9XR.<'I_,?[41C/R5&L3N))M13I M[[\.QS6P]1;###_4;N?ORI\S[."_P#*9(AD7I\>GHQH$>X4G4TS#+H67_M.C MX]J[\I_=EP/&BRG\;LRD_:HT__2YCU2W;+- MS:ZK*W.R(=9;HJE#('PA]R]+#\J&!#[Z ED&BTQ)'LICT>;U5_4L5;HGTENV M^;DPM$M8OHK0N%@Y>&1M3>U$ MW;(IT +=;Y-)_C8 6R0(6)=%B(P>A4'-/_BUI;&/.%\]^TO1N M)<"6K7\N U'S,/X\C*,SS9K]@?/7W]/HM);F7H ,B0MAT4)&E*!,I'W'9M(^ MI3$670*FUJE=Z^!ZTAK07/ M>P@M0+Z=C#_?O(PJL=C0G3\JJ=J(64,(,8!$ MQH4S6(JXJS!G&V58 N-)<[^K6%NV&UH2P!KX@(PICI"R-02H!'#:()C(M<_1 MF:1;4WSE\4^:VFW%V++-T/5E#0HKT0I3L\H$P3"$P*LB(#+2+*[(&8IW5<=N M'_I[TD1N(;R6G80NMHIAB,,1B0UGY UT68A?)B/Z\%GU+^8_+M<:-*V&;$!N M:X)QT0A1&PTZ2.N]]$*XUF?TNMB>?&Y6+R3TD)6SN#I^'W[4>^.+BPBN%=>< M0T%+J!QM1LXJ =*9HH1+F36?3[8".E 5:4M&#SE>?TSF MW?K?3L+XIB+G(%')[""Y.CR'DT7C:,,$S0DQ#U*$TCJY]PXX!ZHAK0CH(?7K M4_B.MSJ"[L*O(?,K^OQ MR(44%I,/!S7ZZ*WUP*.0-2!9(#@3P7AI.%.&)6R=^GLWH@/5C(8T])!)UCF_ M2\XV7NK=1+:0NRE!%LF)![R#1;@JBXI',= M)F-=[3R3G8&818$DBC3>D7Z6'MW4P]:"'<7=0P[:(M#Y"N/\C\DXG:-B.CB> M<@%DF&B1B322R4*N.3<\Z5!C,SV%D*\C.51%V%WL/22NO<*"!"37:5/'2#;. M%5G4-.B(F:EH.1U9H0NU6? Q"# EJ)"=%D&VODN\!]*!JD=+(GI( UMAXUQ1 MY,*90%:2-^/M(5[J":D!&,'HI,V#P MNMZDTQ));R%GEZ,506766A6N//Y N=]6P'VD)-VQ1!-,4"QQ*%G4(:;,@2O2 MUFI:TDG"75)K[A_39=A>5*&1^/M(<;HR?>"L=KX8YDLMQRFNE%I$*<'SX $] M)FX41HW]-"VZQ/ 05Z)M"%K:SV9+X?9Q!9IS)\@P>A^&9.&^#"?#>1@-BA0R M:]3 5J=K)SZ%G%P52ZZ*+=&'7(0-O/7&?QO%83*_N8![N*3Z@'.2!^;7 M83HFEW5VK:RB#-.PBX$1#I^!S!E6N]W3@IV2$+U/7F!V++;> ^Y'=3 JT9B M'JZHKB#J/-?:8GN*7VJGSZ]X%A![.YG5,-B[\BE\'R3-4B"'%:SPEJ2A&?C: M?\=K(XV,P47L(7=J$X@'HSQ]4M/#Y=9M*0P"3Z3&Z,![S6O%/ZU>*0,\V! M M-*#'$QA62;0+&10PGIPB &8"5;+[)4W^T[" M/1AU:"K\'JZW;C1_CS(663/%LZ0_R NJ/=O(&<9H>%99.&E:UU \FB$)N^1: M[R#&QS\D@2Q@+VP=KB0[P90$@99'KT-T4AFF;7,/]+$/2=B(X+6')&PBZ/VT MQU\'T;,=DK 17??WR=]&UOO1 I-M';EE($?1Q<8\G7V,0_ 2LRI:.W_7"/#' MS/[60Q(:D[^)B/Q^AB2PI*35-@*J:H-&1XBDTI %3\B%*"4W?[\?YY"$1E1O(]B&;W4< M3B[BG-=5CUE9C$ZU_6H"Q0T#K\@ XHEYST0)Y*9>)_K6((15G_UDZ6LBK/W< M")T#LYSX"$: 88J.'K((: /1C+YDQCB;C,?63MI*,$^6]K9B[OLFZ!HPE-YF M^@>LK,.L%B4\>I];E\.UG^ER)9?C[ KW MS6QVBGE@O-92Z@ E8&U-(A'(35<@_!>5V=S*.E*9J2AB'7@C"\,(AWG@(49)K/QSK2N\'Q4R3--5:"-F'LP ME8]&H\FW>I;^.IF^FIS&>3D=W1Y(<5%=YGVR"A/D.J]."=JUG"6G3!86A4*K M;&C=\7$C@$]>3_JCHP[W!58Q0%"0H77C\D>@9+'H",%D<@PMCW6PO07&A;?.D=OH>C.;'_J2=!>N M=Q#C0U^2SJ;S2_@?$X[#=#CI[@&T*BK);(FS8FOW^0+.2UI%$E([#$&JM6*G M](0KBD!?72K!RH<_DLO0C8B8U@&UR3WH M?6RO K+?*]!&)$WZDO#>Z#>.6\\Q@,DIDGUK;>U@4ZO1K14FNDS.SM.C?<7= MYSY9WT2P?0P$77F]:Y)RJ@0%3GNR.,@6!>]D@1R8;; M"KH'UW'9;<(:B)YMSLM&=*V1]K"%K/>3\Y*YYD[G6O==VTDXP\^ZUY7$N+,^ M*=F\_/;1Y[PT)G\3$>\GYT7)$KUEM>F4I4,(ZSC+3+!DL2I$$7QIWN?ID>:\ M;,3-_3DOFPAV/SDO3@EM9-; 10T[:2_I7&,2,"//==P2;^[$/]*2\L"*LJNGZUD53\5CP4B.4['U00@5QLQ;J:>6\;$-?$V&MM,9ZSP:X.*%F MDW)68O7G.)SF(?VH53K 78_H*1]@[57UEQ!@&>MJ78!S.MN5"T0_KPUPA%), MZQQ*:GUGWCXAX -^Q?$I_DHO#XFW*^'YK^'\R\O3V9QD.KV85U-G)=#_**X]_ M\B1O*\H>(C\?<32J4\MPC-,PJD,K\S&)L]9\SH=?\?7WDWI"#R1I6O91@+") M5Y_70E1D&R6T1M&/HA.MRR#60[9_7=B:O)O!P/:2[^&M_X SI ^LM].OZ-@: M3;JQJ MPPFI1E(W I8Z_4S32U#W)24DUY+>BMBZ,].=@)ZN-K23\ -X#W]%6C+RYZ. =^#]-_X+Q>@W[$=#KM^GG\.9YB& W_ MB7D!=R!"*2$*!=G7YC[&!W"(7)#)FW,!D7S@4-W(GKZ>M%0XCUDCEXN M2Y%";C\RWN8J@!SEY_)S^(GC\&@;^@?,K"PST M9)WK.%AC2VV%5LCADP5*(F"&"R52ZTX1UP \>:]W>W'V<#HM&IZ^QVE7R/4B MS(;IHNU=*8G43G$0VM1L3]+C*)P HTLV3!DM=.L,J#L!/7GNVXF[ARU^*;A! MD!YEH'VG-L('I7@ ^@8'FX/2R7@7UJMNV%4']L]]0[+648.-)-U#7.2_R!/_ M,L=\])5.M<_XQVF5SKMRJ]3W#*SD@6F9)403.9U)Y(T[EAPHJ8/R&HO(K?,$ M-@)X2.K2'S,]Q$ENBN'5<'1:L2\$0:B$4V3"."?(F$FUC[8LF>22/88021"M M R3W0#JX4V47D?=@/ZZ -R@Z6E?(F4FTOCH9FE36N@3H9$U;TV0IM]Y"5D!Y M^,UB)\K64X>-Y+V_\^4V.$LD6LHLUAYBEH#>B9GO4:P+R> PO H7DK2-E M&T(\++7IDY\^DC=NM..MCC#R#"[0J:IR,>1W>PXI!_I.C!QC:S/UT51D[W)V M["#&QUN1[:(*)ID(2.856=(U"%/S!G(*+*G,2Q1K7=L]X8KLC8B\MR)[$X'N MK21W'5#/J2)[(Y+6JLW=1L+[*\AGJEA6& @T-7(F1.TXA&!5G:*"3ANWUC#E MQT7[QA79[5G?1+ KV=YK!?"5/7ML> <$]A$E6K:K.(1QC/K\3?C^B M)=P&_WXR[58UGT^'\;3+E?HT.6LL/ A=JHO*(&O]OBHUC/T&RKOK6@Y6>?=* AI] M=5:WO'1S7I'2IZ7*,;':^LS1TA*>TCA MN1$$YDD[9R6KW?H"J) 9F;+:U5E$3$5K@U 'VZ9V%ZW808R/^%(D&&]=\L!X M;<"D:0<--@9@18?@+;/!K%6T^(0O138B\OY+D0T$NK]+D35 /:M+D4U(6N]2 M9 L)[XU^Z8TI2A7@JHX71%W T[%#&NY\"3DCRB:]J!_[I4ASUC<1[".Y% FS M+[^.)M]F_5Z%W'[*/BY [EE;C]<>(@;KD$%1+M3N]Q)BHL-$1$/NJPO68F]= M@5M>>U0)OI].O@Y)2B]^_$FR?C.^J&D.").\K2[!&T1NBZ%WQQ7B(:(3R]6QUK4?I MW /I\/6D(24]W!LLXB?OP["&@P?>.\F#*(!1*2"+2T"H%QI)%$Y?2,MSZ\C8 M#0@'KQ&[B+R7QCL7)=$+1%%J5V(W8\#6MH_8)3-;""8ZFVPQ9;V Q49*+S1RRY184"W76<\S 8R[,QV10M+9'U\%U M\.K2G)R&4?#:TWIQT)7)].0<:I49??#P:]=;<#@F*9R>^9$+Z.$2NE1D'9E$ M+K[2 I3UM7K..[",9<>XR;0;WN,S-X!QL&JT;XKZ:8>PIJ0&)(!B;JN4[4FEWHR_DH&V7#!,A9*<-F C MJQ%.Y."38!"C9O0>*)UC:PMYM0>5YS.!)*,#61AG9N MT3Y_90U8STJ+6E#30[CHUNYY)HON>P-KM;-6(42G/.V2WM#:R4O0C"/:5%1[ MV^@N/(>O+ZW(Z#F8]'N8GVM4I;*MK[U;0+\\%5O[_3VD+5Y^]1>C?45 M1I(8)]'R3%MND9P,PMH*6WH/V3#M#&(*MG5KE$TQ/BO-:TY:#V&KQ29-X.CU M^#JJ)J-LJY9IZ?+0C=H46 M;V:STS!.6&>_S0996N31D[XG5GOW&TX'<PXS7B\-?&M 0D]A[H7&^"[ &V&&12S"CQW%GA, M62A7G&P^\?5>4 >O+FUIZ2.8?:[-'W!42Q4^33Z%[W6L\9>S0OCJ$)ZWA*XU M#<=UND/7?H3T'17/PH()]=A&^B,6'L @Z3H:&TQN;O!LB?7PM6P?)/88"R> MM*^>3M,70GC]]U!.U!F:9")J;K)$+:QKWFKY?E3/1J$:$=-# M='Q]@0RB2X:'4B"$.N U*H1@+()VF$201OGF.]7ZZ Y>E7HBJH\I(K3E)?(? M7W\G=1]_Q@^TE[X;5_#UGWK]_#6,SK99DLLPT4Y;?W TSM>_<>4W!U(7+#ZY MFD]:ARK%"!&S(*O0)6X$>2FR=6.^'I;QY)V]AZ:VA[-S-_ V>Q-4T"!LJ8VW M4[4_LZ/3WX3@6$#N6CL#SUL#]T=7'^V#SO#=0'5$&_MT^H/V\/\,HU,<"#1< M216!ZSJ^U',)/M=RK&"-SDFKF%KWEUP+V$'H3EOQ]W!Z7E?>L_:5\P%*CHS6 M#8F1EZ&R)RLQY !!*9F]\C[)W%@GE@)Y\CJPNWA[N)F]#JHVECK'Y;C3HD0. MKBA#^Q5S$ K2 5E2",D80=9DK[1?8CDPYK<4<@_WK+N=:(B2>8L.O&58;?T$ M48<$0I6L26NE6*_=R\,8('N6UEFWR3?C-$7RPU_AV;\OVKQ=M6K/+-T!R[*P M8C20XT;>NKD%OM#-+3/G@>884 MZ]9EBP#/R=W7(4?',:6L6U]Q/I[V?CLHS0YB?+SM_2(YTII;"3+4(A$AZ5 0 M7 "7P3 LS*%KTOGK$;?WVXC(>]O[;2+0O?5W6P?4K[L_JE>3.)U5 MFV;^X^*GUX&VZ?-WU^/VT/!O[=7VU_F/H]2:T>DBL/I:F!"K.VWK;J_'?;V+TMV0^3T>C7R?1;F.9!0IZSX@5X]KP6"2H@)]."]EH(QP+C MO'4T0ZK.N$46))_+=ZSS)*&JK08XD"%+>%%$YQ!P+ M:QVSW!'R82O7/OGLX0:_$TQ-"B5;_LI0H>XV[P_\UOUD-L"LBR4@$'*H,TVE M H^"3NDK^X!I\OF,Q;,KY1)-SC8Z,+1!@_)10$22 M(+<^,VY06-$ZBYWGQY.KW.P5H;%$AIJO1TALA*@924Q9!C M<.U;0SV^*H=]ZEQ;3GK(4OA417 Z_=&!^8##;E<_FK^=?,/IIR]A?)GA_'Y* MFC\P 9ES)@'7.8/*CMP3[LD]T8D[I5BTJG4YU880#UNA^N2KASR(:W"[7?*\ METRN!:B_X_S+) \PL9 XTQ"8(HR!,0A&)&!D(QA7C%:E=1N6=7 ](T5JP4P/ MI>7+PB,N.HFT7097ZE5]2>#0&?!,TP^8I&6W;@)U7U"JK7.S] 4?"*'KA*( M@MPQ4"0$<%R3-R8Y.C*P-4N]+'L3D$\^9-LO+3T$ZVY( MU. \-W5*M,]1!WH_6D?U'TWBR&Z\;RW&ATXP[YP ]-BUMT: MH#9),ME &Y8"VF^R20_$W:RC:B;UO:E$R&3A*59 8]"U=K%VHRH68G)&(\@05*"=Q'MX\Z_Y+F?*>@[,9X/1(JW6E#K1QTGPL6C0(B'W M-B9LWHE[)9A#4(,VDNZE/=:>9+,GS:M;Y9E1)P#C23VQ.,D!#(VJ&U M>[)X@F'@0E0!74'5?##?VN .03_Z8:*'J_/5NUA4UA?!/:126XU*Z0BB%)"D M\2I(R3)K7;IZSWG1,CG[B+\(L^%L4MY/<4:<=W>_89S_G.&DO)[-A\?$W>S= M]',8#__9_? RK_GL-Z_^AY-RWL8EC"Y3GE_5/6(TVR*5>X_@=D_\?BA)-DH3 M_P._T!DDF!M#()Y2UYXZQ9 6\!\B#Y4^]3 MVY9,OTSVX/+62\MWY;?))-?9$.=Y.K./DU$>")E3*9I.ZF[88(D>G#$)2$!6 M6ZXB06P>YEB%YKFI4B->>O"*7V'!Z13SN;(/+*>E>"/!\>ZNNTZWU750,H^\ M.%&L;MXH^ :$YZ8;NS"P!Q_YBKU.2(=I.!\HE85CHO;?(W!*U%932I-#)Y0V MELQN>^FH8_R($I$7RD_2]Y4GZ AH*YIR=8&;P*A:YWK^QBJ]QY6 M;7;DH6%2>)W(?GZN'HVZ7R.QO\=IJMD/D[RXZT1<#/22!K[B]&IC:*2V7"-[5FXL@#7BI M.# 5"QVOR?O2OL1E*93GHC0M&>DAG?LCCNA'GW_#,4[#B!RZHWQ,3-1.V',Z M&%]_KR4S.&!:FB*3 ,DQ@"*+"WR1#*(FF M'KLPL"2JMW,@N'/7_B AG&#=Y,:?S[RU!3SE,9>2%&#HFH6[ -'%#%(GPU,T M*$KK*-_=B)Z;OC3D9XGZM(X*7_22MI[+1+8YQYK!E4JUNX( *U%9EYUQIG5W MB^5(GINZ-.!CB9KL'"O>5BAGA02L'"A-CH#S MR*%8S"ERP9)>JQQWW9:S-P$\5'70'OE?UJ5V)QY:MRH]TZ^KD,X3X-8!U;)3 M[2H@#]BI=C>B)GU)>6\J8 U&+XV&T%W3UJIS;[@#G602*ED93)-NM?NE?IUN MM7M@?A/A-F;\]>F4C/)%"JJF_]6[K&)K+UYF:[ZZLU!\-%D853"UZ#M^]9G[ M,VT;4C!I(+^&Z5 5Q]%L&-Z'V@03JWH\:2BUEX,*Y%1YJR5$JW-@(1B4 M:Z4MW$/FK0<_=49WDV3#U[.S.:8_!G]^K"G8,:0<:@51[;E\YXRA5M*K6%J4:=$QSBEA2S*0;B5 MT?NB0&@ER4Z,!;R6!42*Q0:1>0IKE=S<]RY>>^I39G%'&:Y,[VE9.?!K&$Z[ M-B&_=\4*N^;ZW_EQNV?GKX^V43[]Q0-KPO"\)H*^'88X''63;<]!Y'?C#UBG M=]6\XG'^8S*>+K[L:@DN?7QDM61*ZMI84M:65@5B]!R2QVP$*U[<3%?8.7K2 M= %M2OD_U@_OGO_KUS^&?]+#PFCX3\R_U?=,R2@P.$4NJ":[M$XGIO?,=SVE ME7 Z.VS=\.-^5/L/73ZD%\(Z1\Y02N&(+)&>*\=Z4%-NG6=^-Z3DK5E.^>DC<7[:Y#CCW5GD5 M@<542U7IC\AY )Y3-*4(P\(^CL#GK#<[\])#:OXGLH1IE9>@!IEYCI@+&%$3 M=#$)\N9)>6W-W(VV2-%\ - M$,]92W9CI(_.\5_)$:IW.K].IA_I$+U$]@KC M_ I.@053)A^6VSJJQ>@,/A%LINF Y59(:9J7;:R)[3DK5"_\]="OG>#A\//X M+*4A_5A4VG;R6V:UV12#\=J#M#S5S"I&KT508*UTTFGZB6[=?&%#B,]9Z_ID MLX^4_TY>RX ICLXH03>:229^$"N@G1,MNY-O W.YZQPO?/:0^G MB],9K7TV>SDYCL/QHI-,3<\A'[7VE!GF+LVT1LC/5S'0&).N]_76< 4J%@9. M, 4L%*]9RLHV;WJZ!C>@YJU=#KEI6,-2"TS+\.3D[.2T? 9!X:9X*-) MD(KJ:BL$>&0,N%$R)NNU2#>Z2BTMU+WS(<]1,=I*OH^RA L9O3OI=L,N&W7V M9GSQ_7J%5#L2\(%6D7FE(YCD':@D! 2I),CLM&$IQN1;;S7KHWN.VM4SAWV4 M-]PP!3]-PWA&IB"A7F#\<'YU.= :$X\Q *IJ]J68P6?,H#WCF@?!-6M=4+4^ MNF>M;OUPN$3==@[*WW@SWDX(ZM]QE(]FYU*,L\X5&?B8/*Y?:MX_G#S@['54GM.N+N?@Q_7>GQYW: MSP;961.MD&!)FZ$V, 0?+;FD/@N13%#DB?81.MT-]G-6PGVSOD1S=P[EO\+I M\&O7S^-\+N2B)/]#F./ B82*.0$N5E/21@[!D3>+.:E2E"AYO6J^C?:X.P ] M9VUKQ]02/=HYKG_I ;\C#SA?IB<>G9R0-(9=P.T57O[]#WIU%B>[]*P8GSPP MZ45]"0PX0E_K]J61BEGE6M^%[X+W.6OAWGA>HJ1;!_QKB.9,?%= ?AA^_C*? MU05TD]C_N>9B!B8S%7R)(%(W%#D4<"4J0*,RN4"VN'QC3UP:1VN%YSDJXX/Q MN40I=P[^WYW=75WM 2=D"ID&LG,)(M,2O"!+03LI=53.6]$Z3'(_JN>H>#UQ MMB2M=>>4_/6OP8ZFTVJ8=HFY%YT*CFOYV[MRW\T9'[A";XG)'HJ39'B@)P-6 M1P=<,5-?K*A*ZX*:/2WM.2OX8]2>)6])NZN1'21^UL(C!AX%DQ("3[QF,!CP MF:R<[(0V1DCA^[LYV17\OEKT/![]?AC>'[IUS\7;'49AG/#C%\3YV_/FPEU+ M"L]]\:6&\7VJ@]!S#;$:#XA&.Z7(C]2M>_:NPO)0C7P>2#-N[K\M&.JA^FH9 MKO/R['60]30A?#6JAQD3WH:]-51B!]'O63F$C(&Y5.OM+2AIJNZ2$*HD;9+0S6-^]V':O\'?BK\5;5*;"+^'<'E\I"5T,O-6> MFQPX>-_-0LD9O"D&C)$8?$"O;?/)(RO1'(Q"-!)X7_O$;53>YQR]3E!B5*!< M<4!6/8.8I F2>;2A]67HLKO<&'J-V@>SJ-6+LJY_PY&EM*, >"J4O1NZ^&1/$TPJLLW6RSX$5X4G' M4JS%N1XBAD([#BV?#A^%KO5]\@HHS]N];,%/#[T8NC3#@M/+:9^TY'=E"=K9 M)_K(V?(?G;]5ZZRE)W^TY3H>QH-MHB"W:_4?EMT>S)>F:T(3M_K1*^HFI/:@H.>)W+]-ON)T7''5S,F%D9!< MD-D[D"$(4,K7 #H=8]X&SU4.D9N>RFJ7P=F_2?9P/"_/MM^9I!Y<]=]/QR26 MDS!Z,1GGA=,0>;*&FP#6!4:F1\P0R%LD@[44QI)WBK=VTI?A>,8:LS,M^]IJ M+G,DSD$6GID5D?19* _*U";(@=3;F>C0*C32MY[(MA:P9ZQ,[8GKP3=X.9F> M3*9ACDO!<=H'F2P,O//D##G#:Q$2ASK\E#-A),/6M^]W GK&VM2.J!X"$W]^ M_#3MG.P?)*9+A5_$0BU!X)E4'),&964"IUPF&Y);LAB]U+RU070GH&>L1>V( MZJ/)6XW=O CI'YAO*;BR/HHZ>0XEDKT6L/;DE;7ZEME@3<#4OJ_;:CC/6(-: MD=1#\[;ES78[OY66Z*7'VMK>U'B\C]7<+V"%1;3>BW0SN[RG_LC_"I(V8JF' M4^PR\+\C_61F>_[XW8C8\) MR0TI-4M#9%^CJQHT>2@"DPW,-Y]:E\_RS0YE$J3 MHTI_N%(X9&ZLC4(Q(UL?/8_C1N3!=&-G&OI(>UHKD.ZRB:P(LM:<$G7,./FD MHH[20:=M4"P;W;Q2[''>@#R8\K0GJHXQE)@C M&.\(E;:RUJM'$(YP^:"Y":VS1)8C>4;ZTH"*'L*(OT_&^./W,/T'SG\]O=P$ MN4*CM7$0O3>@C KD''()07N!#(4MS2LKEB-Y1@K2@(H>YC2L6B-'E4?XN,S8+4CI8:3!Q17>BQ]7!D7_.L7_/JT-A;LH=FW\($,";M M065NXGK 1F:M"%U#879BHX=;QRLOS<5?_S[$*3WDRX^W^!5'W7LC5>:I5#LM M"SJL@TW@+"($9[0H 059A/T907<@^Y<=U)B]/J; +GL/;N,]?^/6 ;M'HV@E MT O/I'DZW MUK>?'H=J;<)2GRKU9GQR.I]U$N"+VWVK=.#!0$G,@!))G/5W1">9\SP6*ULG MY-P!YW&83HV(7*4R.[+0I^UT!9I8!+92]"ZJ @Q- 56JW4A0P9LLG=-<,--\ MDOEJ.,]-0;9A84\[B%SH;DPE^VP!K6:DN[4OK"$WP ;A->?5(MR'@LCGJ2#; ML-!#EM9E1Z1:9=0=KU8Q2<0ID$5;4EG4X"5]F91 C4G$9%K/?[N-XGE[53NR MTL,5^75$+\,*=:-".AAW-G#:3) M)B65E2!12=I0+=+[8044)/.=*>NM[&^8T7[5Y!ZW9_]:LHGL&VI';<;W;IJ' MXS#]\9^3.O+@XY247UGGC!.@L7KR&R,3#!E"%SR=:F&!C)#+8!N#(IR4@& MD'9K4+O\TP^*U@8"[&4_3Y-C_#BGE=95O[W:F)N;J$R]-0ADY)"AHR/X("VY M.-)E&5,.HKV]N!+. <>D//TQLW*_^?=?;LCM+7W9_:#[ M?I7+!RP_U7__^>'-A0R_??OVE^J"3$/^"TGCETY^2R/&KW >AB/:=Z]#F0V/ M3T9XCT]SSP?^9D"]C>>]&):Y$#R( P+&E+)&E0=DN1C>TZX?$6H M<\TSX;65J\JB=EWUHKGQ]D0F@/:D$YM(O*_)?G<-H308E9#:@N!9DN&'=0:A M? N5DEKWGK(_%NK]FP-B/\J#]Z1VFV*/+?@Y8'*@SVW MK@1Z@83C"90(":)(M$_G$F4R6J6\CT*7IU(>W+?F;$+'0Y4'9Q6EJ(T)Z1@G M9,G6@15% 2_6<6\=B:>W ^W)E0=O1.@VY<&;L+'2 MK;+8QH?0LC^KZ%N8&X MT2W,*YP.OW:7:I7M9#9[-SYO^?2R\^MHL[P ?&5X#F%_A3/ZK3#'?#3[ M.^;/M.U=^85!C*QV41:@G KT!SD#P=*:2G')";31Q=;I)(V7<$A:]Y#L]F + M7:(^\S>3[#*S"_A$+Y#":" Z&0$#R25*9ZUNW>'B!H1]W6[M8V/:7*:/Y>5^K, MCO+N=8^H^0'3D+J"@T7CBS6P]12=N0O7PX1EVK&X4CT:4;!O-3'&QFQ9 ->E MT8E@Z2TQB;97G[4*3MCFXW[VKQ[WA%X>1CLVD7SC,CNRD+Z%:2YGAA)^3U_" M^#.FC_K1HO;F_NS+4 MQUS#&X*X/L3HZ'@RG0__B?GE9#;OKO\'06A9HE:07.W1R] !2_"F='I\.JI1R-^FD]GLS_$4PZ@NH,8S7W1'^*?P M?<"LL,8+!\R56O;M-"TBD\280X8%M<#6VU@3X,]8$WM@MH=$GVT744/MEXN0 M3FKN4P)>LQ/()580<]W(>0HL1).T:UTFV03XO]2S);,]#(-<+:3KRQE$Y0W* MH*!PU"0IRR$XQZ PE0VW20C6.HZU+K;GI&1-^.EAW,D-Y;^!^NR:P&3E,2@% MUM8:NGKCYVIJB\R%F<1LLJ'][ );!ZDJISQX0P:=Q^BCSBZ:V+I,Z"DG6O>M.9O0\6")UG4L M,Y*IKZ0F&2 /X%+F$)UP(0;EA-S'Z*ZGD6B]$:%;)5IOP$8/4=*599>1:U5R M(32"2U""U^',Z("\0Y&13,%26J?C/[92][ZMF":R[R%T=$?5Y3K(GGL1^T;L MK5^PO(WH]UO$;K,I+J0$*;L"RB=Z%W0P8!)Z BY2SOR)*\6V1>P]Z<0F$N]! M%SY^F4SGGW!Z?-D9>5%!+5+0=)A)B$QSVA=-@A"+ Q-R],I'&V-K75B-YE$5 MKF_$VFT$WH,=T974WT85"^>,D>44LQ)DW8A$YA.!=$$P+Z(,1;5NY+8< MR<&H0 -!]^%X#,>TV&$8729:=OL>[6XV6&&A*$P$RV5P=>(ZVKL^4Z'BB@UD)!)H^,W1ZVL*9KDL8S%:,#[[BMO?<$>&\3D*]OG7C*9AOF-"_^%_8=%>^,.G''* M26T8UZ9U/N1=@/9O<#TL?))W?)E]Q.J[+ M790;Q,Q<\ $PBT!.C.<0>5"@HT@9ZP\[8CJH^/86;'*):RE MNR+C*O&B)" C/TCYK"#:4""Z:*-*16656CN*ZP![QEK5GK@>_,RE(!>*;U&A M9P68,;6+8Q$0E=601!;:H*.3MK41?@>3'_Z"(EMH1BG.C%,7PG)O'L&^CV/FJ;O&)Y],FR2+4C+S.Q 5Y%MPS<*)H*#P8%SW+);?. M ;J.8&_9S[OQ>>L";GLQ/J5L9H76B6K**1T9J%@GT$9C #GW.?*H>.XMJ_#Q M93/O0OH6BAXJ,1ESH-#P6G/-BZ!2AK!6^]!AQ@PA>*S MZ&V$V)-+7-Z(T&T2ES=A8Y^)R\P6%@J2><>D <4X_4TK!\4%YI7ESF/KB[#' MEKC4^^#'A.$R'DVZ=6GKDR2L009$I)#@R48U" MGKDKV<2U?(7'1?N*K7V?K&\BV(?O,GDCYWWW+I.J[RZ3-Q WNM:X##%<.:A_ MFTY.3\BAN[BUN]"AE^&DKNI*7Y"8Z+RN!059IPA*&0F>V0PA*\U)P[0.K1M! M[8IYEY:XEP46DV]CG,Z^#$_J:4M?A\^U[WS.1IH(6=0Y$M;6NTQ)PI A6N5X MTF&=9LEW/N0!HPK[T)&K;6_;";N'.,.;\1RG!.\#)AQ^K=;3V?R1^2 [EJ+G M""P)!ZHVSW*<&RC!*V$LPST9:VI/3@>5ZJ\CM2Y7PAFT!HR1/2 MV58P"6OS"9/H'#;2@U3D%:6,3-G6\$UC)&'D1/NG2ND!@/60//G"ZF4*LUKA6 MQ.SKWNXVWD7$8 VP>TP;6 GTP1,(FC&^SL5>4[H>7,=*3H8Y(:!@[0H>>6UE M&3VDPEQMUR1=\X;:CT"WUL\P>!RJM0E+?:K4F_')Z7S624"3(?_[*XV MSY5T'80]V3/WHWL8(V97'N]4BV8D]!KY68DT/2@K.;@M:P3(5*P MJA@56.N*V8=2DWOLD?UKR2:R;Z@=-;S];IJ'XS#]\9^3.6V59P&G1?&DC*%P M%J 8QFL.G:V-H#(M6OL00D+-;IPI2R\25C]A_^9#:RXFS079T%RHJ-X3+UCG M\.$U1-%B#)XIL,5@[?&5P,F00 A.RBV="+JL0>WR3S\H6AL(<"\7S;]-)OG; M<$363^Z:L+T_G\:8WXSG8?QY2"905ZBX0]W>QH_8_3)ZMU4UNIY>@+@,U@9? MM..95,@*4J:<'42G$4)R7'-9,*?6_0!N@=C5)%A\8%?8. @H&#-D'3O6'7"& MK&/#(@3KE25=5SRTGA!Q#<#^]XS=6+UYR&\OS1[\PP68-\Q; M7V:!#%'!YRK@,P'6T1KHV]M<(>B$FU9Z,$Y6 =F*!2 M;<4*6&HM3PB:U%8Z$,AC8$9&;EL'EQ;//A2R-Y)A#W&!!8ZC]-^G5>E>G=:B MF/7D^C+MKFC'J[.(Z#[+;?8PQC 4IP2HAR#NQ%D)T&:R61K!8G.6MD^?6 M1WU",3!B%AE*+,!0*10Z/3[7.4Z9L M4;O4NNC^;D2'HAD-Y+VR\+G&=1=!>$-'6=AA045+57(C<>9(P8I(G( M=?/6',NA["NSIRWK+>3Z6+)S+K*97IS.2#BSV<>SSYUU(5.?4TXR,TC!DE%K M?8:HR"YB*B9+.YVSS;MTW GHP8J;6C"^JM'+SI+O8^[&&99%I?<:8'JZA;H& MY&$NG!H2=5,%=I9R[]1;%WUD40+]0P:-4-7Z5728L2 4^4+D\K8>TK4'RN^Y M/-H7XYL(M_&5T4OZYC"%T:MA^#R>S.;#=-$]6CJK?% $Q6L")<2P 5Y(Y M@[3PM,Z-T#%LGH- (DU[2HF#2! MR1Z$1EIPX$6H=2J';GWP4Z5M-PD]RFN?P8W@4R\7/P/^ %<_-U?6Z/)G$=SY MM:X!WPZ_W@9PZ1D8'8Q4D?P!QLBFXXF!#Y*!%LH*#/4;K>^%-L'78([2JF=\ MP/JF#<>?CXXGT_GYU>N9:\L'!9-0-0@:3*3W+Y#K%+P3X+@S5K&<66G>/GL[ MJ/O?J7K3KR6CF'HGK\>[K*5!5AT52\4+8+[Z4$P$PD9_L\[7T)EQG+<>X/:X M MI[TYYF-/21+[UZ\7_@_"C.YM.0YF1[^U"DXQ*T2[) MYA5J:R$[8+7I@9H^"AQ7HSR[SV=:.6T5@LF>W+9,!GJP,0%RR2KTR%7S_@+W M8'J U/L>N%Q?738G8K\[S97;_:NG*+T]+!9-+D+1&,GC-T@>@V&0T'MZJ1!S M:)UAL3G*YZ9,+W/G8B> MF]IL2D(/]_I'^7^?GF6Z_CJ97M7=B[77P[J4$ !K>SPEE"!CK Y=YD($J6G] M#EO[H/>!.DA%:4M%']-CKF!Z5VZ*8<"R3<;* BD5.DNU$>"=+N UEIBD]$:T M-FKN1O0 =G!;"F\J2#OY]U(2="[AY6_)Z^]I=)K)Q[O(;$.6LL].0* E, MRNC)\I*EN7&\#JZ#5J/&M/1P;BUU_6ZC9%$:[;4!=-585UG3ULSI;\PS1G]Q MVK1.,%D/V3-2GP;4])J\=K]@7OSX/?SOR?3E*,QF9XDYAMG(91" 6$<'!)\@ M:%00DC!82"54^[2%70#O*Q%N;TJV/_H>2R;=/8?[U45V:20FQ#N3> M.DIL#/>A6DSTJ :;J5PS#A^)^LG"@Y6: 3.\]MHUA:P*,BV*=#YJCO1GZS2" M1Z-V][:L>-Q:MPEUO6C;^^DDX6SV 6=(G_SE:)Q?U89.DY/CRU'TF5D;10S MK/2U0Y "[[.%I+TO67L4/?106@/80_13Z)GB6RK5FI\>,E'NL'MOO5]D*2A9 M!Y<$%WDM$2%#(L@$D6QB9DD-F&X]E7<#>,_/..N+N_U> BY][]:!VU?;TL=P M,M[;N+0OZM=7L6:\[3>E82GL;(IBWEO(G->!65%"S+3K%U.#AMZX8)OW6GX, M:G9?#]-'JF6;T-6#=KT\G=175'O3N6D'QX:EZ#\S_'DV]\GW\Z!2"<\+[$:=(;LNUCK M:GEAP"4KA>E28KEQP;BT_.3:AQXFK;O)KH?W_-Q8Q_P)TY?Q9#3Y_./#\/.7 M^4+'?&UQ(VT!5NIT \L8^$1;7G&EMF[.4K#6[_H]D Y3,?K@HP<;]^TPU7-U M_'_:^[(>MW(ES??Y%8-^YPSW98 >P%5V7110539JP<4\"4$R:&LF+;DEI;O< MOWZ"4BI72:F%/,J4[TO"*=LZWXGX2$8$8_GXYN,,5SV<;S>C8DRMK;(V$K" MAL48) NY))D@FV1;]Q?8"N:R*=)&!QTR!_Z<0<;ZDFL\SD<5LY;,N$1O&1SY M?$HJYE3D%FG7 ]WZHOR/HLMD:5JO7[?Y[,%[/K96/!VZOXDM$4X(DY25:]ADB>ID1D&%3)N1A MV3J?80N4T]M+3,;3V5J>OTT7.!^9&&-.IAY1F0Q?[2.+ /1VP,%GA1A5ZPUA M XSA=X(6VG[:8>(T^78(NC]\S;\FL,JIQ?QV/$_3Z\GBPPP_CZ\_+R\,Z)_. MY]=U_L./T_DJ7=][F2&DPDQ>&KK.,N] ,U&45RYJ\,U'@YT(^3*H-*3>.OBS M]_?LD5%"*5T22\EEIF6.S"^;.A:NHR>Q<-_Z,N?^\R^#$$=+M(/[N>PG\0 0 M9BF5LXD9H[!VAS?D#[O$K(B!&U%$;.YV/@%Q&7H^3;8=W,DG@-;#>#VH%+B3 MC! 1"97,S'L?")P@^S73V=;>#)VLO0!A7'&M9_%M1G(9VF\@Y0ZIX _?].?U9&Y8X+)16_YP-\K= M%.Z7)TB6'V0?,'A,6GUL?\_NCNPR.=-+&4][8MKQ9): D&9/B MVC,C0B&KI5@&GJQ3@=:X+%WVSG8ER*#I_OWU?[A47TJ^?MWK%C=[W>V,L !) ME)SJ6/8@R%.6B87"'XSA7Z#JE(*U&=%Y,JU.U]@S%#A!W,.10134JG#%I*MUMUX6%K(J3,@"1@'/,?;> M!LZ8!S44!PZ1A3KU MB0O!N'?>.?)XA7]D)&Q,8MGYD.&-P19:F/8088>0\RH*OHQ^WP 2'A47*EM? S*%)8$)CFO5>DD_ ?&J==Y&M(W7\1NE[N%Y>XVD!+PQ+K<>VH_$@3-&L M2 E,&\F9QQR8,;P4Z34'\]P5\3./N "MMA%?AT#N0P=C:5@8<+7EGR>'(AFF M579D6!3#9$DJ*I4R3ZU;TCQ%<2D.UXGR[7!/\Q#1O;26?7!UBA !;J>I&$X;7)),1M\KCEI@H&1D9GLM%;*^JCR'H?[,X\Y=QS^ M6%UL<;Y.%>0@[E<14FM/U%7*2Z81*Y.595F7"$;G)$OKOJHD[Q307@7E9"[Y!2F.S@R#-7J;Z"W+ FJ_D5@(H 'N?)AZCG4\*BLM+$7VYO98D6PGI-SGBI+1LQ M&Q8U>>DR*QES$"DW[UUR*,:3VQGO][S?,RSBM M+BQ6'U?L1@B5)/E8-:.1:1L#"UYYLJ%UX@(2*M$HR)[/]2XM14%FH*4?7$/FAM,;M>9ETQ>X<**> M3]F]TNJWB*O"MK:N8*:]6^0Q9)S[:6/=40GCZ%UD.X92!?.KI8*Z969 M_YQ18(O3P5A@11G+M,N<[(%Z$>(M4%AL@RU#P U=U6WOBP\R1\X-%UIGA@)JJ,\A\Z CDT)R++DF];8N!-Z-Z'M81&W4T2'#?4]1W-PK@T@B MV4#@%+_)X$L\T\&!&$$K<*IUK_6CP M^&ZHF3HZ>,6/,-T$V/3?4;YW0D% G M3Z>NT'4639".D>&5F3(B&'-:ZZ3O M7D/N^E^3&<)5[6?S\^0KKG#^@P12+;$;O :Q!D 4PYCJ!"PR_0.'ROW A9)2 M>M%QU]D+XX6QJ+U>.@3)]S#GURU]"^; ::.T44"==5_;A!=.9W9VWNFLP;5. M>]L;W(4QIZ$F.L3)'U\2O;]>U D:SZ)?&GU@# _)!%9 6]HV$5@04; HE?/% MH>8 \B@/? MHD3#(U>6E>)D[5N4&3AN&%K,%AUX\*W-MY=(TF<"#J^5HX=H]P5Q/)Q7NV?#SC[XQ/,\/AL[EW?=GKJ]MY8&^5IWP9<[Z[\2C#9@\55;KZN'0_! M"D?&H9,:5$IH=:][JU]:Y5K_$^NT$,QOON(,/N)OUY6:[\M2GG,B]'P!DSKQ M_0>8C]/(9RF1WI0V3I9P7RS6,S&\7I1/:@_I\O/""[F#_!M6;,ZF\'DXVK* MP(@#;7LF2F:2)H'EZM9C)+>^-HV,09E8VD]B/17UJV?9P(KK8%=M62=OQU?7 M].F3Y3+RH'44GMQW(4R==!-9D$:S:%3$$*1+J75W^ ,AOGI2]51)C_#L9#'. M%1N997]@NIZ1M''^[N]T=4W60DW/KI8;+8:E95?6]L;:UGCSN?:V'_D0=$G@ M&1#!$-EUS7FP@EB/'>&W'RVN(/_1\()S,;39I34^X1P3Z[8X$6Q]^MK'A)RARVE*@ M#2V6): ;'']-YE\PC9M;;0F559%NF(AO3ZU;PDE#ZGU0P2[5=LM8VO+6. J_/<;GC"Y M;O/WG!Y/VP-?OTB:M-'ENK,K+>CPU[5 0I!O*3T7**26MOE AO:1M+L\E)48 MUT,/ZN"K\==Q)MF-C(M*!0Q,N]K)0U8KQ],!)Y4(3F@ X*US5O> ]2*<@4,X M\#2>T5;T'6)EOV_,5EJ&KW&^[.%CLJ*]3XB*T' &/+M:SRL E W%M0XE[P3T MZAG13MP=@EQT6YOGJ3EL/R")N !!G(WBU6T ]B; !; M$YUD=B!%P=AZB]B%Y]4SH9FP.\2@WLU),O_Y%K],Y^/%_'=<)5=/"3(Y38MO M?\ 5D16UU381147TFEPA'HBGM:XUT9LKKF-1K1L[[(/KU1.CN? [!(@>8'P[ MGL?KV7P5@'^"]TWZCVOB>56!&$D.1D5RNJWS-;::JD%M@:%30B:T,>;6]W1' M0KTL&G5248>:^BTERP3+@R5>LZCJC@C.LQ!<8(E;(:Q2TH?6M?-;H+QZ9K00 M<8=!>4]@K ,]T*LA&@*S]"7(@8-J$Y3B'2"^O@Y8ZY:2[4^#,C2.&V02.$?A3.KC& M%U")*PPJ)I:$(W)JD8B<)3"132@"N,Z/>[9>S@74*4H^08PO]P(*3$P&2V$E ME,2T#9X$(@I+3L0<([6(ON(+J(,4^>P%U"$"'>P&8A]0W],%U$%*VNLJ MXA@)#W?_Z%+P62L&KECR0C)9I;P@XZ5D3<<1DOO[^M1^\ 54>ZT?(MA!+J#^ M6)T3/T_*=/9YF15S_"74]N\Z_2)J3YRM+J-63_N=W/?9RCJ[?>R=::"YT(ZL M=F;(*F,Z>\L\>,<266I@R90VL>/;W0Z*NL/NGA-\6T:]3CR35!?+]RA6Y;,:_^'0'&^:_CR70V7GR[ M=X'W\%M6Q>&_XN+3]-[=SGQD) _&^3JFO!;JRDQ^5"R.K/=:QB.EU]"Z^'G MU[M /K]48I(\C(4!E?T_0%B]:H9>5.2"X@I-9WR@.H?-\^ MBYTU?HAP&P_G^V5<\(\TQDFZ+4PWSDC+Q6J0M,X)ZV0>R;A2SL>2$!Z/F-HX MNNW)%Y_-C#U&R--6$FKH654P/]*'XP17;\?P<3*=+\9IW>\L2!#:$AXTM?4G M5Y+Y*"7+(@N X@$>EP]M5-O6![Q6];616(].@U=7R^O!]9ZR'OP74LF!7DQ& M9YF.09"[0OM+5-[HI'3BJ?4E[&8DKU'A#66[->%OD+#LZ)%+>EI@=B1ZAF8? M8^T4G/T=R2U*XZMJB-.I_--T]GY]J_YA-BWCQ3H0L+;,IS].)_/IU3C7/*P[ M3S$5&3#'S))6B4BP; R9'*.CO.0BC8FBDR73^E5>4XA.T&+.D0(7SJ$MU>X5UG\@@O%]UDWH0O1] ^!<%3]5+!QOOB!7Q[N_%#.CYXPG,OBT%\AM) MM5[Z3*^6HKUYPY&S4-^'#*)<(Y[&20;&TX(HAA: 2@Z;IVMU?)U_T?PXZZ-][IY]\B'7(HU)+T8:FI@6+"40L(JKFM0O[ M(?L703MIL4LG[<.OR\F+,H29?,/ :8T@:!:YX8R61DP"E?6A_03=5YC;\!)8 MV%N_'2IN;L5VTY)HM]#F#Z6VNF3B7$NP9.@*;3W9,EZS$()EPM**$DDI :UO MA4]'?:Y+XI=!TT%U_E*NF5?&R5V2_735'_=F-E5VD417.SN)FI246=2\,.L2 M*,NSD:)UDZL=<,YUQ3PT,39:F:">P\]]'-U+@? M/4[0P>!$X<$%*(DS)9*EU8&"!4+)?(JT,+*A0[]]IY7!"?+,[?5Y^'&(Z#OP M@@YZ''^<_'@]F^$D?7LT%,HJPU6L?09CW35ILV2>DX=BI)+@"O=:M(Z9[ 0T MO#G?4'G37I+O$*_=78BYOAYTR>@L"\L\9Z8E2A;1(+-%IA!M(I]AV,'IET>2 MYGKHW^>G? MF9/22 W=B7%#_WTP-:R@W89C^ +:%CK:J?(3!-RX@'8K-EUL!)%UG3&JR(J. M-0%'TODA'EN"#83Q7(P+ M&I72UNVQ4%]LU=RQ"[:-Q,Y<0_4H,^;$&JHU] W(;[[RE!JJ1U@[U5#5A+C% M(S_KE]M[;:FZ2 MJ]E116D#K9EH6+3%,V.@2$=6<;+=YE^]Y!A2>SH<%#4Z1"W=0P?[ M@/E>HT8'*6IG#.$8*7=7O2:K'43V3+M0&1XC TGG:B2SWO#HH\ZMKQQ>>M2H MG<8/$6[_J!%8[:P6#%V-B>3,&3@KF74V ?DHR>3\&J-&!PEY=]3H D-UGG' MHQ<"7?6(N:M'4&)!$\;B;="&FYJQ]IIC",>JKXW$ANN\DS/M)A@* TL;"O$L M,0\6""3!C(38QM85@"\S^'>,PAO*=IB"898I* MF[VT_:IS^KJ9V(T$/U06WSZ8OJ: M04+%G,\)7/:J0'YU2C\\BZ^YS@^1ZY!9?%GIK%1D6-].*ZQC?=Q7>0GO;-XCM R,-G\05M2U91,)EKCJ'/ANP2QUG".MD)M97-7>I7 MD<5W"A,:BGR0B3B_XWPQNTZ+ZQDA_9'\B_F#"T;E0-:[J2-,-1860)%M'Y65P4( USKI<1]W7_&)YA] MQ#GY0MJ DTB4%;(.@?,L(KB:JN1K3]+,4^L[T4TXAG<)FS/AZ>W/B>+NB*.03!UNSU'RQT+IUY28E5')R=9]F[9A MN4!R-!%[EQYT3TG[YPPF\ZM5%XY;XHY2+M$&0T"U\S5Q)C O:O9,4%8%P3WW MK3N^[PWN @G31S$=6L;=#2)Z 'DICZL:GEUZ ZL8K9?:DFL-3)8ZRR#$4OO< MTE885*PR"DJV+DT\ -Y0J4O=N=-+)2\E4>G!6WVX@E6SH S2D-NNF':*=E*= M- NF( D00G16?"-98Z[MVIJ.DW]L>KJ#6$?T]8'7*2-H"Z3RY M20V4]AP-3I#X@(3PT6LE?!UW;:OYS1,+(0I64I'9")NB:]U;:U B/).Q-!P/ M#A%TXYRE=]>SZ1>$R>](PH+)^+^6)M.Z;5-VJ)&3N20X':RQ=@+R)C"4OG@Z M<%.$1S?J&_-@=CWCS.;HL4J8=I!@X_2F-2XZU-Y\QMDX;8&8E LE+!DLZM [ M:QD(CN1:94/&D\HZIP.4_,SC+D??+>7:>%&_R7DI5+C:%ZSS J)VA38TJ6O2 M/Z_58(9!5E:0!:UR#'N0X. 'OWXZ])5UAZC6,XFX*269^9*K)(8L>9VEEEE M'A. E-DWKQA[B:4+0WD([;31@RH/<^GW //=5BP^ MA(1@E0K[#)U]<14+!PEY9\7"(1(:K&(AEF+)_8R,; " M=D'NH;876[%PK/K:2&RX;O?+K85,0I.<0&9Y392 94U,K/=<(DLG(OF4W\%( MC:$LL%::Z'#CN+M/\S[@_C4[XV U'C0;X1@=##X[@P Z;R,=41+J='LIF9>\ M,*6-UL))%6W[4::O:79&/WX<(OHN5OQR8N0_<((SN*J!B?R9A$W;*8'\NF[2 M?]N7,QOI2Z&CE0,P;>ED[D @NRS ,8R7A6Z+(SO*36;4[V M@'5)M&BMA0XQPA_@"L@Y_N,3XL-#%0((I;-C( LR;2P2+DE41@O&:N=-;'U[ MO W+I;LP3730(=]M$ZZ;5;$/LD[.RW94Y_%%:#5#']D(<7RV'DJ_+#B.=IT( BR[4>]K$F<]1T9E:"D@=O-'0F!O[HQO> M]FBET\=-/_HHI.,!YZV*O MYS!=#$V:"G^0(N%?$,BM/KXP^.'_/[T8> >>1@7 O^!\CKA\SEN"_ATKY^DOEK_^B;//(VN@7N(!\\74%+T@&%CRU *O*7I1&:OV27(\^,'# M;P(MF?#@CK2KS'N<&6NH2T35"1MI[I!ST,Q#;8F4$_T),[+".68%7/']FD<= M9:KAG7(TF#KQC,[X%PN/4Z1>\.;^7KUW-6<4:;:N>2$HZ4? M,I$'!(JI*&R4*CAI]ADY\OA[+T.9)TNL0USRX16^F"I7W0&%O'(SORB0IG(3DEC$426.M4BA/@7A:I MAM+;4\KYMC;,HQ<928XUI9E6@:N70Z"1!6X2$P9-+MRKX%NG9NP$=%FT:2?[ MI\0(;8EQR]:+E*',JLZ[2\9QU0.H0AK@C.MP[V[$5TR-4Z2 M_H8 6./(YV-XMRE,[\OJN!W3$3N=+]7QKMY&S,?QBOX7>7"8=1;% S,R2J9C M34^K@K+%:F5R+J<(4:BOJWMK[4-L ZKL@TY$ZV,"2DV.QVZPQER5**PU3OJ;/"2'(]D^: M\9"LXQD%I+ZQFPNUD%O(>P,/3BZ-VG%U\ .6Z:RV$[W^?+W,LGQPEZ!MB-$6 MHJV1F:PSK*GTW+!@O<\ZT38G6J>#'(OULI@TB,8V4.WD:/&N6ZHMD!,&S"HB MD\'6M!>=:]X^F7G)%44.@"REM9%].,KOAEXMM+2!6$>'H!]?B3R""V6!LZV+ M0:'RW&>F!$_D1>3(0JE3'3*0I- EOE>CGB,??QF4&4K^&SC3- 3]Q+LT2F43 MB<8(MC;5%2))&]:5T"_ RD[X <1\I_ S].CA9OQ#>2)6OA7:RIVX(V MLUA3?XVG\Y"@6B5]<3W-E MUF4Z7]08&- X+_Q/KF4=GVU?Z]",^3=$4(V]+ M5$ER9K)63 =G202:]C6H-Q^Q@(&^'O7S&"^+-UTUM"$M[N1@\GVB[P%7^1A( M/H:1'&@%R%([+!)<&4I6'%(2S0F*];ILGN/H_"+-1YA%L=I(Y46JV*R^TM?+(N%;@DDL>/1 M7A;)!M+:!L(U#3OO"3F1W9>#B4RHFE:M:Y XV_X]^+/_\2KK_CK=++X-!\!:=\8/!;K99%L$(UMH%J?:/4NP!9"0J4L"YH,19U+)&M1(XN@R+/U M6(1HW8+N4(R71:VN&MI J9,CW?NNA;K5_OF?TY%V47 5%7. NG8@H"40DF>J M2) >!D;XGM,OB3P]];.#-R?'T@WA.A,"1<\:'#)$EI!\Z:<-BM, 29$RV)EF: MUBFS!X.\+"[UU=&&LN*F(?7=2'D6.MM@&4>3JA>A6TZ.H1_"]Y^FU[.1X(;<36T9F-J'10O-P")G6(QQ@C95LO;.N"55 MC)?%I:X:VD"IIC'TG4!C22)J(VM>0VU,2'\*H03&M2,[3H?LTCGLH\NC4!>- M;*#.,!%S ORFYMLM48^_XDCI+#B7FG&3:0]%1_Z =YQ!23H*&Y3PKXQ[E$D,XTK M*QD7M; 2:_@,!1L-P=0BUTGSE@5I(T.N=8ZJ6.X'31O8!O2RR-1?5QL8UB>*O16M M1^V*KF-+(U^N!\%"RI(5"#SP;+@/K9EU$,#+8E0_W6Q@4J.X]F-)K&:4B"@@ M1TGO+@1YE$(5.FJC(-)'KF)1$7*?<-%&. U9 E=7Y]QM3I?VIF:Y_[V^;E[\ MKW0UG6/^]W];S*[Q[L,I,>_OQ;NK97>(?_^W^6K= ,XU M_Z>9=J>MI=RPN?(2U(H]]R'=3!?8!]0AH\ V(,..]FFHJ&DO*0]&@9@D M,9M\>T)26T6D2(8W$/$#)*\=<&Z:K/YA5;]E@,_0FC]$N TUOK1<9M]&?_TQ M4AAD2C(SIY2BXR]'%E/,S-KD+$B0J'85$5.P7?/ M&\XV;"CXZ4E2:S@!H;[3[[6QX9*.-HO,C0"62TQ,)Z/H'3S]2EX+RN13P+WN MD)]9F;+>;C^N/2 ?W M__YO_Q]02P,$% @ XX-;5YC:I1W#\@ FE0* !0 !B:6\M,C R,S Y M,S!?;&%B+GAM;-2]:W/C.)(N_'U_!=YY/VQWA+'-"WB;V-T3KEM/Q:DNUZER MSYZ-CC<4N-'FC"QZ2,E5WE__ KQ(E"61 C2G-V8+ELFD9D/A <)()'Y[__K MQ\,://&BS/+-?_S)_3?G3X!O:,ZRS=U__.GWVP\P_M/_^L]_^9=__W\@_+]O MOGX"[W*Z>^";+7A;<+SE#'S/MO=@>\_!?^7%W[,G#+ZL\3;-BP<(_[-Z[6W^ M^%QD=_=;X#F>WS[6_K7X E(4)!U>@ZV_S]S_(_!)<<"/,V9?7K?_SI M?KM]_/,OOWS__OW??I!B_6]Y+YSC^+^W3?VH>_W'R_'>_>MH5.OQ2_77_ M:)F=>U TZ_[R?W_[](W>\P<,LTVYQ1LJ!939G\OJPT\YQ=L*]4&]P,4GY&^P M?0S*CZ#K0=_]MQ\E^]-__@L -1Q%ON9?>0KDO[]__7A19/*+?.*7#;^3??N% M%UG.OFUQL?V$"5\+[:O6ML^/_#_^5&8/CVO>?G9?\/1\L^NB.&I5:IE(+=U0 M:OG_7A+VRPCU+>F[/=75@G*5N9]MZ=B'Z6=KZMX*AN#3*]P1,UKE^@OU?L/F M^N[N18U6?7J-;7TM\BU>S_"U.(CIJ+R6'WP2/S5B9$,]9%K)::B[HRK_L>4; MQFNV/&H:9.P__B1^6NU*>(?QX^K;-J=_OWY\+#C-*NK^*J>U\MOUUV^_\0?" MB]5V__U=\0W\_5LKJFI/L[$_:9BUO3 \"U[FNX(>)K:'];G92DQ4A=/GSO_]R,-4&ENOY85R_+H+@CUKE M_^\BE#D]4FXM78B\> E/3O7A.8S14EA689/BDE3&-8W](OVW7_AZ6[:?0/E) M-5#5Y?UR\MVX+EJK<$$'NJEYXA>:"V_J<0N/>BPM\@=#\[>YX=>J[@BAUI] M7C!>"!_ZC(DG7__K]3K_+CW"#WGQ+M^1;;I;7U.:[S;;\BNG7'C(1!(RS85O MGO%R%2'?=UT_@ PS#R(O#B&AV(=1$OF><'U)Y' =^M%58&ELU.H*#LI>@;U1 M0"Q Y J%95OP*2_+*]!8\JS'4MK=I$9:4X(_,8=9QUV;TDS!L\1PVN)G)3Q3 M<%[RGW$[>G3(*5M]P<]_+84'+?<,I,1W64G7>;DKN/#M^,\YOT^@EG:SF2Q#"3GWSC=%=D6S&@WG&R M75'F(R<,"?3B((8(BY^(AST8!W[DQ4P((:[.I*^KP-(F_59_(#L<2'U!G@*I M*3@H+J:CUB@H^A*6XC&]65^[G]1F_2G1GYJO3(#_U@>\]K1OBIZE:5];_*S3 MOBDX+Z=]XW;,"/%F>\^+S\+$75'PS?93ADFVKAIO]@""V*61RR.(G,2'B"$7 MXM3Q(1<_!@(G+PT<'0(<$K@TPJOT!0>%04=C/4X;A%J-PVP".#%G]6$WP4Z+ M*C*6^&A0W*S\HVK\2[Y1?D^/7\IBN_HJO@N\^6XC+XA8FGH0^:X+$0T"&'LX MA9QSQ\<1BBC!*C3RHMVEL<6W+=YFY3:C> U^XUBZKM51[1_O\@><;2Y_V7O! MZR>&$9!,OMMJB(;RT+]@>]\(%Z]T1K?X[3"R7[8VRP"^8$([3B_]66\XDBQ? MO=\5^2/'F^L-NW[@A>B5S5_X$U_GC_*K]?['(]^4?(4H#4+.&$SC@$$48@)Q$/L08S\@(451 MY"JY5TK2EL;6K;+5 .BH"QI]]99I_4"KK=&LP3TC_F^7W#BO7S7;-_]/S;W[=?!%OQM_>;NR]TJT(/PZTLC1N$ MMERHFVWNVFW29_ ;+O[.MZ!2&[R]E\ZU&D4H@#A\3&8/OXG)01&Z*WF&1L47 MU,XYF1H\1D=D TW/=CJF9F+W8$SQ#3//XML]+O@;7'+V-G^0'%,Y+==%(7M7 M,D_YYOGPS!?\+#^[_HX+5OWG5D@53/5%?'<^BV]3O;37"L.;0/[2:.AZO0:5 MMD"JJ[EQ/$D'J3DRK]TW$U/4I>_. M58W^*H1OW^$M_X"SXJ]XO5,*0>QY?6G,*14#E68 E_+(NU(92)W5G;9+4 U[ M:Q90FH7##JB V)V/+(!"(QX. ML5ZK@/DTLG)Q*61M0GL8V-QE<5";S_ MQTYN2'7__N&O\/-'/:X^A5F-<$>!-S%K6L9-F_XN8F.)PT[;GY6(+IKWDDTN M/VBX3[<5[J=<4MZDU=VX^WPM7B[K#KTFY;; =+MBE+@!=6.(0I) X1>F,,$X M@0Z*'4H1=4,WTKLDJR!U:=2Q5UHN&+MJ_VO[_?^C55TQZ$"O$Q0WUVQ#.S&Q M6$'5X/ZL!DK6[M"JR)SY'JT&#*=W:75>-J.G]VG*J1#P_@>MSH6^"I$WF[>X MO)?_DZ*>\)I77I20E]$M9_(/PL=$S(>E M<<1BWW.#1(?,)M!Q:=17FRA':&LDD%:"? .DYE?5?T'' 'E!M+6M_J-T$UY^ MUGE!CS"G^%JHT>LK=_;$9#R^GZ^&.EJTD6^VV68GCX!O'GE1[7=?[G]M:I^P MARQ-!%-H..NT,2'$+R>9*46934GO>,J+@K./&YH_\%O\HW.[X3/?KE**0\H] M#+&892#R8PHZ/:OG9G.ZY5,*Y[9*ORN.$F'+^3Z^BO M_#$OA&M\M]_RB;'+ [$NAX D]@(8!)S[#F)Q2CVM?;<+@I;&%(V> M8*^H^=;:)6@5=],L #;U!IH)5OH;9@- V-HCNR1FWFVQ 6-/=L*&GC=,)M>> M_>%G>3SXMKY,O4*,H0#C$#(>NA AC&&2Q@0F-$D)YLP)HE@K9=Q9,4NCA/W) M_&.MIF;"M_-0JI' >( FIH ]-HV&5Z#1T6)VMEX,;.5@.R]DWDQKO8:>Y%/K M?UI_12!W+9IM=1D8=OTC*U57 F=>7=H@[J@(WG$A\2';U*ZKU/C/ZD[_.9B& MG?V1"$T\BOO!$;.Z4->26]\#A)$[?ZZ]V=SX'F.Z[GO?8V;S\\<-+3@N^3M> M__MQ;#)$ >) Z-$/6)RP*M:$H=X4NC@59WD&U M7L7=K7/AM\JO/%B;9D+2Z@VUB7\JC"THF&!FR7W0 M$CVK4V$"RDM7PZ@-,V)[FQ=B)2-(4D9]'4*-FO07:11@QAP,4Q_)BBW,A21" M#/*$IZ'+4>KI!0/U2EL:=>V5?9DE43/?B!K4:C1E#<")>6D$=MHTI(2))=[I MES4KT2B9_9)9U%XRS(U;7U@K;_-K^H]=5@C:>A*.6/79*G 9)3%Q(4=8, F- M4YB@,(512@,O)H)9(K8Z*2$SG)"U1Z;2<%"KD6,Y<72E7K6G_RA:O1<,7]U, M>Z@NQU<72LK#@)%!%MG!*LT\N'U]HD8YHR&>+1]W#>LV!XVBX*,";/I9;!7P ML)6QMD_4O-EI%8P^R42K\H[^MLG'39F))YOHZ.JRA!@F,NWM)XUD\PJM+.C+ MW6C;1N*#5M^*'*J,OVQ7R,GUD^VT\QHX&6TGJ+0_V_:"AK'=[0:=UPRV"7=K M[CHD<*\+(>)ALV4Z,0/GWUZ:JRVU!%)-Z(+.?7APV^R,<::Q7W@>+X4MP]%0 M3;UK.(B2U8" ?CS,-@_/-SG?_F&O24=;B/U/&N?@VQ8[NA6NW>9.9NDJGKA@ MC4VYKC-!L+_MZOEQ17CDQ"[Q81HGL0Q<=V$2L!!2ET4D(3Z/O-3 75968*&^ M\Y'^H#'@"GS("Y[=;9JC,'DM]V 3^.E7G&U^KFYB:R?R4^PM-4?:+OCS'53H M B[Q!C])O"\7%#3)_Z<'GKU<@(IRY\X+J ?'F1R!F@V,"Z'^RI_X9K<_C2>$ MNIP[!*9NS""B-($QCUP8NA$AQ/%"GVI=1CXO9FENSC[ZMU%S^/!>!U,U%AJ/ MU,24HP^2<5ST>0PLAT._$/(J4=#G#;T4_'SAZ7$1#CDO/^?;K[S:"6A+"LKT M&57V#)/ A_X6ES;VNT?^3*@.-OD6%+7RFJ4M-:%56/E,@NH,KLD^AD("*M0& M7U\ "OZPFJ'%#*S1<18#8EXE_$+-]$M1&8IOCR_2][$L=S+/RDWZ-G]XR#?5 M]>55X'@NC2B"B2.K\B4QA0335"RT/.;&- A0J!5L/2AQ:6QT7 VN55D>0M1* MU]?SS6ONG8<]92@F+F*0(,XABK'P^IPPA!$+$(D1Q3Y")H= 5M!_A9.@5^D$ MQ5,?F]_HJ8]^QN$XJHYA+S83%"X\+^_5*A7VFM]7FK#_1<.[-?2>LYTL>?AK MGK/OV7I]*P]35UZ(4DP#"EU$"$2!YT+,> )])TDXYC2(7*W%Y@4Y2^/X5LTJ MZ6FCJ/"'I*JZ-VLN *M&)1;@FIA C)#2OU?3CX.M:S47I,Q[JZ;?U)-+-0./ MZY<.W">L^97G=P5^O)N5LC0JZ.HW%%VN@67_^+>&T,2C7P<W9B@X.FM4K'@>D;A"Z--&Z/M&.([>CVO[ ,GM@^7U-:[/"ZC5-;>1'A2>I%,/:(+()'"<2)ET(_"AA)Q6J! M!+S=GE#>F>@1:+ M,3%I7-.MT ]\;_0%-"^U(T[[,5;>?1B+VVPI+3=,UD^H M4N/^V/(-XU5$GE0?M/J#QH KT-[HJ()_6WNL[DPHX&9O6Z)/V-Q[$@J&G]F0 M4'G+)MDTOV:\E#L@G*U2ZF+?\3S(4AD8[S@>C/TD@$D@EB8A)I0[SNJ)%R37 MV Y5$*PSB+KB)]W&>\I*&4$B!T?+03;8YP3T,2PT!LB%L='^]J $_& 7J V; MFI8N 3DI/9T(70!-70)"C:XNOFU,6X^\V#[+,E/;ZPV3V12K^J'BYP_91N[9 M?I+?F:_9W?WV)OV]Y-=ER;=ON/@.<:'2[F&WEI[*._Y8<)K5T42RLK',EU+7 M,UYAC+"#> "IF[@0N=R#.* .#.,H=(,XB:(XU3Q^FUKGI2WO6I.OP*,TNL[% MREN[M4ES\BY79MPE=>3TYU9-'WXY].'>Y.JWQFA060TJLV&>0F$XJ"R_ J2R M'72,!UWKFZ+N!_NMLOI"=<[#8+0@4GBR@/".( Q,.9Y!7(*R @N-3^AR M2K97&*RU(^G5>T)MFK +[$RG#(W.PNMNM+XZ(NV#XOU7%;1I6ALL2V2K+G=6 MRM2&XR7QZ3